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1. ACTIVE RENIN, INACTIVE RENIN AND 
PRO RENIN 
1.1. INTRODUCTION 
1.1.1. HISTORY 
Robert Tigerstedt (1853-1923), professor of physiology at the Karolinska Institute 
in Stockholm, discovered renin at the turn of the century1• The scientific 
achievements of Richard Bright (1789-1858), Karl Ludwig (1815-1895) and 
Charles Brown-Sequard (1817-1894) had set the stage for this discovery2 • It was 
Bright who observed that many patients dying with small contracted kidneys 
had cardiac hypertrophy and a 'hard, full, pulse.' Ludwig introduced the mercury 
manometer for recording intra-arterial pressure on a revolving kymograph. Of 
equal importance was the study of the process of internal secretion by Brown-
Sequard. In a series of classic experiments published in 1898, Tigerstedt and 
Bergman3 were able to demonstrate that a saline extract of rabbit kidneys, when 
injected intravenously into rabbits, raised blood pressure up to fifty percent 
within two minutes. The substance concerned was present in the renal cortex 
and in the renal venous effluent. It was absent in renal medulla and urine. 
The substance was soluble in water, non-dialysable, stable at 56 C but not at 
100 C and extremely potent. Tigerstedt and Bergman called this unknown 
substance, renin. Their main conclusion was that renin was a blood pressure-
raising substance released by the kidney into the circulating blood. They 
considered this hormone to be the connection explaining the association between 
renal and cardiac disease described by Bright. 
This discovery laid dormant for more than 30 years before its significance 
was recognized by Goldblatt and coworkers, who produced hypertension in the 
dog by clamping the renal artery4,5• These experiments indicated that the pressor 
substance, renin, was released from the kidney with the constricted artery. 
Goldblatt's group later defined the 'Goldblatt Unit' of renin, which is the quantity 
of renin that, after intravenous injection, raises the directly measured mean arterial 
pressure with 30 mm Hg in an unanaesthetized, trained, dog6• At present renin 
is defined in relation to a standard preparation supplied by the World Health 
Organization. This standard has been accepted as the international reference 
preparation7• It is to be expected that, as a result of the recent purification 
of renin, a less arbitrary definition of the Goldblatt Unit will be established. 
Ruyter8 first described the juxtaglomerular epitheloid granular cells present 
in the wall of the afferent arteriole of the glomerulus of the mouse kidney. 
These cells exhibit features of endocrine and smooth muscle cells and may be 
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considered as 'myoendocrine' cells. It was Goormaghtigh9 who postulated that 
they were the source of renin. Naim10 and Edelman11 demonstrated the loca-
lization of renin in the granules of the juxtaglomerular cells in the afferent arteriole 
by the fluorescent antibody technique. However, because of the unspecific nature 
of the renin antisera, these observations were be questioned. With the introduction 
of highly specific antibodies and by using immunohistochemical techniques, renin 
could be unequivocally demonstrated in the secretory granules of the epithelioid 
cells of the juxtaglomerular apparatus12- 14• By microtechniques Cook et ai.l5 
were able to isolate the content of the granulated juxtaglomerular cells and 
demonstrated that the isolated material had vasopressor activity. 
There is now general agreement that renin is stored in membrane-bound 
cytoplasmic granules of modified cells of the afferent glomerular arteriole, just 
before it enters the glomerular capillary tuft. Both the afferent and efferent 
glomerular arterioles are anatomically and functionally closely associated with 
a group of cells of the distal tubule forming the macula densa. These cells, 
together with the modified cells of the afferent arteriole, form the juxtaglomerular 
apparatus. The anatomy of the juxtaglomerular apparatus has recently been 
reviewed16• 
The proteolytic activity of renin was discovered just before the second world 
war, independently by Brown-Menendez17•18 and his group in Argentina and 
by the group of Page19•20 in the United States. Renin catalyses the hydrolysis 
10 11 12 13 H 15 
Renin substrate 
a 10 
Angiotensin I H - Asp - Arg- Val- Tyr- lie - His- Pro- Phe - His - Leu- OH 
I H - His - Leu- OH I Angiotensin II ' H - Asp- Arg- Val - Tyr- lie - His- Pro- Phe- OH 
Fig. 1.1. Outline of the biochemistry of the human renin-angiotensin system. The aspartic protease 
renin cleaves its substrate (angiotensinogen) between leucine 10 and valine 11 to form the decapeptide 
angiotensin 1. Converting enzyme removes residues histidine 9 and leucine 10 to form the octapeptide 
angiotensin II, the biologically active endproduct of the system. 
of the Leu-10-Val-11 bond of human angiotensinogen21- 23 (Fig.l). Because this 
reaction is the rate-limiting step in a series of reactions leading to the formation 
of angiotensin-II, a highly potent vasoconstrictor and aldosterone-releasing 
hormone, renin is considered to have a key role in blood pressure regulation 
and in sodium and water homeostasis24- 27 . 
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1.1.2. BIOCHEMISTRY OF RENIN 
The family of protein-splitting enzymes or proteases are classified according 
to the structural features of their active site i.e. serine, cysteine, metallo- and 
aspartic (aspartyl) proteases, also called acid proteases, because of their low 
pH optimum of activity29,30. The name aspartyl protease has been adopted by 
the Committee of Enzyme Nomenclature of the International Union of Bio-
chemistry31 because all enzymes in this group have two aspartyl residues in their 
active site29-30,32. The systematic number of the aspartyl pro teases is EC 3.4.23_31. 
Renin (EC 3.4.23.15) belongs to the group of aspartyl proteases, which also 
includes pro teases such as pepsin A (commonly known as pepsin), pepsin C 
or gastricsin, chymosin or rennin, penicillopepsin and cathepsin D29-36. The 
aspartyl proteases are all specific for peptide bonds with large hydrophobic 
residues on either side of the scissile bond32,36. However, the nearly neutral pH 
optimum and the highly restricted substrate specificity of renin are properties 
not shared by the other aspartyl proteases. 
Investigations on the tertiary structure of the aspartyl proteases have shown 
that these enzymes have a bilobal structure32-39. The two domains are separated 
by a deep and extended cleft perpendicular to the largest diameter of the molecule. 
The two aspartyl residues of the active site are located in this cleft and are 
in intimate contact. The two catalytically active residues in the aspartyl proteases 
are Asp-32 and Asp-215, in the amino-acid sequence of porcine pepsin A32) 6. 
Renin is completely inactivated by the active-site specific irreversible inhibitors 
of acid pro teases, i.e diazo compounds and epoxides40-43 . Diazo compounds, 
such as N-diazoacetyl-L-phenylalanine methyl ester, react with un-ionized car-
boxyl groups, specifically with the side chain carboxyl of Asp-21532,36,44-48 . 
Epoxides, such as 1.2-epoxy-3-(p-nitrophenoxy)propanol, which react specifically 
with ionized carboxyls, modify Asp-3232,36,49,50. From measurements of the pH 
dependence of the inhibition, the side chain carboxyl group of Asp-32 and Asp-
215 of porcine pepsin A have been found to have pKa values of 1.2 and 4.5 
respectively32. This implies that, within the pH range of the optimum catalytic 
activity of pepsin A, Asp-32 is in the ionized form, whereas Asp-215 is not 
ionized32. 
The hexapeptide, pepstatin A (isovaleryl-L-valyl-L-valyl-statyl-L-alanyl-sta-
tine) which contains the unusual amino acid statine (4-amino-3-hydroxy-6-
methylheptanoic acid) and which has been isolated from various species of 
actinomyces, is a potent inhibitor of pepsin and other acid proteases51,52. Pepstatin 
binds as an extended chain in the center of the apparent substrate binding site. 
Statine is the major structural component responsible for the inhibition by 
pepstatin and is an analog of the transition state for catalysis by pepsin and 
other aspartyl proteases53. Pepstatin A also inhibits renin in vitro as well as 
in vivo52,54- 56 • The pepstatin concentration required to inhibit human renin by 
50 percent (IC 50) was I0-6 M, which is much higher than the IC 50 for pepsin 
A and cathepsin D, which have an IC 50 of about I0-9 M to I0-10 M51-53 . Recently 
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, some novel inhibitors containing the amino acid statine incorporated into 
analoques of porcine angiotensinogen, have been developed. These are highly 
potent inhibitors of human renin; their IC 50 is I0-9 M to I0-10 M57• Szelke 
et al.58 obtained highly selective potent inhibitors of human renin by reduction 
of the Leu-10-Val-11 scissile peptide bond, i.e. replacement of the peptide bond 
(-CO-NH-) by a reduced bond (-CH2-NH-), in the 5-12 amino acid sequence 
of human angiotensinogen. 
A 56,000-fold purification of hog renal renin, with a specific activity of 780 
Goldblatt Units per mg of protein was reported by Haas and coworkers already 
in 195359 • An important improvement in the purification of renin has been the 
use of chromatography on pepstatin coupled to agarose54,60 • The purification 
of renin from human kidneys is more difficult because its concentration is 20 
times lower than in hog kidney. Recently, the purification of human renal renin 
obtained from cadaver kidneys, with a specific activity of about 1,000 Goldblatt 
Unit per mg of protein has been accomplished60- 63 • Galen and coworkers64 
reported on a fully purified human renin isolated from a renin-secreting tumor. 
Juxtaglomerular cells constitute the main source of renin but the concentration 
is too low to purify it in quantities high enough to allow determination of its 
primary structure. However , as much as five percent of the total protein content 
of the submandibular (often, but less correctly, called submaxillary ) salivary 
glands of an inbred strain of male mice is an isoenzyme of renin. This isoenzyme 
of renin has physicochemical, enzymatic and immunochemical properties closely 
resembling those of mouse renal renin68- 72• 
Using Edman degradation techniques, Misono and coworkers 73,74 demonstrated 
that renin from mouse submandibulary gland consists of two polypeptide chains, 
connected by one sulfide bond. The heavy chain consists of 208 amino acids, 
molecular weight (Mr) 31,306, and the light chain contains 48 amino acids, 
Mr 5,458. The complete amino acid sequence of mouse submandibular gland 
renin precursor has been reported by Panthier and CorvoF5,76• They were able 
to present the analysis of bacterial DNA recombinant clones harbouring an 
essentially complete transcript of renin mRNA from the mouse submandibular 
gland. The decuded amino acid sequence showed that renin was synthesized 
as a Mr 44,209 precursor, preprorenin. 
MurakamF7,78 , Hobart79 and Morris80,81 reported on the primary structure of 
human renin. They also used the technique of nucleotide sequencing of the 
complementary DNA (e-DNA) coding for the human renin precursor. The 
predicted amino acid sequence consists of 406 amino acid residues with a N-
terminal pre- and prosegment consisting of 20 and 46 residues respectively (Fig.2). 
There is a close similarity between the primary structure of human renin and 
mouse renin. A high degree of sequence homology, particularly in the catalytically 
important region, was found upon comparison of human and mouse renins 
with other aspartyl pro teases 73- 81 • This suggest that the tertiary structure of renin 
is similar to that of other acid protesases. Blundell82,83 has presented a model 
for the three dimensional molecular structure of mouse submandibular renin. 
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Fig. 1.2. Schematic representation of structure of human kidney renin and renin precursor. Arrow 
1 depicts the cleavage of the signal peptide (pre-part) from the parent molecule, pre-pro-renin. 
Arrow 2 depicts the processing of prorenin (inactive renin) into renin. 
The tertiary structure of human renin was reported by Morris81 . It consists of 
two lobes forming a cleft where the active-site is located, which is comparable 
to the structure of other acid proteases. 
Aspartyl proteases, such as pepsin A and cathepsin D, are processed from 
inactive precursors, with the release of a prosegment to give the active enzyme. 
These prosegments or proparts are located on the N-terminus of the parent 
molecule. Their is a striking similarity between the prosegment of porcine 
pepsinogen A (44 amino acids), bovine pepsinogen (45 amino acids) and the 
pro part of mouse and human prorenin ( 45 and 46 amino acids respecti-
vely)15-81·84-88. The enzymatic activity of pepsin A is inhibited by fragments of 
the prosegment of pepsinogens86-88. Peptides related to the 12-19 amino acid 
sequence of the prosegment of mouse submandibulary prorenin have been 
synthesized and these peptides were found to inhibit mouse submandibulary 
renin84 as well as human renin85. 
1.1.3. RENIN AS A POLYPEPTIDE HORMONE 
After the classic work of Steiner89 on the precursor of insulin and Chretien90 
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on lipoprotein it has become clear that most, if not all, protein hormones and 
other secretory proteins begin their life as part of a larger precursor molecule. 
These precursor molecules are subsequently processed by limited proteolysis to 
the biologically active proteins91•92 • According to Steiner91 the precursor proteins 
can be classified in two major groups depending on the localization of the 
maturation processes. The first group of proteins are processed within their 
cell of origin, before exocytosis. The polypeptide hormones, insulin and pa-
rathyroid hormone, are examples of this group. The second group consists of 
proteins that are processed only after secretion, either in a single step or in 
a series of sequential cleavages. The cleavage of the proenzymes of the clotting 
system is a typical example of the latter group of proteins. The proenzymes 
are enzymatically inactive and become activated during proenzyme-enzyme 
conversion. 
The precursor proteins contain a short hydrophobic N-terminal extension of 
15 to 30 amino acids, the signal peptide or prepeptide, which is cleaved shortly 
after attachment and penetration of the nascent protein through the lipid 
membrane of the endoplasmic reticulum. The proprotein, which is located 
intracisternally, is transported through the endoplasmic reticulum, Golgi ap-
paratus and condensing vacuoles and finally stored in the secretory granules. 
The polypeptide chain of the propart can vary markedly in size as well in location 
within the full length polypeptide chain of the proprotein. 
Polypeptide hormones are usually converted into the mature hormone during 
this intracellular transportation process or within the secretory granules. The 
cleavage occurs in most cases after a pair of basic amino acids (lysine,arginine). 
The inactive precursors of enzymes, proenzymes or zymogens, are activated 
outside the cell of origin. The mechanism of renin maturation is similar to that 
observed in other cases of preproprotein processing93- 103• Protein synthesis in 
vitro is studied in fractionated cell extracts, also known as cell-free systems. 
The complete machinery of protein synthesis is present in the rabbit reticulocyte 
lysate and other systems. If m-RNA isolated from mouse salivary gland or mouse 
and human kidney is added to such extracts, the added m-RNA will be translated 
to the proteins coded for. Total poly(AtRNA or mRNA isolated from mouse 
salivary gland and mouse and human kidney were translated in the presence 
of 35-S-methionine using the cell-free rabbit reticulocyte system and other systems. 
The translated products were subsequently subjected to immunoprecipitation 
using specific renin antibodies. The cell free translation of m-RNA yielded a 
45,000 Mr preprorenin. 
In the presence of microsomal membranes, mouse preprorenin was rapidly 
converted to prorenin, Mr 43,000 and also, rapidly further converted to a single 
chain form of renin, Mr 38,000. Mouse renin was then slowly hydrolyzed to 
give two chain renin, the heavy chain of Mr 33,000 and the light chain of Mr 
5,000 held together by one disulfide bond93- 100• Both single- and two chain mouse 
renin have an exposed active site. The specific activity of the purified one-chain 
renin has been reported to be five-fold higher than of two-chain renin. This 
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difference in specific activity of the one- and two-chain renin is surprising because 
they differ by only two amino acids. Purified heavy chain, obtained by dithiotreitol 
treatment of the two-chain form, had less then 4% of the activity of the native 
two-chain renin99 • This indicate that the light chain is essential for enzymatic 
activity. The one-chain renin is immediately secreted into the medium after 
synthesis, whereas the two-chain renin is secreted later. This might indicate that 
there are two separate pathways for renin secretion. 
Recently two groups of investigators reported on renin biosynthesis by a human 
juxtaglomerular cell tumor102- 103 • Studies with tissue slices from this tumor showed 
that renin was first synthesized as an inactive 55,000 Mr species followed by 
conversion to the active molecule with an molecular weight of 44,000. Prorenin 
is probably packed and converted to active renin within the secretion granules. 
Renin producing cells isolated from the tissue and grown in culture secreted 
the inactive 55,000 molecular weight form. No conversion to renin was observed. 
Therefore the existence of two pathways for the processing, packaging, and 
secretion of renin in the juxtaglomerular cell were proposed102• Hirose103 and 
coworkers isolated poly(AJRNAfrom a juxtaglomerular cell tumor and translated 
it in rabbit reticulocyte lysate in the absence or presence of microsomal 
membranes. The primary translation product, preprorenin, had a molecular 
weight of 45,000 that was further processed to glycosylated prorenin (Mr 47,000). 
Thus post-translational modification leads to an increase in Mr despite the 
removal of the signal peptide. 
1.1.4. RENIN AS A PROTEOLYTIC ENZYME 
The discussion so far considers renin being a polypeptide hormone secreted 
by the kidney. This consideration, however, does not take into account that 
renin , in contrast to the polypeptide hormones, does not appear to act via 
target cell receptors. Renin acts by virtue of its enzymatic activity. In this respect 
renin is comparable to other proteolytic enzymes in plasma. These enzymes 
have specific functions in important physiological systems, such as coagulation, 
fibrinolysis and the complement cascade104- 109• One important mechanism for 
regulating the proteolytic activity of such systems rests on the fact that the 
individual enzymes participating in the cascade circulate in plasma as inactive 
precursors or proenzymes, which are converted into the active enzyme through 
limited proteolysis by other enzymes of the cascade. The activation step is 
irreversible since proteolysis is an exergonic reaction and since, under normal 
physiological conditions, there is no simple biological mechanism to repair a 
broken peptide bond. Potent protease inhibitors, which are present in plasma 
in abundant quantities, serve to terminate enzymatic action and constitute a 
second mechanism for controlling proteolytic activityl 10• 
It is generally accepted that the precursors of polypeptide hormones are 
processed to the active hormone before or at the time of their release into the 
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circulation. The concentration of precursor in plasma, as compared to the active 
hormone, is usually low. In contrast, the proteolytic enzymes in plasma are 
largely present as inactive precursor molecules that are activated outside their 
site of production. In the case of the coagulation system, for instance, 99 percent 
or more of the total quantity of the individual enzymes circulates in plasma 
as inactive precursor104-109. It was therefore of great interest that Lumbers and 
Morris111·112 and Skinner113 and later others114-122 reported on the presence of 
an inactive form of plasma renin that can be converted into active renin by 
limited proteolysis. 
The literature on the subject of inactive renin has been reviewed by several 
groups of investigators12L 131• It now appears that more than 90 percent of the 
renin in plasma is present in this inactive form. It is therefore tempting to speculate 
that the renin angiotensin system has a dual function. It acts as a circulating 
hormonal system but it may also act as a proteolytic system comparable to, 
and perhaps interconnected with, the coagulation, fibrinolytic and complement 
systems. It is the second possibility that is the subject of this thesis. 
1.1.5. AIM OF THE THESIS 
Our interest in inactive renin originates from the observation that plasma renin 
can be activated by several apparently unrelated modes of treatment. Dialysis 
of plasma against a pH 3.3 buffer at 0 C for 24 hours followed by another 
24 hours of dialysis at neutral pH causes a five-fold increase in renin acti-
vity113·132-137. Renin activity of plasma is also increased, albeit to a lesser extent, 
when plasma is stored at 0 C without prior acidification134-141 . Finally, the addition 
of trypsin and some other proteases, such as plasma kallikrein and plasmin, 
to plasma also increases renin activity137- 155. 
Theoretically, the increase in the enzymatic activity of renin could occur by 
several mechanisms: 
1) changes of the fluid milieu of the enzyme, for instance changes in pH, certain 
metal ions, chaotropic agents, 
2) reversible binding of an activator to the active site or to an allosteric site 
of the enzyme molecule, 
3) destruction of an inhibitor of renin or dissociation of the inhibitor moiety 
from a renin-inhibitor complex, 
4) alteration of the primary structure of inactive renin by limited proteolysis. 
The last possibility of activation by limited proteolysis is in agreement with 
the concept of a proenzyme-enzyme conversion. The existence of inactive forms 
of renin with a molecular weight greater than that of active renin has been 
demonstrated in plasma but the Mr-figures that have been reported are widely 
different126·127·130·131 . Such a concept is also in agreement with the presence of 
an additional nucleotide sequence in mouse submandibulary renin and human 
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kidney renin e-DNA, which may correspond toN-terminal amino acid sequences 
that belong to the so-called prepropart of renin75- 81 • Furthermore, there is recent 
evidence that the propart amino acid sequence of human kidney prorenin is 
also present in inactive renin of human plasma103) 56• Prorenin-renin conversion, 
within or outside the juxtaglomerular cells where prorenin is synthesized, could 
be an important regulatory step in the renin-angiotensin system. With this in 
mind we have studied some biochemical aspects of the activation of inactive 
renin and addressed the the possible physiological and clinical significance by 
measurements of inactive renin in plasma and other body fluids. This thesis 
describes our contributions to this subject in the past five years 
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2. PRORENIN-RENIN CONVERSION; ROLE OF 
ACTIVATORS 
2.1. ACTIVATION OF INACTIVE PLASMA RENIN BY TISSUE KALLIKREINS 
2.1.1. ABSTRACT 
It has been reported that inactive (acid-activatable) human renin could be 
converted into the active form by adding urinary kallikrein to acid-pretreated 
plasma. Without prior acidification, however, only a small portion of the total 
amount of inactive renin present in plasma was converted (activated) by kallikrein, 
probably because native plasma contains protease (kallikrein) inhibitors that 
are destroyed by acid. We have separated inactive renin and active renin by 
DEAE-Sepharose column chromatography of normal human plasma at pH 7.5 
and a linearly increasing sodium gradient. Inactive renin isolated in this way 
could be activated at pH 7.5 by highly purified pancreas and urinary kallikreins. 
With the semipurified preparation of inactive renin, prior acidification was not 
required for obtaining virtually complete activation by kallikrein. The kallikreins 
were effective at concentrations as low as 10 nM. It is therefore possible that 
one or more tissue kallikreins act as physiological activators of inactive renin. 
2.1.2. INTRODUCTION 
Renin activity of normal human plasma increases by a factor of 3-7 after treatment 
at pH 3.0-4.0; this is caused by the conversion of enzymatically inactive renin 
or prorenin into the active form 1- 7• Acid activation of inactive renin is a two-
stage process; renin activity increases slightly during the acidification step, but 
most of the rise in activity occurs after pH has been restored to neutral, probably 
through the action of one or more serine proteases6•8- 10• It seems unlikely that 
this pathway is operative in circulating plasma because of the inhibitory effect 
of various plasma proteins. But in vivo activation of inactive renin at the tissue 
level through a serine protease is a possibility, and there is now some evidence 
to support this. Preliminary experiments by Morris and Day11 showed increased 
renin activity of amniotic fluid after the addition of large quantities of a crude 
preparation of pancreas kallikrein. Sealey et al. 12 reported that the rate of renin 
activation in acid-treated plasma was increased after the addition of urinary 
kallikrein, which is known to originate from the kidneyl 3•14; the renin activity 
ultimately attained was not higher than that attained with acid treatment alone. 
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The possibility that kallikrein acts as an activator of inactive renin is interesting, 
since kallikrein is produced close to the site where renin is synthesized 15- 18 so 
that an effect of kallikrein on renin biosynthesis could influence renal circulation 
and sodium handling. Here we describe additional data on the activation of 
inactive renin by tissue kallikreins. We have separated inactive plasma renin 
from active renin by ion exchange chromatography and found that the inactive 
fraction could be activated at physiological pH by highly purified pancreas and 
urinary kallikreins without prior treatment with acid. 
2.1.3. MATERIALS AND METHODS 
Ion exchange chromatography. Blood from healthy male subjects was collected 
in plastic tubes containing disodium-EDTA (5 mM). Within 5 min, the blood 
was centrifuged at 8,000xg for 10 min. The plasma was immediately frozen at 
-20 C. For ion exchange chromatography, EDT A-plasma was thawed and dialyzed 
for 24 h against 0.024 M Tris/acetate buffer, pH 7.5, which contained 0.02 
M NaCl. The dialyzed plasma (30 ml) was applied to 40 x 2.6-cm columns 
of DEAE-Sepharose CL-6B (Pharmacia Fine Chemicals, Uppsala, Sweden), 
which had been equilibrated with the same buffer. Elution was performed with 
a linear gradient of NaCl up to 0.2 M. Flow rate was 20-22 mllh, and the 
eluate was collected in 5.0 - to 5.5-ml fractions. All procedures were carried 
out at 4 C. 
Activation of inactive renin by acid. Samples (2 ml) of EDT A-plasma or fractions 
isolated from plasma by ion exchange chromatography were dialyzed for 24 
hat 4 C against a glycine/ HCL buffer, pH 3.3, which contained 5mM EDTA19• 
After pH had rapidly been restored to 7.5 with 1 M NaOH the samples were 
dialyzed for various periods, as indicated, at 4 C against a phosphate buffer, 
pH 7.5, containing 1 mM EDTA19• 
Binding of kallikrein to Sepharose. Highly purified hog pancreas kallikrein 
(Kallikrein, Bayer KZ 45/32, Leverkusen, West Germany) was a gift from 
professor GL Haberland and Dr E Wischhi:ifer. This preparation had a specific 
activity of 1180 biological kallikreins units (Frey Units)/mg protein, which 
corresponds with 9.4 enzymatic units. One enzymatic unit is defined here as 
the amount of enzyme hydrolyzing 1 ,uM of the synthetic chromogenic substrate 
H-D-valyl-L-leucyl-L-arginine-p-nitroanilide (S-2266, KABI, Stockholm, Swe-
den)/min under the conditions of the spectrophotometric assay, as described 
below. Urinary kallikrein was isolated from human urine and purified according 
to Geiger et ai.2° using affinity chromatography on aprotinin-Sepharose: its 
specific activity was 6.3 enzymatic units/mg protein. Both kallikrein preparations 
were homogeneous at electrophoresis on 7.5% polyacrylamide gel at pH 8.621 • 
The enzymes were covalently bound to CNBr-activated Sepharose-4B (Pharmacia) 
at a ratio of 10 mg protein/g dry Sepharose22• The advantage of binding the 
enzymes to an insoluble carrier is that they can be removed so that they cannot 
interfere with the assay of renin. The activities of the Sepharose-bound enzymes 
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were measured through their amidolytic actions on the synthetic chromogenic 
substrate S-2266 (KABI) (23) and compared with standard solutions of unbound 
pure hog pancreas kallikrein (Kallikrein KZ 45/32). The enzyme suspensions 
(50 J.ll) in 0.2 M Tris buffer, pH 8.2, were added to 0.15 mM substrate and 
the volume was adjusted to 1.1 ml with the same buffer. The mixtures were 
slowly shaken in a water bath for 30 min at 37 C. The reaction was then stopped 
with 50% acetic acid, and absorbance at 450 nm was measured in a 1-cm 
semimicrocuvette. Identical mixtures with aprotinin (Trasylol, Bayer) added (100 
kallikrein-inhibiting units/ml incubate) served as blanks. 
Activation of inactive renin by Sepharose-bound kallikreins. The immobilized 
kallikreins were suspended in 0.1 M phosphate buffer, pH 7.5, containing 0.075 
M NaCI and 0.1 ml of the suspension was added to EDTA-plasma (1 ml) or 
to fractions (I or 2 ml) isolated from plasma by ion exchange chromatography. 
Pepsin (3000 U/mg protein:Sigma Chemical Co., St.Louis, MO, USA), which 
was bound to Sepharose in the same way as the kallikreins but which is known 
to be inactive at neutral pH, was used as a control. The suspensions were slowly 
shaken at 4 C for various periods up to 48 h, as indicated. The enzymes were 
then removed by centrifugation at 8,000 x g for 10 min. Experiments in which 
the immobilized enzymes were added to 0.15 M NaCI did not result in detectable 
renin activity. 
Assays of naturally occurring active renin and in vitro activated renin. The method 
for measuring naturally occurring active renin, which has previously been 
described3•2\ was slightly modified. Briefly, aliquots (0.1 or 0.2 ml) of EDTA-
plasma or fractions isolated from plasma by ion exchange chromatography were 
mixed with purified sheep renin substrate (final concentration, 0. 7 ,uM angiotensin 
I equivalents/liter), and the total volume was adjusted to 1.0 ml with 0.1 M 
phosphate buffer, pH 7.5, which contained 75 mM NaCL. EDTA (1 roM) was 
present in both substrate and buffer solutions. After the addition of 10 ,ul 8-
hydroxyquinoline sulfate (0.34 M), 5 ,ul phenylmethylsulfonylfluoride (0.3 M) 
in ethanol, and 10 J.d aprotinin (Trasylol, Bayer; 10,000 kallikrein-inhibiting 
units/ml), the mixtures were incubated for 3-12 h at 37 C. At the end of the 
incubation period, no more than 10% of the renin substrate had been consumed, 
and generation of angiotensin I was linear for the whole period. For measuring 
in vitro activated renin, the acid- or kallikrein-pretreated samples were similarly 
incubated with sheep renin substrate. The quantity of angiotensin I that was 
generated during incubation with renin substrate, was measured by RIA and 
compared with the quantity generated by standard human kidney renin (MRC 
standard 68/356, WHO International Laboratory for Biological Standards, Holly 
Hill, Hampstead, London, United Kingdom). With the protease (angiotensinase) 
inhibitors we have used, the recovery of angiotensin I, which was added to 
plasma after treatment with acid or kallikreins, was 98.8 ± 4.9% (mean ± sem; 
n = 15). The recovery of standard renin, which was added to the samples before 
treatment with acid or kallikreins, was 97.0 ± 4.0% (n = 15). Renin concentration 
is expressed as microunits of the renin standard (MRC standard 68/356 ) per 
mi. 
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2.1.4. RESULTS 
In contrast with acid treatment, pancreas and urinary kallikreins had no effect 
on inactive renin in whole plasma (Fig.l ). The elution profile of D EAE-Sepharose 
chromatography showed two peaks of renin activity: peak A at a sodium 
concentration of 0.060 M, and peak B at 0.110 M (Fig.2). The renin content 
of peak B was about 80% of the total quantity of naturally occurring active 
renin present in plasma. Acid treatment of this peak did not alter its renin 
activity. Acid treatment doubled the renin activity of peak A, indicating that 
this peak contained inactive renin. However, acidification of this fraction did 
not activate more than 5% of the total quantity of inactive (acid- activatable) 
renin present in the plasma. In contrast, the addition ofSepharose-bound pancreas 
kallikrein to peak A (final concentration 16 nM), led to the activation of more 
than 80% of the inactive (acid-activatable) renin present in the plasma. Similar 
results were obtained with urinary kallikrein (Fig.l). Both pancreas and urinary 
kallikreins were effective at concentrations as low as 10 nM. The kallikreins 
had no effect on the renin activity in peak B, probably because this peak did 
not contain inactive renin. The inability of added kallikreins to activate inactive 
renin in whole plasma can be explained by the presence of protease inhibitors25 • 
Thus, ion exchange chromatography has resulted in the separation of inactive 
renin from active renin as well as from inhibitors that interfere with the proteolytic 
activation of inactive renin. 
2.1.5. DISCUSSION 
The results demonstrate that pancreas and urinary kallikreins in concentrations 
as low as 10 nM are capable of activating inactive plasma renin at neutral pH 
without prior acidification. The finding with urinary kallikrein confirm and extend 
the results of Sealey et al. 12• The precise chemical relationship between active 
an,d inactive plasma renin is still unknown. While there is agreement that the 
molecular weights of both naturally occurring active renin and in vitro activated 
renin are about 44,000, there is no consensus on whether inactive ( acid-activatable) 
renin in plasma represents a higher molecular weight form4•7•26- 29 • Recent findings 
seem to indicate that the difference in molecular weight with active renin is 
small or even absent4•7• Our findings confirm the results of Shulkes et aU, who 
have shown that the active and inactive forms of renin can be readily separated 
on the basis of their difference in net electrical charge. 
The present study was restricted to tissue kallikreins. They differ in substrate 
specificity from plasma kallikrein30• Nevertheless, we have recently found that 
prekallikrein (Fletcher factor)-deficient plasma had much lower renin activity 
after acid treatment than after trypsin treatment31 , whereas in normal plasma, 
identical results were obtained with the two procedures32• This is strong evidence 
that plasma kallikrein is involved in the acid activation of the inactive renin. 
Under these artificial conditions, plasma kallikrein can unfold its action on renin, 
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Fig. 2.1.1. Activation of inactive renin as a function of time in whole plasma and in a fraction 
isolated by DEAE-Sepharose column chromatography with a linear sodium gradient. Six tubes 
(5 ml each) with the highest renin content from the renin peak which was eluated at a sodium 
concentration of about 0.06 moVl (peak A, see Fig. 2.1.2.) were pooled. Samples were treated 
as follows: 1) dialysis at pH 7.5; 2) dialysis at pH 7.5 with Sepharose-bound pancreas kallikrein, 
urinary kallikrein and pepsin. After these procedures, which were carried out at 4 C, the samples 
were incubated (3-12 h) with an excess of sheep renin substrate at pH 7.5 and 37 C for measuring 
renin. 
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Fig. 2.1.2 Separation of inactive renin (peak A) and active renin (peak B) by DEAE-Sepharose 
column chromatography. Elution was carried out with a linear sodium gradient (--). Eluates were 
treated as follows: I) dialysis at pH 7.5 (48h); 2) dialysis at pH 3.3 (24h), followed by dialysis 
at pH 7.5 (24h); or 3) incubation at pH 7.5 with Sepharose-bound pancreas kallikrein (24 h). After 
these procedures which were carried out at 4 C, the samples were incubated (3-12 h) with an excess 
of sheep renin substrate at pH 7.5 and 37 C for measuring renin. 
probably because the protease (kallikrein) inhibitors have been destroyed by 
acid. Under physiological conditions however, any newly formed kallikrein will 
be rapidly inactivated in the circulating plasma. 
The ability of tissue kallikreins to act as activators of inactive renin may 
have physiological implications. Evidence is accumulating from studies in animals 
that both hormones are produced in close anatomical association with a 
strategically important part of the nephron, the juxtaglomerular apparatus17•18• 
Intrarenal activation of inactive renin by kallikrein might therefore affect some 
aspects of renal function, particularly sodium handling. Recent observations in 
patients with renovascular hypertension have provided some evidence that inactive 
plasma renin can be activated as it passes through the kidney33 • Furthermore, 
several studies have revealed some striking quantitative correlations among 
plasma renin activity, plasma bradykinin, and urinary kallikrein. These hormones 
increased in parallel after both standing and sodium depletion34- 37• Plasma renin 
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and bradykinin were suppressed by excessive mineralocorticoid activity, whereas 
urinary kallikrein was increased37. Another link is formed by the enzyme that 
converts angiotensin I into angiotensin II. This enzyme also inactivates bra-
dykinin30. Thus, there is growing evidence from both in vitro and in vivo work 
favouring the existence of intricate relationships between two important vaso-
active systems, i.e. the renin-angiotensin system and the kallikrein-kinin system. 
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2.2. ACTIVATION OF INACTIVE PLASMA RENIN BY PLASMA AND 
TISSUE KALLIKREINS 
2.2.1. ABSTRACT 
Normal human plasma contains a pro-activator of inactive renin. The pro-
activator is activated at physiological pH in plasma that has been pretreated 
with acid. This activation in vitro leads to the conversion of inactive renin into 
the active form with simultaneous generation of kallikrein activity. The endo-
genous activator of inactive renin has the same pH profile and inhibitor spectrum 
as plasma kallikrein. Inactive renin can also be activated by exposure of plasma 
to exogenous trypsin, and in normal plasma the quantities of inactive renin 
that are activated after acidification and with trypsin are identical. Prekallikrein 
(Fletcher factor)-deficient plasma, however, has much lower renin activity after 
acidification than with trypsin. Thus acid activation of inactive renin depends 
on plasma prekallikrein, whereas the action of trypsin is independent of 
prekallikrein. Highly purified tissue (pancreatic) kallikrein, in a concentration 
of less than 20 nM, activates inactive renin that has been isolated from plasma 
by ion-exchange chromatography. In this respect it is at least 100 times more 
potent than trypsin. It is therefore possible that plasma and/or tissue (renal) 
kallikreins are also involved in the activation of inactive renin in vivo. 
2.2.2. INTRODUCTION 
Plasma and tissue kallikreins act on kininogens in plasma to form bradykinin 
and kallidin respectively. The preferred substrate for plasma kallikrein is high-
molecular-weight kininogen, whereas the tissue kallikreins react more readily 
with low-molecular-weight kininogen1. Furthermore, the formation of kallikrein 
is an early step in the cascade-like activation of proteolytic plasma factors involved 
in coagulation, fibrinolysis and complement-mediated reactions2• Here we report 
evidence that kallikreins are also capable of activating inactive renin. 
2.2.3. METHODS 
Collection of blood. Blood from 20 healthy male subjects was collected in plastic 
tubes, which contained 5 mmol of edetic acid (EDTA)/1 of blood. Within 5 
min the blood was centrifuged at 8,000 g for 10 min. The plasma was pooled 
and immediately frozen at -20 C. Plasma was also obtained from a patient with 
prekallikrein (Fletcher factor)-deficiency (less than 1% of normal). 
Ion-exchange chromatography. EDTA-treated plasma (30 ml) was dialyzed for 
24 h against 24 mM Tris/acetate buffer, pH 7.5, which contained 20 mM NaCL 
The dialyzed plasma was applied to a 2.6cm x 40cm column of DEAE-Sepharose 
CL-6B (Pharmacia, Uppsala, Sweden), which had been equilibrated against the 
same buffer. Elution was performed with a linear gradient of NaCl up to 200 
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mM. Flow rate was kept constant at 22 mllh, and the eluate was collected 
in 5.5 ml fractions. All procedures were carried out at 4 C. 
Activation and assay of renin. 
Activation of inactive renin by acid. Samples (2ml) of EDT A-treated plasma, 
or fractions, isolated from plasma by ion-exchange chromatography, were 
dialyzed for 24 h at 4 C against a glycine/HCl buffer, pH 3.3, which contained 
5 mM EDT AM. After the pH had rapidly been restored to 7.5 with 1M NaOH, 
the samples were dialyzed for another 24 h at 4 C against sodium phosphate 
buffer, pH 7.5, which contained 1 mM EDTN. The pH-dependency of renin 
activation was assessed by adjusting the pH after the first dialysis step to values 
ranging from 4.0 to 9.5, again with 1 M NaOH, followed by dialysis against 
citric acid/phosphate buffers of the same pH. In experiments where the rate 
of activation was followed, the second dialysis step was omitted, and the samples 
were kept in plastic tubes for various times at 4 C as indicated, after pH had 
been adjusted to 7.5. 
Activation of inactive renin by trypsin and kallikrein. Trypsin, 12,000 ~-N-benzoyl­
L-arginine ethyl ester (BAEE) units/mg of protein, was obtained from Sigma 
Chemical Co. Ltd, StLouis, U.S.A. Highly purified porcine pancreatic kallikrein 
was kindly supplied by Professor GL Haberland and Dr E Wischhofer (Kallikrein 
KZC 45/32, Bayer, Leverkussen, West Germany). The specific activity of this 
preparation was 1180 kallikrein units/mg of protein. The enzymes were covalently 
bound to CNBr-activated Sepharose-4B (Pharmacia) in a ratio of 10-30 mg of 
protein/g of dry Sepharose (Pharmacia). The immobilized enzymes were added 
to EDT A-treated plasma or to fractions isolated from plasma by ion exchange 
chromatography. The suspensions were slowly shaken at 4 C, for various times 
as indicated, and the enzymes were then removed by centrifugation at 8000 
g for 10 min. 
Activation of inactive renin by low temperature. Samples (2ml) of EDT A-treated 
plasma were kept in plastic tubes for various times at 4 C as indicated. 
Inhibition of activation in vitro of inactive renin. Samples (2ml) of EDT A-treated 
plasma were dialyzed for 24 h at 4 C against glycine/HCL buffer, pH 3.3. The 
pH was then restored to 7.5 with NaOH 1 M, and the samples were redialyzed 
at pH 7.5 in the presence of various protease inhibitors. The following inhibitors 
were studied: 1) aprotinin (Trasylol, Bayer); 2) soybean trypsin inhibitor (Sigma); 
3) lima bean trypsin inhibitor (Sigma); 4) trypsin inhibitor from chicken egg-
white (ovomucoid, Sigma); 5) benzamidine/HCL (Sigma). 
Assay of naturally occurring active renin. The method, which has previously been 
described\ was slightly modified. Briefly, samples (2ml) of EDT A-treated plasma 
or fractions, isolated from plasma by ion exchange chromatography, were dialyzed 
for 2x24h at 4 C against a phosphate buffer, pH 7.5, which contained 1 mM 
EDT A. Aliquots (0.1 or 0.2 ml) of the dialyzed samples were mixed with sheep 
renin substrate (concentration 6.1 Km), and the total volume was adjusted to 
1.0 ml with phosphate buffer, pH 7.5. After addition of 10 pJ of 8-hydroxy-
quinoline (0,34 M), 5 ~Ll of phenylmethylsulfonylfluoride (0,3 M) in ethanol and 
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10 J.Ll of aprotmm (10,000 kallikrein-inhibiting units/ml) the mixture was 
incubated for 3 h at 37 C. The angiotensin I that was generated during incubation 
with renin substrate was measured by RIA, and compared with that generated 
by standard human kidney renin (MRC standard 68/356). With the protease 
(angiotensinase) inhibitors we have used, recovery of angiotensin I, which was 
added to plasma after dialysis, was 98.8 ± 4.9% (n = 15). The recovery of standard 
renin, which was added to plasma before dialysis, was 97.0 ± 4.8% (n = 15). 
Assay of renin activated in vitro. After the samples had been treated with acid, 
trypsin, kallikrein or low temperature, their renin content was measured as 
described before. 
Assay of kallikrein. The method is based on the amidolytic action of plasma 
kallikrein on the synthetic chromogenic substrate H-D-propyl-phenylalanyl-L-
arginine-p-nitroanilide dihydrochloride (PPAN), as described by Claesson et al. 5• 
Kallikrein was measured in EDT A-treated plasma which had been treated with 
acid, trypsin or low temperature. Aliquots (10 or 100 ,ul) of the treated plasma 
were mixed with the chromogenic substrate (PPAN, Kabi, Stockholm, Sweden; 
concentration 3.7 Km), and the total volume was adjusted to 1.2 ml with pre-
warmed (37 C) 50 mM Trisbuffer, pH 7.5. The increase in absorbance at 405 
nm was followed for 2 min in a 1 em semi-microcuvette at 37 C. In experiments 
where the pH-dependency of kallikrein activity was assessed, the Tris buffer, 
pH 7.5, was replaced by citric acid/phosphate buffers with pH values ranging 
from 4.0 to 9.5. As mentioned before, these buffers were also used for studies 
on the pH -dependency of renin activation. The results of both sets of experiments 
could therefore be compared. 
Units for expression of results. Renin concentration is expressed as micro-units 
of the renin standard (MRC standard 68/356)/ml of plasma ( ,uU/ml). The 
concentration of inactive renin is the concentration of renin measured in plasma 
after dialysis for 24 h at pH 3.3 and subsequent dialysis for 24 h at pH 7.5 
(total renin), minus the concentration of renin measured after dialysis for 2x24h 
at pH 7.5 (active renin). Kallikrein concentration is expressed as units/ml of 
plasma (U/ml), 1 unit being the quantity of enzyme that hydrolyzes 1 ,umol 
of the synthetic substrate PP AN in 1 min at pH 7.5 and 37 C. 
2.2.4 RESULTS 
Simultaneous activation of inactive renin and prekallikrein in plasma. In plasma 
treated at pH 3.3, the activation of inactive renin occurred after pH had been 
restored to a value above 5.0. The pH-dependency of this process followed a 
bell-shaped curve, which was identical with the pH/activity curve of plasma 
kallikrein (Fig.1 ). 
Results of various activation procedures, carried out on whole plasma at 4 
C, are shown in Fig. 2. In normal plasma (Fig. 2a) both inactive renin and 
prekallikrein were simultaneously activated by either acid or trypsin treatment. 
Activation of inactive renin after acidification with subsequent restoration of 
pH to 7.5 was maximal after 16-24 h. The same maximum was reached by 
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Fig. 2.2.1. Identical pH profiles for the amidolytic action of plasma kallikrein on the substrate 
PPAN (4D) and for the activation of inactive renin (0). In this experiment prekallikrein was activated 
by exposure of normal plasma to pH 3.3 followed by restoration of pH; the procedure was the 
same as that for acid activation of renin (see text). Identical results were obtained with trypsin-
and cold-activated prekallikrein. No detectable amidolytic was generated in prekallikrein (Fletcher 
factor)-deficient plasma (see Fig. 2.2.2.), which indicates that PPAN had adequate specificity. 
treatment with trypsin at pH 7.5 for 24 h. Treatment for longer periods up 
to 72 h did not result in any further increase of renin activity. 
In contrast with normal plasma the amount of inactive renin that was activated 
in prekallikrein-deficient plasma after acidification was much smaller than with 
trypsin (Fig.2b, lower part). There was no detectable amidolytic action on the 
chromogenic substrate, PPAN, after acid or trypsin treatment of the deficient 
plasma (Fig.2b, upper part), which demonstrates that, for the purpose of our 
experiments, PPAN has adequate specificity for kallikrein. 
When normal plasma was kept at 4 C, without any other form of treatment, 
the activation of both inactive renin and prekallikrein proceeded more slowly 
(Fig.2a). Renin activity was 31 ± 6% above control after 48 h, and rose to 
45 ± 3% above control after 72 h. The differences from control were significant 
P < 0.01, paired t-test). In prekallikrein-deficient plasma no activation occured 
under these circumstances. 
29 
NORMAL FLETCHER TRAIT 
E Gu : ; 1.00 <:: "iii 0.50 ... 
== iii 0.00 e ::.:: 
1. 00 
~-----l:~,._-----tlltee o. oo 
0.50 
250 500 
200 trypsin ~00 
~ 150 
::J 300 
3-
.:: 100 200 
<:: 
Qj 
~ 
50 pH 3.3 ............ ..........._ 100 
.,. ,""' ------...____. 
0 12 24 36 48 0 12 24 36 48 
TIME OF INCUBATION AT 4°C [h) 
Fig.2.2.2. Effects of various procedures on the generation of active renin and kallikrein in normal 
plasma (M ± SEM,n = 10) and in prekallikrein (Fletcher factor)-deficient plasma. The plasma samples 
were treated as follows: 0, storage at 4 C (cold activation); e, dialysis at pH 3.3 , followed by 
dialysis at pH 7.5; and ~. incubation with trypsin (final concentration 1.2 mM. in normal plasma 
inactive renin and prekallikrein are simultaneously activated with each procedure. No active renin 
is formed in deficient plasma after storage at 4 C or at pH 7.5 after dialysis at pH 3.3 
Effects of protease inhibitors on the activation of inactive renin in plasma. Table 
1 shows the effects of protease inhibitors, which were added to acid-treated 
plasma after the pH had been restored to neutral. The inhibitor/plasma mixtures 
were kept at 4 C for 24 h. Among the substances tested, aprotinin (Trasylol), 
soybean trypsin inhibitor and benzamidine/HCl had the greatest effect on the 
activation of inactive renin. The inhibitor spectrum for renin activation was 
similar to that reported for plasma kallikrein6•7• None of the protease inhibitors 
interfered with the reaction between active renin. and its substrate. This was 
demonstrated by adding the inhibitors to known amounts of human renin (MRC 
standard 68/356) before incubation with excess of sheep renin substrate. 
Activation of inactive plasma renin by tissue kallikrein. Pancreas kallikrein, added 
to whole plasma and left there for 24 h at 4 C, did not activate inactive renin 
(Table 1). This contrasts with the findings when a semipurified preparation of 
inactive plasma renin was used instead of whole plasma. As illustrated in Fig. 
3, the elution pattern, obtained after DEAE- Sepharose column chromatopgraphy 
of plasma, showed two peaks of renin activity at sodium concentrations of 60 
mM (peak A) and 100 mM (peak B). The renin content of peak B comprised 
80-90% of the total quantity of active renin present in whole plasma. Acid 
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Table 2.2.1. Activation of inactive renin by proteases and effects of protease inhibitors. 
The same plasma pool was used in all experiments. The quantity of renin that was activated 
in whole plasma after 24 h dialysis at pH 3.3 with subsequent 24 h dialysis at pH 7.5 without 
serine protease inhibitors was taken as 100%. Acid-activatable renin in the plasma pool was 170 
ILU/ml. As stated in the text, 90-95% of the acid-activatable renin in whole plasma was calculated 
to be recovered as kallikrein-activatable renin after chromatography (concentration of added kallikrein 
in eluate approximately 120 nM). The activation of semi purified inactive renin was therefore considered 
to be complete under these circumstances. 
Protease ( 1) and 
protease inhibitors (2) 
(1) 
Kallikrein 
approx. 120 nM 
approx. 12 nM 
Kallikrein 
approx. 120 nM 
approx. 12 nM 
Trypsin 
approx. 1.2 !LM 
approx. 0.6 !LM 
Trypsin 
approx. 1.2 ILM 
approx. 0.6 !LM 
(2) 
Aprotinin 
1250 I.U./ml** 
125 I.U./ml 
Soybean trypsin inhibitor 
1250 I.U./ml 
125 I.U./ml 
Prior treatment 
of plasma 
None 
Ion-exchange 
chromatography 
(peak A)* 
None 
Ion-exchange 
chromatography 
(peak A) 
Dialysis at pH 3.3 with 
subsequent restoration 
of neutral pH 
Idem. 
Lima bean trypsin inhibitor Idem. 
1250 I.U./ml 
125 I.U./ml 
'Ovomucoid' 
1250 I.U./ml 
125 I.U./ml 
Benzamidine/HCl 
(10 mM) 
Idem. 
Idem. 
Percentage of renin No 
activated (M±SEM) 
<5 6 
<5 6 
100±5 6 
72±4 6 
102±6 6 
75±6 6 
56±6 6 
35±4 6 
11±4 16 
70±4 16 
17±9 16 
26±7 16 
87±4 4 
95±2 4 
81±4 4 
100±1 4 
20±1 4 
* This plasma fraction was eluted at a sodium concentration of 60 mM. Four 5.5 ml fractions 
of peak A (fig. 3) with the highest renin content were pooled. 
** One inhibitor unit inhibits a quantity of trypsin that will produce an absorbance at 253 nm 
of 0.001/min at pH 7.6 and 25 C, with a-N-benzoyl-L-argenine ethyl ester (BAEE) as substrate; 
reaction volume equals 3.2 ml (1 em light-path). 
treatment doubled the renin content of peak A but had no effect on peak B, 
indicating that peak A contained inactive renin. After acid treatment, however, 
only a small proportion of the total quantity of inactive renin present in peak 
A was activated, whereas addition of pancreatic kallikrein, in a concentration 
of 120 nM of eluate, had a much larger effect. The quantity of inactive renin 
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Fig. 2.2.3. Separation of inactive renin from active renin by ion-exchange chromatography of normal 
plasma and its activation with pancreatic kallikrein (final concentration approximately 120 nM 
or acid. The absorbance by plasma proteins and the sodium gradient are shown in the upper part 
of the Figure. Peaks A and B in the lower part of the Figure correspond to inactive renin and 
active renin respectively (for explanation, see the text). Fractions of the column were treated as 
follows: 0, dialysis at pH 7.5 for 2 X 24 h; e, dialysis at pH 3.3 for 24 h, followed by dialysis 
at pH 7.5 for 24 h; 0, dialysis at pH 7.5 for 24 h with subsequent incubation with kallikrein 
for 24 h; •, dialysis at pH 3.3 for 24 h with subsequent restoration of pH to 7.5 and incubation 
with kallikrein for 24 h. These procedures were carried out at 4° C. 
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that could be activated by kallikrein after ion-exchange chromatography was 
calculated to be 90-95% of the quantity that could be activated by acid in plasma 
before chromatography. This indicates that 90-95% of the acid- activatable renin 
in whole plasma is recovered as kallikrein- activatable renin after chromatop-
graphy. Kallikrein had no effect on peak B. In Table I the quantities of kallikrein 
and trypsin that were needed for the activation of inactive renin are compared. 
It can be seen that kallikrein is at least 100 times more potent. 
2.2.5 DISCUSSION 
Kallikrein-mediated activation of inactive renin. Most of the kallikrein and renin 
circulating in plasma is inactive. The activation of the kallikrein-kinin system 
may be linked with the activation of the renin-angiotensin system. The evidence 
for this is as follows: 1) prekallikrein and inactive renin in normal plasma are 
simultaneously activated after exposure of plasma to acid and subsequent 
restoration of pH, 2) the pH-dependency of the endogenous plasma enzyme 
that activates inactive renin closely parallels the pH/activity profile of kallikrein, 
3) after acidification there is little activation of inactive renin in prekallikrein-
deficient plasma, 4) substances that are known to inhibit plasma kallikrein, such 
as aprotinin, soybean trypsin inhibitor and benzamidine6•7 interfere with the 
activation of inactive renin, 5) other protease inhibitors that do not inhibit plasma 
kallikrein significantly, such as lima bean trypsin inhibitor and 'ovomucoid' 
6 
, have little effect, and 6) highly purified tissue(pancreatic) kallikrein is a potent 
activator of inactive renin, which has been isolated from plasma by ion-exchange 
chromatography. Exogenous kallikrein has no effect when added to untreated 
whole plasma, probably because of the inhibitory action of some plasma proteins2 • 
Admittedly, the procedures that active renin, also activate other plasma factors 
besides prekallikrein, and the pH-optimum curve and inhibitor spectrum of 
kallikrein are shared by several serine proteases involved in the processes of 
clotting, fibrinolysis and complement activation. Furthermore although both 
plasma kallikrein and tissue kallikrein are involved in kinin formation, their 
substrate specificity is somewhat different1• Thus we have no proof that inactive 
renin is directly activated by kallikreins. On the other hand, generation of 
kallikrein is an early step in the activation of other serine proteases in plasma2•7• 
Furthermore, in prekallikrein-deficient plasma, renin activity after acidification 
was much smaller than with trypsin, whereas, in normal plasma, the results 
with acid and trypsin were identical. This is strong evidence that acid activation 
of inactive renin depends on plasma prekallikrein. Our data therefore suggest 
that the activation of inactive renin is at least in some way linked with the 
kallikrein-kinin system. During the course of this work some preliminary data, 
which are keeping with this view, have been published8- 11 • Recently Sealey and 
coworkers11 reported that renin activity increased more rapidly when urinary 
kallikrein, which originates from the kidney , was added to acid-treated plasma 
than with acid treatment alone. Our work extends these observations in that 
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it demonstrates that inactive remn can be fully activated by tissue kallikrein 
without prior acid treatment. 
Physiological implications. The physiological importance of these data remains 
to be established, but some observations might be relevant. Active kallikrein 
is secreted by kidneys and salivary glands, and these organs also produce active 
renin 12•13 • Furthermore, there is some evidence for intrarenal activation of inactive 
renin14• Plasma bradykinin and urinary kallikrein increase when the release of 
active renin is stimulated by standing up or sodium depletion15- 17• Furthermore, 
some stimuli for plasminogen activation, such as exercise and isoprenaline 18 , 
increase the release of active renin19- 22 and may activate prekallikrein2• Possibly 
related to this is the frequent association of malignant hypertension with low-
grade disseminated intravascular coagulation and high concentrations of cir-
culating active renin23 • In the intact organism, kallikrein-mediated activation 
of proteolytic enzymes involved in clotting and fibrinolysis is thought to occur 
in close contact with the blood-vessel wall, and after their release into the 
circulation they are rapidly inactivated or removed2• This may also be true for 
components of the renin-angiotensin system, so that circulating levels of these 
hormones correlate poorly with their physiological effects. Finally, the biologically 
active endproducts of the kallikrein-kinin and renin-angiotensin systems act on 
vascular smooth muscle. Kinins are potent vasodilators, and angiotensin II is 
a potent vasoconstrictor. A direct interaction of kallikrein and renin, possibly 
in close association with the blood-vessel wall, might therefore provide a 
mechanism for blood-pressure regulation. 
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2.3. AN INTRINSIC FACTOR XII-PREKALLIKREIN DEPENDENT PATH-
WAY ACTIVATES THE HUMAN PLASMA RENIN ANGIOTENSIN 
SYSTEM 
2.3.1. RESULTS AND DISCUSSION 
Exposure of normal human plasma to an activating (negatively charged) surface 
leads to the activation of the intrinsic coagulation and fibrinolytic system and 
the generation of vasoactive peptides (kinins)1' 2 • This contact activation mecha-
nism is known to be initiated by factor XII (Hageman factor). Surface-activated 
factor XII converts prekallikrein (Fletcher factor) into kallikrein, which leads 
to further activation of factor XII. Prekallikrein circulates in plasma as a complex 
with the kallikrein substrate, high molecular weight kininogen, and the latter 
acts as a cofactor in the reciprocal activation of factor XII by kallikrein. The 
experiments described here demonstrate that the renin-angiotensin system is also 
activated by kallikrein through the factor XII-dependent pathway. 
Normally, about 80% of the renin present in plasma is in an enzymatically 
inactive form3- 5 • It is called 'inactive renin' or 'prorenin', as opposed to naturally 
occurring 'active renin'. Both forms can be separated by ion exchange chro-
matography6. Inactive renin is converted into the active form by limited proteolysis 
at neutral pH, either in acid-pretreated plasma by one or more endogenous 
serine proteases7- 9 and by urinary (renal) kallikrein10, or in untreated plasma 
With exogenous trypsin5- 9• Active renin is also formed during prolonged exposure 
cif plasma to low temperature ( cryoactivation)11 • 
Recent reports have suggested that factor XII and prekallikrein might be 
involved in the generation of active renin, but the results were contradictory12- 13• 
To investigate the possible involvement of the factor XII-dependent pathway 
in the activation of prorenin, we treated normal plasma (n = 10), factor XII-
deficient plasma (n = 2) and prekallikrein-deficient plasma (n = 1) by 1) dialysis 
at pH 3.3 and 4 C for 24 h with subsequent restoration of pH to 7.5 1\ or 
2) incubation with Sepharose-bound trypsin at pH 7.5 and 4 C . Renin was 
then measured by radioimmunoassay of angiotensin I formed after incubation 
of the plasma samples with an excess of purified sheep renin substrate at pH 
7.5 and 37 C for 3 h4• Results in normal plasma showed identical amounts 
of activated renin after acid or trypsin treatment (Fig. 1, left-hand scale). Smaller 
increments of active renin were obtained during cryoactivation. In plasma from 
patients with Hageman trait, levels of naturally occurring active renin were 17 
and 21 J.tU/ml, and those of inactive (trypsin-activatable) renin were 180 and 
210 MU/ml. These values wer_e within the normal range found in our laboratory, 
which is 12-45 J.tU/ml for active renin and 70-230 J.tU/ml for inactive renin 
(n = 25). In samples from the patient with Fletcher trait, active renin was low 
8.4 MU/ml, but inactive renin was markedly elevated, 510 MU/ml. In contrast 
to normal plasma, both factor XII- and prekallikrein-deficient plasma generated 
small amounts of active renin after acidification, whereas trypsin generated normal 
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Fig. 2.3.1. Generation of active renin and kallikrein in normal plasma (mean ± sem, n = 10), 
prekallikrein (Fletcher factor)-deficient plasma and factor XII (Hageman factor)-deficient plasma. 
Two procedures were used: acidification and addition of trypsin.Plasma, which contained 5 mM 
EDTA, was acidified (------) by dialysis against 0.15 M glycine/HCl buffer of pH 3.3 for 24 h 14• 
The pH was then restored to pH 47.5 with 1 M NaOH, and the generation of active renin and 
kallikrein was followed for 1-72 h (e-e). Trypsin (14,000 BAEE units per mg protein (Sigma) 
was covalently bound to CNBr-activated Sepharose (Pharmacia) in a ratio of 10 mg protein per 
g dry Sepharose. The immobilized enzyme was added to the plasma(~-~) at a final concentration 
of 3,000 BAEE units per ml. After 1-48 h it was removed by centrifugation.All these procedures 
were carried out at 4 C. Plasma that was kept at 4 C without any other form of treatment served 
as a control (0 0). Pretreated and control plasma samples were then assayed for renin and kallikrein 
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activity. For renin measurements the samples were incubated with purified sheep renin substrate 
(final concentration 6. 7 x Km)4 at pH 7.5 and 37 C for 3 h in the presence of the following protease 
inhibitors: 5 mM EDTA,3 mM phenylmethylsulphonylfluoride, 3.4 mM &-hydroxyquinoline and 
aprotonin (Bayer) at a concentration of 100 kallikrein-inhibiting units per m1 of incubate. The 
increment of renin after 48 h exposure to trypsin was taken as 100 % activation. Kallikrein was 
measured as amido1ytic activity using the chromogenic substrate ester H-D-Pro-Phe-Arg-p-nitro-
ani1ide (PPAN, Kabi) as a substrate16 • Plasma (15 "1) was mixed at 37 C with 815 "1 Tris buffer 
of pH 7.5 and 200 ul 4.1 mM PPAN. The linear release of p-nitroanilide was followed at 405 
nm for 1-2 min in a 1-cm semi-microcuvette at 37 C. Complete activation of prekallikrein was 
obtained by mixing 100 "I of the untreated plasma with 100 "I dextran sulphate 25 mg/1 18.After 
7 min incubation at 4 C, 30 "! of the mixture was added to 800 "I Tris buffer and 200 "I PP AN, 
and kallikrein was measured as before. The values obtained after dialysis at pH 3.3 and restoration 
of pH to 7.5 and with trypsin were expressed as a percentage of total activatable pre kallikrein 
as obtained with dextran sulphate. Lineweaver-Burk plots for the reactions of acid-activated renin, 
trypsin-activated renin and naturally occurring active renin with sheep renin substrate (1 h incubation) 
gave identical Km values (0.06 "M). Thus, the increase of renin activity after acidification and 
with trypsin is caused by a parallel change in the number of molecules of active renin rather than 
by changes in the enzymatic activity per molecule of active renin. When untreated normal plasma 
was kept at 4 C, small increments in renin and kallikrein activity were observed (P < 0.001 for 
difference of values at 72 h from those at 0 h). Prekallikrein and factor XII were isolated from 
normal human plasma and purified 19• They were added to, respectivily, prekallikrein-deficient plasma 
(final concentration of prekallikrein 50 "g/ml) and factor XII-deficient plasma (final concentration 
of factor XII 28 "g/ml). Deficient plasmas to which Tris buffer of pH 7.5 was added, instead 
of prekallikrein or factor XII, served as controls. The reconstituted plasmas and controls were 
treated by dialysis at pH 3.3 for 24 h, and the renin and kallikrein activities were measured 24 
h after the pH had been stored to 7.5 (results indicated by arrows). 
or increased amounts. There was no detectable cryoactivation of renin in the 
deficient plasmas. This suggested that acid activation and cryoactivation of plasma 
renin depend on the presence of both factor XII and prekallikrein. 
Further experiments substantiated this hypothesis. Reconstitution of factor 
XII-deficient plasma and prekallikrein-deficient plasma with, respectively, pu-
rified factor XII and prekallikrein resulted in a correction of the generation 
of active renin after acidification. Prekallikrein in normal plasma is conyerted 
into active kallikrein after exposure of the plasma to low pH, trypsin or low 
temperature ( cryoactivation)15 • Simultaneous determinations of renin and kal-
likrein measured as amidolytic activity16 showed parallel increments of both 
activities (Fig. I, right-hand scale). 
The acid-activation of prekallikrein was confirmed by the parallel cleavage 
of 125 !-labeled prekallikrein added to normal plasma before acidification (Fig.2). 
Previous experiments in which the activation of prekallikrein by activated factor 
XII was studied had shown that the generation of kallikrein activity was directly 
correlated with the extent of proteolytic cleavage17• Analysis of the reaction 
mixture by SDS-polyacrylamide gel electrophoresis in the presence of reducing 
agents demonstrated that the disappearance of prekallikrein of apparent mo-
lecular weight 85,000 was associated with the simultaneous generation of cleavage 
fragments; the major radiolabeled fragment had an apparent molecular weight 
of 52,000. 
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Fig. 2.3.2. Cleavage of 125 I-prekallikrein in acid-pretreated normal plasma. Prekallikrein was isolated 
from normal plasma19 and labelled by the method of Bolton and Hunter20• 125 I- prekallikrein ( 
2.7 JLCi in 15 JLl) was added to 600 JLl normal plasma. The mixture was dialyzed at pH 3.3 for 
24 h. Immediately (0 h) after restoration of pH to 7.5 with 1 M NaOH, and 4-48 h later, the 
reaction mixtures were analysed for the presence of cleavage products of 125 I-prekallikrein (left) 
and for the kallikrein and renin activity (right). After reduction by ,8-mercaptoethanol the reaction 
mixture was subjected to SDS-polyacrylamide gel (7.5 %) electrophoresis. The gels were sliced and 
the radioactivity in each slice (1.2 mm) was counted. The appearance of cleavage products with 
an apparent molecular weight of 52,000 indicates activation of prekallikrein17• 
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Fig. 2.3.3. Generation of active renin in prekallikrein (Fletcher factor)-deficient plasma and factor 
XII (Hageman factor)-deficient plasma. Plasma was treated with Sepharose-bound trypsin at pH 
7.5 and 4 C for 48 h or was dialyzed at pH 3.3 for 24 h followed by dialysis at pH 7.5 and, 
4 C for 24 h. Factor ,8-XIIa (final concentration 10 ~g/ml) was added to prekallikrein-deficient 
plasma after 24 hdialysis of the plasma at pH 3.3 and restoration of pH to 7.5. Plasma kallikrein 
(final concentration 32 ~g/ml) was added to factor XII-deficient plasma again after 24 h dialysis 
of the plasma at pH 3.3 and restoration of pH to 7.5. The mixtures were incubated at 4 C for 
24 h. Factor ,8-XIIa (600 ~g/ml) (from Dr John Griffin) gave a single band on SDS- polyacrylamide 
gel electrophoresis with an apparent Mr of 28,000. Kallikrein (200 ~g/ml) was prepared by activation 
of plasma prekallikrein by factor ,8-XIIa and was separated from factor ,8-XIIa by DEAE-Sephadex 
chromatography at pH 8.25. 19 
Addition of a physiological amount of purified plasma kallikrein to factor 
XU-deficient plasma after the acidification step, caused complete activation of 
inactive renin (Fig.3). Active factor XII fragment (,8-XIIa) in a physiological 
concentration, however, was not capable of generating active renin in prekal-
likrein-deficient plasma. This indicates that in the factor XU-dependent pathway, 
plasma kallikrein is the major activator of inactive renin. The factor XII 
dependency can be explained by the capacity of this factor to convert plasma 
prekallikrein into kallikrein. 
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We conclude that factor XII and prekallikrein are part of an endogenous 
pathway that activates renin in vitro. It is of interest that inactive (trypsin-
activatable) plasma renin was grossly elevated in the patient with Fletcher trait, 
whereas his plasma level of naturally occurring active renin was abnormally 
low. This may indicate that the the factor XII-prekallikrein pathway is also 
important for the activation of renin in vivo. Possibly, inactive renin that is 
adsorbed or bound to the blood vessel wall, at sites that are inaccessible to 
circulating protease inhibitors, is activated through this pathway. The reported 
activation of prorenin after the addition of renal kallikrein to acid-pretreated 
plasma10, suggest a further analogy with the clotting and fibrinolytic systems: 
plasma kallikrein is part of an intrinsic pathway for activating the renin-
angiotensin system, whereas tissue (renal) kallikrein might be involved in extrinsic 
activation. 
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2.4. PLASMA KALLIKREIN AND PLASMIN AS ACTIVATORS OF 
PRORENIN: LINKS BETWEEN THE RENIN-ANGIOTENSIN SYSTEM 
AND OTHER PROTEOLYTIC SYSTEMS IN PLASMA 
2.4.1. RENIN AND PRORENIN 
Renin is a circulating proteolytic enzyme acting at the physiological pH of blood; 
a circulating inhibitor of this enzyme has not been identified. Therefore, most 
studies on the biological significance of renin are based on the classical model 
of a circulating hormone. Renin, however, does not act on cellular receptors; 
it acts by virtue of its enzymatic activity. 
Evidence has accumulated in recent years that a proportion of the renin in 
human plasma has little or no enzymatic activity. About 80 % of the total 
potential renin activity of normal plasma is in this inactive form1-4• Possibly 
we are dealing here with a proenzyme comparable with the proenzymes that 
are activated by limited proteolysis in important physiological processes, such 
as coagulation, fibrinolysis, inflammatory responses and complement-mediated 
reactions. Usually, these processes are initiated in close contact with the blood 
vessel wall and not in circulating plasma. This could also apply to the renin-
angiotensin system, so that the circulating renin activity is not always a good 
index for the biological activity of the system. The traditional endocrinologist's 
view on renin is perhaps too limited. 
Inactive renin can be separated from active renin by ion exchange chroma-
tography5·6 and by affinity chromatography with pepstatin and certain dye 
ligands7• As will be discussed inactive renin is converted (activated) in vitro into 
an active form of renin by various proteinases. Plasma renin that is activated 
in vitro, naturally occurring active plasma renin and renin isolated from human 
kidneys as described by Haas, Goldblatt and Gibson8 have similar properties, 
in terms of pH optimum, Km and inhibitory effects of pepstatin9- 12. It is not 
certain, however, that inactive renin in plasma is a precursor of active renin 
in the course of its biosynthesis. Despite this uncertainty we will use here the 
term prorenin, because this form of renin has potential renin activity; its reacts, 
after activation, with natural renin-substrate to form angiotensin I. 
Our knowledge of the biochemistry of prorenin is still preliminary. It may 
or may not represent a single molecular entity. A completely inactive form of 
renin has been isolated from plasma7 but other forms of prorenin with some 
enzymatic activity before full activation may exist13. There is much debate on 
differences between prorenin, naturally occurring active renin and active renin 
generated in vitro, in terms of molecular weight and chromatographic beha-
viour4-16. Here we shall not discuss these questions but rather focus on the 
proteolytic enzymes , particularly the enzymes present in plasma, that are involved 
in the various pathways of prorenin activation in vitro. We shall consider the 
possible significance of these pathways in vivo. 
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2.4.2. INTRINSIC, EXTRINSIC AND EXOGENOUS PRORENIN ACTIVATORS 
The term activator is used here to designate proteolytic enzymes that are capable 
of activating prorenin in crude plasma or in partly purified fractions prepared 
from plasma. The use of this term therefore does not imply that such an activator 
directly acts on prorenin. 
2.4.2.1. INTRINSIC ACTIVATORS 
Factor XII kallikrein pathway. The renin activity of human plasma is increased 
after 24 h-dialysis at pH 3.3 with subsequent restoration ofpH2• This also applies 
to human amniotic fluid. Lumbers 1 and Morris and Lumbers17 were the first 
to show that this process of 'acid-activation', which is now known to be caused 
by conversion of prorenin into an active form of renin, is dependent on one 
or more proteolytic enzymes. The renin activity of plasma also increases during 
exposure of plasma to -4 C. Tatemichi and Osmond 18 have provided some evidence 
that this process of 'cryo-activation' depends on clotting factor XII (Hageman 
factor). Thus renin activity did not rise in Hageman-trait plasma. Experiments, 
in which serine proteinase inhibitors were added to plasma in the neutral phase 
after pH 3.3-dialysis, have subsequently shown that one or more serine proteinases 
are responsible for the increase in renin activity19- 21 • Studies carried out inde-
pendently by Derkx, Bouma, Schalekamp & Schalekamp22 and by Sealey, Atlas, 
Laragh, Silverberg & Kaplan23 have demonstrated that both factor XII and 
prekallikrein (Fletcher factor) are involved here; the renin activity of Hageman-
trait plasma and Fletcher-trait plasma did not rise in the neutral phase after 
pH 3.3-dialysis, whereas it rose after addition of trypsin, which seems to act 
on pro renin independently of factor XII and plasma kallikrein (Fig. 1 ). By adding 
active factor XII fragment (factor /1-XIIa, Mr 28,000) and highly purified plasma 
kallikrein (obtained by factor /1-XIIa-activation of prekallikrein) to acid-pre-
treated Fletcher-trait plasma and acid-pretreated Hageman-trait plasma respec-
tively, it could be demonstrated that kallikrein was the more direct activator 
of prorenin in this pathway. The factor XU-dependency of prorenin activation 
can be readily explained by the capability of this factor to convert plasma 
prekallikrein into kallikrein (Fig. 2). 
CcEsterase inhibitor and oa-macroglobulin are the most important inhibitors 
of kallikrein in plasma. The former is activated at pH 4.5-5.0. After treatment 
of plasma at this pH, however, little activation of prorenin is observed. a2-
Macroglobulin is inactivated at pH 3.0-3.5 and this coincides with the generation 
of uninhibited kallikrein and the formation of active renin after pH has been 
restored24• It is possible that acid treatment is not only required for the generation 
of enough uninhibited kallikrein, and possibly other proteinases, but also for 
rendering the prorenin more susceptible to activation by these proteinases25 • 
Plasmin. This also is an intrinsic activator of prorenin26 • a2-Antiplasmin is 
the most important inhibitor of plasmin in human plasma. It is inactivated at 
pH 5.5-6.024• After dialysis of plasma at pH 4.0 for 24h and subsequent restoration 
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Fig. 2.4.1. Activation of prorenin (mean values) at 4°C in normal plasma (n=5), normal plasma 
from which plasminogen was removed by affinity chromatography on lysine-Sepharose as described 
by Deutsch & Mertz [29] (n= 4), factor XU-deficient plasma (Hageman-trait, n=2) and pre kallikrein-
deficient plasma (Fletcher-trait, n=2). Plasmas contained EDTA in a total concentration of 5 mmoll 
L (a) Plasmas were dialyzed against phosphate buffer of pH 7.5, made up 0.15 moll! with NaCl, 
and stored at 4°C for various time periods as indicated. (b) Plasmas were treated with trypsin 
and with acid. Trypsin treatment: plasmas were dialyzed against phosphate buffer of pH 7.5, made 
up 0.15 mol/1 with NaaCl, and incubated at 4°C with Sepharose-bound trypsin in a final concentration 
of 3000 a-N-benzoyl-L-arginine ethyl ester units/ml [22, 27] for various time periods as indicated. 
Acid treatment: plasmas were dialyzed at 4°C for 24 h against glycine/HCl buffer of pH 3.3, made 
up 0.15 moll! with NaCl. The pH was then restored to 7.5 with NaOH solution (1.0 mol/1) and 
the plasmas were stored at 4°C for various time periods as indicated. (c) Plasmas were dialyzed 
at 4°C for 24 h against glycine/HCl buffer of pH 4.0, made up 0.15 molll with NaCL At this 
pH a 2-antiplasmin is destroyed. The pH was then restored to 7.5 with NaOH solution (1.0 moll 
I) and the plasmas were incubated at 4°C with urokinase in a final concentration of 1000 Ploug 
units/ml [27] for various time periods as indicated. 
of pH a2-antiplasmin is not detectable any more, but there is little increase 
in renin activity. In contrast, large quantities of active renin are generated in 
pH 4.0-pretreated plasma after the addition of plasmin or the plasminogen 
activators, streptokinase and urokinase27 (Fig. 1 ). By affinity chromatography 
on Cibacron-blue Sepharose columns, using a 0.02 M phosphate buffer of pH 
7.1, containing 0.2 M NaCl, for elution, we have isolated from plasma a fraction 
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which contained practically all the prorenin and plasminogen present in crude 
plasma. This fraction was virtually free of active renin and plasmin inhibitors. 
Addition of streptokinase, urokinase and highly purified plasminogen activator 
isolated from human uterine tissue28 all led to the activation of prorenin. The 
plasminogen activators did indeed act via generation of plasmin; after removal 
of plasminogen by lysine-Sepharose affinity chromatography29 the plasminogen 
activators had no effect on renin activity (Fig. 1). 
Interactions of plasmin and the factor XII-kallikrein pathway. Experiments with 
purified factors have demonstrated that plasmin is capable of activating factor 
XII and that kallikrein can activate plasminogen. The factor XII-kallikrein 
pathway for prorenin activation, however, can proceed in the absence of plasmin23 • 
Moreover, plasmin-mediated pro renin activation can proceed in the absence of 
factor XII and kallikrein27 (Fig.l ). Kallikrein, via activation of prekallikrein 
by factor XII, and plasmin are the only intrinsic prorenin activators identified 
as yet, but there is no proof that these activators act directly on prorenin. Possibly, 
intermediate steps will be discovered. 
Fig. 2 gives a schematic representation of the intrinsic pathways of prorenin 
activation and their possible connections with other proteolytic processes. The 
discovery that prorenin is activated via the factor XII-kallikrein pathway links 
the renin-angiotensin system with the surface-mediated reactions of coagulation, 
fibrinolysis and kinin formation30• Both prekallikrein and factor XI circulate 
in plasma as complexes with the kallikrein-substrate, high molecular weight 
~ 
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Fig. 2.4.2. Factor XU-kallikrein and plasmin pathways of prorenin activation; connections with 
coagulation, fibrinolysis and kinin formation. 
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kininogen. Factor XII and kallikrein reciprocally activate one another in a positive 
feedback mechanism that also requires high molecular weight kininogen. Initial 
activation of factor XII may occur on exposure to negatively charged surfaces 
such as vascular basement membrane. Activated factor XII then triggers the 
cascades of coagulation and fibrinolysis. The biochemistry of these surface-
mediated reactions ha been reviewed31 • 
2.4.2.2. EXTRINSIC ACTIVATORS 
Glandular kallikrein. Two types of kallikrein are to be distinguished, plasma 
kallikrein and glandular kallikrein. High molecular weight kininogen is the 
preferred substrate for plasma kallikrein, and the product is bradykinin. Glan-
dular kallikrein is found in exocrine glands and in the kidney. It is about equally 
active on low- and high molecular weight kininogen of plasma and the product 
is lysylbradykinin. 
Sealey, Atlas, Laragh, Oza & Ryan32 have demonstrated that glandular 
kallikrein, isolated from urine, is capable of activating prorenin at neutral pH 
in pH 3.3-pretreated human plasma. It has subsequently been shown that 
activation of pro renin by glandular kallikrein does not require prior acidification 
of prorenin33• 
Renal kallikrein has been localized to the distal tubule, possibly including 
the macula densa. This would favour an interaction with renin. Furthermore 
some kallikrein is released in the perfusate of isolated kidneys and small quantities 
of immunoreactive glandular kallikrein have been detected in plasma. However, 
immunochemical staining of kallikrein in the kidney was most intense on the 
luminal surface of tubular cells, whereas renin is localized in the afferent arteriole. 
This localization would indicate that these enzymes are released into urine and 
blood respectively, so that both proteins should never meet. For a more detailed 
discussion on renal kallikrein the reader is referred to Carretero & Scic1P4 and 
Keiser35 • 
Vascular plasminogen activator. We have already mentioned that tissue pla-
sminogen activator, which is probably similar or identical with the vascular 
activator (see the review by Collen36 ), is capable of initiating plasmin-mediated 
pro renin activation. This is an interesting observation since the release of vascular 
activator is increased by stimuli that are also known to increase the renin activity 
of plasma. We will come back to this in a later section of this review. 
2.4.2.3. EXOGENOUS ACTIVATORS 
Trypsin is now often used for the conversion of prorenin into active renin 
in crude plasma in vitro as a first step in measuring prorenin37- 39• The acid 
proteinases, pepsin and cathepsin D, also are capable of activating prorenin40 • 
The effect of these exogenous proteinases on the renin activity of plasma does 
not seem to be mediated by the intrinsic prorenin activators, kallikrein and 
plasmin. We have already mentioned streptokinase and urokinase as exogenous 
initiators of plasmin-mediated prorenin activation. 
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2.4.3. MEASUREMENT OF PLASMA PRORENIN 
A direct assay specific for prorenin is not available. As yet, prorenin can only 
be measured after it has been converted into active renin and the conversion 
has to be complete to obtain a valid estimate. Kinetic studies on the activation 
of prorenin in crude plasma by trypsin, plasma kallikrein (after pH 3.3-dialysis, 
which causes inactivation of C 1-esterase inhibitor and a2-macroglobulin and 
plasmin (after pH 4.0-dialysis, which causes inactivation of a2-antiplasmin) have 
demonstrated that under optimal conditions the same plateau of renin activity 
is reached (Fig. 1). These data indicate that all the prorenin that can be converted 
by serine proteinase is indeed converted under these circumstances. 
It is generally held that equimolar amounts of naturally occurring active renin 
and prorenin that is activated in vitro are equally active, but this has still to 
be proven. With this caveat, the difference between the concentrations of 'total' 
renin and naturally occurring active renin is considered an estimate of the pro renin 
concentration. A difficulty arises when the difference is either small or very 
large. For instance, the plasma concentration of renin in a normal individual 
in the recumbent position may be 20 ,uU/ml (with human kidney renin as a 
standard for expressing activity as described by Bangham et al. 41 before activation 
in vitro, and 120 ,uU/ml after activation. The prorenin concentration is then 
calculated to be 100 ,uU/ml. After this individual has assumed the upright posture, 
his naturally occurring renin may rise by 10 ,uU/ml, a 50% change. If we assume 
that this increase is caused by prorenin into active renin conversion, and if 
we also assume that equimolar quantities of naturally occurring active renin 
and pro renin activated in vitro are equally active, then the calculated concentration 
of prorenin will have decreased from 100 to 90 ,uU/ml, a 10% change, which 
is hard to detect. 
2.4.4. ACTIVATION OF PRORENININ VIVO: DOES IT OCCUR? 
Parallel measurements of 'total' renin and naturally occurring active renin in 
plasma suggested a fall in prorenin in hypertensive subjects after heap-up tilting 
and after intravenous injection ofthe potent vasodilator, diazoxide3; these stimuli 
caused a rapid rise of active renin in plasma. Similar responses to upright posture 
and intravenous injection of the potent diuretic, frusemide, have been observed 
by Weinberger, Aoi & Grim42 and Munday, Noble & Richards43 respectively. 
However other investigators using the competitive angiotensin II antagonist, 
saralasin, or the angiotensin !-converting enzyme inhibitor, captopril, did not 
find that an increase of active renin was associated with decreased prorenin4,44• 
Measurements of renal artery and vein samples before and after intravenous 
diazoxide in patients with renal artery stenosis have shown that the renal vein/ 
artery ratio for measured prorenin on the side of stenosis fell from a value 
not significantly different from 1.0 a value below 1.0, while the renal vein/ 
artery ratio for active renin was significantly above 1.0 and rose after diazoxide45 • 
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A renal vein/artery ratio for prorenin below 1.0 combined with an elevated 
renal vein/artery ratio for active renin on the affected side has also been observed 
in another series of patients with renal artery stenosis46. These findings are 
consistent with conversion of plasma prorenin into active renin as it is passing 
through the kidney. However, parallel increments of both forms of renin have 
been measured in the renal vein after isoprenaline and frusemide in anaesthetized 
pigs47_ 
Administration of the beta-adrenocepter antagonists, propranolol and met-
oprolol, causes a decrease of active renin in plasma and there are reports that 
this is associated with increased prorenin (3,48,49). Propranolol is also capable 
of preventing the rise of active renin and the fall in prorenin after diazoxide45 . 
These findings suggest that the activation of prorenin might be under adrenergic 
control. 
From the above studies it has also become clear that the plasma levels of 
naturally occurring active renin and prorenin are positively correlated under 
steady-state conditions both in normal subjects and in patients with different 
disorders. However, prorenin varies widely for a given level of active renin, 
possibly indicating varying degrees of activation. 
Taken together there is suggestive evidence, but no proof, that the activation 
of prorenin in vivo, inside or outside the kidney, really occurs. 
2.4.5. POSSIBLE ROLE IN VIVO FOR PLASMA KALLIKREIN AND PLASMIN 
IN PRORENIN ACTIVATION 
It is often suggested that the coagulation and fibrinolytic cascades are continuously 
active in vivo and that both systems are in a dynamic equilibrium to maintain 
an intact and patent vascular bed. A similar balance may exist between the 
renin-angiotensin system and the kallikrein-kinin system with their opposite 
effects on vascular smooth muscle tone. The presence of circulating angiotensin 
I and II and circulating bradykinin is good evidence that the renin and kallikrein 
systems are active in vivo. Moreover, a close and positive correlation between 
plasma renin activity and bradykinin has been observed in normal subjects with 
widely different intakes of sodium and potassium and with adrenocorticotropic 
hormone-induced hyperaldosteronism50. Conversely, the evidence for continuous 
low grade coagulation and fibrinolysis is controversial. 
It is possible that small quantities of kallikrein and plasmin are continuously 
formed not so much in the circulating plasma, but rather on the inner surface 
of blood vessels. At this site the activators might be less accessible and also 
less susceptible to circulating inhibitors. Binding of factor XII and the high 
molecular weight kininogen-prekallikrein complex to a negatively charged surface 
is known to enhance the reciprocal activation of factor XII and prekallikrein, 
so that the activation process can proceed in the presence of inhibitors in the 
surrounding fluid phase. In an analogous way plasmin molecules that are bound 
to fibrin and are actively degrading fibrin are inactivated by a2-antiplasmin 
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at a much slower rate than free plasmin, since they have both their active site 
and their a2-antiplasmin-binding sites protected from the inhibitor. The vascular 
plasminogen activator is also strongly bound to fibrin and this favours efficient 
activation of fibrin-bound plasminogen31•36• 
In the light of this knowledge we propose the following hypothesis of pro renin 
activation. Plasma prorenin is bound to the wall of certain blood vessels, perhaps 
including the glomerular capillaries. When conditions are favourable for low-
grade activation of prekallikrein or plasminogen, enough activator is generated 
to convert blood vessel-bound prorenin into active renin. There is indeed, both 
direct and indirect evidence for the existence of vessel wall renin, which is capable 
of increasing smooth muscle tone via local angiotensin II formation (see the 
review by Swales51). 
Evidence that the plasma kallikrein might be involved for the activation of 
prorenin in vivo is provided by the measurements of naturally occurring active 
and trypsin-activatable prorenin in subjects with Fletcher-trait (prekallikrein-
deficiency). Such measurements have shown that the proportion of plasma renin 
that is in the active form is abnormally low in these subjects, whereas prorenin 
is abnormally high22•23•52• Moreover, a positive correlation has been reported 
between the concentration of plasma prekallikrein and the proportions of plasma 
renin that is in the active form in normal subjects with varying degrees of sodium 
depletion 53• 
Strenuous exercise, ,8-adrenoceptor stimulation and oestrogens are known to 
stimulate the release of vascular plasminogen activator. The increase in fibrinolytic 
activity observed after intravenous injections of the diuretic, frusemide, probably 
also depends on the release of vascular activator54• The same stimuli are known 
to increase the renin activity of plasma. Interestingly, the effect of frusemide 
on the fibrinolytic activity of plasma was not seen in nephrectomized subjects, 
and it has therefore been suggested that the diuretic induces the liberation of 
fibrinolytic activator from the vessel wall in the kidney. 
It is conceivable that the parallel stimulation of renin activity and the fibrinolytic 
activity is somehow related to the plasmin-mediated prorenin activation. Redlin, 
Loh & Osmond55 have found that the exercise-induced rise in plasma renin 
activity of women on oral contraceptive medication was associated with increased 
plasminogen activator and a rise in the proportion of active renin to prorenin. 
This proportion also increased after contraceptive medication alone. These data 
indeed indicate some link between fibrinolysis and prorenin activation. 
Admittedly, the evidence so far that kallikrein and plasmin are involved in 
prorenin activation in vivo is only circumstantial, but the data that have been 
collected are encouraging and will stimulate investigators to persue this new 
approach to the renin-angiotensin system. 
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3. PRORENIN-RENIN CONVERSION; ROLE OF 
INHIBITORS 
3.1. PLASMA KALLIKREIN-MEDIATED ACTIVATION OF THE RENIN-
ANGIOTENSIN SYSTEM DOES NOT REQUIRE PRIOR ACIDIFICA-
TION OF PRORENIN 
3.1.1 ABSTRACT 
Activation of prorenin in the neutral phase after pH 3.3 dialysis of plasma depends 
on clotting factor XU-initiated prekallikrein to kallikrein conversion. Acid dialysis 
may be necessary for destroying kallikrein inhibitors or rendering prorenin 
susceptible to attack by kallikrein. If the latter possibility proves true, it is difficult 
to see how the factor XU-kallikrein pathway could activate prorenin in vivo. 
Plasma prorenin was therefore separated from active renin and from the protease 
inhibitors a 2-macroglobulin, Ccinactivator, acantitrypsin, inter-a-trypsin inhi-
bitor, and antithrombin III by gel filtration on Sephadex G-100 and affinity 
chromatography on Blue Sepharose CL-6B at neutral pH. The resulting prorenin 
preparation could be activated at pH 7.5 by highly purified human plasma 
kallikrein, which was prepared from prekallikrein by activation with active factor 
XII fragment /3-factor Xlla. Activation proceeded at 4 and 37 C at a kallikrein 
concentration of 2 ~tglml, which is approximately 5% of the prekallikrein 
concentration in normal plasma. It appears that an acid-induced conformational 
change is not required for its activation by plasma kallikrein. 
3.1.2. INTRODUCTION 
Various enzymes circulate in plasma as inactive precursors. They are activated 
in important physiological processes, such as coagulation and fibrinolysis. 
Usually, the activation does not occur in circulating plasma but in close proximity 
to the blood vessel wall at sites where conditions favor rapid activation without 
interference by inhibitors, which are present in large quantities in the fluid phase1,2. 
A major proportion of renin in plasma is also in an inactive form. This form 
is often called prorenin, but it is not certain that inactive renin is a precursor 
of naturally occurring active renin. 
Prorenin is converted in vitro to renin after acid treatment of plasma. 
Independent studies by Sealey et aP and by our group4•5 have demonstrated 
that endogenous activation of prorenin in the neutral phase after pH 3.3 dialysis 
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of plasma depends on clotting factor XU-initiated prekallikrein to kallikrein 
conversion. 
It has recently been claimed that the acidification is necessary for rendering 
the prorenin molecule susceptible to attack by kallikrein6• Another possibility 
is that acid pretreatment is a necessary first step in prorenin activation, because 
various inhibitors of kallikrein and other proteases are inactivated in plasma 
at low pH. If it is true that an acid-induced conformational change of the pro renin 
molecule is essential for factor XU-kallikrein-mediated conversion to renin, it 
is difficult to see how this pathway of prorenin activation could be operative 
in vivo. 
In view of this uncertainty, we have separated prorenin from protease inhibitors 
of plasma by nonaggressive methods and assessed the effect of purified plasma 
kallikrein on this preparation of prorenin. The experiments were carried out 
at neutral pH. 
3.1.3. MATERIALS AND METHODS 
Collection of plasma. Blood samples from five healthy male volunteers were 
collected into plastic tubes containing EDT A (final concentration, 5 mM). The 
blood was pooled and immediately centrifuged at 8,000 x g for 10 min. Plasma 
was stored at - 20 C. The concentration of renin and prorenin were 33 ± 2 
and 230 ± 21 JLU/ml, respectively (mean± SD; n = 6). 
Isolation of prorenin. Prorenin was separated from protease inhibitors and 
from renin by gel filtration of plasma followed by dye-ligand affinity chroma-
tography. Plasma (4 ml) was applied to a 2.6 x 90-cm column of Sephadex 
G-100 (Pharmacia, Uppsala, Sweden) equilibrated with 0.01 M Tris/HCl buffer, 
pH 7.0, containing 0.15 M NaCl and 1 mM EDTA. The same buffer was used 
for elution. The flow rate was adjusted to 10 mllh, and 2.5 ml fractions were 
collected. The column was calibrated with the following molecular weight markers 
(Pharmacia): ribonuclease A (Mr 13,700), ovalbumin (Mr 43,000), and serum 
albumin (Mr 67,000). Blue dextran (Pharmacia) was used for determining void 
volume. Six fractions at the top of the prorenin peak were pooled and desalted 
on a 1.6 x 90-cm column of Sephadex G-25 (Pharmacia) with 0.02 M sodium 
phosphate buffer, pH 7.1. The desalted prorenin preparation (20 ml) was applied 
to a 1.6 x 24-cm column of Blue Sepharose CL-6B (Pharmacia) equilibrated 
with 0.02 M sodium phosphate buffer, pH 7.1. Elution was performed with 
the same buffer in three steps, i.e without added NaCl, with 0.2 M NaCl, and 
with 1.4 M NaCL The flow rate was 50-60 ml/h, and 2.5-ml fractions were 
collected. Three fractions with the highest prorenin content were pooled and 
dialyzed for 4 h against 0.1 M sodium phosphate buffer, pH 7.5, containing 
0.075 M NaCl and 1 mM EDTA. All of these procedures were carried out 
at4 C. 
Purification of plasma kallikrein. Plasma prekallikrein was isolated from normal 
human plasma according to the method of Bouma et al. 8• Purification involved 
55 
several steps of ion exchange column chromatography, followed by Concanavalin 
A-Sepharose (Pharmacia) chromatography and sucrose density gradient centri-
fugation. This resulted in a 1,500-fold purification from plasma. The highly 
purified prekallikrein isolated in its precursor form consisted of two very similar 
apparent molecular weights near 85,000 on polyacrylamide gel electrophoresis 
in the presence of sodium dodecyl sulfate. A goat antiserum raised against purified 
prekallikrein gave a single precipitation line in double immunodiffusion against 
human plasma and showed a reaction of identity with the single precipitation 
line of purified prekallikrein. No precipitation line was observed when unabsorbed 
antiserum was tested against Fletcher trait plasma, which was deficient in 
prekallikrein. The active factor XII fragment /3-factor XII a was a gift of Dr. 
John Griffin (LaJolla,CA,USA). It gave a single band on sodium dodecyl sulfate-
polyacrylamide gel electrophoresis with an apparent molecular weight of 28,0009• 
Prekallikrein was activated by /3-factor XII a, and active kallikrein was separated 
from /3-factor XII a by DEAE-Sephadex A-50 (Pharmacia) column chroma-
tography, as described elsewhere8• The activated kallikrein gave two protein 
bands on sodium dodecyl sulfate-polyacrylamide gel electrophoresis in the absence 
of reducing agents. These protein bands had apparent molecular weight values 
identical to those seen for the two prekallikrein bands. 
Assay of renin. Purified renin substrate was prepared from the plasma of 
nephrectomized sheep10• In the renin assays, it was used at a final concentration 
of 2.5 ,uM, expressed as the maximal quantity of angiotensin I which could 
be generated at pH 7.5 and 37 C in the presence of a large excess of human 
kidney renin, i.e. incubation of 10 ,ul substrate with 10,000 ,uU MRC renin standard 
(lot 68/356) for 24 h in a total volume of 1 ml. The renin assay has been described 
elsewhere5• Briefly, 0.1 to 0.5 ml samples were mixed with renin substrate, and 
the total volume was adjusted to 1.0 ml with 0.1 M sodium phosphate buffer, 
pH 7.5, containing 75 mM Na Cl and 1 mM EDTA. After the addition of 
10 ,ul 8-hydroxyquinoline sulfate (0.34 M), 5 ,ul phenylmethylsulfonylfluoride 
(0.3 M) in ethanol, and 10 ,ul aprotinin (10,000 kallikrein-inhibiting units/ml; 
Trasylol, Bayer, Leverkussen, West Germany), the mixtures were incubated for 
3 h at 37 C. Mixtures incubated at 4 C served as blanks. The reaction was 
stopped by heating for 10 min in a boiling water bath. The angiotensin I that 
had been generated during incubation was measured by RIA, and results are 
expressed as microunits per ml using the MRC renin standard. 
Assay of prorenin. Prorenin was determined after its activation to renin by 
Sepharose-bound trypsin,,as described previously5• Trypsin from bovine pancreas, 
twice crystallized (Sigma Chemical Co., St. Louis, MO; 12,000 N-a-benzoyl-
L-arginine- ethylester (BAEE) units/mg protein), was covalently bound to CNBr-
activated Sepharose (Pharmacia) according to the directions ofthe manufacturer. 
Sepharose-bound trypsin was diluted in 0.1 M sodium phosphate buffer, pH 
7.5, containing 75 mM NaCl and lmM EDTA. In a pilot study, aliquots of 
plasma pool and of some fractions (1.0 ml) ofthe prorenin peaks in the Sephadex 
G-100 and Blue Sepharose column eluates were incubated at 4 C with suspensions 
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(0.1 ml) of Sepharose-bound trypsin at final concentrations ranging from 0.01-
1.0 mg trypsin/ml for various periods up to 72 h. Trypsin was removed by 
centrifugation. The amidolytic activity of the supernatants was tested with the 
chromogenic substrate N -benzoyl-L-isoleucyl-L-glutamy1glycyl-L- arginine-p-ni-
troanilide (S2222, Kabi, Stockholm , Sweden). For this purpose, 0.1 ml of the 
supernatant of the incubates was mixed with 0.2 mM substrate ( approximately 
10 times the Km for trypsin) in 0.1 M Tris-HCL buffer, pH 8.2, in a total 
volume of 1.0 ml. The linear release of p-nitroaniline was followed for 1-2 min 
at 405 nm in a 1-cm semimicrocuvette at 37 C. With this method, the remaining 
trypsin activity in the supernatants was found to be less than 0.1% of the original 
activity in the incubates. 
The renin activity generated by incubation with trypsin appeared independent 
of the concentration of the activator in the range of 0.01-1.0 mg/ml, unless 
the incubation was continued until a plateau was reached. At trypsin concen-
trations up to 0.3 mg/ml, there was no decrease in renin activity during incubation 
for 72 h. With higher concentrations of trypsin, some renin activity was lost 
when incubation was continued for such a long time. At trypsin concentrations 
of 0.2- 0.3 mg/ml, the activation was maximal within 12-24 h. Incubation for 
24 hat 4 C with 0.3 mg/ml trypsin, which was bound to 7.5-10 mg Sepharose, 
was used as a routine method for activating prorenin. Renin was then assayed, 
as described above, by incubating the samples with sheep renin substrate for 
3 hat 37 C. Less than 10% of the substrate was converted during this incubation, 
and generation of angiotensin I was linear with time with both trypsin-treated 
and untreated samples. 
Assays of kallikrein and prekallikrein. Plasma kallikrein was measured using the 
chromogenic substrate H-D-prolyl-L-phenylalanyl-L-arginine-p-nitroanilide 
(S2302, Kabi)11 . A 4.1 mM solution of this substrate in distilled water was 
prepared. Aliquots (0.1 ml) of the column eluates were diluted with 0.05 M 
Tris-HCL buffer, pH 7.8, containing 0.12 M NaCl to a volume of 0.8 ml. Then, 
0.2 ml substrate solution was added so that the final concentration of substrate 
in the reaction mixture was 0.8 mM (Km for plasma kallikrein, 0.2 mM). The 
linear release of p-nitroaniline was followed for 1-2 min at 405 nm in a 1-cm 
semimicrocuvette at 37 C. Prekallikrein, which was activated by the active 
fragment of clotting factor XII (~-factor XII a), as described before, was used 
as a standard. The lower limit of detection was less than 10 ng. This corresponds 
with a kallikrein concentration of less than 100 ng/ml undiluted sample, which 
is about 0.2% of the concentration in normal plasma when all prekallikrein 
is converted to kallikrein 12 . 
Pre kallikrein was determined after its activation with dextran sulfate13 • Dextran 
sulfate (Pharmacia; Mr 500,000) was dissolved at a concentration of 25 mg/ 
1 in distilled water. Aliquots (0.05 ml) of the column eluates were mixed with 
0.05 ml Fletcher trait plasma as a source of clotting factor XII and high molecular 
weight kininogen. These mixtures were incubated for 10 min at 0 C with 0.10 
ml of the dextran sulfate solution in plastic tubes placed in ice water. The mixtures 
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were then diluted to a volume of 0.8 ml with 0.05 M Tris-HCL buffer, pH 
7.8, containing 0.12 M NaCl, and after the addition of 0.2 ml of the solution 
of chromogenic substrate, kallikrein activity was measured as before. 
Assays of plasmin and plasminogen. Plasmin was determined with the chro-
mogenic substrate D-valyl-L-leucyl-L-lysine-p-nitroanilide (S2251, Kabi)I4• A 3 
mM solution of substrate in distilled water was prepared. Aliquots (0.1 ml) 
of the column eluates were diluted with 0.05 M Tris-HCl buffer, pH 7.4, containing 
0.12 M NaCl to a volume of 0.8 mi. Then, 0.2 ml of the substrate solution 
was added so that the final concentration of substrate in the reaction mixture 
was 0.6 mM (Km for plasmin, 0.3 mM). The linear release of p-nitroaniline 
was followed for 1-2 min at 405 nm in a 1-cm semimicrocuvette at 37 C. Plasmin 
(19 casein units/mg protein; Kabi) was used as a standard. The lower limit 
of detection was 20 ng. This corresponds with a concentration of 200 ng/ml 
undiluted sample, which is less than 0.1% of the concentration in normal plasma 
when all plasminogen has been converted to plasmin. 
Plasminogen was determined after its activation by streptokinasei4• Strepto-
kinase (Streptase, Behring, Marburg-Lahn, West Germany) was dissolved at a 
concentration of 10,000 Christensen units/ml in distilled water. Aliquots (0.1 
ml) of the column eluates were mixed with 0.1 ml 0.05 M Tris-HCl buffer, 
pH 7.4, containing 0.12 M NaCI. After the addition of 0.1 ml of the streptokinase 
solution, the mixtures were incubated for 10 min at 37 C. The activated column 
eluates were diluted to a volume of 0.8 ml with the Tris-HCl buffer, and after 
the addition of 0.2 m1 of the solution of chromogenic substrate, plasmin activity 
was measured as before. 
Immunological detection of protease inhibitors. Samples were tested for the 
presence of armacroglobulin Ccinactivator, ai-antitrypsin, inter-a-trypsin in-
hibitor, and antithrombin III by radial immunodiffusion according to the method 
of Mancini et aU5 using monospecific antisera (Behring). Aliquots (1 ml) of 
the column eluates were concentrated 10-fold in Amicon B-15 concentrators 
(Amicon, Lexington, MA, USA) before being applied to the immunodiffusion 
plates (Partigen plates, Behring). The immunoprecipitate rings were compared 
with those of a series of dilutions of standard plasma according to the directions 
of the manufacturer. The lower limit of detection of a 2-macroglobulin was less 
than 1 p,g for the other inhibitors, it was less than 0.5 p,g. a 2-Macroglobulin 
was applied to the immunodiffusion plates in 20-p,l aliquots, and the other 
inhibitors were applied in 5-p,l aliquots. The level of a 2-Macroglobulin, CI-
inactivator, ai-antitrypsin, inter-a-trypsin inhibitor, and antithrombin III in the 
pooled plasma of five normal subject were 210, 23, 250, 40 and 27 mg/100 
ml (means of two assays) respectively. Since all samples were concentrated 10-
fold before assay, it can be calculated that a 2-Macroglobulin and acantitrypsin 
were detected when they were present in the column eluates at concentrations 
as low as 1% of the concentration in normal plasma. Ccinactivator, inter-a-
trypsin inhibitor, and antithrombin III were detectable when present in the eluates 
at concentrations as low as 5% of the concentration in normal plasma. 
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3.1.4. RESULTS 
Elution patterns of the Sephadex G-1 00 and Blue Sepharose columns are shown 
in Figs. 1 and 2. The apparent molecular weight of prorenin on gel filtration 
was somewhat higher than that of active renin, i.e. 56,000 and 48,000 daltons, 
respectively. This agrees with the results of Sealey et ai.l 6• Recovery of prorenin 
was better than 90% with Sephadex chromatography and better than 70% with 
Blue Sepharose chromatography. The peak fractions of prorenin from the 
Sephadex column that were pooled and subjected to Blue Sepharose chroma-
tography comprised about 50% of the total quantity of pro renin recovered from 
the Sephadex column. The final recovery of prorenin after the two purification 
steps was 32%. The concentration of pro renin in the final preparation, as measured 
after maximal activation by Sepharose- bound trypsin, was 38 ~-tU/ml, and the 
concentration of renin, as measured before activation by trypsin, was less than 
0.5 ~-tU/ml. With the functional assays we have used, prekallikrein, kallikrein, 
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Fig. 3.1.1. Renin and prorenin in eluates from gel filtration of plasma on a Sepharose G-100 column. 
Renin activity was measured before and after activation of prorenin with Sepharose-bound trypsin. 
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Fig. 3.1.2. Separation of renin and prorenin by affinity chromatography on a Blue Sepharose CL-
6B column. The pooled fractions obtained after gel filtration of plasma (see Fig. 3.1.1.) were applied 
to the column. Renin activity was measured before and after activation of prorenin with Sepharose-
bound trypsin. Renin did not bind to the column. Prorenin was eluted at NaCl 1.4 M. Protease 
inhibitors detected in !O-f old-concentrated fractions are indicated by bars. Brackets indicate fractions 
pooled for activation studies with plasma kallikrein and plasmin. 
plasminogen, and plasmin could not be detected in the final preparation of 
prorenin. Immunoreactive cx2-Macroglobulin, Ccinactivator, cxcantitrypsin, in-
ter-a-trypsin inhibitor, and antithrombin III were also not detectable in this 
preparation. One-milliliter aliquots of the final preparation of prorenin were 
incubated with the following activators: 1) Sepharose-bound trypsin (100 1-Ll; 
final concentration, 0.3 mg/ml, 2) human plasmin (100 ,ul; final concentration, 
0.1 mg/ml), and 3) human plasma kallikrein (20 and 5 ,ul: final concentrations, 
8 and 2 ,ug/ml). The concentrations of plasminogen and prekallikrein in normal 
plasma are about 200 and 55 ,ug/mP2•17, respectively. The incubations with 
activators were performed at 4 or 37 C for various periods, as indicated in 
Fig. 3 ; data in this figure are based on renin assays in which activated and 
nonactivated samples were incubated with sheep renin substrate for 3 h at 37 
C, as described in Materials and Methods. Prorenin samples treated for 48 h 
at 4 C or for 60 min at 37 C with trypsin, plasmin, or kallikrein and untreated 
samples were also incubated for 1 and 2 h with sheep renin substrate. The 
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Fig. 3.1.3. Activation of partly purified prorenin (see Fig.3.1.2.) at pH 7.5 with plasma kallikrein, 
plasmin and trypsin at 4 C and 37 C. For details see the text. 
generation of angiotensin I appeared linear with time both with the treated 
samples and the untreated samples. 
As shown in Fig.3, the addition of human plasmin in a concentration which 
corresponds to the concentration of plasminogen in normal plasma led to an 
increase in renin activity at 4 C to a level which was close to the maximal 
activation obtained with Sepharose-bound trypsin. Activation to this maximum 
was also obtained after 48 h of incubation at 4 C with human kallikrein in 
a concentration which corresponds to about 16 % of the prekallikrein concen-
tration in normal plasma. Prorenin activation proceeded more rapidly at 37 
C. When the activators were incubated for 48 h at 4 C or 60 min at 37 C 
with 1 ml 0.1 M sodium phosphate buffer, containing 0.075 M NaCl and 1 
mM EDT A, instead of prorenin, no renin activity could be detected. Measu-
rements of kallikrein in kallikrein prorenin mixtures before and after incubation 
showed no loss of amidolytic activity during 48 h at 4 C or during 60 min 
at 37 C. 
3.1.5. DISCUSSION 
It has recently been reported that an acid-induced conformational change of 
the prorenin molecule is necessary before it can be converted to renin through 
attack by the neutral serine protease, renal kallikrein6• This claim was based 
on experiments in which renal kallikrein was incubated with mixtures of pH 
3.3-pretreated plasma and untreated plasma. The percentage of renin that was 
activated appeared equal to the percentage of acid-pretreated plasma in the 
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mixture. This suggests that only the acid-treated prorenin is activated by kallikrein. 
However, the possibility that kallikrein inhibitors, which are known to be 
destroyed by acid treatment of plasma, were responsible for the result was not 
excluded. It should be noted that the kinetics of kallikrein inhibition in crude 
plasma are very complex: plasma contains a wide range of different inhibitors; 
some fast acting, others slow acting18, 19• The question of whether acid treatment 
is required for kallikrein-mediated activation of prorenin is of more than academic 
interest. If it is true that a reduction of plasma pH to an unphysiological level 
is necessary for rendering the prorenin molecule susceptible to kallikrein attack 
rather than for removing inhibitors, one may doubt the significance of kallikreins 
as activators of pro renin in vivo. 
In our experiments, the inhibitors were separated from pro renin by gel filtration 
and dye-ligand chromatography at neutral pH. The resulting pro renin preparation 
could be activated by plasma kallikrein at pH 7.5 without prior acid treatment 
of prorenin. It appears therefore, that an acid-induced conformational change 
of the prorenin molecule was not essentiaL We have used plasma kallikrein, 
which has a slightly different amino acid bond specificity from that of glandular 
kallikrein used in other laboratories6, 7,20 • It is possible that an acid-induced 
conformational change in prorenin is required for glandular kallikrein, but not 
for plasma kallikrein. In a previous study from our laboratory, however, glandular 
kallikrein was found to be able to activate prorenin in a partly purified preparation 
without prior acid treatment of prorenin21 • Theoretically, it is also possible that 
the prorenin in our preparation was different, although prorenin is not known 
to change after Sephadex and Blue Sepharose chromatography. 
Plasmin was also able to activate prorenin at pH 7.5 in our preparation. 
Since plasma kallikrein is known to activate plasminogen under certain circums-
tances 1, it is theoretically possible that in our experiments, kallikrein acted via 
activation of plasminogen. This, however, is unlikely because the concentrations 
of plasminogen and plasmin in our preparation of prorenin were 0.2 J.Lg/ml 
or less, and when plasmin was added to this preparation in a final, concentration 
of 0.2 J.Lg/ml, no increase in renin activity was observed during incubation for 
48 h at 4 C or for 1 h at 37 C. 
Ccinactivator is the inhibitor in plasma that is known to inactivate active 
Factor XII, and both Ccinactivator and a 2-macroglobulin important inhibitors 
of plasma kallikrein. Ccinactivator is destroyed between pH 4.5-5.0. After 
treatment of plasma at this pH, kallikrein is formed at 4 C when the pH is 
restored to neutraL Kallikrein, however, is bound to a 2-macroglobulin and little 
activation of prorenin is observed under these circumstances. a 2-macroglobulin 
is destroyed below pH 4.0, and this coincides with the generation of uninhibited 
kallikrein and the formation of active renin after the pH has been restored22 • 
These findings and the present results strongly suggest that the main function 
of the acid dialysis step in the activation of prorenin in plasma is to destroy 
inhibitors. 
Activation of the factor XU-kallikrein pathway is known to occur upon contact 
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with negatively charged surfaces, including vascular basement membrane, despite 
the presence of inhibitors in the surrounding fluid 1,2• In the fluid phase, however, 
active factor XII and kallikrein are rapidly inactivated. It is, therefore, conceivable 
that the blood vessel-bound prorenin rather than circulating prorenin is activated 
by this pathway. 
The plasma of patients with the Fletcher trait (hereditary prekallikrein 
deficiency) has been reported to contain low quantities of renin, while plasma 
prorenin is abnormally high16,23 • An inverse correlation between the plasma levels 
of prekallikrein and prorenin has also been reported in normal subjects in different 
state of sodium balance24• Such observations can be taken as evidence that 
activation of prorenin may occur in vivo, and that plasma prekallikrein is involved. 
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3.2. ROLE OF INTRINSIC INHIBITORS IN ACID-ACTIVATION OF INAC-
TIVE PLASMA RENIN (PRORENIN) 
3.2.1. ABSTRACT 
Inactive plasma renin is converted into an active form of renin during dialysis 
of plasma at 4 C against a pH 3.3-buffer. This form of renin is inactivated 
at neutral pH and 37 C. When plasma, after acid-dialysis, is kept at 4 C and 
neutral pH a different form of active renin is generated, which remains active. 
The irreversible activation of prorenin depends on factor XII-initiated kallikrein 
formation. Ccinhibitor (CciNH) and a 2-macroglobulin (a2-M) can be selectively 
denaturated by treatment of plasma at low pH values to which kallikrein and 
renin are resistant. After denaturation of CciNH at pH 4-5, factor XII becomes 
capable of activating prekallikrein. The kallikrein that is formed after restoration 
of pH is complexed with a 2M. This complex has little activity towards natural 
protein substrates including prorenin. a 2M is denaturated at pH 3-4 and, as 
a consequence, kallikrein that is formed after restoration of pH is not complexed 
with a 2M. This kallikrein is able to attack both high molecular weight kininogen 
and prorenin as manifested by the generation of bradykinin-forming and 
angiotensin-forming activities. These observations show a crucial role for C1-
INH and a 2M in prorenin activation and explain, at least in part, why the pH 
of the acid-treatment step has to be less than 4 before irreversible activation 
of prorenin at neutral pH can occur. 
3.2.2. INTRODUCTION 
The surface charge of a protein and therefore its tertiary structure will be affected 
by the pH of the medium in which it is dissolved. Treatment of plasma for 
24 hours at pH 3.0-3.5 at 4 C leads to conversion of inactive renin or prorenin 
into an active form of renin that is inactivated at neutral pH and 37 C1•2• It 
has been suggested that acid-treatment induces a conformational change of the 
pro renin molecule or the dissociation of an inhibitor1- 3• By this the active centre 
of the enzyme becomes accessible to renin substrate. When plasma, after acid-
dialysis, is kept at neutral pH and 4 C a different form of active renin is generated. 
This form of renin remains active. The irreversible activation of pro renin depends 
on clotting factor XU-initiated kallikrein formation4•5• The two types of acid-
activated renin, the reversibly activated form and the irreversibly activated form, 
can be separated by dye ligand affinity chromatography6 . There is some 
controversy on whether the formation of reversibly activated renin is a necessary 
first step for irreversible activation by kallikrein 1•3•5• 7• Acid-dialysis also leads 
to denaturation of serine proteinase inhibitors. Destruction of this inhibitory 
capacity ensures survival of kallikrein in the neutral phase, which is then capable 
of attacking prorenin. This report focusses on the biochemical background of 
the acid-activation of prekallikrein and prorenin and on the role of plasma 
inhibitors in this process. 
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3.2.3. MATERIALS AND METHODS 
Acid-activation. Two ml of normal plasma containing EDT A 5 mM was dialyzed 
for 24 hours at 4 C against buffers of pH 1.5-7.57• pH was then restored by 
dialysis against a pH 7.5 phosphate buffer for 24 hours at 4 C. In some experiments 
pH was restored by adding NaOH 1M. 
Measurement of renin. The method is based upon RIA of angiotensin I generated 
during incubation with sheep renin substrate7,8• 
Measurement of plasma kallikrein. The chromogenic substrate H-D-prolyl-L-
phenylalany1-L-arginine-p-nitroanilide (S2303, Kabi, Sweden) was used9• For 
measuring kallikrein that is bound to cx2-macroglobulin the release of p-nitro-
aniline was followed in the presence of soybean trypsin inhibitor (SBTI, Sigma) 
in a final concentration of 2 mg/ml. Prekallikrein was measured after activation 
by dextran sulfate9• Kallikrein was also measured via its ability to cleave 
bradykinin from added high molecular weight kininogen (HMWK). Bradykinin 
was determined by RIAI 0• Measurements of inhibitors. C1-inhibitor (C1-INH) and 
cx2-macroglobulin (cx2M) were measured by radial immunodiffusion8 and by 
functional assays11, 12• 
3.2.4. RESULTS 
Plasma was dialyzed at low pH followed by dialysis at pH 7.5 both for 24 
hours at 4 C. The enzymes are more resistant to low pH than the inhibitors 
(Figs. 1 and 2). Prekallikrein is converted into kallikrein at pH 7.5 after treatment 
at pH 5.0. Prorenin is activated after treatment at pH below 4.0. The major 
inhibitors of kallikrein, CciNH and cx2M, are denaturated at pH-values below 
5.0 and 4.0 respectively. When cx2M is denaturated plasma acquires the ability 
to activate prorenin. 
In Fig. 3 the generation of kallikrein and renin in pH 3.3-pretreated plasma 
was followed for 24 hours after restoration of pH to neutral with 1 M NaOH. 
Prorenin is already present in an active form before the second dialysis step, 
but this acid-activated renin is rapidly inactivated at 37 C. In contrast, pre-
kallikrein is not activated during pH 3.3-dialysis. Only after a lag period of 
about 4-8 hours is prekallikrein converted into kallikrein. When the acid-
pretreated plasma is kept for 24 hours at neutral pH and 4 C prorenin is irreversibly 
activated. 
As mentioned above prekallikrein is converted into kallikrein at pH 7.5 after 
treatment of plasma at pH below 5.0. However there is little formation of renin 
in pH 4.0-5.0-pretreated plasma. This may be explained by the fact that cx2M 
is resistant to this pH as illustrated in Fig. 2. Under these circumstances kallikrein-
cx2M complexes are formed. The amidolytic activity of such complexes towards 
chromogenic substrates is known to be insensitive to SBTI, whereas kallikrein 
that is not bound to cx2M is very sensitive to SBTI13 • Thus, by measuring kallikrein 
amidolytic activity both in the presence and absence of SBTI the bound and 
66 
>- 12.5 1-
> 
1-
u 10.0 <( 
(.J Kallikrein Z~ 
-I 1-c: 
<( ·-
o::E 
w~ 
z!.. 
wE 
0-I 0 
zE 
a. 
5.0 
z 
::.:: 
>- 2.5 0 
<( 
0:: 
CD 0.0 
4.0 
3. 
Kallikrein 
>- 2.0 
!:::~ 
>I 
_c 
1- .E 
u~ 1.5 
<(!.. 
uE 
-<( 1.0 
1-z ~a. 
o- Kallikrein 0~ 0.5 
~::::l.. with SBTI 
<( 
2 
Prekallikrein 
SECOND DIALYSIS 
pH 7.5 
3 4 5 6 
pH of first dialysis 
7 8 
>-
1. 25 '= 
> 
1-
u 
1. 00 <( 
(.J 
z 
~-~ 
<(I 
0. 75 0::·5 
wE 
z~ 
w!.... QE 
0.50 I-
_o 
I E 
zO. 
U'l 
0.25 ~ 
1-
0 
(.J 
0.00 z 
<( 
Fig. 3.2.1. Normal EDTA-plasma was first dialyzed for 24 h at 4 C against buffers of different 
pH and then against pH 7.5 buffer also for 24 hours. Renin was measured via its ability to form 
angiotensin I from sheep renin substrate. Kallikrein was measured via its ability to cleave p-nitroaniline 
from a chromogenic substrate and via its ability to cleave bradykinin from high molecular weight 
kininogen (HMWK). Kallikrein that is complexed with a 2-M is insensitive to soybean trypsin inhibitor 
(SBTI) and does not attack HMWK and prorenin. Kallikrein that is not complexed with a 2-M 
is sensitive to SBTI, attacks HMWK to form bradykinin and attacks prorenin to form active renin. 
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unbound forms of kallikrein can be discerned. As shown in Fig. 1, all kallikrein 
amidolytic activity in pH 4.0-5.0 pretreated plasma is complexed with CY2M. These 
complexes are not only insensitive to inhibition by SBTI but are also much 
less active towards natural protein substrates than towards the low molecular 
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plasma. 
weight chromogenic substrates 14• Thus kallikrein complexed with a2M is not 
capable of attacking HMWK to form bradykinin and is also not capable of 
activating prorenin (Fig. 1). After a 2M has been denaturated at pH below 4.0 
unbound kallikrein is formed at pH 7 .5. This can be detected as bradykinin-
generating activity and is associated with prorenin activation. 
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3.2.5. DISCUSSION 
CciNH is regarded as the most important inhibitor of activated clotting factor 
XII, and both C 1-INH and a 2M are the major inhibitors of plasma kallikrein. 
As shown in this study these inhibitors can be selectively denaturated by treatment 
of plasma at low pH-values to which kallikrein and renin are resistant. After 
denaturation of CciNH at pH 4.0-5.0 plasma acquires the ability to activate 
prekallikrein. Activation of prekallikrein in acid-pretreated plasma depends on 
factor XII4•5• Apparently, after C1-INH has been destroyed, factor XII becomes 
capable of attacking prekallikrein. The kallikrein that is formed is complexed 
with a 2M. This complex is active towards artificial low molecular weight substrates 
but not towards protein substrates such as kininogen and prorenin. 
a 2M is denaturated at pH 3.0-4.0 and, as a consequence, kallikrein that is 
formed after restoration of pH is not complexed with a 2M. This kallikrein is 
able to attack both HMWK and prorenin, which is manifested by the appearance 
of bradykinin generating and angiotensin-generating activities. 
The active renin that is generated in acid-pretreated plasma by the factor 
XU-kallikrein pathway differs from the active renin that is formed by acidification 
per se. The latter is slowly inactivated at neutral pH at 4 C and more rapidly 
at 37 C, whereas the former remains active under these circumstances. 
Our results strongly suggest that a major function of the acid-dialysis step 
in the activation of prorenin in plasma is to destroy inhibitors i.e. C1-INH and 
a 2M. Experiments with semipurified plasma prorenin have shown that acid-
pretreatment is not a sine qua non for activation by kallikrein and plasmin9•15• 
It is however possible that the prorenin molecule, after a conformational change 
for instance in acid milieu, becomes more susceptible to proteolytic attack. The 
course of events in acid-pretreated plasma can then be depicted as in Fig. 4. 
Activated FXII 
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Fig.3.2.4. Biochemical reactions by which active renin is generated in acid-pretreated plasma. 
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3.3. PRORENIN-RENIN CONVERSION BY THE CONTACT ACTIVATION 
SYSTEM IN HUMAN PLASMA: ROLE OF PLASMA PROTEASE IN-
HIBITORS 
3.3.1. ABSTRACT 
Acid-pretreated normal human plasma generates renin activity at 0 C and neutral 
pH by the activation of pro renin. The activation is caused by kallikrein generated 
from prekallikrein by activated factor XII. N onacidified plasma also generates 
renin at 0 C, but at a lower rate (cold-promoted activation). In normal plasma, 
14 ± 1% of prorenin (mean ± SEM,n = 30) was activated during incubation 
at 0 C for 7 days (range 6% to 26%). Cold-promoted activation of prorenin 
was within the normal range in plasma deficient factor XI,X,IX,VIIIC,VII,V, 
prothrombin, or high molecular weight kininogen. 
Cold-promoted activation of prorenin was less than 1% in plasma deficient 
in factor XII or prekallikrein. Reconstitution of these plasmas with highly purified 
factor XII or prekallikrein restored normal prorenin activation. Correction of 
high molecular weight kininogen deficiency had no effect. Thus cold-promoted 
activation of prorenin depends on the presence of factor XII and prekallikrein, 
whereas the other clotting factors are not essentiaL The influence of the inhibitors 
C1-esterase-inhibitor, az-macroglobulin, antithrombin III, and a1-antitrypsin on 
the activation of prorenin was studied in factor XU-deficient plasma from which 
one or more of these inhibitor had been selectively removed by immunoab-
sorption. Factor XII was subsequently added, and the generation of renin at 
37 C was observed after complete factor XII-high molecular weight kininogen-
mediated activation of prekallikrein induced by dextran sulfate. No activation 
of prorenin was observed at 37 C after depletion of C1-esterase inhibitor, a 2-
macroglobulin, antithrombin III, or a 1-antitrypsin. When prekallikrein was 
activated in plasma depleted of both C1-esterase-inhibitor and az-macroglobulin, 
6% of prorenin was activated in 2 hours at 37 C. After additional depletion 
of antithrombin III, the activation increased to 47%. These results indicate that 
the contact activation system is capable of activating prorenin in plasma at 
physiologic pH and temperature when the three most important kallikrein 
inhibitors, C1-esterase-inhibitor,a2-macroglobulin, and antithrombin III, are 
absent. 
Abbreviations: C1-esterase-inhibitor (C1-INH), a 2-macroglobulin ( azM), antithrombin III (AT III),a1-
antitrypsin ( a1AT), ethylenediaminetetra-acetic dis odium salt (EDTA), phenylmethanesulfonylflu-
oride (PMSF), soybean trypsin inhibitor (SBTI), high molecular weight kininogen (HMWK). 
3.3.2. INTRODUCTION 
Human plasma contains a form of renin with little or no enzymatic activity. 
This 'inactive' renin resembles some proenzymes of the clotting and fibrinolytic 
cascades in that it can be converted to the active form by proteolytic enzymes 
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present in plasma (intrinsic activators) or in tissues (extrinsic activators )1-5. 
Inactive renin in plasma appears to be a more or less homogeneous molecular 
species with an apparent molecular weight of 56,000 on Sephadex gel filtration6-8• 
It is not known if activation occurs in vivo, but inactive renin that is activated 
in vitro has enzymatic and immunologic properties very similar, if not identical, 
to those of naturally occurring active renin in plasma and kidney8- 12. Inactive 
renin is secreted by the kidney, and there is evidence that, with long-term 
stimulation of the secretion of active renin, the rate of secretion of inactive 
renin is increased as well8•12. Inactive renin in plasma may therefore tentatively 
be referred to as prorenin. 
One of the intrinsic pathways of prorenin activation is the clotting factor 
XU-kallikrein pathway, which is initiated at 0 C in plasma that has been dialyzed 
against a pH 3.3 buffer followed by restoration of pH. The most important 
kallikrein inhibitors in plasma are C1-INH, a:2M and AT III. C1-INH also 
inactivates activated factor XII and the active 28,000 molecular weight factor 
XII fragment. These inhibitors are destroyed by acid, and this may promote 
activation of prorenin13 • 
Exposure of plasma to low temperature (-4 C to 4 C) without prior acidification 
also increases its renin activity, but the activation proceeds more slowly than 
in acid- treated plasma14·15. Incubation of untreated plasma at low temperature 
is known to promote the activation of clotting factor VII, a process that depends 
on the presence of factor XII and activated prekallikrein 16. The enzyme responsible 
for cold-promoted prorenin activation in nonacidified plasma has not been 
identified. 
The factor XII-kallikrein pathway of prorenin activation links the renin-
angiotensin system with the contact activation system. Evidence to suggest that 
this link is physiologically important can be derived from reports that in the 
plasma of patients with hereditary prekallikrein deficiency (Fletcher trait), active 
renin is abnormally low, whereas prorenin is abnormally high2·3•17 • 
The issue is confounded by the observation that the addition of kaolin to 
nonacidified plasma failed to raise the renin activity, despite the fact that kaolin 
caused massive activation of the factor XII-kallikrein pathwayl8• This is in contrast 
to the rapid increase in renin activity seen when kaolin was added to plasma 
in the neutral phase after pH 3.3 dialysis. It has been postulated that an acid-
induced reversible conformational change of the prorenin molecule is a necessary 
first step for subsequent activation of prorenin by plasma and tissue kallikrein 12.19• 
The aim of our study was to clarify the role of the contact activation system 
and the involvement of plasma protease inhibitors in the activation of prorenin 
in nonacidified plasma both at 0 C and 37 C. 
3.3.3. METHODS 
Clotting factor deficient plasma. Plasma deficient in factor XII, prekallikrein, 
HMWK, or factor XI was purchased from Georg King, Overland Park, Kan., 
73 
Table 3.3.1. Renin activity in clotting factor-deficient plasma. 
Plasma ReninJ.LU/ml 
Clotting Source Lot No Trypsin pH 3.3, 24 h 
factor No treatment 48 h pH 7.5, 24h 
deficiency (0 C) (0 C) 
None H 27±6* 252±24* 248±20* 
Prothrombin B 500513A 19 153 151 
Factor V D CF 5-46 23 198 151 
B 500315 19 229 219 
Factor VIII:C B 503844A 10 164 140 
H 18 228 220 
Factor IX D 003274 13 150 140 
B A500821A 27 261 233 
Factor X B 504216A 22 241 220 
H 49 171 166 
Factor XI B 500310B 25 219 201 
GK 120569 23 141 144 
H 22 237 231 
Factor XII B A500408A 22 193 34 
GK 120569 22 163 48 
H 1 24 257 44 
H 2 23 241 43 
H 3 22 206 43 
H 4 21 199 42 
H 5 41 221 59 
Prekallikrein GK 1701-520 12 544 34 
LJ I 9.8 262 28 
LJ 2 9.5 269 30 
HMWK** GK 1603-139 10 203 193 
Source of plasma: GK =George King; B = Behringwerke; D =Dade; LJ =La Jolla; H =own 
hospitals. Renin was measured in untreated plasma (naturally occurring active renin) and after 
treatment with trypsin (total renin) or acid-dialysis. 
* Mean ± SD (n = 6). 
** after correction of prekallikrein concentration to normal (50 J.Lg/ml). 
USA. Plasma deficient in factor XI,X,IX,VIIIC,VII, or V was obtained from 
Behringwerke AG, Marburg-Lahn, West Germany, and from Merz-Dade, Du-
dingen, Switzerland (Table 1). Plasma deficient in factor XII,XI,X or VIIIC 
was obtained from homozygous patients from our hospitals. Plasma from two 
added additional patients with prekallikrein deficiency was a gift from 
Dr.J.H.Griffin, Scripps Clinic and Research Foundation, La Jolla, Calif. The 
clotting activity of the respective factors in these plasma samples was less than 
1% of normaL Human plasma, in which prothrombin had been lowered by 
immunoadsorption to less than 0.1% of normal, was obtained from Behringwerke. 
Blood from 30 healthy volunteers was collected in tubes containing 0.1 volume 
of 0.13 M trisodium citrate as anticoagulant. Plasma was prepared by centri-
fugation at 3,000xg for 10 minutes at 22 C. All plasma was stored at -70 C. 
Inhibitor deficient plasma. CJ-INH,azM, AT III, and a1AT were isolated from 
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normal human plasma20-23. Monospecific goat antisera against a2M and AT 
III were prepared24. Monospecific rabbit antisera against C,- INH and a,AT 
were obtained from Behringwerke. Immunopurified antibodies were prepared 
by affinity chromatography of the different antisera on a column of CNBr-
activated Sepharose 4B (2 g) (Pharmacia Fine Chemicals AB, Uppsala, Sweden) 
to which either purified C,-INH (5.6 mg), a2M (10 mg), AT III (9,2 mg), or 
a,AT (7,2 mg) was covalently bound. The antibodies were eluted with 3M KSCN 
in O.OlM sodium phosphate and 0.5M NaCl, pH 7.4, and after dialysis against 
O.lM NaHC03, pH 8.0, the antibodies were coupled to CNBr- activated Sepharose 
4B. The immunopurified antibodies against C,-INH, a2M, AT III or a,AT gave 
one precipitation line against normal human plasma, which showed a reaction 
of identity with the single line observed against human c,-INH, CX2M, AT III, 
or a,AT, respectively. Plasmas deficient in either c,-INH, CX2M, AT III, or a,AT 
were prepared by immunoadsorption of the respective inhibitors from a factor 
XII-deficient plasma, using columns of CNBr-activated Sepharose 4B to which 
immunopurified antibodies were coupled:9,4 mg anti-C,-INH to 2 g Sepharose, 
61 mg anti- a2M to 7 g Sepharose, 22 mg anti-AT III to 3 g Sepharose, and 
4.4 mg anti-a,AT to 3 g Sepharose. Four milliliters of C,-INH-deficient plasma, 
4.5 ml of a2M-deficient plasma, 5 ml of AT III-deficient plasma, and 4 ml 
of a,-AT-deficient plasma were obtained. Plasma deficient in both C,-INH and 
a2M was prepared by successive immunoadsorption of a2M and c,-INH from 
the same factor XII-deficient plasma. Four milliliters of this plasma was applied 
to the anti-AT III column in order to obtain plasma deficient in all three inhibitors. 
The inhibitor-deficient plasmas were completely deficient in the appropriate 
inhibitors as measured quantitatively by rocket immunoelectrophoresis25. Other 
serine protease inhibitors that were not removed, and prekallikrein, HMWK, 
renin, and prorenin remained at normal plasma levels (Table II). Normal plasma 
Table 3.3.2. Concentrations of contact factors, inhibitors, and naturally occurring active renin and 
prorenin in factor XU-deficient plasma after depletion of inhibitors. 
Plasma proteins 
Pre- HMWK C1-INH a2M ATIII a 1AT Renin Prorenin 
kallikrein !Lg/ml !Lg/ml !Lg/ml !Lg/ml !Lg/ml !LU/ml ILU/ml 
Deficiency !Lglml 
None 37 67 162 1.9 193 1620 41 180 
C1 inh 38 68 <1 1.8 144 1600 36 180 
a 2M 39 66 187 <0.02 184 1580 38 186 
A Till 37 63 180 1.9 <1 1600 37 179 
a 1AT 37 80 144 1.6 162 <20 36 180 
C1-INH and 
azM 35 69 <1 <0.02 146 1720 42 162 
C1-INH and 
azM and 
A Till 36 67 <1 <0.02 1880 36 166 
C1-INH, a 2M, A Till, and a 1AT were removed by immunoadsorption. 
Source of factor XU-deficient plasma: own hospital (see also Table 1). 
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was also depleted of a2M by chemical modification of the inhibitor with me-
thylamine. One tenth ml of methylamine 0.4M in l.OM Tris buffer, pH 8.1, 
was added to 0.9 ml normal plasma and incubated for 2 hours at 22 C26. Remaining 
a2M was measured by its capacity to form an SBTI-resistant complex with 
trypsin27. For this purpose, the methylamine-treated plasma was diluted 1:250 
with 0.05M Tris HCl buffer,pH 8.2, and prewarmed at 37 C. Trypsin (Sigma 
Chemical Co.,St.Louis, Mo, USA.), 10 J.Lg in 0.1 ml Tris HCl buffer, was added 
to 0.5 ml of the diluted plasma. After incubation for 1 minute at 37 C, 0.1 
ml SBTI (Sigma) 5 mg/ml was added, and 15 seconds later 0.2 ml of the tripeptide 
substrate N -benzoyl-L-isoleucyl-L-glutamyl-glycyl-L-arginine-p-nitroanilide 
(S2222;Kabi,Stockholm,Sweden) 1.0 mM in distilled water was added, and the 
volume was adjusted to 1.0 ml with 0.05 M Tris HCl buffer, pH 8.2. The change 
in absorbance at 405 nm was followed in a 1 em semimicrocuvette at 37 C, 
and the initial velocity was measured to give delta A/min. The result was read 
from a standard line of dilutions of the untreated plasma. 
Factor XIL prekallikrein, and HMWK. Factor XII (150 J.Lg/ml), prekallikrein 
(315 J.Lg/ml), and HMWK (615 J.Lg/ml) were isolated from normal plasma as 
described elsewhere28·31 . The proteins were stored at -70 C in a buffer,pH 5.0, 
containing 5 mM sodium acetate, 0.15M NaCl,and 0.02% NaN3. Protein was 
measured with the Lowry32 method, using bovine serum albumin as a standard. 
Immunologic assays for contact factors and inhibitors. Monospecific goat antisera 
against factor XII, prekallikrein, and the light chain of HMWK were prepared 
as described elsewhere28-31·33 . The preparation of immunopurified antibodies 
against C1-INH,a2M, AT III, and a1AT is described above. The concentrations 
of the respective proteins in plasma, were measured by rocket immunoelectro-
phoresis25. 
Functional assay of kallikrein. Kallikrein amidolytic activity was measured as 
the initial rate of hydrolysis of the tripeptide substrate H-D-prolyl-L-phenylalanyl-
L-arginine-p-nitroanilide (S2302;Kabi)34. A 4.1 mM solution of the tripeptide 
substrate in distilled water was prepared, and 20 J.Ll of the test sample was added 
to 0.2 ml of the substrate solution. The volume was adjusted to 1 ml with 0.05M 
Tris HCl buffer, pH 7.8. The change in absorbance at 405 nm was followed 
in a 1 em semimicrocuvette at 37 C, and the initial velocity was measured to 
give delta A/min. A second 20 J.Ll test sample was mixed with 10 J.Ll of SBTI 
10 mg/ml at 37 C, and after 15 seconds it was assayed for remaining kallikrein 
activity24·35 . Free kallikrein activity was calculated by subtracting the activity 
that was resistant to SBTI from the total kallikrein activity measured in the 
absence of SBTL 
Functional assay of renin and prorenin. Renin was measured via its ability 
to generate angiotensin I from partially purified renin substrate prepared from 
plasma of nephrectomized sheep, as described elsewhere8·9• Briefly, 0.25 ml of 
the substrate was added to 0.05 to 0.125 ml aliquots of a test sample, and the 
volume was adjusted to 0.5 ml with 0.1M sodium phosphate buffer, pH 7.5, 
containing EDTA,8-hydroxyquinoline sulfate, PMSF, and aprotinin as protease 
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inhibitors. The final concentration of renin substrate in the reaction mixture 
was 2.5 ,u.M, expressed as the maximal quantity of angiotensin I that could 
be generated at pH 7.5 and 37 C in the presence of a large excess of human 
kidney renin. The concentration of homologous substrate in the incubation 
mixtures was less than 0.2 ,u.M angiotensin I equivalents. In our assay system, 
this concentration of homologous substrate did not interfere with the reaction 
of renin with the heterologous substrate9• The reaction mixtures were incubated 
at 37 C for 15 and 30 minutes and for 1,2, and 3 hours. The renin-containing 
samples had been diluted in such a way that no more than 5% substrate was 
cleaved during incubation. Parallel incubations at 0 C served as blanks. In-
cubations of dilutions of the MRC human kidney renin standard (Lot 68/356; 
World Health Organization International Laboratory for Biological Standards, 
London, England) at 37 C and 0 C were run in each assay batch. In all samples, 
the generation of angiotensin I was linear for the first two hours. The reaction 
was stopped by adding 0.5 ml of 0.15 M NaCL, succeeded by heating for 10 
minutes in a boiling water bath. The precipitate was removed by centrifugation. 
The concentration of angiotensin I in the supernatant was measured by RIA, 
and results are expressed as ,u.U per milliliter using the MRC human kidney 
renin preparation as a standard. 
Prorenin was measured after its activation by immobilized trypsin2•8• For this, 
purpose 0.2 to 0.5 ml aliquots of a test sample were incubated with one-fifth 
volume of Sepharose-bound trypsin in a final concentration of 0.25 mg/ml trypsin 
for 24 and 48 hours at 0 C. In normal plasma, maximal activation of prorenin 
is obtained within 24 hours, and there is no further change after 48 hours. 
The degree of prorenin activation by immobilized trypsin at 0 C and neutral 
pH is the same as obtained with the intrinsic factor XU-kallikrein pathway 
at the same temperature and pH in pH 3.3-pretreated plasma5•8• This is an 
indication that the conditions for activating prorenin in our assay were optimal. 
The immobilized trypsin was removed by centrifugation, and the test samples 
were incubated with renin substrate for renin assay. Prorenin concentration was 
calculated as the difference between the renin concentration after activation with 
trypsin (total renin) and the concentration before activation (naturally occurring 
active renin). 
3.3.4. RESULTS 
Cold-promoted activation of prorenin . 
Normal plasma. Plasma samples from 30 normal volunteers were kept at 
0 C. Active renin and total renin were measured at various time intervals, as 
indicated in Fig.l. Total renin was 274 ± 17 ,u.U/ml(mean ± SEM) at time 
zero and remained constant throughout the entire period of incubation at 0 
C. The increase of active renin expressed as a percentage of prorenin at time 
zero was therefore used as an index of the degree of prorenin activation. Active 
renin increased progressively during cold exposure. It was 32 ± 4 ,u.U/ml before 
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Fig. 3.3.1. Cold-promoted activation of prorenin in normal plasma(n = 30) in the absence (8) and 
presence (0) of SBTI (final concentration I mg/ml). Mean± SEM. 
cold exposure and 66 ± 6 ,uU/ml after 7 days (p < 0.001, paired t-test). During 
this period of 7 days, 14 ± 1% of prorenin was activated (range 6% to 26%). 
In the presence of SBTI, less than 1 % of prorenin was activated. 
Clotting factor-deficient plasma. The concentration of naturally occurring active 
renin in these plasmas and the concentration of renin as measured after maximal 
activation by immobilized trypsin for 48 hours are given in Table I. The results 
with trypsin after 48 hours were not different from those after 24 hours. The 
plasmas (2 ml samples) were also activated by dialysis for 24 hours at 0 C 
against glycine HCL buffer, pH 3.3, succeeded by dialysis against sodium 
phosphate buffer, pH 7.5, again for 24 hours at 0 C36• Irreversible activation 
of pro renin occurs during the second dialysis step2•3• The results presented in 
Table I confirm that this process depends on the presence of both factor XII 
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and prekallikrein. After reconstitution of the plasma deficient in these factors 
with factor XII (final concentration 28 Mg/ml) and prekallikrein (final concen-
tration 50 Mg/ml), the activation of prorenin after acid treatment reached the 
same maximum level as with trypsin. In the plasma deficient in factor XI,X,IX,VI-
IIC,VII,V, or prothrombin, the activation obtained via the intrinsic factor XII-
kallikrein pathway after acid treatment also reached the same level as with 
exogenous trypsin. In plasma deficient in HMWK, the activation of prorenin 
after acid treatment was less than with trypsin, but this plasma had a low 
prekallikrein content (16 Mg/ml), and after reconstitution of prekallikrein to 
normal (50 Mg/ml), the degree of activation of prorenin obtained after acid 
treatment was the same as with trypsin. These results indicate that complete 
prorenin-renin conversion had occurred with trypsin not only in normal plasma 
but also in the deficient plasma. 
In a subsequent series of experiments, the deficient plasma was kept at 0 
C without any pretreatment, and both active renin and total renin were measured 
at various intervals. For comparing the results with those obtained in normal 
plasma, the change of active renin was expressed as a percentage of prorenin 
at time zero. By using this index, cold-promoted activation of prorenin was 
within the normal range in plasma deficient in factor XI,X,IX,VIIIC,VII,V, or 
prothrombin, but it was below normal in plasma deficient in factor XII or 
prekallikrein (Figs.2 and 3). Activation was in the lower end of the normal 
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Fig. 3.3.2. Cold-promoted activation of prorenin in clotting factor-deficient plasma. The range for 
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range for plasma deficient in HMWK with low prekallikrein concentration 
corrected to normal (50 ,ug/ml). Reconstitution of the plasma deficient in factor 
XII or prekallikrein with factor XII (final concentration 28 ,ug/ml) and pre-
kallikrein (final concentration 50 ,ug/ml) restored normal cold-promoted pro renin 
activation. Addition of HMWK (final concentration 70 ,ug/ml) to the HMWK-
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Fig. 3.3.4. Cold- promoted activation of prorenin in inhibitor-depleted plasmas. A, C,-INH, azM, 
AT III and a 1-AT were removed from the same factor XU-deficient plasma by immunoadsorption. 
Factor XII (final concentration, 28 !Lg/ml) was added at time zero. B, azM actitivity was also 
removed from normal plasma by chemical modification using methylamine. Source of factor-XU 
deficient plasma: own hospitals (see also Table 3.3.1.) 
deficient plasma had no additional effect (Fig.3). Therefore it appears that also 
in nonacidified plasma, the cold-promoted activation of prorenin depends on 
the presence of factor XII and prekallikrein, whereas the other clotting factors 
are not essential. 
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Inhibitor-deficient plasma. C1-INH, a2M, AT III, or a1AT or combinations 
of these inhibitors were selectively removed, either by immunoadsorption or, 
in the case of a2M, by chemical modification using methylamine. All inhibitor-
deficient plasma was prepared from the same factor XII-deficient plasma. After 
the addition of factor XII (final concentration 28 fLg/ml) ,these plasma samples 
were kept at 0 C for up to 7 days. Active renin and total renin were measured 
at various intervals (Fig.4). Total renin remained constant during the period 
of incubation at 0 C. As in the previous experiments, the change of active renin 
was expressed as a percentage of prorenin at time zero to provide an index 
of the degree of cold-promoted prorenin activation. In 7 days, 29% of prorenin 
was activated in C1-INH-deficient plasma, 56% in a2M-deficient plasma, 24% 
in AT III-deficient plasma, and 23% in a1AT-deficient plasma, compared with 
22% in control plasma. Activation of prorenin in plasma depleted of both C1-
INH and a2M was not different from activation in plasma depleted of azM 
alone. In plasma that had been depleted of the three inhibitors, C1-INH, a2M, 
and AT III, 100% of pro renin was activated in 7 days. After chemical modification 
of a 2M by treatment of normal plasma with methylamine, 42% of prorenin 
was activated in 7 days compared with 12% in the untreated plasma (Fig.4). 
The results demonstrate the importance of these proteins, particularly a2M, in 
inhibiting the activation of prorenin at 0 C. 
Contact-induced activation of prorenin. 
Dextran sulfate, molecular weight 500,000 is a potent inducer of contact 
activation. Addition of dextran sulfate to plasma in a final concentration of 
12.5 fLg/ml causes complete factor XII-HMWK-mediated activation of prekal-
likrein at 0 C within 10 minutes37•38 • At 37 C, activation is not complete, probably 
because of the strong effect of inhibitors at this temperature. Therefore we 
activated the factor XII-kallikrein pathway in plasma with dextran sulfate at 
0 C and incubated the activated plasma at either 0 C or 37 C. These experiments 
were carried out with factor XII-deficient plasma from which one or more 
inhibitors had been removed by immunoadsorption. The same factor XU-deficient 
plasma, but with the inhibitors still present, served as control. Immediately after 
factor XII (final concentration 28 fLg/ml) had been added, 0.9 ml of the 
reconstituted plasma was mixed at 0 C with 0.1 ml dextran sulfate, 125 fLg/ 
ml, in distilled water. The plasma was kept at 0 C for 10 minutes, during which 
complete activation of prekallikrein took place, and then was divided into 0.5 
ml aliquots. One aliquot was kept at 0 C for up to 2 hours, and the other 
was kept at 37 C, also for 2 hours. Active and total renin were measured at 
various intervals (Fig.5). Total renin remained constant during the entire period 
of incubation, and the change of active renin was expressed as a percent of 
prorenin at time zero. There was little change in the concentration of active 
renin at 0 C during the relatively short incubation period of 2 hours in either 
the control plasma or the inhibitor-deficient plasmas. There was also little 
activation at 37 C in the control plasma and in the plasmas deficient in CI-
INH, a2M, AT III, or a1AT. In 2 hours, 6 % of prorenin was activated in 
plasma depleted of both C1-INH and a2M, and 47% was activated in plasma 
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Fig. 3.3.5. Disappearance of kallikrein amidolytic activity (A and B) and activation of prorenin 
(C and D) at 37 C (0, •)and 0 C (.6. .6.) after contact-induced activation of prekallikrein, in the 
presence (A and C) and absence (B and D) of the kallikrein-inhibitors c,-INH, &2-M and AT 
III. The inhibitors were removed from factor XU-deficient plasma by immunoadsorption. The same 
factor XU-deficient plasma, but with the inhibitors still present, was used as control. Factor XII 
(final concentration, 28 ,_.g/ml) was added, and immediately thereafter the factor XU-high mol 
wt kininogen-kallikrein pathway was activated by incubation with dextran sulfate at 0 C for 10 
minutes. The plasma was then kept at 0 C for 120 minutes or incubated at 37 C for 120 minutes. 
Renin was measured before and after activation with trypsin (active renin and total renin respectivily). 
Prorenin concentration was calculated as the difference between the total renin and active renin. 
Total renin remained constant during 120-minute incubation period. The change of active renin 
expressed as a percentage of prorenin at time zero was used as a measure of prorenin activation. 
Kallikrein activity was measured in the absence (total kallikrein) and presence ofSBTI. The difference 
between total activity (0, .6.) and SBTI-resistant activity (a2M-bound kallikrein) was taken as free 
kallikrein(., .6.). Source of factor XU-deficient plasma: our hospitals. (see also Table 3.3.1.) 
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that had also been depleted of AT III (Fig.5). Less than 1% of pro renin was. 
activated in this triple- deficient plasma when factor XII was also absent. Thus 
it appears that prorenin can be activated by the contact activation system at 
37 C in nonacidified plasma with the three most important kallikrein inhibitors 
selectively removed. 
3.4.5. DISCUSSION. 
Previous studies have demonstrated the importance of factor XII and plasma 
kallikrein in the activation of prorenin in acid-pretreated human plasma2,3• Our 
study describes. the role of the contact activation system in the activation of 
prorenin that occurs when nonacidified plasma is kept at 0 C (cold-promoted 
activation), or when nonacidified plasma is incubated at 37 C after activation 
of the contact system with dextran sulfate (contact-induced activation). The 
activation process was studied in normal plasma, in plasma from patients with 
clotting factor deficiencies, and in plasma with one or more inhibitors of activated 
factor XII and kallikrein selectively removed. 
Tatemichi and Osmond39 have reported preliminary data showing that the 
cold-promoted increase of renin activity in two factor XII -deficient plasma 
samples was half the increase in two normal samples, whereas the increase in 
prekallikrein-deficient plasma was about equal to that in the normal plasma. 
However, the increase in renin activity was not expressed as a percentage of 
the total concentration of prorenin that was available for activation. These results 
are therefore difficult to interpret, even more so since prorenin in prekallikrein-
deficient plasma is higher than in normal plasma17,40 • In our study, factor XII-
deficient plasma and prekallikrein-deficient plasma showed little or no cold-
promoted increase in renin activity. Normal activation of prorenin was observed 
in such plasma after reconstitution with normal concentrations of factor XII 
and prekallikrein. The HMWK-deficient plasma we used contained about 30% 
of the normal concentration of prekallikrein as measured by clotting time assay 
and rocket immunoelectrophoresis. Plasma prekallikrein was therefore added 
to give a normal concentration of this protein. This plasma showed a significant 
degree of cold-promoted prorenin activation, which was not influenced by the 
addition of a normal concentration of HMWK. These results clearly show that 
the factor XII-kallikrein pathway is important for cold-promoted prorenin 
activation and that, under the conditions we have used, this pathway was similarly 
effective whether HMWK was present or not. 
The possibility that other clotting factors are also involved cannot be excluded, 
but they appear to be less important than factor XII and plasma kallikrein 
because significant degrees of prorenin activation were observed in plasma 
deficient in factor XI,X,IX,VIIIC,VII,V, or prothrombin. The importance of 
factor XII and plasma kallikrein as opposed to the other clotting factors is 
also supported by the observations on prorenin activation in plasma that was 
dialyzed at pH 3.3 and then redialyzed at pH 7.5. Complete activation ofprorenin 
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occurred during the second dialysis step in plasma deficient in HMWK after 
restoration of normal prekallikrein concentration, and in plasma deficient in 
either factor XI,X,IX,VIIIC,VII,V, or prothrombin; however, no increase in 
renin was observed in plasma deficient in either factor XII or prekallikrein. 
It has previously been shown that in the factor XU-kallikrein pathway of 
prorenin activation in acid-pretreated plasma, it is kallikrein and not factor 
XII that is the more direct activator2,3• It has further been reported that active 
human plasma kallikrein, not activated bovine factor XII or the active human 
28,000 molecular weight factor XII fragment, was capable of activating highly 
purified plasma prorenin41 . Therefore, it is also likely that in the cold-promoted 
activation in nonacidified plasma, it is factor XU-activated pre~allikrein rather 
than factor XII itself that causes prorenin activation. 
Five inhibitors of plasma kallikrein with varying potencies have thus far been 
characterized in human plasma: CciNH, a 2M, AT III, a 1AT, and a 2-antiplas-
min42. C1-INH and a 2M have been shown to be the most important inactivators 
of kallikrein in plasma at 37 C. However, after these two inhibitors have been 
removed, kallikrein is bound to AT III and possibly other inhibitors24,26. At 
0 C, a2M appears to be a more potent inhibitor than C1-INH37• C1-INH is 
further considered to be the most important inhibitor of both activated factor 
XII and the active 28,000 molecular weight factor XII fragment. Our results 
are in agreement with these data. Selective removal of either C1-INH, AT III, 
or a1AT had little influence on the cold-promoted activation of prorenin. In 
contrast, the removal of a2M resulted in a three times higher rate of prorenin 
activation. Depletion of both C1-INH and a2M had little or no additional effect, 
whereas the rate of activation was further increased by a factor of three after 
the plasma had also been depleted of AT III. In this triple-deficient plasma, 
47% prorenin activation was observed during incubation at 37 C for 2 hours 
after rapid and complete factor XII-HMWK-mediated activation ofprekallikrein 
with dextran sulfate at 0 C. During incubation at 37 C, kallikrein activity had 
a half-life of about 2 hours in this plasma (Fig.5). The half-life of kallikrein 
activity at 37 C in plasma deficient in C1-INH is about 30 minutes, and it is 
about 60 minutes in plasma deficient in both C1-INH and a2M24. In spite of 
this, we observed no activation of prorenin at 37 C in C1-INH-deficient plasma, 
and only 6 % in 2 hours in plasma deficient in bo~ C1-INH and a2M. Thus 
a great excess of the enzyme kallikrein (50 ~-tglml, approximately 0.6 ~-tM) over 
the substrate prorenin (200 ~-tU/ml, approximately 5 pM) was required for 
activation to be detected. This requirement may be necessitated by the extremely 
low concentration of substrate rather than a low affinity of the activating enzyme. 
We conclude that the cold-promoted activation ofprorenin in plasma depends 
on the contact activation system, and that this system is capable of activating 
prorenin in the plasma milieu at 37 C when the three most important kallikrein 
inhibitors, C1-INH, a2M and AT III, have been removed. 
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4. PRORENIN-RENIN CONVERSION: A TWO-STEP 
PROCESS 
4.1. TWO FORMS OF PLASMA RENIN AFTER ACTIVATION IN VITRO 
AND THEIR RELATION TO NATURAL PLASMA RENIN 
4.1.1. ABSTRACT 
Inactive renin in human plasma can be activated by pH 3.3-dialysis (generation 
of acid-activated renin), by clotting factor XII- mediated prekallikrein to kallikrein 
conversion after pH has been restored to neutral (generation of acid-kallikrein-
activated renin) or by the addition of trypsin (generation of trypsin-activated 
renin). Natural active renin, acid-kallikrein-activated renin and trypsin-activated 
renin behave similarly during affinity chromatography on Blue-Sepharose CL-
6B and during gel filtration on Sephadex G-100. They also show similar reaction 
kinetics with similar pH-optimum curves when acting on sheep renin substrate. 
Acid-activated renin is different. It is retained on Blue-Sepharose columns and 
it is inactivated at neutral pH during incubation at 37 C. This contrasts with 
the other forms of renin activated in vitro and with natural active renin. The 
pH-optimum curve of acid-activated renin, when acting on sheep renin substrate, 
is also different from that of the other forms of active renin. It is to be proven 
that the renins generated in vitro by neutral serine proteinases are identical with 
natural active renin, but clearly they bear more resemblance to natural renin 
than acid-activated renin does. Our preliminary conclusion is that acid-activated 
renin is a 'laboratory renin', which does not circulate in normal peripheral venous 
plasma. 
4.1.2. INTRODUCTION 
Inactive renin (prorenin) in human plasma can be activated by pH 3.3-dialysis 
of plasma (generation of acid-activated renin)\ by clotting factor XII-mediated 
prekallikrein to kallikrein conversion after pH has been restored to neutral 
(generation of acid-kallikrein- activated renin)2•3 or by the addition of trypsin . 
(generation of trypsin-activated renin2•4•5• It is not known whether inactive renin 
is a precursor of naturally occurring active renin. It is also not known whether 
the forms of renin activated in vitro are identical with natural renin. 
Some biochemical properties of the renins activated in vitro were therefore 
compared with those of natural renin. 
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4.1.3. METHODS 
Collection of blood 
Blood from five healthy male volunteers was collected into plastic tubes 
containing disodiumethylenediaminetetra-acetic acid (EDTA) in a final concen-
tration of 5 mM. The blood was pooled and immediately centrifuged at 8,000 
g for 10 min and plasma was stored at -20 C. Plasma was also obtained from 
a patient with Hageman trait (clotting factor XII less than 1% of normal) and 
a patient with Fletcher trait (plasma pre kallikrein less than 1% of normal). 
Activation procedures 
Generation of acid-activated renin. EDT A-plasma was dialyzed against glycine/ 
HCL buffer, pH 3.3, at 4 C for 24 h. pH was then restored to 7.5 with NaOH 
solution (1.0 M)5•6• 
Generation of acid- kallikrein-activated-renin. 
EDTA-plasma was dialyzed against glycine/HCL buffer, pH 3.3, at 4 C for 
24 h and then redialyzed against phosphate buffer, pH 7.5, again at 4 C, for 
24 h5• 
Generation of trypsin-activated renin. EDT A-plasma was incubated with Se-
pharose-bound trypsin in a final concentration of 0.3 mg of trypsin/ml at 4 
C for 24h5• 
Gelfiltration 
Samples (4 ml) of activated and non-activated EDTA-plasma were applied 
to 2.6 em x 90 em columns of Sephadex G-100 (Pharmacia) equilibrated with 
Tris/HCL buffer (0.01 M, pH 7.5, containing NaCl (0.15 M). This buffer was 
also used for elution. Flow rate was 10-12 mllh, and 2.5 ml fractions were 
collected. Void volume was determined with Dextran Blue (Pharmacia) and the 
columns were calibrated with the following molecular-weight markers (Phar-
macia): ribonuclease A (Mr 13,700), ovalbumin (Mr 43,000) and human serum 
albumin (Mr 65,000). 14C Ovalbumin (598 mCilmmol) (Amersham) was used 
as an internal standard in each run. Gel filtration occurred at 4 C. 
Affinity chromatography 
Samples (4 ml) of activated and non-activated EDTA-plasma were applied 
to 1.6 em x 24 em columns of Blue-Sepharose CL-6B (Pharmacia). The columns 
were equilibrated with sodium phosphate buffer (0.02 mM), pH 7.1. Elution 
was performed with the same buffer in three steps i.e. without NaCl, with NaCl 
at 0.2 M and with NaCl at 1.4 M7• Flow rate was 60 ml/h and 2.5 ml fractions 
were collected. Chromatography occurred at 4 C. 
Renin assay 
The method was based upon radioimmunoassay of angiotensin I (ANG I) 
generated during incubation with sheep renin substrate in the presence of 
proteinase inhibitors and EDT A5• 
Kinetic studies 
Aliquots (0.1 ml) of activated and nonactivated EDT A-plasma were incubated 
at 37 C with sheep renin substrate in concentrations ranging from 0.125 M 
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to 2.5 Min phosphate buffer, pH 7.5, in a final concentration of 1.0 ml. Incubation 
times were 15, 30 and 60 min to check for linearity of angiotensin I generation. 
Km was calculated from Lineweaver-Burk plots. For constructing pH-optimum 
curves, sheep renin substrate was dialyzed against phosphate buffers with pH 
values ranging from 4.5 to 8.5. Aliquots (0.1 ml) of activated and non-activated 
EDT A-plasma were incubated for 30 min at 37 Cat these pH values. 
4.1.4. RESULTS 
Gel filtration and chromatografy 
Natural renin, acid-kallikrein-activated renin and trypsin-activated renin had 
similar apparent molecular weights on Sephadex G-100 columns (Mr 48,000-
54,000, three experiments). Estimations of molecular weight of acid-activated 
renin were hindered by inactivation of this form of renin at neutral pH (see 
below). The behaviour of acid-activated renin on Blue-Sepharose columns was 
clearly different from that of natural renin, acid-kallikrein-activated renin and 
trypsin-activated renin. Acid-activated renin was retained on the columns, whereas 
the other renins were not (Fig.l). 
Reaction kinetics 
The initial velocity of angiotensin I formation at pH 7.5 and 37 C from sheep 
renin substrate with non-activated normal plasma was 0.12 nmol of ANG I 
min-1.1-1. The initial velocities with acid-activated normal plasma, acid-kallikrein-
activated normal plasma and trypsin-activated normal plasma were 1.16, 1.25 
and 1.27 nmol of ANG I min-1.1-1 respectively (mean values of two experiments). 
Acid-activated renin was inactivated during prolonged incubation at pH 7.5 
and 37 C (Fig.l). When acid-activated normal plasma was kept for 1 h at 37 
C after pH had been restored to 7.5, the initial velocity of angiotensin I formation 
from sheep renin substrate at pH 7.5 and 37 C was reduced from 1.16 to 0.24 
nmol of ANG I min-1.1-1• When, after 1 h storage at 37 C, the plasma was 
redialyzed at pH 3.3 for 24 h at 4 C, the initial velocity rose again to 0.84 
nmol of ANG I min-1.1-1• 
The initial velocity of angiotensin formation at pH 7.5 and 37 C from sheep 
renin substrate with non-activated factor XU-deficient plasma was 0.04 nmol 
of ANG I min-1.1-1• It was 0.25 nmol of ANG I min-1.1-1 with acid-activated 
factor XU-deficient plasma and it was 0.43 nmol of ANG I min-1.1-1 with trypsin-
treated factor XII- deficient plasma (mean values of two experiments). The initial 
velocity of angiotensin I formation with non-activated prekallikrein-deficient 
plasma was 0.08 nmol of ANG I min-1.1-1• It was 1.48 nmol of ANG I min-1.1-1 
with acid-activated prekallikrein-deficient plasma and 3.13 nmol of ANG I 
min-1.1-1 with trypsin-treated prekallikrein-deficient plasma (mean values of two 
experiments). From the results it appears that the generation of acid-activated 
renin does not depend on the factor XU-kallikrein pathway. Dialysis at pH 
7.5 for 24 h after pH 3.3-dialysis of the deficient plasmas did not result in 
greater velocities of angiotensin I formation than with the non-activated deficient 
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Fig. 4.1.1. Comparison between active renins in untreated plasma and activated plasmas. Natural 
active renin, trypsin-activated renin and acid-kallikrein-activated renin have similar pH optimum 
curves, when acting on sheep renin substrate (incubation at 37 C, pH 4.5- 8.5) (lower panel). These 
renins are not retained on dye-ligand chromatography (Blue Sepharose) columns (middle panel) 
and are not inactivated during incubation with sheep renin substrate at pH 7.5 and 37 C (upper 
pannel). Acid-activated renin has a different pH-optimum curve, is retained on Blue-Sepharose 
columns and is inactivated during incubation with sheep renin substrate at pH 7.5 and 37 C. 
plasmas, since the factor XU-mediated kallikrein generation did not occur in 
these plasmas2• Km values for natural renin, acid-kallikrein-activated renin and 
trypsin-activated renin were 0.28, 0.25 and 0.24 MM of ANG I respectively (mean 
values of two experiments). Km for acid-activated renin could not accurately 
be determined because of rapid inactivation during incubation with sheep renin 
substrate at neutral pH. The pH-optimum curve for acid-activated renin appeared 
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somewhat different from the curves for natural renin, acid-kallikrein-activated 
renin and trypsin- activated renin (Fig.l ). 
4.1.5. DISCUSSION 
The forms of active renin that are generated in plasma by acidification per se 
and by acidification followed by incubation at neutral pH at 4 C are different. 
They can easily be separated by dye-ligand chromatography, and their reactions 
with sheep renin substrate show different pH-optimum curves. The form of active 
renin that is generated by acidification per se is inactivated at neutral pH and 
37 C, whereas the form of active renin that is generated by acidification followed 
by incubation at neutral pH and 4 C is not inactivated during subsequent 
incubation at neutral pH and 37 C. This agrees with the results of Leckie & 
McGhee1• 
The generation of active renin in plasma by acidification per se (acid-activated 
renin) does not depend on factor XII and plasma kallikrein, whereas the 
generation of active renin at neutral pH after acid-treatment depends on Factor 
XU-mediated kallikrein formation (acid-kallikrein-activated renin)2• Acid-kal-
likrein-activated renin and trypsin-activated renin behave similarly during dye-
ligand chromatography and gel filtration. They also show similar reaction kinetics 
with similar pH-optimum curves, when acting on sheep renin substrate. 
It is not certain that the active renins that have been generated in vitro by 
neutral serine proteinases are identical with natural active renin, but clearly 
they bear more resemblance to natural renin than acid-activated renin does. 
Our preliminary conclusion is that acid-activated renin is a 'laboratory renin', 
which does not circulate in normal peripheral venous plasma. 
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4.2. TWO-STEP PRORENIN-RENIN CONVERSION. ISOLATION OF AN 
INTERMEDIARY FORM OF ACTIVATED PRO RENIN 
4.2.1. SUMMARY 
Prorenin is an inactive form of the aspartic protease, renin. Like pepsinogen, 
it is activated at low pH. The kinetics of acid activation of prorenin were studied 
in human amniotic fluid and plasma and in preparations of purified prorenin 
isolated from amniotic fluid and plasma. Conversion of pro renin (pR) into active 
renin (R) appeared to be a two-step process involving the generation of an 
intermediary form of activated prorenin (pRa). The pR - pRa step is an acid-
induced reversible change in the conformation of the molecule, and the pRa 
- R step is proteolytic. 
pRa - R conversion occurred in amniotic fluid at low pH by the action 
of an endogenous aspartic protease. In plasma pRa - R conversion occurs after 
restoration of pH to neutral and is caused by the serine protease, plasma kallikrein. 
pRa - R conversion did not occur in purified preparations of prorenin. Thus, 
in contrast to pepsinogen, the acid-induced reversible conformational change 
is not followed by autocatalysis. 
pRa of amniotic fluid and plasma could be separated from R by affinity 
chromatography on Cibacron Blue F3GA-agarose, and R but not pRa was 
detected by an immunoassay using monoclonal antibodies reacting with R and 
not with pR. The first-order rate constant for pR - pRa conversion depends 
on the protonation of a polar group (or groups) with pK ~ 3.4, the rate constant 
being proportional to the fraction of pR molecules that has this group protonated. 
This is analogous to the reversible acid-induced conformational change of 
pepsinogen that occurs before its proteolytic conversion into pepsin. kcat/Km 
for pRa - R conversion by plasmin and plasma kallikrein at pH 7.4 and 37 
C was 7.8 x 106 and 5.2 x 106 M-1 min-1 respectively, which was about 50 to 
70 times greater than for pR - R conversion. The susceptibility of pRa to 
proteolytic attack is high enough for the intrinsic factor XII-kallikrein pathway 
to cause rapid pRa- R conversion at 37 C even in whole blood with its abundance 
of serine protease inhibitors. Formation of pRa may occur in vivo in an acidic 
cellular compartment, such as exo- or endocytotic vesicles. 
The abbreviations used are: pR,prorenin; pRa, intermediary form of activated 
prorenin; R, protease-activated prorenin or naturally occurring active renin. 
4.2.2. INTRODUCTION 
Renin is a key enzyme in the formation of angiotensin II, which regulates blood 
pressure and fluid and electrolyte balance. An inactive form of renin, prorenin, 
circulates in plasma. Acidification of human plasma at 4 C initiates a process 
by which prorenin is converted into active renin (EC 3.4.23.15) after pH has 
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been brought back to neutral. This process involves the inactivation of one 
or more protease inhibitors at low pH, followed by activation of prekallikrein 
by factor XII and conversion of prorenin into renin at neutral pH by the action 
of kallikrein itself or by other pro teases activated by kallikrein 1- 3• The importance 
of inactivation of serine protease inhibitors for subsequent activation of prorenin 
was clearly demonstrated by the enhanced spontaneous pro renin-renin conversion 
at 4 C in plasma from which C1-esterase inhibitor, az-macroglobulin and 
antithrombin III had been selectively removed by immunoadsorption4• 
However, renin is an aspartic protease, and, like pepsinogen, prorenin is 
activated by acidification independently of factor XII and kallikrein5•6• In contrast 
with the factor XII- kallikrein-mediated proteolytic prorenin-renin conversion 
at neutral pH after exposure of plasma to low pH, the activation of prorenin 
during exposure to low pH appears to involve a reversible process, since the 
activated prorenin is inactivated at neutral pH and is reactivated when again 
exposed to low pH5•6• 
Prorenin can be converted into active renin by plasma kallikrein without prior 
acidification7•8 , but it has been suggested that an acid-induced conformational 
change of the prorenin molecule causes it to become more susceptible to 
proteolytic activation by kallikrein9• If the latter possibility proves to be true, 
then the acid pretreatment of whole plasma serves at least two functions. First, 
it inactivates one or more protease inhibitors so that activation of the factor 
XU-kallikrein pathway is initiated at neutral pH. Second, it induces a confor-
mational change of the prorenin molecule, by which it becomes active tow~rds 
angiotensinogen to produce angiotensin I and by which it also becomes more 
susceptible to irreversible activation by serine protease. 
In this paper we report the kinetics of acid activation of prorenin and the 
isolation of an intermediary form of activated prorenin, which indeed is more 
susceptible than native prorenin to proteolytic conversion into renin. 
4.2.3. MATERIALS AND METHODS 
Prorenin. Prorenin was isolated from normal human amniotic fluid. Amniotic 
fluid, free of contaminating blood, was collected from normal pregnant women. 
Benzamidine HCl, final concentration 10 mM, was added in order to prevent 
inadvertent activation of prorenin. It was also added to the buffers that were 
used during purification. All purification steps were carried out at 4 C. The 
first step was ion-exchange chromatography on DEAE-Sepharose CL-6B (Phar-
macia Fine Chemicals, Uppsala ,Sweden) at pH 7.4 using a linear gradient of 
NaCl up to 0.2 M10• The prorenin- containing fractions were pooled and subjected 
to dye-ligand chromatography on Cibacron Blue F3G-A agarose (Blue Sepharose 
CL- 6B, Pharmacia)11 • The next step was antibody-affinity chromatography12 
on a column of CNBr-activated Sepharose 4B (Pharmacia) to which the renin 
antibody R 2-1-21 (Ciba-Geigy, Basel, Switzerland, vide infra) was coupled, 10 
mg antibody to 2 g of dry Sepharose. The prorenin fraction that was eluted 
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from this column contained traces of active renin. They were removed by 
chromatography on a column of pepstatin-aminohexyl Sepharose 4B (Pharmacia), 
30 mg pepstatin to 1 gram of dry Sepharose13 • Prorenin does not bind to pepstatin, 
whereas renin is bound to this inhibitor. After this step highly purified human 
serum albumin (Behring AG, Marburg, West Germany), in a final concentration 
of 0.1 %, was added in order to stabilize prorenin. The prorenin solution was 
dialyzed against 0.1 M sodium phosphate/0.05 M NaCl pH 7.4 and concentrated. 
It contained 16,000 pg prorenin per ml as measured with an assay using 
monoclonal antibodies directed against human kidney renin and reacting with 
both prorenin and naturally occurring active renin (vide infra). It contained less 
than 10 pg renin per ml as measured with an assay using monoclonal antibodies 
specific for active renin (vide infra). A similar procedure was used for isolating 
prorenin from human plasma. The concentration of prorenin in the final 
preparation was 450 pg/ml, and active renin was undetectable. 
Activators ofprorenin. Factor XII and prekallikrein were isolated from human 
plasma and purified according to previously published methods14•15 • $-Factor 
Xlla and plasma kallikrein (both the two-chain molecule, Mr 85,000, and its 
enzymatically active light chain, Mr 28,000) were prepared from factor XII and 
plasma prekallikrein as described before16- 18• Trypsin from bovine pancreas, twice 
crystallized, 12,000 N-a-benzoyl-L-arginine-ethylester (BABE) units per mg 
protein, was from Sigma Chemical Co (St Louis, MO, USA). Pepsin A from 
porcine stomach, twice crystallized, 3,000 units per mg protein, was from 
Worthington (Freehold, NJ, USA). Human plasmin, 25 caseinolytic units per 
mg protein, was from KABI Diagnostica (Stockholm, Sweden). Thrombin, 64 
NIH units per mg of protein, was from Hoffmann-La Roche Ltd (Basel, 
Switzerland. Urokinase 5,000 Ploug units per ml, was from Leo Pharmaceuticals 
(Ballerup, Denmark). 
Monoclonal antibodies: Monoclonal antibodies R 3-27-6, R 3-36-16 and R 2-
1-21 were donated by prof K Hofbauer and dr C Heusser (Ciba-Geigy). The 
characteristics of the R3 antibodies have been described elsewhere19• They react 
equally well with human kidney renin and human chorionic cell culture prorenin 
and also with prorenin, trypsin-activated prorenin and naturally occurring active 
renin of human plasma20• The antibodies recognize different epitopes on the 
renin molecule and do not inhibit each other in their binding to renin. They 
were used for the direct radioimmunoassay of total renin i.e. renin plus prorenin. 
The R2 antibody also reacts with both prorenin and active renin but with lower 
affinity. It was used for the purification of prorenin. Monoclonal antibodies 
3E8 and 4G 1 specific for active renin, and not reacting with prorenin, were 
donated by prof J Menard (INSERM,Paris,France) The characteristics of these 
antibodies were described by Galen et alY. They react equally well with human 
kidney renin and both trypsin-activated prorenin and naturally occurring active 
renin of human plasma. These antibodies were used for the direct radioimmu-
noassay of either serine protease-activated prorenin or naturally occurring active 
renin. 
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Dye ligand chromatography. Naturally occurring active renin, acid-activated 
prorenin and protease-activated prorenin were separated on a 1 x 16 em column 
of Blue Sepharose. The column was equilibrated with 0.02 M sodium phosphate 
buffer pH 7.2 containing 0.2 M NaCl. Elution was performed in two steps, 
i.e. with the phosphate buffer containing 0.2 M NaCl and with the phosphate 
buffer containing 1.4 M NaCl. The flow rate was 50-60 mllh and 2.0-2.5-ml 
fractions were collected. 
Activation of prorenin. Prorenin-containing samples were activated by acidi-
fication or by adding proteases. For acidification the samples were diluted with 
an equal volume of buffer. A 0.05 M glycine/HCl buffer containing 0.1 M NaCl 
was used in the pH 2.5-4.0 range, and a 0.1 M sodium citrate/sodium phosphate 
buffer containing 0.05 M NaCl was used in the pH 3.5- 5.0 range. Samples 
were neutralized by adding an equal volume of 0.1 M sodium phosphate buffer 
containing 0.05 M NaCl pH 8.0. Fine adjustment to pH 7.4 was made by adding 
1M NaOH or 1M HCL The phosphate buffer also contained protease inhibitors 
i.e. 4 ,uM phenylmethylsulfonyl fluoride (PMSF) and 40 ,uM soybean trypsin 
inhibitor (SBTI, from Sigma). 
Direct RIA of naturally occurring active renin and activated prorenin. The total 
concentration of immunoreactive renin, i.e. active renin plus prorenin, was 
determined with a solid phase sandwich assay19,20 , by using the monoclonal 
antibodies R 3-27-6 and R 3-36-16. Antibody R 3-36-16 was labeled with 125!. 
Results are expressed as pg/ml using highly purified human kidney renin (Ciba-
Geigy), specific activity 700 Goldblatt units per mg of protein, as the standard. 
The lower limit of detection was about 20 pg/ml. 
The direct RIA of naturally occurring active renin and protease-activated 
pro renin was carried out by using the monoclonal antibodies 3E8 and 4G 1. 
Antibody 4G 1 was labeled with 125I. Details of the procedure were described 
elsewhere21 • Results are expressed as pg/ml using the same renin standard as 
in the assay of total immunoreactive renin. The lower limit of detection was 
10 pg/ml. 
Indirect RIA of naturally occurring active renin and activate prorenin. This assay 
depends on the generation of angiotensin I from purified sheep renin-substrate, 
as described previously22• The samples were incubated with substrate for ten 
time periods ranging from 0 to 24 min. Angiotensin I (ANG I) was quantitated 
by RIA. The slope of the linear part of the ANG I generation curve was used 
for calculating renin activity. Renin activity is expressed as pmol ANG I ml-1 
min-1• Concentrations of naturally occurring active renin and activated prorenin 
are expressed as ,uU/ml using the MRC human kidney renin standard 68/356 
(Medical Research Council, National Institute for Biological Standards and 
Control, London ,UK) as a reference. One ,uU MRC renin standard corresponds 
with 1.4 pg Ciba-Geigy renin standard. 
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4.2.4. RESULTS 
Characteristics of acid-activated prorenin. Dialysis of amniotic fluid for 48 h 
at pH 3.3 and 0-4 C causes conversion of prorenin, pR, into a form of active 
renin that is very similar, if not identical, to naturally occurring active renin23- 25 • 
Both the naturally occurring active form of renin and the form that is generated 
in amniotic fluid after 48 h dialysis at pH 3.3 we designate here as R. However, 
when in the present study amniotic fluid was acidified either by dialysis at pH 
3.3 or by dilution in low pH buffer in the presence of 4 MM pepstatin (pepstatin 
A, Sigma), an inhibitor of aspartic proteases, an activated form of prorenin 
was generated that was cleaiiy different from naturally occurring active renin. 
This form we designate here as acid-activated prorenin, pRa. pRa was also 
generated after acidification of purified prorenin isolated from amniotic fluid 
and plasma, both in the presence and absence of pepstatin. 
pRa and R of either amniotic fluid or plasma were readily separated by column 
chromatography on Blue-Sepharose, because, at neutral pH and low sodium 
concentration (0.2 M NaCl), pRa was retained on this column, whereas R was 
not (Fig.l). pRa was eluted at 1.4 M NaCL Purified prorenin activated by 
incubation for 48 h at pH 7.4 and 0 C with either trypsin (Sepharose-bound 
trypsin, 10 MM)22; plasmin (0.5 MM) or plasma kallikrein (Mr 85,000, 0.12 MM) 
behaved on the column in the same way as R. Purified prorenin activated by 
incubation for 48 h at pH 3.3 and 0 C with pepsin (0.1 MM) was also not 
bound to the column. 
Previous acid activation experiments with purified human kidney prorenin 
have demonstrated that pRa differs from R also in the fact that the enzymatic 
activity of pRa progessively falls at neutral pH26 • This was also observed in 
our acid activation experiments with purified amniotic fluid pro renin (Table 1 ). 
After acid treatment the activated prorenin was almost completely inactivated 
at neutral pH within 2 h at 37 C and after 72 hours at 0 C. This treatment 
had no effect on naturally occurring active renin of amniotic fluid nor did it 
affect the enzymatic activity of protease-activated prorenin. Similar results were 
obtained with purified plasma prorenin. Acid activation experiments with whole 
amniotic fluid and plasma demonstrated that after 48 h pR was converted into 
R in amniotic fluid but into pRa in plasma. pRa was also formed when pepstatin 
had been added to artmiotic fluid or in a mixture of amniotic fluid and plasma 
(Table 2). Thus, in whole amniotic fluid a pepsin-like enzyme, which is inhibited 
by pepstatin and by plasma protein(s ), appears to be involved in the formation 
ofR. 
A third way to distinguish pRa from R was by direct radioimmunoassay with 
antibodies that reacted with naturally occurring active renin from human kidney 
and plasma but not with native prorenin (Tables 1 and 2). This radioimmunoassay 
detected naturally occurring active renin of human amniotic fluid and plasma. 
It also detected purified prorenin of both amniotic fluid and plasma after it 
had been activated by protease but it did not detect pRa. Both pRa and R 
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Fig. 4.2.1. Effects of various modes of treatment of prorenin (inactive) on its behavior during 
chromatography on Blue Sepharose CL-6B. a: no treatment; b: pH 3.3, 0 C,48 h, and chromatography 
immediately after adjustment of pH to 7.4; c: pH 3.3, 0 C, 48 h in the presence of 4 MM pepstatin, 
and chromatography immediately after adjustment of pH to 7.4. e: assay of renin activity immediately 
after elution. 0: assay of renin activity after treatment of the eluate with 0.5 MM plasmin, pH 
7.4, 0 C, 48 h. Arrow: change to elution buffer containing 1.4 M NaCl. The first peak contains 
naturally occurring active renin (R) or proteolytically activated prorenin (R). The second peak contains 
native prorenin (pR) or non- proteolytically activated prorenin (pRa). 
Table 4.2.1. Effect of various treatments on purified prorenin isolated from amniotic fluid and plasma \0 
00 
Treatment Indirect RIA Direct RIA 
active renin total renin active renin 
before J.!U/ml pg/ml pg/ml 
Amniotic Plasma Amniotic Plasma Amniotic Plasma 
assay fluid fluid fluid 
None 14 <I 16,270 270 <10 <10 
2 Reversible activation-inactivation 
a) pH 3.3, 0 C, 48 h 9,400 400 14,900 280 <10 <10 
b) as 2a in presence of pepstatin 4 11M 9,500 380 14,200 290 <10 <10 
c) as 2a followed by pH 7.4,37 C,2 h 16 <I 15,400 280 <10 <10 
d) as 2c followed by pH 3.3,0 C,48 h 8,900 380 15,300 260 <10 <10 
3 Irreversible activation with aspartic protease 
a) pH 3.3, 0 C,48 h with pepsin 0.1 f.!M 9,200 410 15,900 290 15,200 270 
b) as 3a followed by pH 7.4,37 C, 2 h 9,100 390 14,400 260 14,700 280 
4 Irreversible activation with serine protease 
a) pH 7.4, 0 C, 48 h with plasmin 0.5 f.!M 10,200 400 16,100 270 15,200 270 
b) as 4a followed by pH 7.4, 37 C, 9,800 360 13,900 280 14,600 250 
2 h,in presence of SBTI and PMSF 
c) pH 7.4, 0 C, 48 h with plasma 9,400 390 14,600 270 15,600 290 
kallikrein (Mr 85,000) 0.5 f.!M 
d) as 4c followed by pH 7.4, 37 C, 9,600 370 14,900 250 13,900 270 
2h in presence of SBTI and PMSP. 
Indirect RIA: renin assay with angiotensin I antibodies, in which angiotensin I is generated from purified sheep renin substrate. 
Direct RIA: renin assay with monoclonal renin antibodies. 
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were detected when using antibodies that reacted with naturally occurring active 
renin as well as with native prorenin. 
Kinetics of acid-activation of prorenin. The acid-induced formation of pRa 
( pR - pRa ) in purified preparations followed first-order kinetics. The observed 
rate constant (kobs) for pR- pRa conversion was not altered by dilution (Fig.2), 
indicating that the activation is a unimolecular process. Activation was not 
inhibited by pepstatin (Table 1), in a concentration that was high enough to 
block the action of pepsin (0.1 ~tM) on prorenin. kobs for the disappearance 
of pR during acid-treatment of amniotic fluid or plasma was not different from 
kobs in the purified preparations (Fig.2), which indicates that pR - pRa 
conversion also occurs in whole amniotic fluid and plasma. 
NATIVE 
PRORENIN 
J,JU /ml 
30,000 
10,000 
6,000 
3,000 
1, 000 
600 
300 
100 
0 q 8 12 16 20 21l 
TIME AT pH 3. 3 AND 0°C h 
Fig. 4.2.2. Disappearance of prorenin (inactive) during acid-activation. Samples were brought to 
pH 3.3. At the time indicated, pH was restored to 7.4, and samples were immediately assayed 
for renin activity. Prorenin was determined as the difference between the renin activity after maximal 
activation of prorenin with 0.5 JLM plasmin and the renin activity after acid-treatment. Results 
are expressed as microunits of the MRC kidney renin standard. Maximum activity after activation 
by plasmin was the same as after treatment at pH 3.3 and 0°C for 72 h. e: amniotic fluid. 11: 
plasma. 0: prorenin isolated from amniotic fluid, D: prorenin isolated from plasma. 
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A more detailed kinetic study on the acid-activation of pro renin at 0 C showed 
that kobs depends on the protonation of a polar group (or groups). For such 
a reaction kobs (h-1) is given by the equation: 
kobs = k. a, in which k = first-order rate constant of conversion of protonated 
species, a = fraction of molecules that has the polar group in the protonated 
form = [H'] (K + [H']), in which K = dissociation ·constant of group being 
protonated. Our measurements of kobs at different levels of pH (Fig.3) could 
be fitted in this model, giving a pK value of3.4 (Fig.4). 
The inactivation, at neutral pH, of pRa of amniotic fluid and plasma in purified 
preparations also followed first-order kinetics. The rate constant (kobs) at pH 
7.4 and 37 C was 5.8 h-1 (mean of 3 experiments). It was independent of the 
initial concentration of pRa, which was equal to the concentrations of pR we 
had used in the acid-activation experiments shown in Fig.2. This is in accordance 
with a previously reported study on the inactivation of acid-activated human 
kidney prorenin26 • Thus, there is good evidence that this is also a unimolecular 
process. Moreover, for prorenin of human kidney and plasma it has been 
demonstrated that both the activation at low pH and the subsequent inactivation 
at neutral pH are reversible processes, because acid-treated prorenin, after its 
inactivation at neutral pH, is fully reactivated when again exposed to low pH5•27• 
In the present study this was also found to be true for purified prorenin isolated 
from human amniotic fluid (Table 1 ). 
Proteolytic conversion of acid-activated prorenin into renin. Our kinetic studies 
on the activation of pro renin in acidified amniotic fluid indicate that the activation 
proceeds in two steps (Figs.2-5). First, pRa is formed (pR - pRa), which is 
Table 4.2.2. Effect of various treatments on prorenin in amniotic fluid and plasma. 
Treatment Indirect RIA" Direct RIAb 
active renin active renin 
,uU/ml pg/ml 
before Amniotic Plasma Amniotic Amniotic Plasma Amniotic 
assay fluid fluid fluid fluid 
+ + 
plasma plasma 
1. No treatment 480 22 260 680 32 360 
2. Acid-treatment 
a) pH 3.3,0 C,48 h 8,100 240 4,160 11,300 44 440 
b) as in 2a in presence 7,800 790 
of pepstatin 4 M 
c) as in 2a followed by 7,900 34 320 10,700 37 420 
pH 7.4, 37 C, 2h 
d) as in 2b followed by 530 720 
pH 7.4, 37 C, 2h 
a Indirect RIA: renin assay with angiotensin I antibodies, in which angiotensin I is generated 
from purified sheep renin substrate. 
b Direct RIA: renin assay with monoclonal renin antibodies. 
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then converted into active renin (pRa- R) by a pepsin-like enzyme. That pRa 
is an intermediary product is also indicated by the fact that it is converted 
by trypsin, plasmin or plasma kallikrein into a form of active renin that is 
very similar, if not identical, to naturally occurring active renin. The two active 
species, i.e. naturally occurring active renin and protease-treated pRa, behaved 
in the same way during chromatography on Blue-Sepharose. Both were not 
inactivated at neutral pH, and both were bound to antibodies that reacted with 
naturally occurring active renin and not with prorenin. 
pRa is much more susceptible than native prorenin to proteolytic conversion 
NATIVE 10,000 
PRORENIN 
J-lU/mL pH s. oo---. 
6,000 
3,000 
1, 000 
600 
300 
100 
0 
pH 4. 50 
......... 
pH 4. 25 
pH 4. 00 
pH 3. 75 
pH 3. 30 
2 3 4 
TIME AT 0°C 
\ 
5 
days 
6 7 
Fig. 4.2.3. pH-Dependence of kinetics of acid activation of prorenin (inactive) isolated from amniotic 
fluid. Prorenin was determined as described in the legends to Fig. 2. Disappearance of prorenin 
(pR- pRa) followed first-order kinetics. The observed rate constant (kobs) was highly pH-dependent. 
At pH <3.0 pR and/or pRa are destroyed. 
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Table 4.2.3. Kinetics of proteolytic conversion of native renin and the intermediairy acid-activated 
form of prorenin into active renin by serine proteases. 
kcat/Km 
Serine M-1• min-1 
Protease Native Acid-treated 
prorenin pro renin 
Plasma kallikrein 
Mr 85,000 1.2xl05 52x1Q5 
Plasma kallikrein (light chain) 
Mr 28,000 0.7xl05 48xl05 
Plasmin 1.2xl05 78xl05 
Trypsin 18xl05 960xl05 
Concentration of serine protease ranged from 0.005 to 0.1 JLM. Results are the means of 3 experiments. 
into renin (Fig. 6). Conversion by either trypsin, plasmin or plasma kallikrein 
followed pseudo-first-order kinetics. The rate constant, which equals kcat/Km, 
was 50 to 70 times greater for pRa --.. R conversion than for pR - R conversion 
(Table 3). In contrast, kcat/Km for conversion of pRa that had been inactivated 
at neutral pH was not different from kcat/Km for conversion of native prorenin. 
Thrombin, urokinase and /3-factor Xlla, in concentrations up to 0.1 MM, which 
is comparable to those we had used with the other serine proteases, had no 
effect neither on native prorenin nor on pRa. Figure 7 shows that pRa could 
be converted into renin by the intrinsic factor XU-kallikrein pathway even in 
whole blood. In this experiment purified amniotic fluid prorenin, after it had 
been treated at low pH, was added to blood at neutral pH. The factor XU-
kallikrein pathway was then activated at 37 C by adding dextran sulfate (Mr 
500,000) in a final concentration of 50 Mg/ml28 • This resulted in rapid pRa __. 
R conversion. 
4.2.5. DISCUSSION 
This study confirms that prorenin is reversibly activated after acidification5•6•26•27 • 
Our kinetic analysis indicates that the activation (pR- pRa) is an intramolecular 
process. It appears, therefore, that the activation does not depend on the 
interaction of pR with pRa or R (autoactivation) or with other enzymes. The 
process was not affected by pepstatin, indicating that the activation of prorenin 
was not caused by a contaminating aspartic protease. A previous study on the 
kinetics of inactivation of acid-activated prorenin at neutral pH showed that 
this is probably also an intramolecular process26 • This implies that the inactivation 
(pRa - pR) is not caused by the interaction of pRa with an inhibitor. 
The first-order rate constant for the acid-induced activation of prorenin is 
highly pH dependent. Our kinetic data suggest that the activation depends on 
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Fig. 4.2.4. pH-Dependence of kinetics of acid-activation of pro renin (inactive) isolated from amniotic 
fluid. Data from Fig.3 were used for calculating pK of the polar group (or groups) in prorenin 
that must be protonated for pR - pRa conversion to occur. Calculation was based on the the 
equation: kobs = k . a, in which k =first order rate constant of conversion of the protonated 
species, and a = fraction of molecules that has the polar group in the protonated form = [Hj/ 
(K + [H+]) in which K = dissociation constant of the group being protonated. The equation can 
also be written as follows: 
-log (kobslk) =pH+ log(K + [W]). 
The curves are constructed by computer. The lower group of curves describe -log(kabs/k) as a 
function of pH, each curve corresponding with a different value of pK. All curves that describe 
-log kobs as a function of pH and belong to the same pK are parallel. The uppur curve describes 
this function when pK = 3.4 and -log k = 1.03, so that k = 0.1 h-1• Our data (e) showed a good 
fit with this curve. 
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Fig. 4.2.5. Generation of an intermediary acid-activated form of prorenin in amniotic fluid. Amniotic 
fluid was kept at pH 3.3 and 0 C for up to 48 h. Renin activity was measured both immediately 
after restoration of pH to 7.4 and after incubation at pH 7.4 and 37 C for 2h. The immediate 
assay (•) measures both the intermediary reversibly acid-activated form of prorenin (pRa) and 
the irreversibly protease-activated form (R). The assay after 2h incubation at 37 C (0) measures 
only R. The difference between the results of the two assays (D) is therefore a measure of pRa. 
Results are the means of 6 experiments. The lines are computer-constructed according to the following 
reaction model: 
k3 kl k2 
R +-pR ~pRa~R, 
in which kl, k2 and k3 are first-order rate constants with values of 0.095 h-1, 0.130 h-1 and 0.002 
h-1 respectively. 
the protonation of one or more polar groups with a pK value of 3.4, which 
is followed by a conformational change that exposes the active site of the enzyme 
molecule. This is analogous to the effect of low pH on pepsinogen. Interactions 
between positively charged amino acid residues of the 'pro-part' polypeptide 
chain (activation peptide) and negatively charged residues of the 'enzyme-part' 
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Fig. 4.2.6. Kinetics of proteolytic conversion of native prorenin (pR) and the intermediary acid-
activated form of prorenin (pRa) into active renin (R). Prorenin isolated from amniotic fluid was 
used, and pRa was generated by incubation at pH 3.3 and 0 C for 72h. Generation of R from 
pR or pRa occurred during incubation with 0.01 J.LM trypsin (not immobilized) at pH 7.4 and 
37 C.The reaction was stopped by 40 J.LM SBTI and 4 JLM PMSF. Renin activity was measured 
after incubation at pH 7.4 and 37 C for 2h. This assay measures R but not pRa. : generation 
of R from pRa. : generation of R from pRa that had been converted into pR by incubation_ at 
pH 7.4 and 37 C for 2h. : generation of R from native pR. Results are the means of 3 experiments. 
The lines are constructed by computer according to the following reaction model: 
k2 kl k3 
R +-pR---+ pRa---+R, 
in which kl, k2 and k3 are first-order rate constants with values of 0.095 min-I, 0.980 min-I and 
0.024 min-I respectively. 
are thought to stabilize the pepsinogen molecule in its inactive form29•30• By 
protonation of negatively charged amino acid residues at low pH, the bonds 
are broken and the pro-part moves away from the bulk of the molecule, thereby 
uncovering the active site of the 'enzyme-part'. In the case of acid-activated 
prorenin, however, the molecule has little or no catalytic activity at low pH, 
despite the fact that its active site is exposed. This is because of the high pK-
value of the carboxyl groups of the aspartic acid residues (Asp-38 and Asp-
226, sequence numbering from Ref 31 and 32) in the active site of renin, as 
compared with the pK -value of the corresponding aspartic acid residues in pepsin 
(Asp-32 and Asp-215)32• The pH must be above 5.0 for Asp 38 in renin to 
be ionized ,which is a prerequisite for renin's catalytic activity. 
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Fig. 4.2.7. Proteolytic conversion of native prorenin (pR) and of the intermediary acid-activated 
form of prorenin (pRa) into active renin (R) by the factor XU-kallikrein contact activation system 
in whole blood. Prorenin isolated from amniotic fluid was used, and pRa was generated by incubation 
at pH 3.3 and 0 C for 72h. After restoration of pH to 7.4, 50 J.Ll pR or pRa (200 pg) was added 
to 1 ml of fresh, citrated, blood at 37 C. Immediately thereafter 50 I dextran sulfate (Mr 500,000) 
was added in a final concentration of 50 J.Lg/ml, by which the factor XU-kallikrein pathway is 
activated. The mixture was incubated at 37 C for up to 10 min. The reaction was stopped by 
40 J.LM SBTI and 4 J.LM PMSF. Renin activity was measured after incubation at pH 7.4 and 37 
C for 2h. This assay measures R but not pRa. R was also measured by direct RIA using antibodies 
specific for active renin (figures in parentheses). 0: with dextran sulfate. •: with H 20 instead of 
dextran sulfate. 
It has been reported that semipurified prorenin isolated from amniotic fluid 
is bound to the Cibacron Blue F3GA dye after acid-activation but not after 
activation by pepsin. We assume that this acid-activated form of prorenin is 
identical with pRa. Its affinity for Cibacron Blue F3 GA and other dye ligands, 
such as Procion Red HE3B (Matrix-gel red A, Amicon group, Lexington, MA, 
USA) (unpublished observations), can be used for separating it from naturally 
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occurring active renin and also from protease-activated prorenin. Our studies 
show that the presence of the pro part in pRa interferes, in the direct radio-
immunoassay with the binding to antibodies that reacted with naturally occurring 
active renin and not with prorenin. This too can be used to distinguish pRa 
from naturally occurring active renin and protease-activated prorenin. 
Activation of prorenin is a two-step process (Fig.8). The first step (pR -
pRa) is reversible. The second step (pRa - R) is proteolytic. In amniotic fluid 
both steps occur at low pH, the second step being caused by an endogenous 
aspartic protease. The action of this protease was inhibited by pepstatin and 
also by contaminating plasma proteins. In plasma the pR - pRa step also occurs 
at low pH but the pRa - R step occurs after restoration of pH to neutral, 
and is initiated by the intrinsic serine protease factor XII-kallikrein pathway1•2•4• 
Franks et aP4 reported that the activation of prorenin after overnight dialysis 
of amniotic fluid against pH 3.3 buffer at 4 C was completely reversible. In 
our study about half of the activated prorenin was in the pRa form after 12-
h dialysis at pH 3.3. Franks et aP4 used concentrated amniotic fluid and it 
is therefore possible that in their experiments the pRa - R step was inhibited 
by contaminating plasma protein(s). 
R 
Pro renin -.-----1111>~ Prorenin H 
Prorenin * -.-----llillo~ Prorenin * H 
active 
Serine 
protease 
Aspartic 
protease 
Renin 
.------ Renin H 
Neutral pH Low pH 
Fig. 4.2.8. Reaction steps involved in prorenin-renin conversion. H: protonated species. *: species 
with active site exposed. Asp 38 and Asp 226 are the two aspartic acid residues in the active site. 
Asp 226 but not Asp 38 must be protonated for rendering the molecule enzymatically active. 
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Our study supports the conclusion that the molecular conformation of prorenin 
is changed by acidification in such a way that the molecule becomes highly 
susceptible to proteolytic conversion into renin. It appears, therefore, that the 
acid-induced exposure of the catalytic site of prorenin, which causes reversible 
activation (pR - pRa), coincides with the exposure of cleavage sites susceptible 
to attack by aspartic and serine proteases that cause irreversible activation (pRa 
- R). One or more of these cleavage sites are so susceptible to proteolytic attack 
by serine protease that the intrinsic factor XII- kallikrein pathway of plasma 
is capable of generating renin at physiological pH and physiological temperature 
even in whole blood with its abundance of serine protease inhibitors. 
Further studies are needed to answer the question of whether the effect of 
acid in vitro is only a test tube phenomenon or whether this has a physiological 
correlate. Given the low pH of secretory granules35,36 , one might speculate that 
renin is present in these granules in a form corresponding with the pRa form 
produced by acidification in vitro and that pRa is irreversibly converted into 
R by a protease before it is released into the circulation. It is also possible 
that the proteolytic activation of pRa occurs during its release, as soon as it 
enters a milieu where it is rapidly activated by a serine protease. Circulating 
prorenin might be taken up into endocytotic vesicles of the vascular endothelium. 
The formation of these vesicles is known to be followed by rapid acidification 
of its content to a pH as low as 537- 41 • pH may be lower at sites near the 
proton pump at the inner side of the vesicle membrane. After its uptake pro renin 
might undergo the acid-induced conformational change, while it is transported 
by the vesicles to the luminal or contraluminal side of the endothelial cell. It 
might then be released into a milieu where it is rapidly activated by a serine 
protease. 
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5. PHYSIOLOGICAL REGULATION OF PLASMA 
PRO RENIN 
5.1. RELEASE OF ACTIVE AND INACTIVE RENIN BY THE PORCINE 
KIDNEY 
5.1.1. ABSTRACT 
We studied the relative rates of release of active and inactive renin by the kidney 
in anesthetized pigs. Renin concentration was determined in arterial and renal 
venous plasma as follows: 1) before and after stimulation of renin release with 
isoproterenol or furosemide, 2) after suppression of renin release by extracellular 
fluid volume expansion, and 3) after administration of propranolol or indome-
thacin. Inactive renin was activated by dialysis of plasma at pH 3.3 for 24 hours. 
Renin concentration was estimated by radioimmunoassay determination of 
angiotensin I after a 3-hour incubation with excess homologous renin substrate. 
Following isoproterenol, the release of active renin increased from 8 ± 4 (SEM) 
to 58 ± 34 ng/min, and inactive renin increased from 53 ± 33 to 321 ± 136 
ng/min. Similarly, furosemide stimulated the release of both active and inactive 
renin. Both forms of renin were suppressed by propranolol or indomethacin. 
Although changes in renin release following volume expansion were not sta-
tistically significant, the direction of change for both forms of renin was similar. 
Following logarithmic conversion of the rate of release, the plot of active vs. 
inactive renin formed a straight line. Values for active renin as a percentage 
of the total renin in simultaneously drawn arterial and renal venous plasma 
samples were not different. Thus, under the conditions of these experiments, 
release of active and inactive renin appears to be controlled by similar mechanisms. 
Both stimulation and suppression of renin result in parallel changes in release 
of the two forms. Data on relative amounts of active renin in arterial and renal 
venous plasma suggest that there is no systemic conversion of the two forms. 
5.1.2. INTRODUCTION 
Recent reports suggest the presence of an inactive form of renin in plasma and 
in renal tissue of both normotensive and hypertensive patientsl-4. Studies from 
several laboratories have centered on that form of renin which is inactive at 
physiological pH but activated by treatment at acid pH2,3. This acid-activated 
or inactive renin has also been reported to be present in several species in addition 
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to man5- 10• Whether inactive renin represents a true proenzyme or renin bound 
to an inhibitor remains unclear11 • It also has been suggested that inactive renin 
may be the intrarenal storage form of the enzyme8• 
Acid-activated renin has been measured in systemic and renal venous plasma 
of man under varying conditions2, 3• These data suggest that changes in the 
concentration of active and inactive renin in plasma may be dissociated under 
certain circumstances. However, no data are available relating the release of 
active and inactive renin in experimental animals. Therefore, studies were carried 
out to determine the rate of release of both forms of renin by the porcine kidney. 
The pig was selected as the experimental animal because acid-activated renin 
has been isolated from its kidney5,6• In addition, inactive renin has been reported 
to be released by the isolated perfused pig kidney5• To correlate the rate of 
release of active and inactive renin, renin release was stimulated with either 
isoproterenol or furosemide, and suppressed by volume expansion, propranolol, 
or indomethacin. By varying widely the rate of release of renin, we could better 
observe the relationship between release of the active and inactive forms. 
5.1.3. METHODS 
Surgical Procedures Experiments were carried out on pigs 45-57 days old weighing 
3.0-13.5 kg. These pigs were small enough to study easily but still had mature 
renal function 12• Anesthesia was induced with intraperitoneal pentobarbital 
sodium (35 mg/kg). Additional anesthetic was given during the experiment as 
required. The pigs were intubated and ventilated (Loosko Amsterdam Infant 
Ventilator) monitored and body temperature maintained with a heating pad 
and radiant heat lamp. A catheter was placed in the femoral artery to obtain 
arterial blood samples and to measure blood pressure using a strain gauge 
transducer. A catheter was placed in the external jugular vein for infusion of 
saline and drugs. A second catheter was placed in the bladder via a small midline 
abdominal incision. 
The left kidney was exposed through a retroperitoneal flank incision and the 
left ureter cannulated. The renal artery and vein were carefully dissected free 
from the surrounding tissue, and a noncannulating electromagnetic flowmeter 
probe (Transflow 500 Electromagnetic Bloodflow Meter) was placed on the renal 
artery. A curved 22- gauge needle attached to a polyethylene catheter was inserted 
into the renal vein to obtain renal venous blood samples. A curved 27-gauge 
needle attached to a polyethylene catheter was inserted into the renal artery 
for infusion of saline or isoproterenol. A period of 45-60 minutes was allowed 
for stabilization following completion of surgery. 
Experimental Protocols 
Effects of Isoproterenol, Furosemide, Propranolol and Indomethacin. The following 
protocol was observed in six pigs. During a control period, two sets of arterial 
and renal venous blood samples were obtained 5 minutes apart. An infusion 
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of a solution of isoproterenol (1.0 J,tg/ml per kg) was started into the renal 
artery at a rate of 0.1 ml/min with a Braun infusion pump. The infusion rate 
was increased gradually until renal blood flow increased. After 5-7 minutes two 
more sets of arterial and renal venous blood samples were obtained 5 minutes 
apart. The infusion of isoproterenol then was stopped, and following a 45-60 
minute recovery period a third collection of urine and two more blood samples 
were obtained. Following recovery from the isoproterenol, the pigs were given 
furosemide, 1 mg/kg,iv. As urine flow increased, isotonic saline containing KCL 
( 4.5 mM) was infused into the jugular vein at a rate equal to urinary output. 
Ten minutes after the diuretic was given, two sets of arterial and renal venous 
blood samples were collected 5 minutes apart. A second injection of furosemide, 
2 mg/kg, was given and the sampling repeated. 
The effect of two inhibitors of renin secretion then was determined. Immediately 
after sampling, following the second dose of furosemide, propranolol, 1 mg/ 
kg, was given intravenously, and after 10 minutes two sets of blood samples 
were obtained. Indomethacin, 2 mg/kg was given intravenously and a final set 
of blood samples obtained. 
Effects of Volume Expansion, Furosemide, and Indomethacin In five pigs the 
response to volume expansion and furosemide was determined. After control 
blood samples were obtained, the pigs were given isotonic saline equivalent to 
5% body weight, infused over 30 minutes. The infusion rate then was adjusted 
to equal urine flow rate. When an apparent steady state urine output was reached, 
two sets of arterial and renal venous blood samples were drawn 5 minutes apart. 
The pigs were then given furosemide, 2 mg/kg per hr, as a constant intravenous 
infusion and the saline infusion increased to match urine flow rate. When urinary 
output had stabilized, blood samples again were obtained. The pigs then received 
indomethacin, 2 mg/kg, and a final set of samples was drawn. 
Analytical Techniques and Data Handling. 
All blood samples were collected in tubes chilled on ice and containing disodium 
ethylenediaminetetraacetic acid (EDT A 5mM) . Blood samples were centrifuged 
within 5 minutes of collection and the plasma removed. The red blood cells 
then were reconstituted to the original hematocrit in saline and returned to 
the pig. Plasma for renin determinations was stored at -20 C until assayed. 
Hematocrit was determined by the micro method. 
Renin in arterial and renal venous plasma was estimated as described by Derkx 
et aF. Plasma was dialyzed at either pH 4.5 or 3.3 for 24 hours at 4 C and 
then returned to pH 7.4 by dialysis for another 24 hours. After dialysis, plasma 
was incubated with excess homologous substrate, and the angiotensin I generated 
was determined by radioimmunoassay. The renin concentration dialyzed at pH 
4.5 was active renin. Following dialysis at pH 3.3, the concentration of renin 
was greater, representing the sum of active renin and acid-activated renin, i.e.,total 
renin. Inactive renin was calculated as the difference between total renin and 
active renin. Renin substrate was prepared according to the method of Skinner13 • 
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The substrate was found to be free of renin and angiotensinase activity. Incubation 
of substrate with renin resulted in zero order kinitics. The concentration of 
renin in plasma was expressed as nanograms of angiotensin I generated per 
milliliter per hour (ng/ml/h). Renin release was calculated as the product of 
the venous-arterial difference and the renal plasma flow. Mean arterial blood 
pressure, heart rate, and mean renal blood flow were taken directly from digital 
readout. 
Statistical analysis was carried out using analysis of variance and t.,;test for 
paired and unpaired comparisons. The level of significance was set 5 %. Because 
significant heterogeneity of variance in renin release existed, all data were 
converted to logarithms prior to statistical analysis. 
5.1.4. RESULTS 
Effects of isoproterenol, furosemide, propranolol, and indomethacin; 
The release of total renin increased following intrarenal arterial infusion of 
isoproterenol (Fig.l ). This increase in the release of total renin was due to an 
increase in the rate of release of both active and inactive renin. During perfusion 
of isoproterenol renal blood flow increased from 73 ± 10 to 94 ± 6 ml/min, 
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Fig.5.1.1. Effects of isoproterenol on the release of total, active, and inactive renin. C = control; 
ISO = isoproterenol; n = 5. *Significantly different from control (p < 0.05). 
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whereas mean systemic blood pressure decreased from 114 ± 3 to 107 ± 4 
mm Hg. Both changes were significant. 
Following the first dose of furosemide (1 mg/kg) there was an increase in 
the release of total renin from the kidney (Fig.2). As with isoproterenol, the 
increase was due to to changes in the release of both active and inactive renin. 
Although renal blood flow increased in each pig, the change from 87 ± 8 to 
95 ± 9 mllmin was not statistically significant. No consistent changes in mean 
arterial pressure were noted. 
The second injection of furosemide (2 mg/kg) did not result in any further 
increase in the release of total, active, or inactive renin (Fig.2). No significant 
changes in hemodynamics were noted, although blood flow averaged 102 ± 
9 ml/min after the second dose of diuretic. 
The systemic administration of propranolol resulted in a significant decrease 
in the release of total renin (Fig.3). This change again was accompanied by 
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a significant change in both the active and inactive forms of the enzyme. 
The administration of indomethacin produced a further fall in the rate of 
release in total renin from 104 ± 47 to 37 ± 20 ng/min. Active renin decreased 
from 32 ± 9 to 9 ± 3 ng/min, and inactive renin decreased from 74 ± 47 
to 39 ± 15. Although these changes were not statistically significant, they were 
seen in five of the six pigs. The effects of isoproterenol, furosemide, propranolol, 
and indomethacin on renal blood flow, and the concentration of renin in renal 
venous plasma are shown in Table 1. Although each drug tended to cause a 
change in blood flow, the concentration of renin in renal venous plasma increased 
with isoproterenol and furosemide and decreased with propranolol and indo-
methacin. 
117 
Table 5.1.1. Renal blood flow (RBF) and renal venous renin (RVR) concentration in pigs during 
control periods (C) and following isoproterenol (ISO), furosemide (F), propranolol (P), and 
indomethacin (IM). 
c ISO c F-1 F-2 p IM 
RBF 73 94 87 95 102 85 75 
(mil min) (10) (6) (8) (9) (9) (8) (7) 
T-RVR 4.8 12.3 4.2 14.1 19.2 9.2 4.4 
(ng/ml) (0.4) (4.9) (1.0) (3.0) (3.6) (1.4) (5.9) 
A-RVR 0.8 1.9 0.8 2.0 3.3 1.6 0.8 
(ng/ml) (0.1) (0.8) (0.2) (0.5) (0.8) (0.3) (0.2) 
1-RVR 4.1 10.3 3.4 12.0 14.9 7.6 3.6 
(ng/ml) (0.3) (3.7) (0.8) (2.8) (3.4) (1.3) (0.5) 
Values are mean (SEM in parentheses); n = 5. F-1 = furosemide 1 mg/kg, F-2 = furosemide 
2 mg/kg: T = total renin; A = active renin; I = inactive renin. 
Effects of volume expansion, furosemide, and indomethacin. 
In this group of pigs, the treatments resulted in changes in release of total, 
active, and inactive renin (Table 2). However, because of the wide variation 
among animals, the changes were not statistically significant. 
Table 5.1.2. Renin release (ng/min) under control conditions and following saline volume 
expansion, furosemide, and propranolol. 
Control Saline Furose- Propra-
mide nolo! 
Total 121 77 1035 621 
(57) (42) (664) (342) 
Active 23 14 190 47 
(8) (8) (87) (47) 
Inactive 98 57 937 574 
(44) (38) (538) (334) 
Values are mean (SEM in parentheses); n = 5. 
Relation of release of active and inactive renin 
When the logarithm of the rate of release of active and inactive renin was 
plotted, the relative proportions of the two forms of the enzyme remained constant 
(Figs.4 and 5). This relationship appears to hold regardless of the treatment. 
This finding is supported by the data demonstrating that the relative concentration 
of active renin in either arterial or renal venous plasma is not changed by treatment 
(Table 3). In addition, there was no significant difference between the relative 
concentration of active and inactive renin in arterial and renal venous blood 
(Table 3). 
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Table 5.1.3. Percent active renin in arterial and renal venous plasma. 
Control Isopro- Furo- Propra-
terenol semide nolo! 
Arterial 19.6 16.6 16.1 18.4 
(3.9) (2.5) (2.5) (5.3) 
Renal 16.7 14.4 17.4 19.5 
venous (0.9) (I. 7) (2.3) (2.6) 
Values are mean (SEM in parentheses); n = 5. 
5.1.5. DISCUSSION 
An acid-activated form of the enzyme renin has been demonstrated in kidneys 
of several animal species including the pig5•6•7•8•10• The studies of Leckie and 
McConnell (1975) suggest that inactive renin may be coupled to an inhibitor, 
which is destroyed by acidification. Most studies on experimental animals to 
date have concentrated on the estimation of tissue renin content, although 1 ames 
and Hall (1974) did measure acid-activated renin in dog plasma. 
Boyd (1974) has demonstrated that porcine kidney contains at least two forms 
of renin. Renin A had a molecular weight of 40,000 and was more active than 
renin B, which had a molecular weight of 60,000. Renin B could be converted 
to renin A by acidification. Furthermore, he demonstrated stimulation of release 
of renin A and B in response to isoproterenol in the isolated perfused kidney. 
Therefore, it appeared reasonable to carry out experiments in the anesthetized 
pig. 
In the present studies, the plasma concentration and release by the kidney 
of two forms of renin were determined. Several authors have demonstrated that 
renin is activated by dialysis of human plasma at pH 3.32•3 , and by dialysis 
of renin extracted from pig and rabbit kidneys at similar pH5•6.7. In the studies 
reported here, a comparison of plasma renin concentration at pH values above 
4.5 to concentrations at 4.5 and 3.3 was not made. However, in view of the 
reported data and the low concentration of active renin in renal venous plasma 
under all conditions (Table 1 ), it is unlikely that there was any significant activation 
at pH 4.5 in these studies. 
Stimulation of renin release from the intact pig kidney resulted in increases 
in both active and inactive forms of the enzyme (Fig.l and 2), whereas suppression 
of release caused both to decrease (Fig.3). Determination of renin release over 
a wide range of values indicates a consistent relationship between the release 
of active and inactive renin under the conditions of these studies(Figs.4 and 
5). Furthermore, the change in concentrations of both active and inactive renin 
in renal venous plasma indicates that the effects of the drugs on renin release 
were a:t least partially independent of renal blood flow (Table 1). 
The plasma concentration of active and inactive renin has been determined 
under varying conditions in man. Both Derkx et al. (1976) and Weinberger 
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et al. (1977) found that acute stimulation or suppression of renin release could 
result in opposite changes in the active and inactive forms. Weinberger et al. 
(1977) reported that, in normal subjects, saline infusion suppressed active but 
not inactive renin, whereas furosemide caused both to increase, although the 
relative increase inactive renin was greater. Derkx et al. (1976) reported that 
isoproterenol increased active but not inactive renin concentration in plasma, 
and propranolol suppressed active but elevated inactive renin. These authors 
also found that the plasma concentrations of active and inactive renin were 
directly related. 
There are several possible explanations for the differences between the present 
results and those reported for man. First, studies were carried out in anesthetized 
animals. Whereas there is no evidence that anesthesia will qualitatively modify 
the response of renin release to the drugs used, anesthesia cannot be eliminated 
as a cause for the differences. Second, although there may be species differences, 
available data do not suggest significant qualitative differences in the control 
of renin release in man and in other animal species. 
Third, it has been suggested that inactive renin may represent a storage form 
of the enzymes. Therefore, the rate of release of either active or inactive renin 
could be related to the state of intrarenal synthesis and storage of renin in 
an inactive form and to the activity of mechanisms for conversion of inactive 
to active renin in the kidney. Such a mechanism is suggested by the differences 
in concentration of active and inactive renin in renal venous plasma from stenotic 
and nonstenotic kidneys and peripheral venous plasma3• The nature of the 
mechanisms which could possibly lead to interconversion of the two forms of 
renin are unknown. The amount of intrarenal renin present in the the inactive 
form may be related to a balance between synthesis and releases. However, 
the reason that the inactive form is released and is not all converted first to 
active renin is unknown. Further physiological and biochemical studies will be 
required to clarify these issues specially. 
A fourth possible source for the differences between the results of these studies 
and those obtained for man may be related to the interconvension of active 
and inactive renin in plasma and/ or the relative rates of metabolism of the 
two forms of the enzyme. The failure to find any change in the relative 
concentration of active renin in simultaneously obtained arterial and renal venous 
plasma samples (Table 2) suggests that there is no major interconversion of 
the two forms in plasma. However, changes could be masked by differences 
in the rate of catabolism of the two forms of the enzyme. 
In the present studies the biochemical differences in the forms of renin were 
not determined. Although it has been demonstrated by several authors that 
acidification appears to activate an inactive form of renin2•3•5•7, there is still 
confusion concerning the molecular nature of the product. Until further bio-
chemical clarification is available, the possibility remains that the activated 
enzyme may not be renin but may act nonspecifically on angiotensinogen to 
form angiotensin 114• 
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We conclude from these studies that both the active and acid- activated form 
of inactive renin are released from the kidney of the pig. The mechanisms 
controlling release of both forms of the enzyme in this animal model appear 
to be similar. The physiological significance of inactive renin remains obscure, 
and additional studies will be required to clarify its importance in regulation 
of the renin-angiotensin system. 
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5.2 RELEASE OF ACTIVE AND INACTIVE RENIN BY THE PIG KIDNEY 
DURING DEVELOPMENT 
5.2.1. ABSTRACT 
The release of both active and acid-activatable (inactive) renin was determined 
in piglets ranging in age from 3 to 53 days. The concentration of active renin 
in arterial plasma during control periods decreased from 4.4 ± 1.1 ng ANG 
1/ml/h in 3-5 day-old animals to 0.7 ± 0.1 ng ANG 1/ml/h in 42-53 day-old 
animals, while the rate of release of active renin was unchanged (11.8 ± 5.1 
ng/min and 7.5 ± 3.4 ng/min,respectively). Both isoproterenol and furosemide 
stimulated release of renin in all age animals while propranolol supressed renin 
release. The data indicate that the qualitative control of renin release is similar 
in animals of various ages and stages of development. However, the differences 
in the concentration of renin in plasma of newborn and more mature animals 
may depend on factors other than release of renin by the kidney. Newborn 
animals release both active and inactive renin from the kidney. 
5.2.2. INTRODUCTION 
Although plasma renin activity and angiotensin II concentration have been 
reported to be higher in fetal and newborn than in adult animals and hu-
mans9·11·12·17, recent studies suggest that control of the release of renin from 
the kidney is qualitatively similar in animals of different ages 15·17. The elevated 
plasma renin activity of younger animals could be due to several factors including: 
(a) a more rapid rate of release of renin from the newborn kidney; (b) a smaller 
volume of distribution of renin in the extracellular space in younger animals; 
(c) a more rapid rate of catabolism of renin in the mature animals, and (d) 
a change in the form of renin from a more to a less active state in the mature 
animal. While changes in plasma renin activity with maturation have been 
reported, none of the studies have actually estimated the rate of release of renin 
by the kidney in the same animals. In addition, in studies on the control of 
renin release the actual rate of release from the kidneys was not estimated. 
Changes in release were inferred from changes in plasma renin activity15·17. 
The present studies were carried out in anesthetized piglets during the first 
8 weeks of life in order to further define the control of renin release and plasma 
renin activity during maturation. In addition to the measurement of the 
concentration of renin in plasma and the rate of release of renin by the kidney, 
the plasma concentration and release of an inactive form of the enzyme was 
also determined. Observations were made under control conditions, following 
stimulation of renin release with isoproterenol or furosemide and suppression 
of renin release with propranolol. The results suggest that factors other than 
the rate of release of renin from the kidney may be important in the regulation 
of plasma renin concentration in newborn animals. The data also indicate, as 
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previously suggested 15•17 , that control of renin release is qualitatively similar in 
animals of various ages. 
5.2.3. METHODS 
. Surgical procedures. 
Experiments were carried out on pigs divided into three age groups: 3-5, 19-
23 and 42-53 days. The younger animals were taken from the sow lh prior 
to starting the experiment. Anesthesia was induced with intraperitoneal pen-
tobarbital sodium (25 mg/kg in 3-5-day-old animals and 35 mg/kg in older 
animals). Additional anesthetic was given during the experiment as required. 
The animals were intubated and ventilated (Loosko Amsterdam Infant Ven-
tilator). Rectal temperature was monitored and body temperature maintained 
at 37 C with a heating pad and radiant heat lamp. A catheter was placed in 
the femoral artery to obtain arterial blood samples and to measure blood pressure 
using a strain-gauge pressure transducer. A second catheter was placed in the 
femoral vein for infusion of a solution of inulin (3g/ dl) at 0.05 mllmin/kg resulting 
in plasma concentrations of inulin of 25-35 mg/dl. A third catheter was placed 
in the external jugular vein for infusion of saline and drugs, and a fourth placed 
in the bladder via a small midline abdominal incision. 
The left kidney was exposed through a retroperitoneal flank incision and the 
left ureter cannulated. The renal artery and vein were carefully dissected free 
from the surrounding tissue and a noncannulating electromagnetic flowmeter 
probe (Transflow 500 Electromagnetic Bloodflow Meter) placed on the renal 
artery. A curved 22-gauge needle attached to a polyethylene catheter was inserted 
into the renal vein to obtain renal venous blood samples. A curved 27-gauge 
needle attached to a polyethylene catheter was inserted into the. renal artery 
for infusion of isotonic saline or isoproterenoL Renal blood flow was monitored 
during insertion of the needles, and no change in blood flow was noted. A 
period of 45-60 min was allowed for stabilization following completion of surgery. 
Experimental protocols. 
In order to study the effects of various stimuli on renin secretion the following 
protocols were carried out on 5 animals in each of the three age groups. During 
a control clearance period, two sets of arterial and renal venous blood samples 
were obtained 5 min apart. Infusion of a solution containing isoproterenol (1 
,ug/mllkg) was started into the renal artery at a rate of 0.1 mllmin using a 
Braun infusion pump. The rate of infusion was gradually increased until renal 
blood flow increased. After 5-7 min a second timed urine collection was started 
and two more sets of arterial and renal venous blood samples were obtained 
5 min apart. The infusion of isoproterenol was then stopped, and following 
a 45- to 60-min recovery period a third collection of urine and two more blood 
samples were obtained. 
Following recovery from the isoproterenol the animals were given furosemide 
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(1 mg/kg i.v.). As urine flow increased, saline was infused into the jugular vein 
at a rate equal to urinary output. 10 min after giving the diuretic, a timed 
urine sample and two sets of arterial and renal venous blood samples were 
again collected. A second injection of furosemide (2 mg/kg) was given and the 
sampling repeated. 
The effect of an inhibitor of renin secretion, propranolol, was then determined .. 
Propranolol (1 mg/kg) was given intravenously and after 10 min urine and blood 
samples were obtained as previously described. 
Analytical techniques and data handling 
All blood samples were collected in tubes chilled on ice and containing EDT A 
(5 mM). Blood samples were centrifuged within 5 min of collection and the 
plasma removed. The red blood cells were then reconstituted in saline and returned 
to the animal. Plasma for renin determinations was stored at -20 C until assayed. 
Plasma and urine were analyzed for inulin using the method of Schreiner14• 
Hematocrit was determined by the micro method. Total and active renin in 
arterial and renal venous plasma was estimated as described by Derkx et al. 4 
Plasma was dialyzed at either pH 4.5 or 3.3 for 24h at 4 C and then returned 
to pH 7.4 by dialysis for another 24h. Plasma dialyzed at both pH 3.3 and 
4.5 was incubated with excess homologous renin substrate and the angiotensin 
I generated determined by radioimmunoassay6• The renin concentration of plasma 
dialyzed at pH 4.5 was designated active renin. Following dialysis at pH 3.3 
renin concentration was higher (total renin) representing the sum of the active 
and acid-activated renin. Inactive renin was calculated as the difference between 
total renin and active renin. The renin substrate was prepared according to 
the method of Skinner16• The substrate was found to be free of renin and 
angiotensinase activity. Incubation of substrate with renin resulted in zero order 
kinetics. The concentration of renin in plasma was expressed as nanograms of 
angiotensin I generated per milliliter per hour (ng ANG I/ml/h). 
Mean arterial blood pressure, heart rate and mean renal blood flow were 
taken directly from a digital readout. Glomerular filtration was estimated from 
the clearance of inulin and renal vascular resistance was calculated as the mean 
arterial blood pressure divided by the renal blood flow and expressed as mm 
Hg/ml/min. Renin release was calculated as the product of the venous-arterial 
renin concentration differences and the renal plasma flow. Statistical analysis 
was carried out using analysis of variance and t test for paired and unpaired 
comparisons. The level of significance was set at 5%. Since significant hete-
rogeneity of variance existed in values for renin secretion and renin concentration 
between animals, statistical analyses were performed on log values as previously 
reported2. 
5.2.4. RESULTS 
The total renin concentration in arterial plasma during control periods was highest 
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Fig. 5.2.1. Age-related changes in plasma renin concentration (PRC) for total renin, active renin 
and inactive renin during control periods in anesthetized piglets. Mean ± SEM; n 
= 5.* =Significantly less than 3- to 5 and 19- to 23-day-old animals (p < 0.05) 
in the youngest animals and decreased with maturity (Fig. I). This change in 
total renin concentration was due to a decrease in the concentration of both 
active and inactive renin. Determination of the rate of release of active and 
inactive renin during control periods (Fig. 2) demonstrated an insignificant rise 
between 3-5 and 19-23 days, a time when the arterial renin concentration was 
beginning to decline (Fig 1). By 42-53 days renin release had returned to values 
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Fig. 5.2.2. Release of active renin (e) and inactive renin (0) during control periods in piglets of 
three age groups. Mean ± SEM; n = 5. 
which were the same as those in the 3- to 5-day-old animals while plasma renin 
concentration was 4-6 times less than that during the first 3 days of life. Overall, 
during the first 53 days after birth no significant changes in the rate of renin 
release was found (Fig. 2). 
Renin release was stimulated with two drugs. Isoproterenol infused directly 
into the renal artery resulted in an increase in the release of both active and 
inactive renin in all three age groups (Fig. 3). Following isoproterenol the animals 
were allowed to recover and were then given intravenous furosemide (Table 
I). Since the rate of renin release following recovery in 1-3 to 5-day-old animal 
did not return to the control, these animals had a higher mean value in the 
prefurosemide periods than the control values prior to isoproterenol (Fig.l ). 
The response to furosemide was more variable than that of isoproterenol (Table 
I). Furosemide (1 mg/kg) increased the release of active renin in all three age 
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groups. While the rate of release of inactive renin was increased in all three 
age groups, this change was not statistically significant in the youngest animals. 
Furthermore, the second injection of furosemide (2 mg/kg) failed to significantly 
increase the rate of renin release further in any age group. 
Propranolol was then given to inhibit the release of renin and resulted in 
a decrease in all three age groups (Fig.4). Agaip the change in 3- to 5-day-
old animals was not statistically significant because of the variation between 
animals. 
When the relative concentration of active renin in arterial plasma was calculated 
(active renin concentration/total renin concentration), active renin accounted 
for 31 ± 2% of the total renin in 3- to 5-day-old animals, 28 ± 2% in the 
19- to 23-day- old animals and 20 ± 5% in the animals with an age of 42-
53 days. This latter value in the older animals was significantly less than that 
in the two younger groups. 
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Table 5.2.!. Release of renin in piglets in the three groups following furosemide. Values are given 
in ng/min. 1 
Age, days Active renin Inactive renin 
Pre-F F-1 F-2 Pre-F F-1 F-2 
3-5 45 140* 282* 153 741 637 
(27) (56) (78) (82) (524) (439) 
19-23 52 414* 789* 204 1014* 2782* 
(23) (113) (209) (64) (489) (1334) 
42-53 8 61* 107* 17 349* 483* 
(4) (20) (39) (13) (87) (180) 
Pre-F = Prefurosemide; F-1 =furosemide 1 mg/kg i.v.; F-2 =furosemide 2 mg/kg i.v. 
1 Mean values; standard errors of the mean are given in parenthesis; n = 5. 
* Significantly different from control (p < 0.05). 
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Over the age range of animals used in this study, kidney weight increased 
from 10.4 ± 0.9 g in the 3- to 5-day-old animals to 25.7 ± 2.0 g in the 42-
to 53-day-old animals. This change was associated with an increase in body 
weight from 2.9 ± 0.6 to 11.9 ± 0.8 kg, respectively. Control values for mean 
systemic blood pressure, glomerular filtration rate and renal blood flow increased 
with increasing age of the animals (Fig.5). Systemic blood pressure appeared 
to approach a plateau earlier than glomerular filtration rate or renal blood flow. 
Renal resistance decreased from 6.1 ± 1.9 mmHg/ml/min in 3- to 5-day-old 
animals to 2.7 ± 0.2 in 19- to 23-day-old animals and 1.7 ± 0.3 mmHg/ml/ 
min in 42- to 53-day-old-animals. 
5.2.5. DISCUSSION 
The present experiments demonstrate that the concentration of both active and 
inactive renin is higher in the arterial plasma of newborn piglets (4.4 and 10.7 
ng/ ANG Ilml!h, respectively) and decreases to 0.7 and 3.0 ng ANGI/mllh 
by 53 days of age (Fig.l). However, while arterial plasma renin concentration 
decreased, the rate of release of both forms of the enzyme by the kidney was 
not suppressed (Fig.2). These results indicate that factors other than a change 
in the rate of release of the enzyme may be related to the fall in plasma renin· 
concentration observed during the first 8 weeks of extrauterine life in the piglet. 
Several additional possibilities which might explain the changes in the amount 
of renin in the plasma include: (a) an increase in the volume of distribution 
of renin as plasma volume increases with age; (b) an increase in the rate of 
catabolism of renin with maturation, and (c) a shift in the form of renin from 
a more to less active enzyme. 
No data have been reported on the catabolism or half-life of renin in the 
newborn animals. Since the liver is a major site of catabolism of renin 13 , 
maturation of hepatic function could be involved in control of the concentration 
of renin in plasma of newborn animals. However, preliminary observations from 
this laboratory (unpublished data) suggest that the rate of catabolism of renin 
during this period of development does not change. Plasma volume changes 
during development in both humans and piglets3•18• Talbot and Swenson18 
demonstrated a 6-fold increase in total plasma volume of the piglet between 
birth and 6 weeks of age. This change in plasma volume could not account 
for the fall in renin concentration in the present study. During the period of 
the present study, body weight increased fourfold while renin concentration in 
arterial plasma decreased by a similar amount (Fig. 1). While the body weight 
may only indirectly reflect changes in plasma volume, the changes in weight 
support a possible relationship between renin concentration and volume. 
The fact that arterial plasma renin concentration is higher in the newborn 
than in the adult animal, while rates of renin secretion are similar, suggest that 
the responsiveness of the kidney to the inhibitory effect of angiotensin II in 
the feedback control of renin secretion may be less in the newborn. At the 
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present time no data is available on the sensitivity of the newborn kidney to 
circulating angiotensin IL 
In addition to the usual form of renin (active renin) an acid-activated form 
of the enzyme was also determined in the present experiments. This form of 
renin has been isolated form plasma and kidneys of animals of several species 1•4•10• 
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While the physiological significance of multiple forms of renin is not clear, the 
present studies demonstrate that an acid-activatable, inactive renin is present 
in plasma of newborn piglets and is released by the kidney. Furthermore, the 
decrease of the total renin concentration as active renin from 30 to 20% could 
account, in part, for the observed changes in plasma renin concentration with 
maturation. However, the finding does not explain a similar decline in the 
concentration of inactive renin without a change in the release of this form 
of the enzyme (Figs. 1,2). 
In the present experiments renin release was estimated directly, rather than 
relying on determination of changes in the plasma renin activity as an index 
of release. The response to stimulation with isoproterenol and furosemide and 
the suppression with propranolol were qualitatively similar in immature (3-5 
day) and mature (45-53 day) animals. 
Previous studies describing developmental ch<mges in the renin-angiotensin 
system9, 12, 17 and the capacity of the kidney from the immature animal to release 
renin 15, 17,19 have depended on measurements of arterial plasma renin activity 
as the index of renin release. Over a wide range of ages in the developing animals, 
plasma renin activity can be increased by a variety of stimulil 5, 17, 19 also suggesting 
that the control of renin release is qualitatively similar in the immature and 
in the mature animals. Thus, the present studies confirm these observations 
by direct measurement of renin release. 
Finally, the physiological significance of the renin-angiotensin system and the 
relatively elevated concentrations of renin and angiotensin II in the newborn 
remain to be clarified. The increase in renal blood flow and in glomerular filtration 
rate and decrease in renal vascular resistance with maturation are well documented 
in this study (Fig 5) and in others5,7• The data of Jose et al. 8 suggest that the 
renin-angiotensin system is not involved in the control of renal hemodynamic 
in newborn animals. However, changes in response to angiotensin II and effects 
of this hormone on age-related changes in renal function are still possible and 
need to be studied. · 
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5.3. ASYNCHRONOUS CHANGES IN PRORENIN AND RENIN SECRE-
TION AFTER CAPTOPRIL IN PATIENTS WITH RENAL ARTERY 
STENOSIS 
5.3.1. SUMMARY 
An assay of plasma prorenin was developed in which the conversion to renin 
occurred under apparently optimal conditions. Some characteristics of the assay 
were 1) prorenin was activated by Sepharose-bound trypsin at 4 C; 2) the 
concentration of activator was not critical provided that incubation was prolonged 
until renin activity had reached a plateau; and 3) this plateau was stable and 
had the same height as after maximal activation with acid, pepsin, plasmin or 
urokinase. Maximal activity with Sepharose-bound trypsin at 4 C was higher 
than with cryoactivation, and optimal conditions were more readily reproduced 
than with trypsin at 37 C or with acid-activation. The assay was used for 
measurements in peripheral and renal vein plasma after captopril in hypertensive 
patients with unilaterai renal artery stenosis. Peripheral renin rose within 30 
minutes after a first dose of captopril, 50 mg orally, and it remained high with 
chronic treatment. In contrast, peripheral prorenin fell initially and rose after 
4 hours. These changes in peripheral plasma were related to changes in the 
secretion rates of the two forms of renin from the affected kidney. Thus chronic, 
but not acute, stimulation of renin release was associated with an increased 
secretion rate of prorenin. The late rise in prorenin is probably an indication 
of enhanced synthesis in the kidney, so that more prorenin is available for 
conversion. The data suggest that prorenin is indeed a biosynthetic precursor 
of renin and that, at least under certain circumstances, a major proportion of 
circulating prorenin originates from the kidney. 
5.3.2. INTRODUCTION 
About 80% of the renin in normal human plasma is thought to circulate in 
an inactive form!-3. Inactive renin is often called 'prorenin' because it can be 
converted in vitro to active renin4 • It is not certain that prorenin is a precursor 
of naturally occurring renin, however. 
Activation of the factor XU-kallikrein pathway causes irreversible prorenin-
to-renin conversion after dialysis of plasma against acid followed by restoration 
of pH to neutral (acid-activation)5,6 and possibly also in plasma that is stored 
at low temperature (cryoactivation)1. Prorenin can also be activated by adding 
trypsin or pepsin9, 10 to plasma. These exogenous activators act independently 
of factor XII and kallikrein. 
Prorenin is measured by functional assays in which prorenin is converted 
to renin. The difference in renin activity before and after activation is taken 
as a measure. The implicit assumptions are that all prorenin molecules are 
converted and that one molecule of activated prorenin has the same enzymatic 
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activity as one molecule of naturally occurring renin. Cryoactivation, however, 
often leads to incomplete prorenin-to-renin conversion3• Acid activation appears 
more complete but careful adjustment of pH is of critical importance11•12• For 
trypsin activation, high concentrations of trypsin are required to overcome the 
inhibitors in plasma but such high concentrations may destroy renin3•13•14• Trypsin 
may also attack renin substrate and may interfere with the radioimmunoassay 
of angiotensin I, the final step in the assay of renin. Soybean trypsin inhibitor 
(SBTI) has therefore been used to prevent this. However, some commercial SBTI 
preparations appear to have angiotensinase activity resulting in considerable 
loss of angiotensin I during the assay15 • 
The present paper describes an assay of prorenin in which it is activated by 
trypsin that is bound to Sepharose·. The immobilized activator can quantitatively 
be removed by centrifugation. Optimal conditions were worked out for activation 
in plasma and the results were compared with maximal acid activation and 
with maximal activation by pepsin, plasmin and the plasminogen activator 
urokinase. The behaviour of naturally occurring active renin on gel filtration 
and dye affinity chromatography columns was compared with that of prorenin 
activated by immobilized trypsin. Some enzymatic properties of the two forms 
of renin were also compared. The assay was then applied to a study of the 
effects of angiotensin converting enzyme inhibition by captopril on peripheral 
and renal vein plasma prorenin in patients with unilateral renal artery stenosis. 
5.3.3. MATERIALS AND METHOD 
Reagents 
Trypsin from bovine pancreas, 2 X crystallized, was purchased from Sigma, 
St. Louis., Missouri. Its specific activity was 12,000 a-N-benzoyl-L-arginine-ethyl 
ester (BAEE) units/mg of protein. Pepsin A, specific activity 3,200 units/mg 
of protein, was also from Sigma. Activator-free highly purified human plasmin, 
specific activity 19 casein units/mg of protein, was a product of Kabi, Stockholm, 
Sweden. Urokinase was the urokinase reference standard of Leo, Copenhagen, 
Denmark. Aprotinin (Trasylol) was obtained from Bayer, Leverkusen, West 
Germany. Ile-5-Angiotensin I (ANGI) from Serva, Heidelberg, West Germany, 
was dissolved in Tris/acetate buffer of pH 7.5 (vide infra) and stored at -20 
C at a concentration of 40 ,uM. Its strength was tested by bioassay in the rat 
against Val-5-Angiotensin II (Hypertensin) from Ciba- Geigy, Basel, Switserland. 
When allowance was made for the impurities present in the Ile-5-ANGI 
preparation as stated by the manufacturer, the pressor activities of Val-5-AII 
and Ile-5-ANGI on a molar base were found to be equal11 • Renin substrate 
was prepared from sheep plasma, which was taken 4-5 days after bilateral 
nephrectomy16 • It was dissolved in phosphate buffer pH 7.5 and stored at -
20 C at a concentration of 5 ,uM, expressed as the maximal quantity of Ile-
5-ANGI equivalents that could be generated in the presence of a large excess 
of renin. Renin substrate prepared from human plasma16 was also used in some 
experiments. A human kidney renin standard, lot MRC 68/356, was kindly 
135 
supplied by the WHO International Laboratory for biological Standards, London, 
England. This standard was dissolved in phosphate buffer pH 7.5 containing 
0.35% bovine serum albumin. It could be stored at -20 C at a concentration 
of 10,000 J.LU/ml for up to 3 months without loss of activity. 1251-labeled Ile-
5-ANGI and anti-Ile-5-ANGI rabbit antiserum were prepared as described 
previously11 • Radioactive ANGI in 0.05 M acetic acid, containing 0.1% bovine 
serum albumin, 0.01% thiomersalate, 0.001% neomycin sulfate and 0.1 M NaCl, 
was stored in 0.25 ml portions at -20 C. 
CNBr-activated Sepharose 4B, Sephadex G-100, Blue Sepharose CL-6B, Blue 
Dextran 2000, and the molecular weight markers for gel chromatography, 
ribonuclease A (Mr 13,700), chymotrypsinogen A (Mr 25,000), ovalbumin (Mr 
43,000), and human serum albumin (Mr 67 ,000) were purchased from Pharmacia, 
Uppsala, Sweden. 14C-ovalbumin (Mr 46,000) and 14C-bovine serum albumin 
(Mr 69,000) were also used as molecular weight markers and were obtained 
from the Radiochemical Centre, Amersham, England. 
Buffer solutions 
Phosphate Buffer, pH 7.5. This buffer contained 12.2 mM Na H 2 P04 , 86.7 
mM NA2 HP04 , 75.9 mM NaCl and 1.0 mM disodium ethylenediamine-
tetraacetate (EDT A). 
Glycine/HCI Buffers, pH 3.3 or pH 4.0. These buffers contained 50 mM glycine, 
94.9 mM NaCl, and 5.1 mM EDTA. The pH was adjusted with concentrated 
HCI. 
Tris/Acetate Buffer, pH 7.5. This buffer contained 0.1 M Tris, 0.35% bovine 
serum albumin, 0.1% lysozyme, and 0.2% neomycin sulfate. The pH was adjusted 
with glacial acetic acid. 
Preparation of plasma 
Blood was collected in chilled plastic tubes contammg EDT A in a final 
concentration of 5 mM. It was centrifuged at 3,000 X g and 4 C immediately 
after collection. Plasma was kept frozen at -20 C before use. 
Preparation of immobilized trypsin and pepsin 
The enzymes were covalently bound to CNBr-activated Sepharose 4B in a 
ratio of 30- 40 mg of protein per g of dry Sepharose according to the directions 
of the manufacturer. In this manner more than 97% of protein was bound to 
Sepharose. Sepharose-bound trypsin was diluted in phosphate buffer pH 7.5. 
Suspensions of Sepharose- bound pepsin were stored in glycine/HCl buffer pH 
3.3. 
Activation of prorenin 
Activation by Immobilized Trypsin. Dilutions of Sepharose-bound trypsin (100 
J.Ll, 0.05 - 4.0 mg trypsin) were added to 1 ml plasma. The mixtures were incubated 
at 37 and 4 C for various time periods as indicated in the results section. Trypsin 
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was removed by centrifugation. The supernatants were checked for amidolytic 
activity with the chromogenic substrate N-benzoyl-L-isoleucyl-L-glutamylglycyl-
L-arginine-p-nitroanilide (S2222, Kabi,Stockholm , Sweden). For this purpose 
0.1 ml of the supernatant of the incubates was mixed with 0.2 mM substrate 
(about 10 times Km for trypsin) in 0.1 M Tris/HCL buffer pH 8.2 in a total 
volume of 1.0 ml. The linear release of p-nitroaniline was followed for 1-2 minutes 
at 405 nm in a 1-cm semi-microcuvette at 37°. With this method the remaining 
trypsin activity in the supernatants was found to be less than 0.1% of the original 
activity in the incubates. 
Acid activation. Plasma samples (2 ml) were dialyzed against glycine/HCl buffer 
pH 3.3 for 24 h at 4 C, followed by dialysis against phosphate buffer pH 7.5, 
containing 6% polyvinylpyrrolidone, again for 24 hours at 4 C. Polyvinylpyr-
rolidone had been added to the buffer to prevent dilution of the plasma due 
to colloid-osmosis. The dialysis bags were emptied in calibrated plastic tubes 
and rinsed with phosphate buffer pH 7.5 and the volume was adjusted to 2 
ml with the same buffer. 
Activation by immobilized pepsin. Plasma samples (2ml) were dialyzed against 
glycine/HCl buffer pH 3.3 for 24 h at 4 C. To 1 ml of the dialyzed plasma 
was added Sepharose-bound pepsin (100 p.l,0.3 mg pepsin). The mixture was 
incubated at 32 C for various time periods, as indicated in the Results. Pepsin 
was removed by centrifugation and pH was restored to 7.5 with 1M NaOH. 
Activation by plasmin and urokinase. Plasmin was dissolved at a concentration 
of 20 casein units/ml in phosphate buffer pH 7.5. Urokinase was dissolved in 
this buffer at a concentration of 1000 Ploug units/mi. The plasma samples were 
dialyzed against glycine/HCl buffer pH "4.0 for 24 hours at 4 C and pH was 
restored to 7.5 with 1 M NaOH. The activator solutions (100 p.l) were added 
to 1 ml of the pH 4.0-pretreated samples and incubated at 4 C for various 
time periods as indicated in the Results. 
Assay of naturally occurring renin and prorenin that is activated in vitro 
For this assay, 0.10-0.25-ml samples were added to 0.5 ml of renin substrate, 
and the volume was adjusted to 1.0 ml with phosphate buffer pH 7.5. The 
final concentration of renin substrate in the mixture was 2.5 p.M Ile-5-ANGI 
equivalents, which corresponds to about 10 times Km (see Results). After addition 
of protease inhibitors, i.e., 10 p.l of 0.34 M 8-hydroxyquinoline sulfate, 5 p.l 
of 0.28 M phenylmethylsulphonylfluoride in ethanol, and 10 p.l aprotinin (10,000 
kallikrein-inhibiting units/ml), the mixtures were incubated at 37 C. The 
incubation time was 3 hours except when stated otherwise. The renin-containing 
samples had been diluted in such a way that no more than 5% of the substrate 
was cleaved during incubation. Parallel incubations at 4 C served as blanks. 
Incubations of dilutions of standard human kidney renin at 37 C and 4 C were 
run in each assay batch. The concentration of homologous substrate in the 
incubation mixtures was less than 0.2 p.M Ile-5-ANGI equivalents. Previous 
studies have shown that this concentration of homologous substrate did not 
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interfere with the reaction of renin and the heterologous substrate11 • The reaction 
was stopped by adding 1 ml of 0.15 M NaCl followed by heating for 10 minutes 
in a boiling water bath. The precipitate was removed by centrifugation. The 
concentration of ANGI in the supernatant was measured by radioimmunoassay, 
using 125I-labeled Ile-5-ANGI and rabbit anti-Ile-5-ANGI antiserum11 • Renin 
concentration is expressed as microunits of the renin standard per ml (MDI 
ml). Prorenin was measured as the difference between the renin concentration 
after activation of the test sample ('total renin') and the concentration before 
activation. For routine measurements in plasma, 1.0 ml plasma was incubated 
with 100/Ll Sepharose-bound trypsin in a final concentration of 0.25 mg trypsin/ 
ml for 24 hours at 4 C. The reasons why this procedure was selected are presented 
and discussed in the results and discussion sections. 
Interassay variability was evaluated by weekly measurements of naturally 
occurring active renin and prorenin in a normal plasma pool(stored at -20 C 
during a 9-month period. The mean value of naturally occurring active renin 
was 27 ILU/ml (36 assays) with a standard deviation of 3 /LU/ml (coefficient 
of variation 11 %). The mean value of'total renin' was 254/LU/ml, with a standard 
deviation of 26 IL U/ml (coefficient of variation 10% ). The mean value of prorenin 
was 227 ILU/ml with a standard deviation of 24 ILU/ml(coefficient of variation 
11 %). In normal plasma the contribution of naturally occurring active renin 
to total renin is small but it becomes greater after stimulation of renin release. 
The coefficient of variation of prorenin measurements then also becomes greater 
since prorenin is taken as the difference between total renin and naturally 
occurring active renin. In 17 healthy men (aged 24-45 years) who were recumbent 
for at least 1 hour before blood sampling, naturally occurring renin had a mean 
value of 23 ILU/ml (antilog of arithmetic mean after logarithmic transformation 
of data) with a range of 14 to 43 ILU/ml. The mean value of prorenin was 
196/LU/ml with a range of 138 to 312/LU/ml; the mean value of the proportion 
of renin that was in the active form was 10.9%, with a range of 4.3% to 17.5%. 
Gel filtration 
Untreated plasma (2ml) or trypsin-activated plasma (2ml) was applied to 2.6x90 
em columns of Sephadex G-100 equilibrated with 0.01 M Tris/HCl buffer pH 
7.0 containing 0.15 M NaCl and 1 mM EDTA. The same buffer was used for 
elution. Flow rate was adjusted to 10 mllhr and 1.5-ml fractions were collected. 
The columns were calibrated with ribonuclease A, chymotrypsinogen A, human 
albumin and ovalbumin. Blue dextran 2000 was used for determining void volume. 
14C-ovalbumin and 14C-BSA were used as internal standards. Gel filtration was 
carried out at 4 C. 
Affinity chromatography 
Untreated plasma (4 ml) or trypsin- activated plasma (4 ml) was applied to 
1.6x25 em columns of Blue Sepharose CL-6B equilibrated with 0.02 M phosphate 
buffer pH 7.1. Elution was performed with this buffer in 3 steps, i.e., without 
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added NaCl, with 0.2 M NaCl and with 1.4 M NaCl added to the buffer. 17 
Flow rate was 50 to 60 ml/hr and 2.5-ml fractions were collected. Affinity 
chromatography was carried out at 4°C. 
Studies in patients Fifty-four hypertensive patients were studied after they had 
given their informed consent. All had unilateral renal artery stenosis as dem-
onstrated by renal arteriography. Treatment was stopped at least 3 weeks before 
the studies began. The patients were recumbent for at least one hour before 
blood sampling. 
Group I (n = 14) Renal arteriography had already been performed before 
this study. The patients received a first dose of captopril, 50 mg orally. Peripheral 
venous blood was sampled from an indwelling needle for renin and prorenin 
measurements before and at different time intervals after captopril. Renin before 
captopril was 81 ,uU/ml (antilog of arithmetic mean after logarithmic trans-
formation of data) with a range of 19 to 250 ,uU/ml, and prorenin was 190 
,uU/ml with a range of 77 to 410 ,uU/ml. The patients were then treated with 
captopril, 50 mg 3 times a day, and blood was taken after 1, 2, and 4 weeks 
1-2 hours after the morning dose. Group 2 (n = 15) Blood was sampled from 
both renal veins and from the abdominal aorta before and 30 minutes after 
a first dose of captopril, 50 mg, just before renal arteriography. Because some 
time elapsed between sampling of the renal vein of one side and sampling at 
the other side, two aortic samples were taken each at exactly the same time 
that a renal vein sample was collected. Peripheral vein renin before captopril 
was 51 ,uU/ml (range 16-190 ,uU/ml) and prorenin was 170 ,uU/ml (range 57-
320 ,uU/ml). 
Group 3(n = 15) Blood was sampled from both renal veins and from the 
abdominal aorta 16 hours after a first dose of captopril, 50 mg, just before 
renal arteriography. This time interval was chosen because studies in Group 
I had shown that peripheral prorenin was significantly increased after 16 hours. 
Peripheral vein renin before captopril was 58 ,uU/ml (range 15-480 ,uU/ml) and 
prorenin was 130 ,uU/ml (range 20-490 ,uU/ml). 
Group 4(n = 10) Blood was sampled from both renal veins and from the 
abdominal aorta while the patients were taking captopril, 50 mg three times 
a day, for 2 weeks. Sampling occurred 1-2 hours after the last 50 mg dose 
and just before renal arteriography. Peripheral vein renin before captopril was 
66 ,uU/ml (range 30-360 ,uU/ml) and prorenin was 210 ,uU/ml (range 72-520 
,uU/ml). 
5.3.4. RESULTS 
Activation of plasma prorenin by immobilized trypsin: selection of optimal conditions. 
Normal plasma pool was incubated at 4 C and 37 C with Sepharose-bound 
trypsin at concentrations ranging from 0.05 to 0.50 mg per ml of plasma at 
4 C and from 0.05 to 4.0 mg/ml at 37 C. The results at 4 C and 37 C were 
markedly different (Fig.l). First, the reaction velocity was higher at 37 C than 
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Fig. 5.3.1. Activation of prorenin in a pool of normal plasma by immobilized trypsin at 4 C (left) 
and 37 C (right). The concentrations of trypsin, in mg/ml of plasma, are indicated. Results are 
the means of three experiments. 
at 4 C, but for a given trypsin concentration, the maximum level of renin activity 
ultimately obtained was higher at 4 C than at 37 C. Second, with trypsin 
concentrations ranging from 0.12 to 0.50 mg/ml, this maximum of renin activity 
was independent of trypsin concentration during incubation at 4 C and not 
at 37 C. Third, very high concentrations of trypsin were required at 37 C for 
approaching the maximal renin activity obtained at 4 C but these high con-
centrations also caused inactivation or destruction of renin. 
As shown in figure 1, with the use of 0.25 mg trypsin per ml of plasma at 
37 C, activation had reached its maximum after 2 hours of incubation, and 
at that time the renin activity was about half the maximum obtained with the 
same concentration of trypsin at 4 C. With this concentration of trypsin the 
generation of active renin at 37 C had stopped because not enough uninhibited 
trypsin was left. This was demonstrated by the following experiments. Plasma 
(1 ml) was incubated with Sepharose-bound trypsin (100 ~1) in a concentration 
of 0.25 mg trypsin per ml of plasma for 4 hours at 37 C. After incubation 
the plasma was separated from the activator by centrifugation. The supernatant 
was transferred to a new tube and renin was measured; it was 140 ~U/ml as 
compared to 32 ~U/ml before incubation with trypsin. The supernatant was 
mixed with fresh Sepharose-bound trypsin, again in a concentration of 0.25 
mg/ml, whereas the trypsin pellet was resuspended in fresh plasma (1 ml). The 
mixtures were then incubated for 24 hours at 4 C and renin was measured. 
Newly added trypsin caused further generation of active renin to its maximal 
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value of 250 ,uU/ml in the supernatant but addition of fresh plasma to the 
precipitate was without effect. In contrast, at 4 C maximal activation of pro renin 
was obtained while active trypsin was still present. This was shown as follows: 
plasma (1 ml) was incubated with Sepharose-bound trypsin (100,ul) in a con-
centration of 0.25 mg/ml for 24 hours at 4 C. Plasma was then separated from 
the activator by centrifugation. The supernatant was transferred to a new test 
tube and renin was measured; it was 240 ,uU/ml as compared to 34 ,uU/ml 
before incubation with trypsin. Fresh plasma (1 ml) was added to the trypsin 
pellet and mixed. Renin was generated during subsequent incubation at 4 C, 
whereas no further activation occurred after addition of fresh trypsin to the 
supernatant. It is therefore very likely that at 4 C all the prorenin that could 
be converted by trypsin was indeed converted. 
Recovery of prorenin and renin during incubation with immobilized trypsin 
The possibility that some loss of prorenin has occurred during trypsin treatment 
at 4 C cannot be excluded but the fact that the same maximum of renin activity 
was reached irrespective of the trypsin concentration in the incubate argues against 
such a loss of prorenin. Renin activity decreased with prolonged incubation 
with trypsin at 37 C but not at 4 C, thereby indicating that active renin was 
inactivated or destroyed at 37 C. This was substantiated by the following 
experiment (Fig.2). Standard human kidney renin (1,000 ,uU/ml) in phosphate 
buffer pH 7.5 was incubated at 4 C and 37 C with Sepharose-bound trypsin 
in a concentration of0.25 mg/ml. After various time intervals trypsin was removed 
by centrifugation, and renin activity in the supernatant was determined. In-
cubation for 24 hours at 4 C had practically no effect on renin activity but 
at 37 C renin was rapidly inactivated or destroyed. It should be noted that 
these incubates are free of trypsin inhibitors, so that the concentration of 
uninhibited trypsin is higher under these circumstances than when the same 
quantity of trypsin is added to plasma. As shown in figure 2, at 37 C some 
destruction of renin occurred in the absence of trypsin. This may be due to 
a change in pH; in some examples it rose during 24 hours of incubation at 
37 C from 7.4 to maximally 8.1. Renin has been reported to be destroyed at 
this temperature at alkaline pH3• 
Recovery of Angiotensin I in trypsin-treated plasma 
Aliquots of normal plasma (1 ml), to which Ile-5-ANGI had been added in 
a final concentration of 0.04 ,uM, were incubated for 24 hat 4 C with immobilized 
trypsin (100 ,ul ) in a concentration of 0.25 mg/ml or with phosphate buffer 
7.5 (100 ,ul ). After incubation the immobilized trypsin was removed by 
centrifugation and 0.5 ml of the plasma samples was incubated with 0.5 ml 
of sheep renin substrate in the presence of protease inhibitors as described in 
the methods section. The recovery of added Ile-5- ANGI was 98 ± 10.1% in 
trypsin-treated plasma and 98 ± 9.3% in untreated plasma (mean± SEM, n = 5). 
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Fig. 5.3.2. Inactivation or destruction of human kidney renin (MRC standard) by immobilized trypsin 
(0.25 mg/ml of incubate) at 4 C (closed squares) and at 37 C (open circles). Controls without 
trypsin are shown as closed symbols. 
Comparison between trypsin activation of prorenin and other activation procedures 
The following procedures were compared (Fig. 3): 1) incubation of normal 
plasma pool at 4 C with immobilized trypsin (0.25 mg/ml); 2) dialysis for 24 
hours at pH 3.3 and 4 C followed by dialysis at pH 7.5 again at 4 C;3) dialysis 
for 24 hours at pH 4.0 and 4 C followed by restoration of pH to 7.5 with 
1 M NaOH and incubation at 4 C with plasmin (2 casein units/m1) or with 
urokinase (100 Ploug units/ml); and 4) dialysis for 24 hours at pH 3.3 and 
4 C followed by incubation at 32 C with immobilized pepsin (0.3 mg/ml) and 
subsequent restoration of pH to 7.5 with 1 M NaOH. The maximum levels 
of renin activity obtained with each of these procedures appeared not different. 
This is an indication that all the prorenin that could be converted to active 
renin by proteolytic attack was indeed converted. 
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Fig. 5.3.3. Comparison between various activation procedures:(a) incubation of a pool of normal 
plasma with immobilized trypsin (0.25 mg/ml of plasma) at 4 C;(b) dialysis at pH 3.3 followed 
by dialysis at pH 7.5 both at 4 C; (c) incubation with plasmin (2 casein units/ml or urokinase 
(100 Ploug units/ml) at 4 C following by dialysis at pH 4.0 and restoration of pH by 1 M NaOH; 
and (d) incubation wih pepsin (0.3 mg/ml) at pH 3.3 and 32 C followed by restoration of pH 
by 1 M Na OH. Results are the mean of three experiments. 
Comparison between trypsin-activated prorenin and naturally occurring renin 
Gel filtration. The eluates were treated with trypsin for measuring prorenin. 
The conditions were the same as for plasma, i.e., incubation with immobilized 
trypsin (0.25 mg/ml) for 24 hours at 4 C. We have not rigorously checked 
whether the conditions chosen for plasma were also appropriate for measuring 
prorenin in the column eluates. They probably are because, when normal plasma 
was treated with immobilized trypsin (0.25 mg/ml) for 24 hours at 4 C before 
it was subjected to chromatography, the quantity of renin in the eluate was 
the same as when native plasma was applied to the column and the eluate was 
subsequently treated with trypsin. This quantity was 15 times higher than the 
quantity of renin that was recovered from the column, when trypsin-treatment 
had been omitted both before and after chromatography. The factor of 15, as 
found in the column eluates, was the same as the ratio between total renin 
and naturally occurring active renin in the plasma itself. 
When plasma was activated prior to chromatography, only active renin was 
recovered from the column, with its peak appearing at the same elution volume 
as the peak of naturally occurring active renin (Fig.4). Mr of naturally occurring 
active renin was 49,000 and Mr of prorenin was 56,000 (mean value of three 
experiments). 
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Fig. 5.3.4. Gel filtration on Sephadex G-100 of untreated normal plasma and of plasma treated 
with immobilized trypsin (0.25 mg/ml) for 24 hours at 4 C. The molecular weight markers 14C 
bovine serum albumin (Mr 69,000) and 14C-ovalbumin (Mr 46;000) were used as internal standards. 
Renin was determined in the eluate before (closed circles) and after (open circles) incubation with 
immobilized trypsin. Calculated Mr-values; plasma prorenin 56,000, plasma renin 49,000 and human 
kidney renin (MRC standard) 42,000 
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Dye-ligand affinity chromatography 
The eluates were treated with immobilized trypsin in the same way as after 
gel filtration. When native plasma was subjected to affinity chromatography, 
the bulk of active renin passed through the column, while prorenin was eluted 
with 0.2 M NaCI. The quantity of renin that was recovered after trypsin-treatment 
of the eluate was about 15 times higher than before trypsin-treatment, which 
agrees with the ratio between total renin and naturally occurring active renin 
in the plasma itself. This suggests that the method of trypsin-treatment was 
appropriate for measuring prorenin in the column eluates. 
When plasma had been activated by trypsin prior to chromatography, all 
the renin appeared to pass through the column, since no renin was detected 
both before and after trypsin treatment of the eluates at 0.2 M NaCl and at 
1.4 M NaCl (Fig.5). 
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Fig. 5.3.5. Affinity chromatography on Blue Sepharose of untreated normal plasma and of plasma 
treated with immobilized trypsin (0.25 mg/ml) for 24 hours at 4 C. Renin was determined in the 
eluate before (closed circles) and after incubation with immobilized trypsin (open circles) 
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Enzyme kinetics of naturally occurring renin and prorenin that is activated by 
trypsin 
Under the conditions of the renin assay the generation of ANGI from sheep 
renin substrate by both forms of renin proceeded linearly with time and was 
proportional to the concentration of active renin. The activity of human kidney 
renin (MRC standard) was not influenced by the addition of untreated or trypsin-
treated normal plasma, indicating that substances interfering with the reaction 
between renin and its substrate were absent. Active renin was isolated from 
plasma of a patient with hypertension and renal artery stenosis. The concentration 
of naturally occurring renin in this plasma was very high, 1,200 J,LU/ml. Renin 
was isolated by Sephadex G-100 gel filtration and further purified by DEAE-
Sepharose ion exchange chromatography10•18 followed by affinity chromatography 
on Blue-Sepharose17• The preparation was free of renin substrate and prorenin. 
Prorenin was isolated from normal plasma by Sephadex-G-100 gel filtration 
followed by chromatography on Blue Sepharose. The preparation was free of 
renin substrate and renin. Prorenin was then activated with immobilized trypsin 
as described above. The renin preparations were incubated with sheep renin 
substrate for 1 hour at 37 C and ANGI that had been formed was determined 
for constructing Lineweaver-Burk plots (Fig.6). Km-values for naturally occurring 
plasma renin and standard human kidney renin and for plasma prorenin that 
was activated by trypsin appeared similar; they ranged from 0.21 to 0.28 J,LM. 
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Fig. 5.3.6. Enzyme kinetics of naturally occurring active plasma renin (closed circles), trypsin-activated 
prorenin (open circles) and human kidney renin (MRC standard, triangles). The renins were incubated 
at 37 C with sheep renin substrate for 5, 10, 20, 30, and 60 minutes. v =initial velocity in ,.,M 
angiotensin I per hour. s = substrate concenration in I-'M angiotensin !-equivalents 
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pH-Optimum curves of naturally occurring renin and prorenin that is activated 
by trypsin 
The sources of naturally occurring renin and of prorenin that was activated 
by trypsin were the same as in the previous experiment. The renin preparations 
and sheep renin substrate were dialyzed for 24 hours at 4 C against phosphate 
buffers with pH values ranging from 4.5 to 9.0. The renin preparations were 
then incubated with sheep renin substrate or with human renin substrate at 
these various pH-values for 1 hour at 37 C. The concentrations of sheep substrate 
in these incubates was 2.5 ~-tM ANGI equivalents/ml, and the concentration 
of human substrate was 0.4 ~-tM ANGI equivalents/mi. The pH-optimum curves 
of naturally occurring renin and of pro renin that was activated by trypsin appeared 
not different (Fig.7). The pH-optimum was 7.5 for the reaction with sheep 
substrate and 5.8 with human substrate. 
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Fig. 5.3.7. Optimum pH curves for naturally occurring active plasma renin (closed circles) and 
trypsin-activated prorenin (open-circles) with human renin substrate and with sheep renin substrate. 
Results are the mean of two experiments. 
Measurements of plasma renin and prorenin in patients 
Group 1 Results are shown in Figure 8. Renin in peripheral plasma rose within 
30 minutes after the first dose of captopril and reached a peak value after 1-
2 hours. It remained high with chronic treatment. Prorenin fell initially (p < 
0.05; paired t-test) but with long-term treatment it reached a value as high or 
higher than renin. 
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Fig. 5.3.8. Effects of a first dose of captopril, 50 mg orally, and of chronic captopril treatment, 
50 mg three times a day, on blood pressure and on renin and prorenin in peripheral plasma. Prorenin 
at 30 and 60 minutes after the first dose of captopril was significantly below the control value 
(p < 0.05, paired t test). At 4 and at 16 hours it was above control (p < 0.001). During chronic 
treatment blood was sampled 1 to 2 hours after the morning dose of captopril. Prorenin in these 
samples was 3 times higher than control (p < 0.001). Values in normal plasma (n = 17 ) are 
23 fLU/ml (range 14-43 fLU/ml) for renin and 196 fLU/ml (range 138-312 fLU/ml) for prorenin. 
Groups 2, 3 and 4 Basal values of peripheral vein renin and prorenin were 
comparable in the three groups (see Methods section). Blood pressure fell from 
208±6/112 ±5 mmHg to 164±10/94±6 mmHg 30 minutes after captopril in 
Group 2. Blood pressure was 211±7 /110±6 mmHg before captopril and 198±8/ 
104±7 mmHg 16 hours after captopril in Group 3. In Group 4 blood pressure 
was 202±9/109±4 mmHg before captopril and 143±6/91±5 mmHg 1-2 hours 
after the last dose of captopril. Data collected at the time of renal vein sampling 
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Fig. 5.3.9. Effects of a first dose of captopril, 50 mg orally, and of chronic captopril treatment, 
50 mg three times a day, on plasma renin and prorenin in the renal vein and the abdominal aorta. 
Statistics of these data and details on the study design are presented in Tables 5.3.1. and 5.3.2. 
are shown in figure 9 and in table 1. Renin in the renal vein on the affected 
side, but not contralaterally, was higher than in the aorta before captopril and 
30 minutes after a first dose of captopril (p < 0.001, Group 2), and at 16 hours 
after a first dose of captopril (p < 0.00 1, Group 3), and also with chronic captopril 
treatment (p < 0.001, Group 4). Prorenin in the renal vein on the affected side 
was significantly higher than in the aorta before and 16 hours after a first dose 
Table 5.3.1a Renin and prorenin in plasma of renal vein and aorta in patients with renal artery stenosis. 
10Log renin (1-1U/ml) 
Affected side Contralateral 
Patient Study Blood Aorta Renal Aorta Renal 
group design sampling vein vein 
time 
Group 2 Captopril Before first 1.73 2.09 1.72 1.79 
(n = 15) 50 mg dose of (0.10) (0.10) (0.09) (0.09) 
single dose Captopril 
30 min after 2.66 3.12 2.70 2.71 
first dose (0.11) (0.13) (0.11) (0.10) 
of Captorpil 
Group 3 Captopril 16 h after 2.02 2.37 2.01 2.01 
(n = 15) single dose Captopril (0.15) (0.19) (0.15) (0.15) 
Group 4 Captopril 1-2 h after 2.91 3.42 2.89 2.89 
(n = 10) 50 mg tid last dose (0.13) (0.12) (0.12) (0.13) 
for 2 weeks of Captopril 
For details see Methods section. Values are mean (SEM in parentheses). 
10Log prorenin (1-1U/ml) 
Affected side Contralateral 
Aorta Renal Aorta Renal 
vein vein 
2.23 2.26 2.21 2.21 
(0.04) (0.06) (0.06) (0.06) 
2.02 1.93 2.01 1.89 
(0.09) (0.20) (1.14) (0.19) 
2.41 2.57 2.41 2.42 
(0.13) (0.14) (0.12) (0.12) 
2.99 3.16 3.01 3.02 
(0.06) (0.06) (0.05) (0.05) 
....... 
.j:>. 
'0 
Table 5. 3.1 b Renal vein-to-aorta ratio of renin and inactive renin. 
Renal vein-to-aorta 
ratio of renin 
Patient Study Blood Affected 
group design sampling side 
Group 2 Captopril Before first 2.38*** 
(n = 15) 50 mg dose of (0.21) 
single dose Captorpil 
30 min after 3.25*** 
first dose (0.50) 
of Captopril 
Group 3 Captorpil 16 h after 2.72*** 
(n = 15) single dose Captopril (0.50) 
Group 4 Captopril 1-2 h after 3.39*** 
(n = 10) 50 mg tid last dose (0.48) 
for 2 weeks Captropil 
For details see Methods section. Values are mean (SEM in parentheses) 
* p < 0.05, ** p < 0.01, *** p < 0.001 for the difference from 1.00. 
Renal vein-to-aorta 
ratio of prorenin 
Contra- Affected 
lateral side 
1.16 1.19* 
(0.09) (0.08) 
1.05 1.14 
(0.05) (0.26) 
1.00 1.53** 
(0.02) (0.16) 
1.00 !.50** 
(0.03) (0.11) 
Contra-
lateral 
1.04 
(0.08) 
1.04 
(0.13) 
1.03 
,(0.03) 
1.03 
(0.02) 
....... 
Vl 
0 
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of captopril (p < 0.05 and p < 0.01 in Groups 2 and 3 respectively), and also 
with chronic captopril treatment (p < 0.01, Group 4). Contralaterally the prorenin 
levels in the renal vein and aorta were not different neither before captopril 
nor after captopril. High levels of renin were measured in the aorta 30 min 
after a single dose of captopril and with chronic treatment. High levels of pro renin 
were measured in the aorta with chronic captopril. This is in agreement with 
the measurement of peripheral vein renin in Group 1. 
5.3.5. DISCUSSION 
Methodological Aspects 
For the results of functional assays of prorenin to be valid, conversion of 
the prorenin in the test sample should be complete and the enzymatic activities 
of equimolar quantities of activated prorenin and naturally occurring renin should 
not differ. These criteria are likely to be met when immobilized trypsin is used 
for prorenin activation in human plasma under the assay conditions we have 
worked out. Several lines of evidence support this conclusion. First, identical 
results were obtained with acid-activation, with activation by pepsin, plasmin, 
and urokinase and with immobilized trypsin, provided that optimal conditions 
were selected. A plateau of maximal renin activity was obtained, and the level 
of this plateau had the same height with each of these procedures. 
Second, Km-values and pH-optimum curves for the reactions of trypsin-
activated prorenin and naturally occurring renin with sheep renin substrate did 
not appear different. Third, the behaviour of trypsin-activated prorenin on 
Sepha.dex-G-100 and Blue Sepharose chromatography columns was similar to 
that of naturally occurring renin. The Mr-values of naturally occurring active 
renin (49,000) and prorenin (56,000) as estimated by gel filtration, are in agreement 
with those reported by others19•20 and confirm that the Mr of these plasma renins 
is greater than the Mr of human kidney renin ( 42,000). 
Maximal activation of prorenin was observed, when plasma was incubated 
with trypsin at 4 C. Other workers have incubated at 37 C14• Our results indicate 
that it is difficult if not impossible, to obtain complete activation of prorenin 
at this temperature. Moreover, the results at 37 C are strongly dependent on 
the concentration of trypsin and on the incubation time. At 4 C these variables 
are less critical, provided that incubation is prolonged until renin activity has 
reached a plateau. At 37 C a larger proportion of added trypsin is inhibited 
by plasma than at 4 C, and at 37 C the remaining uninhibited trypsin causes 
progressive inactivation or destruction of renin. Both the inhibition of trypsin, 
which leads to incomplete activation of prorenin, and the inactivation of renin 
by trypsin are the cause of measuring falsely low prorenin values. Low values 
have also been obtained after cryoactivation. It is therefore not surprising that 
the results of pro renin measurements reported in the literature are widely different. 
A literature search showed that the measured percentage of renin in normal 
plasma is highest with cryoactivation (35%-53%),8•21- 23 whereas it is intermediate 
with acid-activation (20%-50% ), 1•2•10•11•13•22•24- 32 and lowest with trypsin (12%-
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34% )3• 12• 14•33 • In our study, 11% of the renin in normal plasma was in the active 
form. 
The methodological difficulties are amplified when prorenin is measured after 
maneuvers that are known to increase circulating renin. The accuracy of renin 
assays expressed as absolute values is inversely correlated to the height of the 
measured value. Thus, the higher the renin, the less accurate is its measurement. 
This causes problems particularly when the difference in renin before and after 
activation of plasma is small. It explains why there is confusion on whether, 
after certain stimuli, increments in circulating renin are associated with decrements 
in pro renin 1,2,25,27,30,31,34,35. 
Changes in Prorenin after Captopril 
As shown by the present study on patients with renal artery stenosis, stimulation 
of renin release by angiotensin converting enzyme inhibition with captopril causes 
a precipitous rise in circulating renin with initially no change or even fall in 
prorenin. Later also prorenin begins to rise. A transient fall in plasma prorenin 
after captopril has recently been reported36- 37 , whereas earlier studies had failed 
to demonstrate such a fal138•40 • 
Before stimulation with captopril we found a renal vein-to-aorta prorenin 
ratio of 1.19±0.08 (mean±SEM) on the affected side and of 1.04±0.08 con-
tralaterally; the value on the affected side was just significantly different from 
1.00 (p < 0.05). Also in earlier studies renal secretion of prorenin was difficult 
to demonstrate under basal conditions2•11•25•27•41 • It has therefore been postulated 
that pro renin is formed by extrarenal inactivation of intrarenally produced renin. 
However, since prorenin appears to have a longer plasma half-life than renin11, 
a relatively low secretion rate of prorenin may suffice to maintain a relatively 
high plasma level. It is possible therefore that the venoarterial difference in · 
prorenin across the kidney is often too small to detect with an assay that has 
an accuracy that is not better than 10%. 
After acute stimulation with captopril the secretion of pro renin by the affected 
kidney was not significantly increased, despite a tenfold rise in the secretion 
of renin. With chronic stimulation however, the venoarterial difference in pro renin 
became large enough to be easily detectable. Thus it appears that the kidney 
is indeed capable of secreting prorenin. This finding is probably not an artifact 
since secretion could be demonstrated on the affected side but not contralaterally. 
In fact, our data indicate that the changes in peripheral prorenin concentration 
after captopril are a consequence, at least in part, of corresponding changes 
in the rate of prorenin secretion from the affected kidney. Both the concentration 
of prorenin in peripheral plasma and its secretion are increased with prolonged 
stimulation of renin release but not with acute stimulation. An extrarenal source 
of plasma prorenin, however, cannot be entirely ignored since low to normal 
concentrations of prorenin are present in the plasma of nephrectomized sub-
jects 11,25,42. 
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This pattern changes in renin and prorenin after captopril is similar to that 
of insulin and proinsulin following an oral glucose load; insulin rises within 
a few minutes but proinsulin begins to rise not earlier than after 1-2 hours43 • 
The late rise in proinsulin is a manifestation of an increased rate of synthesis 
in the pancreas. More prohormone is then available for conversion to the active 
hormone before it is released into the circulation. These points of resemblance 
between the two hormonal systems should not distract from the fact that under 
normal basal conditions the concentration of insulin in peripheral plasma is 
8-9 times higher than that of proinsulin, whereas the reverse is true for renin 
and prorenin. 
Our results do not answer the question whether or not prorenin is a storage 
form of renin but they do suggest that prorenin enters the circulation either 
by leakage from the juxtaglomerular cells or by corelease before it is converted 
to renin. In conclusion, these data indicate that prorenin is indeed a biosynthetic 
precursor of renin and that under some circumstances, if not mostly, a major 
proportion of prorenin in the circulation originates from the kidney. 
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5.4. RENAL VEIN IMMUNOREACTIVE RENIN IN PATIENTS WITH RENAL 
ARTERY STENOSIS OR ESSENTIAL HYPERTENSION 
5.4.1. ABSTRACT 
In 36 patients with unilateral renal artery stenosis and in 24 with essential 
hypertension the plasma levels of total immunoreactive renin, and enzymatically 
active renin were measured in both renal veins (V) and in the aorta (A) by 
direct RIA by using monoclonal renin antibodies. Active renin and trypsin-
activatable inactive renin were also measured by indirect RIA with angiotensin-
! antibodies. The VI A ratio for the different forms of renin calculated from 
the results of .direct and indirect RIA were not different. The VI A ratio of 
active renin for the kidney with the stenotic artery was 3.04 ± 0.28 (mean ± 
sem) with direct and 3.02 ± 0.25 with indirect RIA. The contralateral ratio 
was 1.04 ± 0.02 with the direct and 1.05 ± 0.02 with the indirect RIA. In 
essential hypertension it was 1.28 ± 0.04 with direct RIA and 1.28 ± 0.04 with 
indirect RIA. 
Chronic treatment with captopril had no influence on this ratio in both patients 
groups. The VI A ratio of total immunoreactive renin was lower than that of 
active renin and this ratio had lost discriminative power for lateralization. This 
ratio was significantly greater than one on the affected side in renal artery stenosis 
but not contralaterally and in essential hypertension. This study shows that renin 
activity after trypsin-activation of plasma is an accurate measure of the total 
renin concentration,i.e. active renin plus prorenin. It also shows that a kidney 
with a stenotic artery secretes inactive renin, which is immunologically related 
to active renin and is likely to be prorenin. 
Direct RIA for measuring active renin is technically more simple than indirect 
RIA. Direct RIA however is somewhat less sensitive. For measuring the VI 
A ratio for active renin in patients with renal artery stenosis this can be overcome 
by stimulating the renin-angiotensin system for instance by captopril. 
5.4.2. INTRODUCTION 
Split renal vein sampling for demonstrating increased production of renin by 
the kidney supplied by a stenotic artery is helpful in the diagnosis of renovascular 
hypertension. The renal vein-to-artery (VI A) ratio of renin on the affected kidney 
versus the contralateral kidney is considered to be a useful index of the functional 
importance of the stenosis1•2• Furthermore a high ratio on the affected side with 
a suppressed ratio contralaterally is believed to predict operative curability1•3• 
A variety of stimulatory maneuvers has been employed to increase the sensitivity 
of this index by treating the patient with diuretics, vasodilatators and angiotensin-
converting enzyme inhibitors4- 9• 
In the studies reported so far, renin was determined by the enzyme kinetic 
method in which angiotensin I, generated from renin substrate in vitro, is measured 
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by RIA (indirect RIA). Monoclonal antibodies with high affinity for both active 
renin and inactive renin and monoclonal antibodies that only recognize active 
renin are now available and such antibodies can be used for direct RIA of 
renin. The purpose of the present study was to compare the results of direct 
RIA with those of indirect RIA in order to evaluate whether or not direct renin 
RIA is useful in the diagnostic work-up of patients with renal artery stenosis. 
5.4.3. MATERIAL AND METHODS 
Patients. Thirty-six hypertensive patients with unilateral renal artery stenosis 
and 28 with essential hypertension were studied. Renal artery stenosis was caused 
by atherosclerosis in 32 and by fibromuscular dysplasia in 4 patients. Eighteen 
patients with unilateral renal artery stenosis and 14 with essential hypertension 
were off therapy for at least two weeks before the study. The remainder of 
the patients were on captopril, 50 mg t.i.d. Blood was sampled from both renal 
veins and from the abdominal aorta. Since plasma renin may change during 
the course of the catheterisation procedure and since some time elapses between 
the samplings at the two sides, we prefer to measure the renal vein-to-aorta 
(VI A) renin ratio for each kidney instead of measuring the ratio between the 
veins of the two kidneys. The arterial samples were collected at exactly the 
same time as the corresponding renal vein samples. No radiocontrast drugs were 
used before or during the sampling procedure. Blood was collected in tubes 
containing 0.1 vol 0.13 M trisodium citrate. The samples were immediately 
centrifuged at room temperature and, plasma was stored at - 20 C. 
Renin measurements. The plasma concentrations of enzymatically active renin 
(active renin) and inactive renin (prorenin) was measured by an enzyme kinetic 
assay9•10• In this assay plasma is incubated at 37 C with saturating amounts 
of sheep renin substrate, and angiotensin I that is formed is quantitated by 
RIA (indirect RIA). For measuring prorenin by indirect RIA plasma was 
incubated at 0 C with immobilized trypsin before assay, in order to convert 
prorenin into active renin9• Total immunoreactive renin (active renin and 
prorenin) and active renin were also measured by direct RIA, using monoclonal 
antibodies that were reacting with both active renin and prorenin or by antibodies 
that only recognize active renin. Total immunoreactive renin was measured using 
the monoclonal antibodies R 3-27-6 and R 3-36-16 (Ciba-Geigy, Basle, Swit-
zerland)ll. Details of the procedure have been described elsewherell,l2_ Active 
renin or trypsin activated inactive renin were measured by using the monoclonal 
antibodies 3E8 and 4G 1 (Diagnostic Pasteur, Marnes-la-Coquette, France) as 
described elsewhere13 • Results of direct -RIA are expressed as picograms per ml, 
using highly purified human kidney renin (Ciba-Geigy), specific activity 760 
Goldblatt Units per mg of protein, as the standard. 
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5.4.4. RESULTS 
The plasma levels of active renin and total renin in the aorta in patients with 
renal artery stenosis and in essential hypertensive subjects measured with the 
enzyme kinetic assay (indirect RIA) and with the immunological assay (direct 
RIA) are summarized in Table 1. 
Table 5.4.1. Total renin and active renin in plasma of aorta measured with direct and indirect 
RIA. 
Patient Active renin Total renin 
group Direct RIA Indirect RIA Direct RIA Indirect RIA 
pg/ml 11U/ml pg/ml 11U/ml 
Essential hypertension 
no therapy 25.2 17.9 141 106 
(10* -79.1) (5.9 -54.3) (32.0-620) (23.8-470) 
captopril 50 mg tid 102 76.9 470 343 
(10* -1650) (94.8-1221) (72.1-3070) (54.1-2170) 
Renal artery stenosis 
no therapy 72.0 52.6 331 238 
(10* -376) (10.1-274) (105 -1040) (75.6-751) 
captopril 50 mg tid 376 273 1040 763 
( 42.1-3370) (31.0-2390) (22.4-4830) (161 -3630) 
Mean values and 95% confidence intervals (in parentheses) are shown. Data were analysed after 
logarithmic transformation of the results to obtain a Gaussian distribution. Direct RIA of active 
renin was measured by monoclonal antibodies specific for active renin, direct total renin was 
determined with monoclonal antibodies that recognize active renin and prorenin. *lower limit of 
detection 10 pg/ml. 
Table 5.4.2. Comparison of results of direct and indrect RIAs of renin. 
Source of Trypsin Direct RIA Direct RIA Indirect RIA 
plasma treatment total renin active renin active renin 
pg/ml pg/ml 11U/ml 
Essential hypertension no 184±17 18.7±3.7 14.2±1.2 
yes 181±19 189 ±20 139 ±10 
Renal artery stenosis no 398±36 92.5±6.7 54.8±5.1 
yes 402±29 396 ±39 290 ±26 
Mean and SD of five experiments. 
For measuring total renin with the indirect RIA plasma is treated with 
Sepharose-bound trypsin8• This treatment may lead to degradation of renin or 
activated prorenin. We therefore have measured total immunological renin and 
active renin with direct RIA in a plasma pool of patients with essential 
hypertension and renovascular hypertension before and after trypsin treatment 
of plasma. The result of the direct RIA for total renin was not altered by trypsin 
treatment of plasma (Table 2). 
The VI A ratios for active renin and total renin calculated from the results 
from direct and indirect RIA are not different (Fig.l and Table 3). The VI 
( 
Table 5.4.3. Renal vein-to-aorta ratio of active renin, total renin and inactive renin. 
Active renin Total renin Inactive renin 
Patient group Captopril Direct Indirect Direct Indirect Direct Indirect 
Essential hypertension 
Right side no 1.28±0.04 1.27±0.05 1.07±0.02 1.06±0.02 1.03±0.02 1.02±0.02 
yes 1.30±0.04 1.31±0.04 1.11±0.03 1.10±0.03 1.03±0.02 1.04±0.02 
Left side no 1.27±0.04 1.29±0.04 1.08±0.02 1.08±0.02 1.04±0.02 1.05±0.03 
yes 1.29±0.04 1.31±0.05 1.12±0.03 1.13±0.03 1.07±0.02 1.09±0.04 
Renal artery stenosis 
Affected side no 3.04±0.28 3.02±0.25 1.71±0.11 1.74±0.10 1.25±0.06 1.23±0.05 
yes 3.05±0.27 3.07±0.27 2.27±0.19* 2.24±0.18* 1.59±0.16* 1.64±0.14* 
Contralateral side no 1.04±0.02 1.05±0.02 1.03±0.02 1.03±0.02 1.03±0.03 1.02±0.03 
yes 1.05±0.02 1.04±0.02 1.04±0.03 1.04±0.03 1.04±0.03 1.05±0.04 
Mean ± SEM are presented. Direct RIA: active renin was measured with a monoclonal antibody specific for active renin, total renin was measured 
with monoclonal antibodies that recognize active renin and prorenin. Indirect RIA was measured with angiotensin I antibodies. In this assay total renin 
was measured after trypsin-treatment of plasma. Inactive renin is calculated as the difference between total renin and active renin. *difference p < 
0.01 from no treatment (unpaired t-test). Captopril dosage was 50 mg t.i.d. for three to four weeks. 
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Fig.5.4.1. Renal vein-to-aorta ratio for active renin measured by the direct and indirect RIA on 
the affected side in patients with unilateral renal artery stenosis. 
A ratios for active renin in the kidney with the stenotic artery calculated from 
the results of the direct RIA or the indirect RIA were elevated as compared 
to the ratios in essential hypertension, and stimulation of the renin angiotensin 
system with captopril had no effect on these ratios. VI A ratios of active renin 
on the contralateral side in patients with renal artery stenosis were suppressed, 
also when the patients were treated with the converting enzyme inhibitor. 
The VI A ratios for active renin measured with either the direct or indirect 
RIA on the affected side in patients with renal artery stenosis were higher than 
the VI A ratios for total renin (active renin and prorenin) on this side (Table 
3). The VI A ratios for prorenin were significantly greater than one on the affected 
side in patients with renal artery stenosis but not contralaterally and in essential 
hypertension. During captopril treatment the VI A ratio for prorenin on the 
affected side rose significantly from 1.25 to 1.59 (Table 3). 
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5.4.5. DISCUSSION 
An elevated VI A renin ratio for the kidney with the stenotic renal artery and 
a suppressed renin ratio contralaterally is considered to be good index of the 
functional importance and is also believed to predict operative curability1- 3• 
Therefore renin measurements are of crucial importance in the diagnostic work-
up of patients with suspected renovascular hypertension. 
Most investigators use PRA measurements for calculating the VI A renin ratio's. 
However PRA measurements depends not only on the concentration of active 
renin but also on the concentration· of endogenous renin substrate and the 
contribution of each of the two components has not been precisely quantitated. 
It is conceivable that high concentrations of active renin in the plasma of the 
renal vein of the affected kidney leads to erroneously low PRA levels due to 
renin substrate exhaustion. This will lead to a relatively low VI A ratio for PRA 
on the affected side. We therefore prefer measurements of active renin con-
centration in which saturating amounts of exogenous renin substrate are added 
and the generation of angiotensin I solely depends on renin concentration. 
This study shows that the VI A ratios for active renin measured with the 
direct RIA are not different from those measured with the indirect RIA. The 
use of monoclonal antibodies has some advantages 1) the method is independent 
of endogenous or exogenous substrate, 2) the generation step of angiotensin 
I, with problems such as recovery and pH of the incubation mixture, is not 
longer necessary, 3) there is no need for a centrifuge and water bath and, 4) 
one technician can easily handle up to a 100 samples in one day. The indirect 
RIA for renin normally takes two days. A disadvantage is the relatively low 
level of detection of about 10 pglml, which leads to a relatively high intra-
and interassay variability (the intra-assay coefficient of variation is 16% for 
a plasma pool with an active renin concentration of 21.2 pglml (n = 6) and 
only 3.6 % for a pool with a mean value of 66.4 pglml (n = 6). This problem 
can easily be solved when renal vein sampling is done during stimulation of 
the renin-angiotensin system by captopril. 
Stimulation of the renin-angiotensin system by captopril, leading to a 6-fold 
increase in the peripheral level of active renin, does not influence the VI A renin 
ratios. Why is this so ? It is often implied that the high renin ratio is caused 
by a high secretion rate of renin from the affected kidney and a low secretion 
rate contralaterally. However, a high ratio is not necessarily caused by such 
a difference in secretion rate but is an indication of diminished renal plasma 
flow on the affected side rather than an index of increased renin secretion2• 7• 
It is interesting to note that despite captopril treatment the VI A ratio for active 
renin on the contralateral side in patients with unilateral renal artery stenosis 
is still suppressed. A suppressed ratio in untreated patients could be explained 
by elevated angiotensin II levels which will inhibit renin secretion contralaterally. 
During converting enzyme blockade with the captopril dose we have used 
angiotensin II levels are low14• Thus it is unlikely that the suppressed ratio is 
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caused by elevated angiotensin II levels. This phenomenon· therefore remains 
unexplained. 
Normally about 90 percent of the renin in plasma circulates in the enzymatically 
inactive form (prorenin). For the indirect RIA of plasma prorenin, we activated 
the samples with immobilized trypsin at 0 C. The two important questions about 
the validity of the method are, 1) is active renin or activated pro renin degraded 
into inactive fragments and, 2) are all prorenin molecules in the sample converted 
into active renin. Our results of the direct RIA for total renin was not altered 
by trypsin-treatment of the plasma, therefore it is unlikely that naturally occurring 
active renin or activated renin are destroyed during the activation step with 
trypsin. With our method of trypsin treatment prorenin activation in plasma 
reached a plateau independent of the trypsin concentration over a wide range 
of concentrations9• Km for naturally occurring active renin is not different from 
that of trypsin-activated prorenin9• The Vmax, expressed as the catalytic activity 
per unit weight of renin is also the same for both renins12• Thus the renin activity 
after trypsin-activation of plasma is an accurate measure of the. total renin 
concentration that is active renin plus prorenin. In some reports, Skinner's 
method15 was used for measuring plasma total renin concentration: plasma was 
dialyzed for 24 h at pH 3.3 and 4 C followed by 24 h at pH 7.5 and 4 C 
before the indirect RIA to convert prorenin to active renin. The VI A ratio 
on the affected side was greater for active renin or PRA than for total renin16- 19• 
A reason for this discrepancy could be the method of activation of prorenin. 
The degree of prorenin to active renin conversion is critically dependent on 
pH and duration of dialysis. In our hands e.g., acid-activation of prorenin in 
plasma (24-h dialysis at 4 C against a pH 3.3 buffer followed by dialysis for 
24 h against a pH 7.5 buffer) is too short in many plasma samples to activate 
prorenin completely. However, even with the use of monoclonal antibodies that 
recognize both prorenin and active renin , VI A ratios of total renin are much 
lower than the VI A ratios for active renin. Therefore the VI A ratios of total 
renin on the affected side in patients with renal artery stenosis have less 
discriminative power for lateralization of the disease. 
The present study also demonstrates that immunoreactive renin (active renin 
and prorenin) is secreted by the kidney with the stenotic artery especially when 
the renin-angiotensin system is stimulated by a converting enzyme inhibitor. 
This confirms an earlier study of our group9 and other reports 16•20 that the kidney 
with the stenotic artery secretes inactive renin, which is immunologically related 
to active renin and is likely to be prorenin. 
In summary direct RIA of active renin in plasma of renal veins and aorta 
for calculating the VI A ratios is a powerful tool for diagnosis and lateralization 
in patients with suspected renal artery stenosis. 
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5.5. ACTIVATION OF PLASMA PRORENIN BY PLASMINOGEN ACTIVA-
TORS IN VITRO AND INCREASE IN PLASMA RENIN AFTER STI-
MULATION OF FIDRINOLYTIC ACTIVITY IN VIVO. 
5.5.1. ABSTRACT 
Plasminogen can be activated by intrinsic activators that circulate in plasma 
in a precursor form, by extrinsic activator originating from tissues or the vessel 
wall and by the exogenous activators, urokinase and streptokinase. Tissue 
activator and vascular activator are probably identical. Dialysis of plasma against 
pH 4.0 buffer causes denaturation of the plasmin inhibitors, a2-antiplasmin and 
C1-inhibitor, while armacroglobulin is left intact. Incubation of pH 4.0 pretreated 
plasma with urokinase or streptokinase at pH 7.5 led to activation of plasminogen 
and prorenin. Incubation of a plasma fraction, which contained plasminogen 
and prorenin but no a2-antiplasmin and renin, with highly purified tissue 
plasminogen activator also led to activation of prorenin. Incubation of a plasma 
fraction, which contained plasminogen and prorenin but no a2- antiplasmin and 
renin , with highly purified tissue plasminogen activator also led to activation 
of prorenin. The vasopressin analoque, 1-des-amino-8-D-arginine vasopressin 
(DDA VP), is a potent stimulant for the release of extrinsic activator into the 
blood stream. After infusion of DDA VP, 0.4 p.g/kg, into normal subjects, parallel 
increments in plasma fibrinolytic activity and renin were observed. Infusion of 
DDA VP into patients with type IV hyperlipoproteinaemia had little effect on 
plasma fibrinolytic activity and the response of plasma renin was also subnormal. 
These observations warrant further studies on a possible role for plasminogen 
activators in prorenin activation in vivo. 
5.5.2. INTRODUCTION 
Two intrinsic activators of prorenin have been identified: plasma kallikrein and 
plasmin 1. These activators are present in plasma precursor form. Acidification 
of plasma to pH 3.0-3.5 causes denaturation of C1-inhibitor (C1-INH) and a2-
macroglobulin (a 2M), the major inhibitors of kallikrein. By this treatment plasma 
acquires the ability to convert its prorenin into active renin by kallikrein that 
is formed by factor XU-initiated activation of prekallikrein2- 4• However, contact 
activation of the intrinsic factor XU-kallikrein pathway by kaolin without prior 
treatment of plasma with acid does not lead to activation of prorenin. Similarly, 
the addition of the plasminogen activators, streptokinase and urokinase, to 
untreated plasma does not lead to activation of prorenin. The most important 
inhibitor of plasmin is a2-antiplasmin but C1-INH and azM are also effective 
plasmin inhibitors.az-Antiplasmin is denaturated by acid as are C1-INH and 
a 2M. 
We have studied the effects of adding plasmin, streptokinase or urokinase 
to plasma pretreated with buffers of various pH. We have also studied the effect 
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of adding highly purified tissue plasminogen activator to a plasma fraction, 
which contained plasminogen and prorenin but was free of a2-antiplasmin and 
active renin. 
Tissue plasminogen activator and vascular plasminogen activator are likely 
to be identical. This activator is released into the blood by various stimuli5• 
Some of these, for instance physical exercise and certain vasodilator substances, 
also stimulate the release of renin. A particularly powerful stimulus for the release 
of vascular activator is the vasopressin analogue , 1-desamino-8-D-arginine 
vasopressin (DDA VP)6• It has antidiuretic activity but its vasoconstrictor activity 
is much less than that ofL- arginine vasopressin. We have administrated DDAVP 
to normal volunteers and to patients with type IV hyperlipoproteinaemia. In 
such cases the release of vascular plasminogen activator is less responsive to 
DDAVP than in normals7 • Because of this we thought it might be of interest 
to compare the effects of DDAVP on plasma renin in these patients and in 
normals. 
5.5.3. METHODS AND SUBJECTS 
Measurement of plasmin, plasminogen and a2-antiplasmin 
Plasmin was measured via its amidolytic action on the chromogenic substrate 
D-valyl-leucyl-1-lysine-p-nitroanilide (S2251, Kabi,Sweden)8' 9• The release of p-
nitroaniline was followed in a spectrophotometer. Plasminogen was determined 
as amidolytic activity of the streptokinase-plasminogen complex. Measurement 
of a2-antiplasmin was based on the rapid inhibitory action of this plasma protein 
on the amidolytic activity of added plasmin. 
Measurement of fibrinolytic activity 
An euglobulin fraction was prepared from plasma and fibrinolytic activity 
of this fraction was determined by the fibrin plate method10, 11 • 
Measurement of renin and prorenin 
Renin was measured via its ability to cleave angiotensin I from sheep renin 
substrate. Angiotensin I was determined by radioimmunoassay. Prorenin was 
measured in the same way after complete conversion into active renin by 
immobilized trypsin8• 
Normal subjects and patients 
Nine healthy volunteers and nine subjects with type IV hyperlipoproteinaemia 
received DDA VP (Ferring, Denmark), 0.4 ,ug/kg intravenously, over 10 minutes. 
The subjects were lying in bed for at least one hour before the infusion was 
started. Blood samples were taken at various time intervals as indicated under 
'Results'. EDT A-plasma was used for determinations of plasmin, plasminogen,a2-
antiplasmin, renin and prorenin. Citrate-plasma was used for measurement of 
fibrinolytic activity. 
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5.5.4. RESULTS 
· Effects of acid-pretreatment of plasma on plasminogen,l¥2-antiplasmin and prorenin 
Normal plasma was dialyzed for 24 h at 4 C against buffers of pH 4.0-7.53• 
pH was then restored by dialysis against a pH 7.5 phosphate buffer for 24 
hours at 4 C. As shown in Fig.l ,a2-antiplasmin was denaturated at pH 5-
6 but there was no evidence that plasminogen and prorenin were activated; 
consumption of streptokinase activatable plasminogen and trypsin-activatable 
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Fig. 5.5.1. Normal EDT A-plasma was first dialysed for 24 hours at 4 C against buffers of different 
pH and then against pH 7.5 buffer also for 24 hours. The levels of plaminogen and prorenin after 
maximal activation in non-dialyzed plasma by streptokinase (SK) and immobilized trypsin respectively 
were taken as 100%. Also for a 2-antiplasmin the level in non-dialyzed plasma was taken as 100%. 
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prorenin was undetectable, and plasmin and renin activities were not generated. 
Thus, plasma pretreated at pH 4.0 could serve as a source of prorenin and 
plasminogen with little or no a2-antiplasmin activity. Pretreatment of plasma · 
at pH 4.0 also destroys C1-INH but leaves a2M intact3• 
Effects of plasmin, streptokinase and urokinase on prorenin in pH 4.0- pretreated 
plasma 
When untreated plasma was incubated at pH 7.5 with plasmin (final con-
centration 2 casein units/ml) or urokinase (100 Ploug units/ml) little activation 
of prorenin occurred. There was some activation with streptokinase in high 
concentration (1000 Christensen units/ml). This contrasts with the results when 
pH 4.0-pretreated plasma was incubated with these activators at pH 7.5 (Fig.2). 
Effects of highly purified tissue plasminogen activator on a semipurified fraction 
of plasma prorenin 
Highly purified plasminogen activator isolated from human uterine tissue12 
was a gift of Dr Kluft (Gaubius Institute, TNO, Leiden, The Netherlands). 
Prorenin was isolated from normal plasma by affinity chromatography on 
columns packed with Blue-Sepharose CL-6B (Pharmacia,Sweden). Prorenin was 
eluted with phosphate buffer pH 7.1 containing 0.2 mol/1 NaCl. Plasminogen 
appeared in the same fraction but active renin and a2-antiplasmin were un-
detectable. When this fraction was incubated with the tissue activator (final 
concentration 10 Ploug units/ml), prorenin was progessively activated (Fig.3). 
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Fig. 5.5.3. A prorenin-containing fraction was isolated from plasma by dye-ligand chromatography 
(see text). This fraction also contained plasminogen but active renin and a2-antiplasmin were 
undetectable. Results are compared with those obtained in crude plasma. 
It is of interest that in semipurified prorenin high concentrations of strep-
tokinase were less effective than low concentrations. At low concentrations a 
relatively small proportion of plasminogen is complexed with streptokinase. These 
complexes convert the remaining uncomplexed plasminogen into plasmin, which 
then activates prorenin. Streptokinase-plasminogen complex is a good activator 
of plasminogen but towards prorenin it may be less potent than plasmin. Besides 
being less potent than plasmin these complexes are also less sensitive to inhibitors 
including a 2-antiplasmin13 • These differences between the active streptokinase-
plasminogen complex and plasmin may explain why in untreated plasma high 
concentrations of streptokinase are more effective in prorenin activation than 
low concentrations, whereas the reverse is true in semipurified prorenin fractions. 
Urokinase converts plasminogen into plasmin but does not form complexes with 
plasminogen. 
Effects of DDA VP in normal subjects and in patients with type IV hyperlipo-
proteinaemie 
Fig.4 shows the results in eleven healthy volunteers in whom the effects were 
followed for 60 minutes. Systolic arterial pressure did not change significantly 
but diastolic pressure fell by about 10 mm Hg ( P<0.05) during the first 20 
minutes after DDA VP infusion had been started. Plasma fibrinolytic activity 
rose markedly and this was accompanied by a parallel increase in plasma renin. 
A significant change in prorenin was not observed. 
In Fig.5 the effects in nine normal subjects and in nine patients with type 
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Fig. 5.5.5. Effects (mean±SEM) of DDAVP, 0.4 J.Lglkg i.v. 10 minutes, in nine normal subjects 
and in nine patients with type IV hyperlipoproteinaemia. Blood was sampled just before and 30 
minutes after DDAVP infusion had been started. Nx = nephrectomized patients, CRF = chronic 
renal failure. 
IV hyperlipoproteinaemie are compared. DDA VP was infused in the same way 
as in Fig. 4, and blood samples were taken just before DDAVP and 30 minutes 
after the infusion had been started. In the patients with hyperlipoproteinaemie 
plasma fibrinolytic activity did not change after DDA VP and plasma renin in 
these patients was also less responsive than in the normal subjects. Again there 
were no significant changes in prorenin. 
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5.5.5. DISCUSSION 
Plasminogen activation may occur by an intrinsic pathway involving the plasma 
proteins factor XII, prekallikrein and high molecular weight kininogen and 
possibly other plasma components as welL An extrinsic pathway also exists in 
which the activator originates from tissue or from the vessel wall and is released 
into the blood by certain stimuli. Finally plasminogen can also be activated 
by an exogenous pathway in which activators , streptokinase and urokinase, 
are added to plasma or are infused into patients for therapeutic purposes. Diurnal 
variations in the so-called fibrinolytic activity of plasma are mainly caused by 
changes in the level of extrinsic activator. The increased fibrinolytic activity 
of plasma after physical exercise and after DDA VP also reflects a higher content 
of extrinsic activator, due to stimulation of the release of this activator into 
the bloodstream 11 • 
Our experiments in vitro demonstrate that not only the exogenous activators, 
streptokinase and urokinase, but also the extrinsic tissue plasminogen activator, 
which is probably identical with vascular activator, are capable of activating 
prorenin. The studies in normal subjects and patients show parallel increments 
of the fibrinolytic and renin activities of plasma after DDA VP. This of course 
does not imply that the rise in fibrinolytic activity is the cause of the rise in 
renin. It is however interesting that analogous results have been obtained with 
cultures of islets of Langer hans from rat pancreas14• By raising the glucose content 
of the medium the release of insulin and the release of plasminogen activator 
were stimulated in a parallel fashion. There is further some biochemical evidence 
that proinsulin can be cleaved by plasmin to yield an insulin-like fragment. 
Our studies have been performed in small groups of subjects and need to be 
extended to elucidate the possible role of plasmin and plasminogen activators 
in prorenin activation. 
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5.6. IMMUNOREACTIVE RENIN, PRO RENIN AND ENZYMATICALLY AC-
TIVE RENIN IN PLASMA DURING PREGNANCY AND IN WOMEN 
TAKING ORAL CONTRACEPTIVES. 
5. 6.1. ABSTRACT 
Direct RIA of renin with monoclonal renin antibodies and indirect RIA with 
angiotensin I antibodies were performed in plasma of 44 pregnant women, 44 
women taking an oral contraceptive (OC) and 54 normal women. The following 
parameters were measured: immunoreactive renin, naturally occurring enzyma-
tically active renin (active renin), trypsin-activatable inactive renin (prorenin), 
plasma renin activity (PRA), and renin substrate. 
Immunoreactive renin (mean; 95% confidence interval) was significantly higher 
in pregnant women (1090; 420-2800 pg/ml,third trimester) than in normal women 
(248; 101-562 pg/ml,P<O.OOl), and lower in OC-treated women (131; 41-415 
pg/ml,P<O.OO 1 ). Pro renin and active renin also were increased in pregnant women 
and decreased in OC-treated women. The fraction of renin that was in the active 
form was lower in pregnant women (4.8; 1.4-18%) than in OC-treated women 
(8.8; 3.0-25%,P<0.001) and in normal women (9.1; 2.9- 29%,P<0.001). Renin 
substrate was increased to comparable levels in pregnant women and OC-treated 
women, but PRA was increased in pregnant women and normal in OC-treated 
women. 
The maximum velocity per unit weight of renin was the same for active renal 
renin as for active plasma renin and trypsin- activated plasma prorenin. Maximum 
velocity and Km-values measured in mixtures of purified active renin and renin 
substrate and the concentrations of active renin and renin substrate measured 
in whole plasma were entered into the Michaelis-Menten equation for calculating 
PRA. The calculated values were similar to the measured results in all three 
groups ,indicating that PRA was determined by the molar concentrations of 
enzyme and substrate. Thus, we found no evidence of unknown substances in 
plasma interfering with the enzyme-substrate reaction. The percentage of cir-
culating renin in the active form was much lower during pregnancy than in 
other conditions where the renal release of active renin is stimulated and where 
prorenin is as high as during pregnancy. This suggests that a smaller fraction 
of prorenin is intrarenally converted into active renin before its release into 
the circulation or that a larger fraction of circulating prorenin is of extrarenal 
origin. The finding that PRA is normal during OC treatment suggests that the 
estrogen-induced increase in renin substrate is compensated for by suppressed 
renal release of active renin. 
5.6.2. INTRODUCTION 
Both pregnancy and the use of oral contraceptives (OC) induce impressive changes 
in the renin-angiotensin system, but the pathophysiological consequences of these 
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changes are not clear. Part of the uncertainty is related to the fact that 
measurements of the various components of the renin-angiotensin system are 
not always easy to interpret. There is general agreement that both the plasma 
concentration of renin substrate (angiotensinogen)1- 5 and the plasma renin activity 
(PRA)1- 3' 6' 7 are increased during pregnancy. Renin substrate is also increased 
in women taking oc, but it is uncertain whether PRA is altered by OC8- 18• 
PRA depends on the concentration of renin and renin substrate, and the 
contribution of each of the two components has not been precisely quantitated. 
A large proportion of renin circulates in plasma in an enzymatically inactive 
form (pro renin). In previous studies, it was often· not clear whether only active 
renin or both active renin and prorenin were measured and to what extent 
activation of prorenin had occurred during storage and handling of the plasma 
samples. Measurements of prorenin during pregnancy have yielded widely 
different results depending on the method of measurement1,3, 19,20• Data on 
prorenin in women taking OC are lacking. 
In the studies reported so far, renin was determined by the enzyme kinetic 
method, in which angiotensin I (ANG I) generated from renin substrate in vitro 
is measured by bioassay or RIA. The enzyme kinetic assay of inactive renin 
depends on the conversion in vitro of prorenin to active renin. Antibodies with 
high affinity for both the active and inactive forms of renin are now available, 
and such antibodies can be used for the assay of immunoreactive renin. 
Here, we report measurements of immunoreactive renin, enzymatically active 
and inactive renin, PRA, and renin substrate in plasma of women who were 
pregnant or taking OC. In this paper we refer to measurements of renin by 
RIA of in vitro generated angiotensin I as indirect RIA, as opposed to the direct 
RIA, which makes use of antibodies against renin. The assays were improved 
to be able to compare the results of the indirect assays with those of the direct 
assay and to express results in terms of catalytic activity per unit weight of 
renin. This, in turn, enabled us to examine whether the measured changes in 
PRA can be explained by changes in the molar concentrations of renin and 
renin substrate or whether other factors, such as a change in the kinetic constants 
of the reactants or the presence of interfering substances in plasma, are also 
involved. 
5.6.3. MATERIALS AND METHODS 
Subjects. Caucasian pregnant women (n = 44 ) referred to the obstetric out-
patient clinic of our hospital were studied. All were in the last trimester of 
pregnancy, between 30 and 38 weeks gestation (mean 34.8 weeks). Their age 
ranged from 19-39 yr (mean, 30 yr). Seventeen women were primigravida. 
Women taking OC (n = 44; 21-33 yr old; mean, 25 yr) and normal women 
(n = 54; 20-37 yr old; mean, 27 yr), who were hospital personnel or students 
were also studied. The former had been taking OC for at least 6 months. The 
OC contained 30 or 37.5 /1-g ethinyl estradiol as the estrogen and 0.15 mg 
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levonorgestrel or 0.15 mg desogestrel as the progestagen [Microgynon 30, 
(Schering, Weesp, Netherlands), Stederil 150/30 ( Wyeth, Hoofddorp, Nether-
lands), Marvelon (Organon, Oss, Netherlands)]. The normal women were studied 
in the first 7-12 days of the menstrual cycle. All were normotensive, were eating 
unrestricted sodium diets, and were not taking any medication, with the exception 
of some pregnant women who used ferrous sulfate and/or a multivitamin 
preparation. 
Blood sample collection 
An indwelling catheter was inserted into the left antecubital vein, and the 
women rested quietly in the recumbent position for 45 min before blood samples 
were drawn. The pregnant women were lying on the left side. Blood was collected 
in tubes containing either 0.1 vol 0.13 M trisodium citrate or 0.1 vol 0.13 M 
trisodium citrate to which soybean trypsin inhibitor (Sigma, St Louis, MO; USA, 
10 mg/ml), had been added. The blood samples were immediately centrifuged 
at 3000 X g for 10 min at room temperature, and plasma was stored in 1 ml 
aliquots at -70 C. 
Various forms of renin: terminology 
The following terms are used to designate the various forms of renin and 
the different types of renin assay. 
Active renin, the naturally occurring enzymatically active species; 
Prorenin, the enzymatically inactive species that is converted into active renin 
by trypsin; 
Immunoreactive renin, the form recognized by monoclonal renin antibodies; 
Direct RIA, assay of renin with monoclonal renin antibodies; 
Indirect RIA, assay of renin based on the generation of angiotensin I (ANG 
I) in vitro, quantitated using antibodies against ANG I; 
Concentrations of active renin and prorenin, these were measured by the indirect 
RIA; ANG I was generated at saturating amounts of exogenous renin substrate, 
and prorenin was activated by trypsin before assay; and PRA, this was measured 
by the indirect RIA; ANG I was generated from endogenous renin substrate. 
Renin measurements 
Direct RIA. The concentration of immunoreactive renin in plasma was determined 
with a solid phase sandwich assay using two monoclonal antibodies, R 3-27-
6 and R 3-36-16 (Ciba-Geigy,Basel,Switzerland), as described by Hofbauer et 
al. 21 • The two antibodies react equally well with active human kidney renin 
and chorionic cell culture prorenin. 
Antibody R 3-27-6 was coupled to microtiter plates (Dynatech Laboratories, 
Inc., Alexandria, VA, USA). The coupling buffer was 0.057 M carbonate-
bicarbonate, pH 8.6, containing 0.1 M NaCl and 0.2% sodium azide. Antibody 
R 3-27-6 was dissolved in this buffer in a final concentration of 10 f,tglml. The 
antibody-containing coupling buffer (150 Ml) was pipetted into each well of the 
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microtiter plate and incubated for 2 h at 37 C in a moist chamber. After washing 
the plates with 0.1 M sodium phosphate, pH 7.5, containing 0.05 M NaCl, 
(phosphate buffered saline, PBS), the remaining protein-binding sites in the wells 
were blocked by adding 250 fLL PBS containing 1% BSA and 0.2% sodium 
azide (PBS-BSA) and by incubation for 1 h at 37 C, followed by washing with 
PBS. 
Monoclonal antibody R 3-36-16 was labeled with 1251. The specific activity 
was 16 mCi/mg protein. Renin-free plasma was prepared from normal plasma 
by immunoadsorption on a column of CNBr-activated Sepharose .4 B (Pharmacia 
Fine Chemicals AB,Uppsala,Sweden) to which the monoclonal antibody R 3-
36-16 had been coupled (5 mg antibody to 2 g Sepharose). 
For the assay, 50 fLl PBS-BSA and either 50 fLl serial dilutions of highly purified 
human kidney renin (Ciba-Geigy); 20 to 20,000 pg/ml in renin-free plasma) 
or 50 fLl of the unknown sample were added to the wells together with 50 fLl 
of labeled antibody (100,000 cpm/50 fLl). Purified human kidney renin (MRC 
standard no 68/356, Medical Research Council,National Institute for Biological 
Standards and Control,London,UK) was also run in each assay. All samples 
were assayed in quadruplicate. The mixture were incubated at 37 C for 2 h, 
followed by incubation at 4 C for 30 min in a moist chamber. The plates were 
thoroughly washed with PBS, and the wells were cut and counted in a scintillation 
counter. 
Results were derived from a standard curve (Fig.1) with subtraction of the 
blank and are expressed as picograms per ml plasma, using the Ciba-Geigy 
renin preparation as a standard. Interassay variability (coefficient of variation) 
was determined by repeated measurements in pooled plasma from pregnant 
women , women taking OC, and normal women (8%,20% and 17% respectively; 
n = 8). The concentration of immunoreactive renin (mean) in these plasrria pools 
were 1035, 121, and 278 pg/ml. Thus, the interassay variability was rather high 
when the level of immunoreactive renin was relatively low, due to the relatively 
high blank. Repeated freezing and thawing of the plasma samples leads to 
erroneously low results. We, therefore, froze these samples only once and assayed 
them immediately after thawing. 
Indirect RIA. The assay was described previously22• The concentration of active 
renin was measured in plasma samples containing soybean trypsin inhibitor at 
a final concentration of 2 mg/ml. The plasma was thawed rapidly at 37 C before 
assay to prevent inadvertent activation of prorenin. The concentration of pro renin 
was measured in samples that did not contain soybean trypsin inhibitor, after 
activation by incubating plasma with immobilized trypsin at 0 C. Purified pro renin 
was activated by trypsin after addition of human serum albumin (Behringwerke 
AG, Marburg, West Germany) in a final concentration of 30 mg/ml. In this 
way, degradation of renin by trypsin was prevented. Aliquots (0.05 to 0.25 ml) 
of the unknown sample were added to 0.50 ml of purified sheep renin substrate 
and the volume was adjusted to 1.0 ml with PBS. After addition of protease 
inhibitors, i.e. EDT A, 8-hydroxyquinoline sulfate, phenylmethylsulfonylfluoride, 
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Fig. 5.5.1. Direct radioimmunoassay of renin. Human kidney renin (Geigy) was added to plasma 
from which renin (prorertin and renin) had been removed by immunoadsorption. Data are the 
mean(± SD) of eight experiments. 
and aprotinin22 the samples were incubated at 37 C for 0, 10, 30, 60, 120 and 
180 min. Endogenous renin substrate might influence the results, particularly 
when its level is high as in plasma of pregnant women and women taking OC. 
Under the conditions of our assay, the maximum velocity (Vmax) of the reaction 
of active renin with sheep renin substrate was 3 times the Vmax of the reaction 
with human renin substrate; Km values were 240 pmol/ml and 1200 pmol/ 
ml respectively (see below). The concentration of sheep renin substrate was 1500 
pmol/ml, and the maximum concentration of human renin substrate was 1250 
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pmollml. By using the Michaelis-Menten equation for reactions involving one 
enzyme and two substrates, it can be calculated that the contribution of human 
renin substrate to ANG I formation was less than 4%. By adding known amounts 
of MRC human kidney renin standard to plasma of pregnant women and women 
taking OC, we could demonstrate that the rate of ANG I generation was not 
significantly influenced by the presence of endogenous renin substrate (see 
Results). Generation of ANG I was linear for the whole 180-min incubation 
period. The concentration of ANG I was measured by RIA. The concentrations 
of active renin and prorenin are expressed as microunits of MRC human kidney 
renin standard per ml plasma. The prorenin concentration was calculated as 
the difference between the result of the indirect RIA after activation by trypsin 
and the result before activation. 
Plasma samples containing soybean trypsin inhibitor were also used for 
measuring PRA. They were rapidly thawed at 37 C and incubated in the presence 
of protease inhibitors, without the addition of sheep renin substrate, for 0, 10, 
30, 60, 120, and 180 min. The ANG I formed was measured by RIA. Only 
the linear part of the ANG I generation curve was used. Results are expressed 
as picomoles ANG I generated by 1 ml plasma during 1 h. 
In most laboratories, blood for measuring renin has been collected in chilled 
tubes kept on ice for some time before centrifugation and storage in the freezer 
before the incubation step of the indirect assay. It is now known that prorenin 
is activated by exposure of plasma to low temperature (cryoactivation). Cry-
oactivation is enhanced in plasma of pregnant women and women taking OC23•24• 
Large increments in renin activity may occur in such plasma samples when they 
are kept at -20 C and remain liquid, as they occasionally do. The effect of 
cryoactivation is illustrated in Fig. 2, which shows the results of an experiment 
in which blood samples were kept on melting ice for 2 h and subsequently 
stored at -20 C. There was a significant increase in PRA in plasma of pregnant 
women and women taking OC, but not in plasma of normal women . The 
activation was largely prevented by prior addition of soybean trypsin inhibitor25 • 
Skinner26 pretreated the plasma samples for PRA measurement by dialysis at 
pH 4.5 for 24 h, followed by dialysis at pH 7.5 for 24 h, both at 4 C. With 
this procedure, we found a 3-to 5-fold increase of PRA in plasma of pregnant 
women and women taking OC compared with a 1.5- to 2-fold increase in plasma 
of control women. For the present study we, therefore, collected blood samples 
in an anticoagulant fluid containing soybean trypsin inhibitor, centrifuged them 
immediately at room temperature, stored the plasma samples at -70 C, thawed 
them once at 37 C, and assayed them immediately after thawing. 
Measurement of renin substrate 
The concentration of renin substrate in plasma was determined as the maximal 
quantity of ANG I generated during incubation at 37 C and pH 7.5 with an 
excess of active renin. Aliquots (5 to 40 ,ul) of plasma were incubated with 
purified active renin from human amniotic fluid (see below) in a final con-
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Fig. 5.6.2. Activation of prorenin during collection and handling of blood samples. Open bars: 
Blood was collected in anti-coagulant containing soybean trypsin inhibitor (see text) and immediately 
centrifuged at room temperature; the plasma was snap frozen and stored at -70 C. Hatched bars: 
Blood was collected in anti-coagulant without soybean trypsin inhibitor and kept at 0 C for two 
hours, and then centrifuged at 4 C; the plasma was stored at -20 C. Data are the mean ± SEM 
of six plasma samples. Results of the two methods of sample handling are different (p < 0.001, 
by paired t-test) for OC-treated and pregnant women but not for normal women. 
centration of 40,000 pg/ml. The incubation volume was 1 mi. Results are expressed 
as picomoles per ml plasma. 
Enzyme kinetic studies 
These studies were performed by using semipurified preparations of active 
renin from plasma, amniotic fluid and kidney, and trypsin-activated preparations 
of purified prorenin from plasma and amniotic fluid. Active renin and prorenin 
were isolated from normal human plasma and amniotic fluid using a four-step 
procedure including two affinity chromatography steps. Benzamidine-HCl at 
a final concentration of O.OlM was added to the equilibration and elution buffers 
to prevent inadvertent activation of prorenin. The first step was ion exchange 
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chromatography on DEAE-Sepharose (Pharmacia) at pH 7.5 using a linear 
gradient of NaCl up to 0.2 M. This caused partial separation of prorenin and 
active renin. The second and third steps were affinity chromatography on Blue 
Sepharose CL-6B (Pharmacia)27 and on pepstatin-aminohexyl Sepharose CL-
6B (Pharmacia)28• The last step was gel filtration on Sephadex G-100 (Pharmacia). 
The final preparations of active renin and prorenin were dialyzed against PBS 
and concentrated. They were calibrated against highly purified human kidney 
renin (Ciba- Geigy) with the direct RIA. The renin preparations had no detectable 
prorenin, and the prorenin preparations contained less than 0.5% active renin. 
The preparations also had no renin substrate and angiotensinase activity. 
For the enzyme kinetic studies, purified active renin or trypsin-activated purified 
prorenin was diluted in PBS and incubated with sheep or human renin substrate 
at 37 C for 2, 5, 10, 20, 30 and 60 min. The final concentration of active renin 
or trypsin-activated prorenin in the incubation mixture was 500 pg/ml. Reaction 
velocity was measured with the indirect RIA of renin at 10 different concentrations 
of renin substrate ranging from 25-750 pmol/ml for sheep renin substrate and 
from 125-2500 pmol/ml for human renin substrate. These concentrations were 
chosen in such a way that an even distribution of reciprocal values was obtained. 
The linear part of the ANG I generation curve, at which no more than 4 % 
of substrate (s) was hydrolyzed, was used for calculating reaction velocity (v). 
Samples were run in triplicate. Km and Vmax were determined by the linear 
plot of s/v against s using the statistical method of Wilkinson29• 
5.6.4. RESULTS 
Results of renin measurements in semipurified preparations by direct and indirect 
RIAs showed a relationship that was the same for active renin isolated from 
human plasma, amniotic fluid, and kidney as for trypsin-activated semipurified 
prorenin from plasma and amniotic fluid (Tables 1 and 2). This relationship 
also was not significantly different from that for trypsin-activated prorenin in 
whole plasma from pregnant women, women taking OC, or normal women. 
The results of the direct RIA were not altered by trypsin treatment of the samples 
(Table 1). The renin preparations, i.e. highly purified active kidney renin, 
semipurified active renin of plasma and amniotic fluid, and trypsin-activated 
semipurified prorenin of plasma and amniotic fluid, had reaction kinetics that 
were similar in terms of Km and Vmax (Table 2). 
Pregnancy and the use of OC caused a 3- to 4-fold increase in the plasma 
concentration of renin substrate, but the effects on the plasma concentrations 
of immunoreactive renin, pro renin, and active renin concentration were different 
in the two situations (Fig.3 and Table 3). Immunoreactive renin, prorenin, and 
active renin were increased during pregnancy compared with those in normal 
women. In contrast, they were all decreased in women taking OC. 
In pregnant women, PRA was 4-5 times higher than in normal women. This 
increase was due to the increased concentration of renin substrate and by the 
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Table 5.6.1. Comparison of results of direct and indirect RIAs of renin. 
Source of Trypsin Number Direct Indirect Ratio 
renin treatment of RIA RIA indirect RIA/ 
assays pg/ml J.LU/ml direct RIA 
J.LU/pg 
Amniotic Fluid 
semi purified prorenin no 3 36,400 171 
yes 3 34,500 20,400 0.6 
semi purified active renin no 3 4,530 2,630 0.6 
yes 3 4,610 2,810 0.6 
Plasma 
semi purified prorenin no 6 874±79 4.4±0.3 
yes 6 890±84 542± 47 0.6±0.1 
semi purified active renin no 6 85±16 52±4.9 0.6±0.2 
yes 6 81±13 48±5.1 0.7±0.1 
plasma pool control women no 8 278±46 15±1.1 
yes 8 292±47 190±12 0.7±0.1 
plasma pool OC-users no 8 121±24 8.6±0.6 
yes 8 131±26 98±9.8 0.7±0.1 
plasma pool pregnant women no 8 1,035±84 40±3.9 
yes 8 1,140±93 678±53 0.7±0.1 
Mean± SD 
Table 5.6.2. Enzyme kinetic parameters. 
Source of Trypsin Vmax/pg renin Km 
human renin treatment pmol Ang Ilh pmollml 
Sheep Human Sheep Human 
substrate substrate substrate substrate 
Kidney 
MRC standard no 0.22 0.08 240 1,250 
Geigy standard no 0.20 O.o7 230 1,200 
Amniotic fluid 
semipurified active renin no 0.21 0.06 230 1,280 
semi purified prorenin yes 0.20 O.o7 250 1,150 
Plasma 
semi purified active renin no 0.19 O.o7 240 1,160 
semipurified prorenin yes 0.21 0.08 260 1,220 
Measurements were made in triplicate. 
2-fold increase in the concentration of active renin (Table 3). Experiments in 
which known quantities of human kidney renin (MRC standard) were added 
to plasma of pregnant women and normal women, demonstrated that for a 
given quantity of added active renin, PRA in pregnancy was about 1.5 times 
the PRA in normal women (Fig.4 ). PRA in women taking OC was not different 
from that in normal women, but, again, for a given quantity of added active 
renin, PRA in women on OC was 1.5 times PRA in control women. Thus, 
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Fig. 5.6.3. Plasma concentrations of immunoreactive renin in normal women (control), women taking 
OC, and pregnant women. Mean (horizontal line) and 95% confidence intervals (vertical line) are 
shown. The results in OC-treated and pregnant women are different from those in normal women 
(p <0.001, by unpaired t test). 
the 3- to 4-fold increase of renin substrate in pregnant women and women taking 
OC caused PRA to increase by a factor of 1.5. In contrast, measurements of 
the plasma concentration· of active renin, made in the presence of saturating 
amounts of sheep renin substrate, were not influenced by the level of endogenous 
substrate. 
5.6.5. DISCUSSION 
Methodological aspects 
For the indirect RIA of plasma prorenin, we activated the samples with 
immobilized trypsin at 0 C. There are two important questions about the validity 
of the method. Are all prorenin molecules in the sample converted into active 
renin? Is active renin or activated prorenin degraded into inactive fragments? 
Table 5.6.3. Concentrations of renin substrate and different forms of renin and PRA. 
PRA 
Source Renin- Prorenin Active Fraction of 
of substrate renin measured calculated renin that is 
plasma pmollml ~-tU/ml ~-tU/ml pmolAngllml.h pmolAngllml.h active(%) 
Normal women 1545 151 15.4 0.88 1.04 9.1 
(n =54) (745-2340) (62-357) (4.7-59) (0.24-3.25) (0.27-3.95 (2.9-29.0) 
OC-users 4560* 94* 8.9* 1.02 1.02 8.8 
(n = 44) (1940-7620) (33-268) (2.434) (0.26-3.82) (0.30-3.66) (3.0-25.1) 
Pregnant women 5130* 645* 32.8* 4.36* 3.90* 4.8* 
(n = 44) (3050-7210) (263-1583) (10-103) (1.25-16.6) (1.20-12.7) (1.4-18.0) 
Mean values and 95% confidence interval (in parentheses) are shown. Statistical analysis was performed after logarithmic transformation of the results 
to obtain a Gaussian distribution. Results are expressed as the antilog. For calculating PRA, the plasma concentration of active renin, which is expressed 
as microunits of the MRC human kidney renin standard per ml plasma (~-tU/ml), was converted into picograms per ml by dividing by 0.7 (see Table 
1). The concentrations of active renin and renin substrate were entered in the Michaelis-Menten equation, and calculations were based on Vmax = 
0.08 pmolAngl/h per pg of active renin and Km = 1,200 pmol/ml (see Table 2). The measured and calculated values of PRA were not significantly 
different. OC = oral contraceptives. 
* P < 0.001 vs. normal women (by unpaired t-test). 
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Fig. 5.6.4. The effect of the addition of active kidney renin to plasma on the result of two types 
of indirect RIA of renin, i.e. assay of the concentration of active renin using exogenous renin substrate 
and assay of PRA using endogenous renin substrate. The date are presented as mean values. 8, 
Plasma of normal women (mean renin substrate concentratio·n, 1360±181 (±SEM) pmollml; n = 5). 
D, Plasma of OC-treated women (renin substrate concentration, 4280±618 pmol/ml; n = 5). Ll., 
Plasma of pregnant women (renin substrate concentration, 5310±431 pmol/ml; n = 5). For each 
quantity of added renin, PRA was higher in OC treated and pregnant women than in normal 
women (p<0.001, by unpaired t test). 
By comparing the results of indirect RIA with those of direct RIA, we found 
that after trypsin treatment of plasma prorenin, the maximum enzymatic activity 
per unit weight of renin at saturating concentrations of renin substrate was 
very similar, if not identical, to the enzymatic activity of active plasma renin 
and active kidney renin. There was also no decrease in immunoreactivity after 
trypsin treatment. With our method of trypsin treatment prorenin activation 
in plasma reached a plateau independent of the trypsin concentration over a 
wide range of concentrations22• These data lend support to the conclusion that 
the difference between the result of indirect RIA before and after trypsin treatment 
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is indeed a valid measure of the prorenin content of plasma. In some reports, 
Skinner's method26 was used for measuring plasma prorenin; plasma was dialyzed 
for 24 h at pH 3.3 and 4 C before the indirect RIA to convert prorenin to 
active renin1,3. The degree of prorenin to active renin conversion, however, is 
critically dependent on pH and duration of dialysis. In our hands, dialysis for 
24 h was too short for many plasma samples to obtain maximal conversion. 
A special problem in measuring active renin is caused by the enhanced 
cryoactivation of prorenin in plasma of pregnant women and women taking 
OC23·24. This might be related to elevated levels of factor XII and prekallikrein 
in these women24·30·31 , whereas the concentration of C1-inactivator, which is an 
important inhibitor of factor XII and plasma kallikrein, is decreased24-32. This 
may lead to erroneously high values of active renin, particularly in pregnancy, 
where a high concentration of prorenin is available for cryoactivation. The 
overestimation is even greater for PRA measurements because of the high 
concentration of renin substrate in pregnancy and women taking OC. 
Effects of pregnancy and OC on the plasma concentrations of renin substrate, 
immunoreactive renin, prorenin, and active renin 
We found that both during pregnancy and with the use of OC, plasma 
concentration of renin substrate were increased to approximately 4500-5000 pmol/ 
ml, a value also reported by others1-6·8--13·15·17·18: Our data confirm other reports 
that PRA and prorenin and active renin concentrations are increased during 
pregnancyl-3·6·7·19·20, but two qualifications have to be made. Firstly, our PRA 
results in pregnant women are lower than those in other reports, related, in 
part, to the fact that in our assay ANG I was generated during incubation 
at physiological pH, whereas others used pH 5-6, closer to the pH optimum 
of the reaction of active renin with human renin substrate. However, our results 
are also lower than those of investigators who incubated their samples at the 
same pH as we did1·3. Inadvertent activation of prorenin during storage and 
handling of the plasma samples is likely to be the cause of this discrepancy. 
Secondly, our prorenin values are higher than those of previous studies, probably 
due to more complete activation. That the prorenin to active renin conversion 
was indeed complete is confirmed by our observation that the enzymatic activity 
per unit weight of renin in trypsin-treated plasma did not differ from the activity 
of purified active plasma renin. 
In pregnant women, the fraction of renin in the active form was 4.8%. This 
is much higher (30-50%) than that in conditions in which the renal rekase of 
active renin is stimulated and plasma levels of prorenin are as high as during 
pregnancy22·33• This finding may indicate that a smaller fraction of prorenin 
is converted intrarenally to active renin before its release into the circulation 
or that a larger fraction of circulating prorenin is of extrarenal origin. 
Vmax and Km values measured in mixtures. of purified active renin and renin 
substrate and the concentrations of active renin and renin substrate measured 
in whole plasma were entered into the Michaelis-Menten equation for calculating 
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PRA. Calculated PRA values in normal women were not significantly different 
from the actual measurements. This was also true in pregnant women. At any 
rate, we found no evidence for the existence of plasma factors in pregnancy 
modulating the reaction between renin and its substrate. 
PRA has been reported to be increased in women taking OC8- 15 • It is, however, 
important to note that PRA increases during the luteal phase of the normal 
menstrual cycle9•14•34.35• Yet, PRA was higher in women taking OC than in women 
not taking OC and in the luteal phase of the menstrual cycle9•14• In some other 
studies 16- 18 , including a survey of a large number of women18, no difference 
in PRA was found between women taking OC and women not taking OC. PRA 
in women taking OC was within the normal range in our study, and the mean 
value was not different from the mean value in normal women during the first 
7-12 days of the menstrual cycle. The increased PRA in women taking OC reported 
in some previous studies might be related to the higher estrogen content of 
the older OC preparations. Another explanation might be the overestimation 
of PRA in women taking OC due to inadvertent activation of prorenin during 
the storage and handling of the plasma samples. The finding in previous 
studies9•11•36 that the renin activity of acid-pretreated plasma, in which part of 
the prorenin is activated, is reduced in women taking OC can be explained 
by the fact that the concentrations of both prorenin and active renin were 
decreased in these women. Accordingly, the plasma concentration of immu-
noreactive renin also was lower. The Km for the hydrolysis of renin substrate 
by active renin is probably not altered by the use of OC37 • The Michalis-Menten 
equation predicts that PRA in women taking OC will not be different from 
PRA in normal women. Our results are in agreement with this prediction. In 
other words, the normal PRA levels in women taking OC can be fully accounted 
for by the lower concentration of active renin and the higher concentration 
of renin substrate. There was no evidence for other factors, besides changes 
in the molar concentrations of enzyme and substrate, affecting PRA. 
In summary, immunoreactive renin, prorenin, and active renin were increased 
during pregnancy and decreased in women taking OC. Stimulation of renin 
release during pregnancy may be a defense mechanism against one or more 
vasodilator factors, possibly prostaglandins38• The fact that, in contrast with 
other conditions in which the release of renin by the kidney is stimulated, pro renin 
is more elevated than active renin may indicate that in pregnancy, a larger fraction 
of circulating prorenin is of extrarenal origin. Suppression of renin release by 
OC is perhaps a physiological adaptation to enhanced formation of ANG II 
by the estrogen-induced increase in renin substrate. Our measurements of various 
components of the renin-angiotensin system explain most of the discrepancies 
reported in the literature and may serve as a background for a more accurate 
analysis of the role of these components in the hypertensive states related to 
pregnancy and the use of OC. 
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5. 7. HIGH CONCENTRATIONS OF IMMUNOREACTIVE RENIN, PRO RE-
NIN AND ENZYMATICALLY ACTIVE RENIN IN HUMAN OVARIAN 
FOLLICULAR FLUID 
5.7.1. SUMMARY 
Pro renin (enzymatically inactive) and renin (active) were measured by radio-
immunoassay, using monoclonal antibodies reacting either with both prorenin 
and renin or with renin alone, in pre-ovulatory follicular fluid (FF) from women 
in an in vitro fertilization programme who were stimulated with human me-
nopausal/human chorionic gonadotrophin. The concentration of prorenin in FF 
was 40 times higher than in plasma taken at the time of FF collection; renin 
in FF was 10 times higher. The plasma concentration of prorenin, but not of 
renin, in these women was higher than in non-stimulated women in the late 
follicular phase of the menstrual cycle. The concentration of renin substrate 
and angiotensin-converting enzyme in FF was 60 percent of that in plasma. 
Contamination of blood, which may occur at the time of FF collection, was 
less than 5 percent. Prorenin in FF was irreversibly converted into renin after 
adding trypsin or by endogenous serine protease using procedures that also cause 
conversion of prorenin in plasma. These results support the hypothesis that 
the increased plasma level of prorenin in women whose ovulation is stimulated 
for the collection of oocytes has originated from the ovary and is under 
gonadotrophic control. This may also be true for the increase of plasma pro renin 
that has been observed in non-stimulated women during the luteal phase of 
the cycle and in early pregnancy. 
5. 7.2. INTRODUCTION 
There is growing evidence that the plasma level of pro renin is under gonadotrophic 
control. In normal ovulating women prorenin is increased by a factor of 1.5 
in the first week of the luteal phase\ and by a factor of 5-6 in pregnancy, 
the increase in early pregnancy being proportional to the increase of chorionic 
gonadotrophin in plasma2• An increase of plasma prorenin comparable to that 
in pregnancy has been reported in a case-study of a woman in an in vitro 
fertilization programme who received gonadotrophin injections3• Ovarian fol-
licular fluid from such women contains renin-like activity4 • The findings suggest 
that under those circumstances part of the pro renin in plasma may have originated 
from the ovary. 
It is not known whether prorenin is present in follicular fluid nor whether 
the renin-like activity of follicular fluid is caused by the hydrolytic action of 
renin itself or whether other proteases capable of generating angiotensin I are 
involved. Here we report on measurements of prorenin (enzymatically inactive) 
and renin (active) in follicular fluid by direct radioimmunoassays using mo-
noclonal antibodies reacting either with both prorenin and renin or with renin 
alone. 
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5. 7.3. MATERIALS AND METHODS 
Patients 
Fifteen white European women in an in vitro fertilization programme were 
included in the present study. Their age ranged from 30 to 39 years (mean 
34 years); they had normal ovulatory cycles but suffered from tubal abnormalities. 
Follicular development was stimulated with human menopausal gonadotrophin 
(Pergonal, Serono Laboratories, Rome, Italy), i.e. 225 I.U. of follicle-stimulating 
hormone and 225 I.U. of luteinizing hormone intramuscularly, once a day from 
day 3 or 4 of the cycle. Human chorionic gonadotrophin (Pregnyl, Organon, 
Oss, The Netherlands), 10,000 I.U., was given intramuscularly when the largest 
follicle was 17 mm in diameter. Follicle puncture was performed 3>-36 hours 
later. Oocytes were removed from the follicular fluid and contamination with 
blood was estimated by hemoglobin measurement, the follicular fluid was stored 
at -20 C. At the time of follicle puncture a blood sample was drawn from a 
forearm vein and collected in plastic tubes containing 0.1 volume of 0.13 M 
trisodium citrate as anticoagulant. Blood was centrifuged and plasma was stored 
at -20 C. 
Fifteen women aged between 28 and 37 years (mean 33 years), selected from 
hospital personal or students, acted as controls. They were in the 9th-14th day 
of the menstrual cycle. All patients and control subjects were normotensive. 
They had an unrestricted sodium intake and were not on any medication. 
Direct radioimmunoassay of active renin and prorenin 
The concentration of total immunoreactive renin, i.e. active renin and prorenin, 
was determined with a solid-phase sandwich assay5,6• The two monoclonal 
antibodies R 3-27-6 and R 3-36-16 (Ciba-Geigy, Basle, Switzerland) that were 
used in this assay react equally well with active human kidney renin and chorionic 
cell culture prorenin as with prorenin, trypsin-activated prorenin and naturally 
occurring active renin of human plasma. Antibody R 3-27-6 was coupled to 
microtiter plates. Antibody R 3- 36-16 was labeled with 125!. Results are expressed 
as picograms per ml using highly purified human kidney renin (Ciba-Geigy), 
specific activity 760 Goldblatt units per mg of protein, as the standard. The 
sensitivity of the assay was about 20 pg/ml. 
The direct radioimmunoassay of naturally occurring active renin or serine 
protease-activated prorenin used the monoclonal antibodies 3E8 and 4G 1. The 
first antibody was bound to magnetizable gel beads (Magnogel, Diagnostics 
Pasteur, Marnes La Coquette, France). The second antibody was labeled with 
125!. Details of the procedure have been described7• The antibodies react equally 
well with active human kidney renin as with naturally occurring active renin 
and trypsin-activated prorenin of human plasma. Results are expressed as 
picogram per ml using the same renin standard as in the assay of total 
immunoreactive renin. The lower limit of detection was 10 pg/ml. The con-
centration of prorenin was calculated as the difference between the results of 
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the direct immunoassay of total renin and the direct immunoassay of naturally 
occurring active renin. 
Indirect radioimmunoassay of active renin and prorenin. 
In this assay renin was measured by its capacity to generate angiotensin I 
from purified sheep renin substrate as described previously8•9 • Angiotensin I was 
quantified by radioimmunoassay. Renin concentration is expressed as microunits 
of the MRC human kidney renin standard per ml10• Prorenin has to be activated 
before it can be measured by the indirect radioimmunoassay. This was done 
by adding Sepharose-bound trypsin in a final concentration of 0.25 mg/ml9• 
Prorenin concentration was calculated as the difference between renin concen-
tration after trypsin-activation and renin concentration before activation. 
Assay of renin substrate. 
The concentration of renin substrate was measured as the maximal quantity 
of angiotensin I generated after addition of an excess of semipurified human 
kidney renin8•9• Results are expressed as picomoles per ml. 
Assay of angiotensin-converting enzyme 
This assay was carried out as described before11 
5. 7.4. RESULTS 
Four components of the renin-angiotensin system, i.e. prorenin, renin, renin 
substrate and angiotensin-converting enzyme, are present in follicular fluid (Table 
1, Fig. 1 ). The most striking finding was the very high concentration of total 
Table 5.7.1. Different forms of renin in follicular fluid and plasma. 
Source Method of Total Active Pro renin Active 
assay renin renin total 
renin ratio 
% 
Plasma of Immunological 228 21.1 207 9.2 
control women (pg/ml) (90-471) (7.1-32.4) (112-445) (4.0-21.4) 
Enzyme kinetic 173 15.4 158 8.9 
(,uU/ml) (67-352) (6.7-24.3) (58.1-343) (3.8-24.6) 
Plasma of Immunological 472** 25.7 443** 5.9* 
women treated (pg/ml) (251-886) (12.7-41.8) (230-885) (2.1-9.9) 
with gonadotrophin Enzyme kinetic 359** 20.5 338** 6.0* 
(,uU/ml) (191-674) (10.2-41.4) (174-645) (1.9-10.1) 
Follicular fluid Immunological 16930 243 16670 1.5 
of women (pg/ml) (7130-40 190) (100-592) (6710-39680) (1.1-2.1) 
treated with Enzyme kinetic 12140 194 12110 1.6 
gonadotrophin (,uU/ml) (3890-39590) (80-474) (3810-39130) (1.2-2.0) 
Statistical analysis was performed after logarithmic transformation of results. Results (mean value 
and 95 percent confidence interval) are expressed as the antilogs. *p < 0.01, **p < 0.001 for difference 
from control women (unpaired t-test). 
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Fig.5.7.1. Total renin and enzymatically active renin, as measured with renin-antibodies reacting 
with either both prorenin and active renin or with active renin alone, in follicular fluid and plasma 
of women treated with gonadotrophin. Plasma was taken at the time of follicular fluid collection. 
Open circles: no plasma samples were taken from these women. 
renin, 98 percent of which is pro renin. The concentration of prorenin in follicular 
fluid was about 40 times higher th,an in plasma that was taken at the time 
of follicle puncture. That we are indeed dealing with renin and prorenin, and 
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Table 5.7.2. Prorenin-renin conversion in follicular fluid. 
Treatment of 
follicular fluid 
1. None 
2. Dialysis 48 h, pH 3.3, OC, followed 
by rapid neutralization by dilution 
in 0.1 M phosphate buffer pH 
7.5 containing SBTI 1 mg/ml 
and PMSF 3 mM and immediate assay: 
reversible activation. 
3. As in no. 2 and incubation at 37 C 
for 2 h in the presence of SBTI 
and PMSF prior to assay: reversible 
activation-inactivation. 
4. Dialysis 48 h, pH 3.3, OC, followed 
by dialysis 48 h, pH 7.5, OC: 
irreversible activation by endogenous 
serine protease. 
5. Dialysis 48 h, pH 3.3, OC, followed 
by dialysis 48 h, pH 7.5, OC, in the 
presence of SBTI and PMSF: 
irreversible activation by endogenous 
serine protease in the presence of 
inhibitors. 
6. Addition of trypsin-Sepharose 
0.25 mg/ml, incubation 48 h, pH 7.5, 
OC: irreversible activation by 
exogenous serine protease. 
Enzyme kinetic 
JLU/ml 
360 
20,900 
2,600 
21,880 
2,900 
19,900 
Renin assay 
Immunoloilcal 
Total renin 
pg/ml 
23,600 
24,000 
20,800 
21,500 
21,000 
22,700 
Active renin 
pg/ml 
610 
3,700 
3,200 
22,170 
3,400 
20,400 
Results are mean values of two experiments. PMSF = phenylmethylsulfonylfluoride, SBTI = soybean 
trypsin inhibitor. 
not with other aspartic proteases capable of generating angiotensin was dem-
onstrated by the use of the monoclonal antibodies specific for both prorenin 
and renin (antibodies R 3-27-6 and R 3-36-16) and the antibodies that only 
recognized active renin (antibodies 3E8 and 4G 1). 
Prorenin in follicular fluid was irreversibly activated by Sepharose-bound 
trypsin or by 48 h dialysis at pH 3.3 followed by 48 h dialysis at pH 7.5 both 
at 0 C (Table 2). Dialysis at pH 3.3 followed by rapid neutralization also leads 
to activation of prorenin but in this case the activation was reversible, i.e. the 
activated prorenin was inactivated at 37 C within two hours. Similar observations 
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Table 5.7.3. Renin-substrate and angiotensin-converting enzyme in follicular fluid and plasma. 
Angiotensin-
Renin substrate enzyme converting 
pmol/ml mU/ml 
Plasma of 1785 13.5 
control women (985-2840) (7.0-20.0) 
Plasma of women 2234 13.8 
treated with (1076-4639) (7.2-19.4) 
gonadotrophin 
Follicular fluid of 1462** 8.3* 
women treated with (695-3076) (4.1-16.6) 
gonadotrophin 
Statistical analysis was performed after logarithmic transformation of results. Results (mean and 
95 percent confidence interval) are expressed as the antilogs. 
*p < 0.01, **p < 0.001 for difference from plasma of women treated with gonadotrophin. 
were made after acid-treatment of plasma !3-Js. Irreversibly activated pro renin 
was detected by the assay in which the antibodies 3E8 and 4G 1, specific for 
active renin, were used. Reversibly activated prorenin was not detected by this 
assay. Both the irreversibly and reversibly activated forms of pro renin were bound 
to the antibodies R 3-27-6 and R 3-36-16. Irreversible activation of prorenin 
also occurs in acid-treated plasma after pH has been restored to neutral. This 
depends on the proteolytic action of plasma kallikrein, which is generated from 
prekallikrein by clotting factor XII16•17 • Formation of an endogenous serine 
protease causing irreversible activation of prorenin at neutral pH may also have 
occurred in acid-pretreated follicular fluid. This was confirmed by the addition 
of SBTI and PMSF to acid-treated follicular fluid after restoration of pH to 
neutral; irreversible prorenin activation was blocked by these serine protease 
inhibitors (Table 2). 
Renin substrate and angiotensin-converting enzyme were present in follicular 
fluid in a concentration about 60 percent of that in plasma (Table 3). The 
concentration of hemoglobin was 0.3 mM (SD 0.1mM) ,which is less than 5 
percent of the hemoglobin concentration in blood. It is therefore unlikely that 
the presence of renin substrate and angiotensin-converting enzyme in follicular 
fluid is caused by contamination of blood at the time of follicle puncture. 
The plasma prorenin concentration in the women stimulated with gonado-
trophin was 2-3 times higher than in control women, whereas the concentration 
of naturally occurring active renin was not significantly different (Table 1). 
5. 7.5. DISCUSSION 
This study demonstrates the presence of prorenin and renin as well as renin 
substrate and angiotensin-converting enzyme in pre-ovulatory follicular fluid 
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in women stimulated by injections of gonadotrophin. The concentration of these 
components of the renin-angiotensin system in follicular fluid is too high for 
explaining their presence by contamination with blood at the time of follicular 
fluid collection. Prorenin was 40 times and renin was 10 times higher in follicular 
fluid than in plasma. Because of the magnitude of this difference, it seems likely 
that prorenin is secreted by follicle cells and that its presence is not merely 
caused by transudation of plasma and subsequent concentration. 
From a case report3 it appears that the rise of plasma prorenin, caused by 
gonadotrophin injections for inducing ovarian stimulation, occurs mainly in the 
first days after ovulation. Our results also indicate that the pre-ovulatory plasma 
levels of prorenin in gonadotrophin-stimulated women are higher than in non-
stimulated women. These findings are further evidence that the ovary produces 
prorenin and that part of it may reach the circulation. 
The presence of prorenin, renin, renin substrate and angiotensin-converting 
enzyme in follicular fluid poses a question concerning the role of the renin-
angiotensin system in the follicle. Follicle and corpus luteum development require 
extensive neovascularization18• Rabbit corpus luteum, mouse ovarian extract and 
human and porcine follicular fluid have been shown to initiate angiogenesis19- 22 • 
Angiotensin II stimulates new collateral vessel formation in ischaemic areas23 , 
and corneal implants of this peptide in rabbits initiate the local formation of 
new blood vessels24 • Thus local prorenin-to-renin conversion and angiotensin 
formation may be important for the vascularization of the developing follicle 
and corpus luteum. It may also play a role in the vascularization of the area 
of implantation of the developing embryo since the elevated plasma concentration 
of pro renin in the luteal phase of the cycle rises further when ovulation is followed 
by pregnancy2 • 
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5.8. SOURCE OF PLASMA PRORENIN IN EARLY AND LATE PREG-
NANCY. OBSERVATIONS IN A PATIENT WITH PRIMARY OVARIAN 
FAILURE 
5.8.1. ABSRACT 
The plasma levels of enzymatically active renin (active renin) and inactive renin 
(prorenin) were measured in a woman with primary ovarian failure, in whom 
pregnancy was established by the induction of an artificial cycle and in vitro 
fertilization of a donated oocyte fertilized with the sperm of her husband. The 
results were compared with those in 9 normal pregnant women. Pre-pregnancy 
plasma active renin and prorenin levels were normal in the patient. Active renin 
rose two-fold during pregnancy both in the patient and in the normal pregnant 
women. In the first eight weeks of pregnancy prorenin rose by 156 J.tU/ml in 
the patient, whereas it rose by 869± 169 Jl U /ml ( mean±SD) in the normal pregnant 
women. Thus, the rise in prorenin in our patient was much less than normaL 
Prorenin remained abnormally low throughout the pregnancy, which lasted 40 
weeks. Therefore, the high prorenin levels that occur normally during pregnancy 
may depend on normal ovarian function. 
Amniotic fluid prorenin in the patient was similar to that in normal pregnant 
women, and was 75 times times higher than in plasma. This finding suggests 
that prorenin production by the chorionic cells was normal in the patient and 
that chorionic prorenin does not contribute in any major degree to the level 
of pro renin in maternal plasma. 
Because of these findings and in the light of recent evidence that the ovary 
secretes prorenin and produces high plasma prorenin levels in women with 
hyperstimulated cycles, we conclude that the ovary is the main source of the 
elevated plasma prorenin of pregnant women. 
5.8.2. INTRODUCTION 
During pregnancy the levels of enzymatically active renin (active renin), inactive 
renin (prorenin) and renin substrate (angiotensinogen) in maternal plasma are 
all increased1- 4• As a result angiotensin II formation is increased and aldosterone 
secretion is stimulated. This may be a physiological response to maintain normal 
blood pressure, by counteracting vasodilator mechanisms operative in pregnancy5 • 
The kidney is the major, if not the only, source of active renin in plasma 
of men and non-pregnant women, and this is believed to be the case in pregnant 
women as well6• The kidney is also an important source of prorenin7•8, but there 
is evidence that, at least in women who are in the luteal phase of the menstrual 
cycle, part of the circulating pro renin originates from the ovary9• In pregnancy 
it is not known whether maternal plasma prorenin originates mainly from the 
kidney, the ovary, the placenta or other organs. Here we repqrt measurements 
of active renin and prorenin in a patient with primary ovarian failure, in whom 
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pregnancy was achieved by the induction of an artificial cycle and in vitro 
fertilization of a donated oocyte fertilized with the sperm of her husband. 
5.8.3.SUBJECTS AND METHODS 
Patient and normal subjects. At the time of embryo transfer the age of the patient 
with primary ovarian failure was 36 yr. Her menarche occurred when she was 
14 yrs old, but she then became amenorrheic after a few irregular cycles. Her 
plasma FSH and LH levels were above 100 miU/ml and serum estradiol levels 
were below 0.01 ng/ml. At the age of 29 yr, laparotomy was performed. The 
ovaries were atrophic; one ovary was removed for histological examination. This 
showed absence of follicles and reduced stromal cellularity. Her karyotype was 
46,XX. 
Exogenous estrogen (17 ,8-estradiol tablets) and progesterone (suppositories) 
therapy were given to mimic the steroid profile of the normal ovulatory cycle10• 
On day 14 of the cycle, she received four embryos three days after in vitro 
fertilization. The donor oocytes were fertilized with the sperm of the patient's 
husband. In vitro fertilization and embryo transfer were performed as described 
by Navot et al. 10• 
Substitution therapy was maintained for 12 weeks (from day 1 of the cycle). 
By the eighth week the fetus was appropriately developed for gestational age, 
as judged by ultrasonography. Pregnancy progressed normally. The patient's 
blood pressure remained normal, 105-115 mm Hg systolic and 65-75 mm Hg 
diastolic. After 40 weeks of pregnancy a healthy girl weighing 3550 g was born 
by vaginal delivery. The placenta, which was delivered 10 min later, weighed 
600 g and looked normaL Parturition was uncomplicated. 
Plasma 17 ,8-estradiol, progesterone, ,8-hCG, active renin and prorenin were 
measured before embryo transfer and during and after pregnancy. For comparison 
measurements of active renin and prorenin were also made, during pregnancy 
and 6 - 8 weeks after delivery, in 9 normal women, aged 28 to 38 yr. Their 
pregnancies were uncomplicated and, apart from ferrous sulfate and/or mul-
tivitamin preparations, they received no drugs. Active renin and prorenin were 
also measured in amniotic fluid obtained at delivery in both the patient with 
primary ovarian failure and the normal women. 
Measurements of hormones. Venous blood samples were taken after the subjects 
had been in the left lateral recumbent position for 30 min. The plasma 
concentration of progesterone was measured by RIA according to De J ong et 
al_II. The plasma levels of 17 ,8-estradiol and ,8-hCG were measured by using 
commercially available RIA kits (Estradiol kit, Diagnostic Products Corporation, 
Los Angeles, Ca, and ,8-hCG kit, IRE, Fleurus, Belgium). In the assay for the 
,8-hCG subunit, 1 mg ,8-hCG standard equaled 790 IU MRC 751551 standard 
(Medical Research Council, National Institute for Biological Standards and 
Control, London, United Kingdom). The inean normal value between weeks 
7 and 11 of pregnancy was 246±47 (SD) ng/ml (n = 15). 
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Plasma active renin and prorenin concentrations were measured by indirect RIA. 
In this assay, angiotensin I generated by incubation of plasma with an excess 
of sheep angiotensinogen under standardized conditions was quantitated by 
RIA4•7• The results are expressed as J.LU MRC standard 68/356 (active renin 
from human kidney) per ml plasma. Plasma prorenin was measured by indirect 
RIA after it had been converted into active renin by immobilized trypsin at 
0 C7• For conversion in amniotic fluid we incubated the samples with immobilized 
trypsin after addition of human serum albumin in a final concentration of 30 
mg/ml. The difference between the results of indirect RIA before and after 
treatment with trypsin was taken to be a measure of prorenin concentration. 
Plasma and amniotic fluid may contain substances interfering with the renin-
angiotensinogen reaction. Active renin was, therefore, not only measured by 
indirect RIA but also by direct RIA, using monoclonal antibodies, which react 
with active renin but not prorenin12•13 • The validity of the indirect RIA ofprorenin 
was confirmed by measuring total immunoreactive renin (active renin plus 
prorenin) by direct RIA, using monoclonal antibodies, which react with both 
active renin and prorenin4•14• The results of the direct assays of active renin 
and total immunoreactive renin are expressed as pg of the Ciba-Geigy standard 
(active renin from human kidney, Ciba-Geigy, Basel, Switzerland) per ml sample. 
One J.LU MRC standard equaled 1.41 pg Ciba-Geigy standard. 
5.8.4. RESULTS 
Before substitution therapy the patient's plasma estradiol level was below 0.01 
ng/ml. In the first four weeks of substitution therapy the plasma estradiol and 
progesterone levels were similar to those of normal ovulatory cycles (Fig.1). 
Plasma estradiol reached a value of 1.1 ng/ml on day 8. Plasma progesterone 
rose to 9.9 ng/ml on day 18, four days after embryo transfer, and it was 9.2 
ng/ml on day 21. During this period there was little change in the plasma active 
renin and prorenin levels. Plasma 1$-hCG was 25.4 ng/ml on day 30 and .it 
reached a peak value of 437 ng/ml in week 8. After 12 weeks, when the estrogen 
and progesterone therapy was discontinued, the placenta was able to maintain 
high levels of these steroids in maternal plasma. 
Plasma active renin rose from 15-20 J.LU/ml in the first 10 weeks to 30-35 
J.LU/ml in weeks 35-40. Plasma prorenin began to rise after four weeks from 
a value of 140 J.LU/ml on day 30 to a peak value of 287 J.LU/ml in week 9. 
It then declined and reached a plateau of about 200 J.LU/ml after 12 weeks. 
The change in the patient's active renin levels during pregnancy resembled 
that in the normal women. In contrast, the rise of prorenin was much smaller 
than in the normal women (Fig.2). The increments of prorenin in the first eight 
weeks in the normal women ranged from 439 to 1,040 J.LU/ml (mean 869±169 
(SD) J.LU/ml,n = 9), whereas in our patient it rose by 156 J.LU/ml. Throughout 
pregnancy, from week 8 onwards, the patient's plasma prorenin was below the 
95% confidence interval of the normal women. Active plasma renin, but not 
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Fig.5.8.1. Substitution therapy with estradiol and progesterone and plasma levels of these steroids 
and /3-hCG, active renin and prorenin during and after pregnancy in a patient with primary ovarian 
failure. The renin and prorenin measurements were done by indirect RIA. 
prorenin, fell during the first 24h following delivery both in the patient and 
in the normal women. During· the following five days pro renin fell to pre-
pregnancy levels. 
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Fig.5.8.2. Mean (±SD) plasma active renin and prorenin levels measured by indirect RIA, during 
and after pregnancy, in nine normal women. 
Both active renin and prorenin in the amniotic fluid of our patient were slightly 
above the upper 95% confidence limit of the values in the normal pregnant 
women (Table 1), but in one of the normal women active renin was nearly 
as high as in the patient (1,170 ,uU/ml), while prorenin was higher (18,300 ,uU/ 
ml) (Table 1). 
The ratio between the results of the direct and indirect RIAs was the same 
for active renin as for total renin (active renin plus prorenin), both in plasma 
and in amniotic fluid (Table 1). This finding indicates that the trypsin-induced 
prorenin to active renin conversion was complete and that the renin-angioten-
sinogen reaction was not modified by unknown substances in plasma or amniotic 
fluid. 
5.8.5. DISCUSSION 
Plasma active renin in a patient with primary ovarian failure increased two-
fold during pregnancy, an increase similar to that in normal women. The rise 
of plasma pro renin in the first trimester of pregnancy, however, was much smaller 
in our patient than in normal women, in whom prorenin increased five- to six-
fold, as has been described by others3• Furthermore, the patient's plasma pro renin 
Table 5.8.1. Levels of active renin and total renin (active renin plus prorenin) in pregnancy plasma and amniotic fluid. measured by direct and indirect 
RIA. 
Total renin Active renin 
Subjects Number of Direct Indirect Ratio Direct Indirect Ratio 
subjects RIA RIA RIA RIA 
pg/ml J,~U/ml J.lU/pg pg/ml J,~U/ml J.lU/pg 
Normal women 
Plasma, week 8 of pregnancy 6 1630* 1140 0.70±0.11** 24.6 17.5 0.71±0.12 
(1240-2140) (896-1450) (15.3-39.6) (10.6-28.9) 
Plasma, week 36 of pregnancy 6 957 689 0.72±0.12 50.8 34.1 0.67±0.08 
(536 -1710) (399-1190) (27 .4-94.1) (14.4-81.0) 
Plasma, week 6-8 after parturition 6 249 192 0.77±0.12 21.1 15.4 0.73±0.11 
(115-538) (56.9-378) (5.8-76.5) (4.6-52.0) 
Amniotic fluid 7 7680 5410 0.70±0.09 
' 
254 168 0.66±0.10 
(2710-21800) (1890-15500) (90.9-710) (57.4-492) 
Patient with primary ovarian failure 
Plasma, day 1 of pregnancy 243 148 0.61 22.1 16.8 0.76 
Plasma, week 9 of pregnancy 423 309 0.73 30.0 22.2 0.74 
Plasma, week 12 of pregnancy 368 216 0.71 30.0 21.0 0.70 
Plasma, week 34 of pregnancy 324 243 0.75 46.6 31.2 0.67 
Plasma, week 8 after parturition 126 82 0.65 15.9 10.2 0.64 
Amniotic fluid 25400 17150 0.68 1810 1290 0.71 
* Mean value and 95% confidence limits (in parentheses); statistical analysis was performed after logarithmic transformation of results to obtain Gaussian 
distribution and results are expressed as antilog. 
**Mean value and SD. 
N 
0 
VJ 
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remained abnormally low (220 J.tU/ml) in the second and third trimesters of 
pregnancy. In an earlier study of 44 normal women, we found a mean prorenin 
level of 645 J.tU/ml (95% confidence limits 263 to 1,583 J.tU/ml) in the third 
trimester of pregnancy\ which corresponds with the results of this study. It 
appears, therefore, that the high prorenin levels that normally occur in pregnancy 
may depend on normal ovarian function. 
Since chorionic cells are known to produce prorenin, one might expect the 
placenta to be a major source of prorenin in maternal plasma15 • At term the 
concentration of prorenin in amniotic fluid is about 10 times higher than in 
plasma1,2_ It is possible that the ovary is indirectly involved by stimulating the 
placenta to secrete prorenin. In our patient amniotic fluid prorenin was not 
lower than in the normal women, which suggests that chorionic prorenin does 
not contribute in any major degree to the in maternal plasma prorenin levels. 
The disappearance rate of plasma prorenin after delivery in the normal women 
was much lower than the disappearance rate we previously found after bilateral 
nephrectomy16• Maternal plasma prorenin did not fall until the second day after 
parturition both in the normal women and in the patient with primary ovarian 
failure, again suggesting that the placenta is not a major source of maternal 
plasma prorenin. However, we cannot exclude the possibility that Jhe plasma 
half-life of non-renal prorenin is longer than the plasma half-life of renal prorenin. 
Because of the findings of this study and in the light of recent reports that 
the ovary secretes prorenin17 and that plasma prorenin in women with hyper-
stimulated cycles may rise to levels as high as in pregnancy18 , it is conceivable 
that the ovary is the main. source of the elevated prorenin in plasma of pregnant 
women. 
High prorenin concentrations in follicular fluid obtained at the time of oocyte 
collection in women with hyperstimulated cycles have been reported13, 17 , and 
local production of prorenin is postulated to play a role in the development 
of the corpus luteum9,1 7,18• The finding in our patient with primary ovarian failure 
that plasma prorenin was abnormally low; not only in the first trimester of 
pregnancy but also in the second and third trimester, is in accordance with 
previous reports that the corpus luteum continues to be hormonally active during 
the whole period of pregnancy19 • 
The stimulus for the large increase of maternal plasma prorenin in pregnancy 
is not known. Plasma prorenin is suppressed in women taking estrogen-containing 
contraceptives4• Progesterone on the other hand may stimulate the renal secretion 
of active renin and perhaps also of prorenin, because it acts as an aldosterone 
antagonist20 • However, the changes in prorenin in normal pregnant women did 
not closely follow the changes in progesterone that are known to occur during 
pregnancy. After prorenin had reached its peak value at about 12 weeks, it 
fell until week 20 , whereas progesterone is known to rise continuously from 
week 12 onwards21 , a rise that also occurred in our patient with ovarian failure. 
The increase of plasma prorenin in women with hyperstimulated cycles and 
in normal pregnancy may be due to gonadotropic stimulation3, 18 • A positive 
205 
correlation has been reported between plasma pro renin and the changes in plasma 
hCG during the five weeks following conception3• In our patient with primary 
ovarian failure the rise of prorenin, albeit small, closely followed the /3-hCG 
peak in the first weeks of pregnancy, which lends some support to the hypothesis 
that also in this patient the rise of prorenin early in pregnancy was due to 
stimulation by chorionic gonadotropin. 
Note: After completion of this paper we were informed by Dr J. Sealey from 
New York, NY, about similar results in a patient with primary ovarian failure, 
who became pregnant after embryo transfer and was followed for five weeks22• 
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6. SAMENVATTING 
6.1. DOEL VAN HET ONDERZOEK 
De hoogte van de bloeddruk wordt voor een groot deel bepaald door het renine-
angiotensinesysteem. Dit systeem is samengesteld uit een aantal enzymen en 
enzymsubstraten die zich in plasma bevinden en oefent zijn bloeddrukverhogende 
werking uit door de vorming van angiotensine II, het biologisch actieve eind-
product (Fig. I.). Hoe belangrijk dit systeem is blijkt uit het feit dat antagonisten 
van angiotensine II en remmers van de enzymen die bij de vorming van angiotensine 
II zijn betrokken de bloeddruk verlagen. Remmers van het enzym dat zorgt 
voor de omzetting van angiotensine I in angiotensine II ('angiotensin-converting 
enzyme'), worden op het ogenblik op grote schaal toegepast bij de behandeling 
van patienten met hoge bloeddruk. 
Op theoretische gronden ligt het voor de hand om de plasmaspiegel van 
angiotensine II te hanteren als maat voor de activiteit van het renine-angiotensine 
systeem in vivo. Practisch stuit dit echter op problemen omdat de concentratie 
van angiotensine II in plasma zeer laag is, enkele picogrammen per ml, en omdat 
de bij de radioimmunoassay gebruikte antilichamen behalve met angiotensine 
II ook met in het plasma aanwezige afbraakproducten van dit peptide reageren. 
V oor klinische toepassingen is de bepaling van de zogenaamde plasmarenine-
activiteit (PRA) nog steeds de meest gebruikte maat voor de vorming van 
angiotensine II in vivo. Bij bepalingen van PRA wordt het plasma van de patient 
gedurende een bepaalde tijd geincubeerd bij 37 C. Tijdens deze incubatie in 
vitro wordt door de hydrolytische werking van het protease, renine, op reni-
nesubstraat (angiotensinogeen) het biologisch niet actieve peptide, angiotensine 
I, gevormd. Plasma heeft angiotensinase activiteit, waardoor angiotensine I wordt 
afgebroken. Dit wordt voorkomen door angiotensinaseremmers aan het plasma 
toe te voegen. Deze stoffen remmen echter ook het eveneens in plasma aanwezige 
'angiotensin-converting enzyme', dat het decapeptide, angiotensine I, omzet in 
het octapeptide angiotensine II, zodat de reactie stopt bij · de vorming van 
angiotensine I. Het gevormde angiotensine I kan vervolgens worden bepaald 
met behulp van radioimmunoassay. 
Onder normale omstandigheden ligt de concentratie van reninesubstraat in 
plasma op het niveau van de Km-waarde, hetgeen betekent dat de snelheid 
waarmee angiotensine I wordt gevormd niet alleen afhankelijk is van de 
concentratie van renine maar ook van die van reninesubstraat. In bepaalde 
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Fig.6.1. Componenten van het renine-angiotensine systeem. FXII = stollingsfactor XII. 
FXlla = geactiveerde FXII. HMWK = Kininogeen met hoog molecuul gewicht. 
gevallen, namelijk wanneer de substraatconcentratie sterk afwijkt van de norm, 
wordt de interpretatie van PRA bepalingen bemoeilijkt. Om de reactiesnelheid 
in vitro onafhankelijk te maken van de substraatconcentratie zijn bepalingsme-
thoden ontwikkeld, waarbij renine voor incubatie wordt gescheiden van het 
substraat of het endogene substraat tevoren wordt gedenatureerd. Hierna wordt 
een grote overmaat min of meer gezuiverd substraat toegevoegd, zodat het enzym 
renine verzadigd is met substraat. 
De hoeveelheden angiotensine I die bij deze bepalingen van de plasmareni-
neconcentratie (PRC) worden gevormd zijn groter dan bij bepalingen van PRA. 
Dit verschil berust echter niet alleen op de aanwezigheid van een overmaat aan 
exogeen substraat. Bij de meeste van de bovengenoemde PRC bepalingen wordt 
het plasma aangezuurd (pH 3-4) om het endogene reninesubstraat te denatureren. 
Daarna wordt de pH van het plasma weer hersteld en wordt substraat toegevoegd. 
Uit experimenten van Lumbers en Morris 1 bleek dat de renine-activiteit van 
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menselijk vruchtwater na aanzuren veel hoger was dan voor aanzuren; tijdens 
incubatie bij 37 C bij neutrale pH werd na aanzuren per tijdseenheid meer 
angiotensine I gevormd dan voor aanzuren, ondanks het feit dat ervoor gezorgd 
was dat de substraatconcentratie in het incubatiemengsel gelijk was. Een dergelijk 
resultaat werd ook verkregen wanneer, in plaats van vruchtwater, menselijk 
plasma werd gebruikt. Dit bleek te berusten op de activatie van een enzymatisch 
inactieve vorm van renine. Verondersteld werd dat dit z.g. inactieve renine een 
pro-enzym is (prorenine) en dat de activatie (zuur-activatie) tot stand komt door 
beperkte proteolyse onder invloed van een protease werkzaam bij lage pH. De 
mogelijkheid dat inactief renine niet zozeer een pro-enzym is maar een enzym-
remmercomplex dat bij lage pH uiteenvalt is ook geopperd2• Activatie van inactief 
renine kan echter ook optreden bij neutrale pH wanneer plasma bij 0-4 C wordt 
bewaard ( cryo-activatie ). 
Het is duidelijk dat deze waarnemingen belangrijke consequenties hebben voor 
de technische uitvoering en de interpretatie van plasmareninebepalingen .. Wat 
ons echter intrigeerde was, dat ongeveer 90% van het bij gezonde personen in 
plasma aanwezige renine zich in de enzymatisch inactieve vorm bevindt en dat 
het renine-angiotensinesysteem in dit opzicht enig&zins vergelijkbaar is met andere 
proteolytische system en in plasma, zoals het stollingssysteem en het fibrinolytische 
systeem. Tot voor kort werd het renine-angiotensinesysteem opgevat als een 
circulerend hormonaal systeem. In feite berust de huidige interpretatie van PRA 
bepalingen, waarbij de in vitro generatie van angiotensine I in plasma geacht 
wordt een maat te zijn voor de in vivo genera tie van angiotensine I (en II), 
op deze zienswijze. Het onderzoek dat in dit proefschrift is beschreven werd 
uitgevoerd met de gedachte dat het renine-angiotensinesysteem niet aileen zijn 
fysiologische werking uitoefent door de proteolytische activiteit van circulerend 
renine op circulerend reninesubstraat, maar dat misschien ook locale activatie 
van prorenine optreedt en dat bij deze activatie enzymen betrokken kunnen 
zijn die deel uitmaken van het stollingssysteem en het fibrinolytische systeem. 
Het proefschrift bestaat uit twee delen, namelijk biochemische in vitro ex-
perimenten en fysiologisch onderzoek met behulp van dierexperimenten en 
bepalingen van prorenine in plasma van gezonde personen en patienten met 
verschillende aandoeningen en in menselijk vruchtwater en ovariele follikelvloei-
stof. 
6.2. ACTIVATIE VAN PRORENINE IN VITRO 
6.2.1. Zuur-activatie en cryo-activatie 
Bij de bepaling van PRC volgens Skinner3 wordt plasma voor incubatie met 
een overmaat exogeen reninesubstraat gedurende 24 uur gedialyseerd bij 0-4 
C tegen een pH 3.3-buffer en vervolgens, eveneens gedurende 24 uur, bij 0-
4 C tegen een pH 7.4-buffer. Onze kinetische studies toonden aan dat de renine-
activiteit direct na het herstel van de pH naar pH 7.4 hoger was dan voor aanzuren. 
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De grootste toename van de renine- activiteit trad op gedurende de 24 uur durende 
dialyse bij pH 7.4. Deze activatie bij pH 7.4 kon worden geremd door toevoeging 
van serineproteaseremmers, zoals aprotinine (Trasylol), soyaboon-trypsinerem-
mer en benzamidine. Experimenten met plasma: afkomstig van patienten met 
een erfelijke deficientie van hetzij stollingsfactor XII (Hageman-factor) hetzij 
plasma-prekallikreine (Fletcher-factor) toonden aan dat beide factoren onont-
beerlijk zijn voor de activatie van prorenine in aangezuurd plasma, nadat de 
pH is hersteld. Geactiveerde factor XII (factor XIIa) en kallikreine zijn seri-
neproteasen die in aangezuurd plasma na herstel van de pH worden gevormd 
uit respectivelijk factor XII en prekallikrein. Verder onderzoek m.b.v. gezuiverd 
actief j3-factor XIIa ( lichte keten met Mr 28.000 die de actieve groep bevat) 
en plasmakallikreine (zowel het gehele molecuul met Mr 85.000 als de lichte 
keten met Mr 28,000) toonden aan dat of kallikreine zelf of door kallikreine 
geactiveerde enzymen verantwoordelijk zijn voor de activatie van prorenine in 
met zuur voorbehandeld plasma en dat de functie van factor XII beperkt is 
tot de activatie van prekallikreine, waardoor kallikreine wordt gevormd. Ki-
ninogeen met hoog molecuulgewicht, Fitzgerald factor, ( HMWK, Mr 110.000), 
dat nodig is voor de snelle activatie van factor XII en prekallikreine in de 
aanwezigheid van een negatief geladen oppervlak (contactactivatie), is niet 
essentieel voor de toename van de renine-activiteit van met zuur voorbehandeld 
plasma: de renine-activiteit nam normaal toe in plasma van een patient met 
een erfelijke deficientie van HMWK. 
Hoewel plasmakallikreine onder bepaalde omstandigheden in staat is plasmi-
nogeen te activeren en plasmine op zijn beurt in staat is de renine-activiteit 
van met zuur voorbehandeld plasma te verhogen, bleek de door factor XII-
kallikreine veroorzaakte activatie van prorenine in met zuur voorbehandeld 
plasma normaal te verlopen, ook na selectieve verwijdering van plasminogeen. 
Het is bekend dat, wanneer plasma bij 0-4 C wordt bewaard, factor XII en 
prekallikreine worden geactiveerd. Wij vermoedden daarom dat dit de oorzaak 
was van de eerder vermelde z.g. cryo-activatie van prorenine in plasma bij neutrale 
pH. Inderdaad bleek deze cryo-activatie van prorenine niet op te treden in het 
plasma van patienten met een erfelijke deficientie van factor XII of prekallikreine. 
Weer bleek HMWK niet essentieel te zijn voor dit fenomeen. Met behulp van 
plasma afkomstig van patienten met een erfelijke deficientie van factor V, VII, 
VIIIC, IX, X en XI en met behulp van plasma, waaruit prothrombine door 
immunoadsorptie was verwijderd, kon worden aangetoond, dat al deze stol-
lingsfactoren, in tegenstelling tot factor XII en plasmakallikreine, geen belangrijke 
invloed hadden op de stijging van de renine-activiteit in plasma dat bij 0-4 C 
wordt bewaard. 
De cryo-activatie van prorenine in plasma is een langzaam proces. Dit proces 
verliep veel sneller in plasma waaruit de belangrijkste remmers van factor XII 
en kallikreine, nl. C1-esterase remmer, az-macroglobuline en antithrombine III, 
d.m.v. immunoadsorptie waren verwijderd. Wanneer aan een dergelijk plasma 
het polyanion dextraansulfaat (Mr 500.000) wordt toegevoegd, treedt bij 0-4 
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C snelle en volledige activatie van prekallikreine op. Deze z.g. contactactivatie 
van prekallikreine is afhankelijk van de aanwezigheid van factor XII en HMWK, 
waarbij dextraansulfaat als een negatief geladen oppervlak fungeert. Wanneer 
vervolgens het plasma enkele minuten na deze maximale contactactivatie werd 
verwarmd tot 37 C, nam ook de renine-activiteit toe. Dit gebeurde niet wanneer 
de bovengenoemde serineproteaseremmers niet tevoren uit het plasma waren 
verwijderd. 
We ktinnen dus vaststellen dat de toename van de renine-activiteit in plasma 
bij neutrale pH, zowel met als zonder voorbehandeling met zuur, afhankelijk 
is van de activatie van factor XII en prekallikreine. In beide gevallen wordt 
de activatie van factor XII en prekallikreine waarschijnlijk bevorderd door: 
denaturatie of inactivatie van serineproteaseremmers. Wanneer plasma werd 
aangezuurd tot pH 3.3 en gedurende 24 uur op deze pH werd gehouden bij 
0-4 C, was inderdaad na herstel van de pH tot 7.4 geen activiteit van C1-esterase 
remmer en antithrombine III meer aantoonbaar. De activiteit van a2-macro-
globuline was verminderd maar niet geheel verdwenen. Verder is het bekend 
dat de activiteit van deze serineproteaseremmers bij 0-4 C veel geringer is dan 
bij 37 C. 
Ret onderzoek naar de activatie van prorenine in vitro werd uitgebreid met 
experimenten met gezuiverd prorenine geisoleerd uit menselijk vruchtwater en 
plasma. Bij de zuivering werd gebruik gemaakt van kolomchromatografie over 
de ionenwisselaar DEAE-Sepharose, van affiniteitschromatografie over een 
kolom van Cibacron Blue gebonden aan Sepharose en over een kolom van een 
aan Sepharose gebonden monoclonaal renine-antilichaam dat reageerde met 
zowel prorenine als actief renine. Sporen actief renine werden verwijderd d.m.v. 
Qhromatografie over een kolom van aan Sepharose gebonden pepstatine. Peps-
tatine is een remmer van aspartylproteasen, inclusief enzymatisch actief renine. 
Prorenine wordt niet gebonden aan pepstatine. Door aan preparaten van 
gezuiverd prorenine hoog gezuiverd plasmakallikreine (zowel het intacte molecuul 
als de Iichte keten) of plasmine of trypsine toe te voegen kon worden aangetoond, 
dat elk van deze stoffen in staat was prorenine om te zetten in enzymatisch 
actief renin e. Gezuiverde factor XIIa (a-factor XIIa, het hele molecuul met Mr 
80.000),,8-factor XIIa (actieve lichte keten met Mr 28.000), thrombine en urokinase 
waren daartoe niet in staat, althans niet in de concentraties van maximaal 0.1 
f.LM. De conversie geschiedde bij 37 C en neutrale pH en voorbehandeling met 
zuur was niet noodzakelijk. 
6.2.2. Activatie met en zonder proteolyse 
Intussen werd door andere onderzoekers aangetoond dat prorenine kan worden 
geactiveerd door aanzuren tot pH 3.3, ook wanneer de bovengenoemde seri-
neproteasen afwezig zijn2•4• Deze onverwachte bevinding konden wij bevestigen. 
Dit stelde ons voor de vraag naar het verband tussen de z.g. zuur-activatie in 
plasma en vruchtwater enerzijds en de door serineprotease veroorzaakte activatie 
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anderzijds. Een van de mogelijkheden was dat prorenine niet zozeer een inactief 
pro-enzym is maar een complex van actief renine en een remmer en dat dit 
complex in zuur milieu uiteenvalt, terwijl de remmer vervolgens, wanneer de 
pH hersteld is, door een serineprotease wordt geinactiveerd. Hiermee in over-
eenstemming is het feit dat de zuur-activatie in gezuiverde preparaten van 
prorenine een reversibel proces is: in neutraal milieu daalt de renine-activiteit 
weer tot de oorspronkelijke waarde voor aanzuren. Ook deze inactivatie is een 
reversibel proces, omdat na opnieuw aanzuren de renine-activiteit weer stijgt. 
· Ook in plasma blijkt zuur-activatie een reversibel proces te zijn, althans wanneer 
activatie van factor XII en prekallikreine wordt voorkomen door toevoeging 
van serineproteaseremmers, zoals aprotinine, soyaboon-trypsineremmer of ben-
zamidine. 
Kinetisch onderzoek over de reactie tussen renine en renine-substraat, waarbij 
gebruik gemaakt werd van gezuiverd actief renine gei:soleerd uit menselijk 
vruchtwater, plasma en nierweefsel, van gezuiverd prorenine geisoleerd uit 
menselijk vruchtwater en plasma en van gezuiverd reninesubstraat · gei:soleerd 
uit menselijk plasma of schapeplasma, toonde aan dat het door trypsine 
geactiveerde prorenine van vruchtwater en plasma dezelfde enzym-kinetische 
eigenschappen (Km en Vmax) heeft als het natuurlijk voorkomende actieve renine 
van vruchtwater, plasma en nierweefsel. Ook was er geen verschil in pH-optimum. 
Inmiddels hebben andere onderzoekers aangetoond dat een monoclonaal an-
tilichaam gericht tegen het pro-segment van renaal prorenine, de biosynthetische 
voorloper van actief renaal renine, reageert met prorenine in plasma, terwijl 
het niet reageert met het actieve renine in plasmaS.6• Het is dus zeer aannemelijk 
dat de proteolytische activatie van prorenine berust op afsplitsing van dit pro-
segment van de rest van het molecuul. Inactief renine kan daarom met recht 
prorenine worden genoemd. 
Om meer inzicht te verkrijgen over de rol van proteasen bij de zuur-activatie 
van prorenine werd een meer gedetailleerd onderzoek verricht naar de kinetiek 
van dit proces, zowel in plasma en vruchtwater als in preparaten van gezuiverd 
prorenine. Daarbij bleek dat de zuur-activatie van prorenine (pR) in vruchtwater 
in twee stappen verloopt. Eerst wordt een intermediaire vorm van geactiveerd 
prorenine (pRa) gegenereerd: pR - pRa. Deze wordt vervolgens omgezet in 
een vorm van geactiveerd prorenine die identiek is aan of in ieder geval zeer 
sterk gelijkt op natief renine (R): pRa - R. Beide reacties vinden in vruchtwater 
plaats bij lage pH. 
De Vmax van de reactie van pRa met reninesubstraat verschilt niet voor die 
van de reactie van R met substraat. De, beide actieve vormen, pRa en R, zijn 
echter in andere opzichten duidelijk verschillend van elkaar. Ten eerste verliest 
pRa, in tegenstelling tot R, zijn enzymatische activiteit bij pH 7.4. Ten tweede 
wordt pRa, in tegenstelling tot R, gebonden aan 'Cibacron Blue'-Sepharose. 
Ten derde kon pRa niet, en R wel, worden aangetoond met behulp van een 
radioimmunoassay waarbij gebruik gemaakt werd van monoclonale renine-
antilichamen niet affiniteit voor R maar niet voor pR. De omzetting van pRa 
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in R is een proteolytisch proces en vindt in vruchtwater plaats onder invloed 
van een aspartylprotease.i Ip. plasma vindt de omzetting van pRa in R niet plaats 
tijdens de behandeling md zuur maar pas na herstel van de pH, en wei onder 
invloed van factor XII-kallikreine. 
Kinetisch onderzoek toonde verder aan dat de pR - pRa stap, die bij lage 
pH plaats vindt, een unimoleculair proces is, evenals de inactivatie van pRa 
in neutraal milieu (pRa - pR). De zuur-activatie is dus niet het gevolg van 
dissociatie van een complex van renine en een renineremmer. De eerste-orde 
reactiesnelheidsconstante voor het proces pR - pRa is afhankelijk van de 
protonering van een in een bepaald aminozuurresidu (of residuen) aanwezige 
atoomgroep (of groepen) met een pKa van ongeveer 3.4. Deze reactieconstante 
is evenredig met het percentage pR moleculen, waarbij deze groep is geprotoneerd. 
Dit komt overeen met de activatie v,an pepsinogeen. Interactie van positief geladen 
aminozuurresiduen in het 44 aminozuren tellende N-terminale pro-segment van 
varkenspepsinogeen en negatief geladen carboxylgroepen van aminozuren in het 
enzym-segment houden het pepsinogeenmolecuul in zijn enzymatisch inactieve 
vorm. Na aanzuren worden deze electrostatische bindingen verbroken en on-
dergaat het molecuul een reversibele conformatieverandering, waarbij het ca-
talytisch apparaat wordt geexponeerd. Dus na aanzuren wordt het activerings-
peptide losgemaakt van zijn oorspronkelijke positie waarin het de actieve groep 
blokkeert. De proteolytische activering van pepsinogeen vindt daarna plaats. 
De pRa - R conversie onder invloed van plasma kallikreine, plasmine of trypsine 
verloopt ongeveer 50-70 maal sneller dan de activatie van natief prorenine (pR 
- R) door deze serineproteasen. Dus pRa is veel gevoeliger dan pR voor 
proteolytische omzetting in R. 
Op grond van deze resultaten zijn we nu in staat ons een duidelijker beeld 
te vormen van de activatie van prorenine in vitro. Dit beeld kan als volgt worden 
samengevat. Cryo-activatie van prorenine in plasma berust op beperkte proteolyse 
van prorenine, waarbij actief renine wordt gevormd (pR - R). Deze proteolyse 
komt tot stand door de werking van kallikreine dat op zijn beurt is gevormd 
uit prekallikreine door de werking van geactiveerd factor XII. Deze processen 
treden bij lichaamstemperatuur niet of nauwelijks op, vanwege de inhiberende 
werking van de in plasma aanwezige remmers van factor XII en kallikreine. 
Bij de zuur-activatie ondergaat het prorenine een niet-proteolytische, reversibele, 
verandering in conformatie, waarbij het katalytische apparaat van het molecuul 
wordt geexponeerd en een binding kan aangaan met het reninesubstraat. Ret 
actieve centrum heeft echter bij lage pH, in tegenstelling tot met zuur geactiveerd 
pepsinogeen, geen katalytische actiyiteit. Dit komt doordat de aspartylresiduen 
(Asp-38 en Asp-226), die deel uitmaken van het actieve centrum, een hogere 
pK~waarde hebben dan de overeenkomstige aspartylresiduen bij pepsine (Asp-
32 en Asp-215). Voor de katalytische activiteit van renine is het noodzakelijk 
dat Asp-38 in de ge1oniseerde vorm is, terwijl Asp-226 in de niet-geioniseerde 
vorm dient te zijn. Dus het bij zuur gevormde pRa dient op neutrale pH te 
worden gebracht alvorens het in staat is uit reninesubstraat angiotensine I te 
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vormen. In met zuur behandeld plasma worden echter, na terugkeer van de 
pH, factor XII en prekallikreine geactiveerd, waarschijnlijk omdat remmers van 
factor XII en kallikreine na zuur-behandeling gedeeltelijk zijn gedenatureerd. 
Omdat pRa zeer gevoelig is voor proteolytische omzetting in R door kallikreine, 
wordt, na het neutraliseren van aangezuurd plasma, snel actief renine gevormd 
(pRa ~ R) en is er, althans onder optimale omstandigheden, geen vorming van 
prorenine (pRa ~ pR ). Terwijl in plasma de omzetting pRa - R na herstel 
van de pH plaats vindt, gebeurt dit in aangezuurd vruchtwater voor herstel 
van de pH door de werking van een endogeen aspartylprotease. 
In vivo vindt de activatie van pepsinogeen in de maag bij pH 2-3 plaats. Het 
is mogelijk dat de vorming van de intermediaire actieve vorm van prorenine 
(pRa) in vivo gebeurt in bepaalde intracellulaire compartimenten met lage pH, 
zoals secretiegranula en endo- of exocytotische blaasjes 7 • De membraan van 
endocytotische blaasjes (receptosomen), die betrokken zijn bij de receptor-
afhankelijke endocytose, bezit een actieve protonpomp, die ervoor zorgt dat 
de pH binnen deze blaasjes daalt tot 5 of misschien lager. Waarschijnlijk is 
de pH in de nabijheid van de protonpomp zelfs nog lager. In een dergelijk 
milieu is de vorming van pRa mogelijk. De intermedaire vorm is uiterst gevoelig 
voor beperkte proteolyse, waardoor er lokaal renine kan worden gevormd. Het 
is mogelijk dat een deel van het locaal gevormde renine afkomstig is van 
circulerend prorenine8- 10• 
6.3. REGULA TIE VAN PRORENINE IN VIVO 
6.3.1. Directe en indirecte radioimmunoassay van prorenine 
Bij de meeste onderzoekingen die in dit proefschrift zijn beschreven werd het 
reninegehalte van plasma en andere lichaamsvloeistoffen bepaald met behulp 
van een enzym-kinetische methode. Daarbij wordt de snelheid, waarmee an-
giotensine I onder gestandaardiseerde omstandigheden in vitro wordt gegenereerd, 
gemeten met behulp van radioimmunoassay (indirecte RIA). Voor de bepaling 
van prorenine met behulp van de indirecte RIA is het noodzakelijk dat prorenine 
eerst volledig wordt omgezet in enzymatisch actief renine. Bovendien mogen 
prorenine, geactiveerd prorenine en het natuurlijk voorkomende actieve renine 
niet door de voor activatie van prorenine gebruikte behandeling van het 
plasmamonster worden gedenatureerd. Tenslotte moet het in vitro geactiveerde 
prorenine dezelfde enzym-kinetische eigenschappen bezitten als het natuurlijk 
voorkomende renine. 
De omzetting van prorenine in het enzymatisch actieve renine in vitro kan 
op verschillende manieren plaats vinden: 1) door bewaren van plasma en andere 
lichaamsvloeistoffen bij lage temperatuur, 2) door zuur-behandeling en 3) door 
toevoeging van proteolytische enzymen. 
Zoals besproken in het eerste gedeelte van de samenvatting, zijn de cryo-
en zuur-activatie in plasma afhankelijk van de aanwezigheid van factor XII en 
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prekallikreine. W anneer deze stoilingsfactoren afwezig zijn of wanneer hun 
concentraties laag zijn, zijn deze methoden niet bruikbaar. De cryo-activatie 
verloopt langzaam, ook in normaal plasma, waardoor cryo-activatie niet geschikt 
is voor praktische toepassing. Na een week is slechts 15% van het in plasma 
aanwezige prorenine bij 0 C geactiveerd. De zuur-activatie van prorenine verloopt 
weliswaar sneiler en voilediger, maar een nadeel is dat de hoogte van de pH 
erg kritisch is. Beneden pH 3.1 worden prorenine en actief renine gedenatureerd 
ook bij 0 C, terwijl er boven pH 4.0 bij 0 C nauwelijks activatie optreedt. Een 
veel gebruikte methode om prorenine te activeren is die door toevoeging van 
trypsine aan plasma. De concentratie van trypsine en de duur van de incubatie 
zijn hierbij van grote invloed. Bij een te hoge concentratie of bij te lang incuberen 
worden prorenine en actief renine gedenatureerd. Wij hebben aanvankelijk minder 
aggressieve serineproteasen gebruikt, zoals plasmine en urokinase. Het nadeel 
van deze methode is dat activatie van prorenine met deze enzymen aileen optreedt 
wanneer van te voren antiplasmine uit het plasma is verwijderd. Wij hebben 
een methode ontwikkeld, waarbij volledige omzetting van prorenine in het actieve 
renine plaats vindt zonder enig verlies van prorenine, van geactiveerd prorenine 
of van het reeds tevoren aanwezige actieve renine. Voor deze methode wordt 
plasma bij 0 C geincubeerd met aan Sepharose gebonden trypsine. Hiermee 
stijgt de renine-activiteit tot een plateau, waarvan de hoogte onafhankelijk is 
van de gebruikte trypsineconcentratie, althans in het bereik van 2 tot 20 JLM. 
Bij een trypsineconcentratie van 10 JLM treedt voiledige activatie op binnen 24 
uur. Het trypsine kan eenvoudig worden verwijderd door centrifugeren. 
In de laatste twee jaar zijn monoclonale antilichamen beschikbaar gekomen, 
die een grote affiniteit bezitten voor zowel actief renine als prorenine. Ook zijn 
antilichamen beschikbaar die aileen de actieve species herkennen. Met behulp 
van deze antilichamen is het mogelijk het z.g. immunoreactieve renine te bepalen 
(directe RIA). Door de uitkomsten van de directe en indirecte RIA met elkaar 
te vergelijken, zowel in plasma als in preparaten van gezuiverd prorenine en 
actief renine, konden wij bevestigen dat de door ons toegepaste indirecte RIA 
van prorenine, waarbij het prorenine m.b.v. geimmobiliseerd trypsine bij 0 C 
wordt omgezet in het actieve renine, een goede maat is voor het proreninegehalte 
van plasma. 
Tijdens het verwerken en bewaren van de plasmamonsters kan onbedoeld 
cryo-activatie van prorenine optreden. Dit leidt bij de indirecte RIA tot foutief 
hoge waarden van actief renine en te lage waarden van prorenine. Het bleek 
ons dat dit vooral het geval was bij plasma afkomstig van vrouwen die een 
oraal anticonceptivum gebruiken of zwanger waren. Dit hangt waarschijnlijk 
samen met de verhoogde concentratie van factor XII en/of prekailikreine in 
het plasma van deze vrouwen. Daar komt nog bij dat bij zwangeren de concentratie 
van C,-esterase remmer in het plasma verlaagd is. Bovendien is bij deze vrouwen 
de prorenineconcentratie verhoogd, zodat meer prorenine beschikbaar is voor 
activatie. Door bij het afnemen van bloed en bij het verwerken en bewaren 
van de plasmamonsters speciale voorzorgsmaatregelen in acht te nemen kon 
deze onbedoelde activatie van prorenine grotendeels worden voorkomen. 
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6.3.2. Concentratie van prorenine in plasma en andere lichaamsvloeistoffen onder 
fysiologische en pathologische omstandigheden 
Gegevens over het gehalte aan prorenine en enzymatisch actief renine in plasma 
van gezonde personen en patienten met verschillende aandoeningen zijn samen-
gevat in Tabel 1. Plasma van patienten, bij wie de nieren waren verwijderd, 
bevatte vrijwel geen actief renine. Dus het circulerende actieve renine is vrijwel 
Table 6.1. Plasmaspiegels van actief renine en prorenin bij normale personen met verschillende 
aandoeningen. 
Actief renine Prorenine Actief renine 
n J.LU/ml J.LU/ml %van totaal 
Normalen 112 17.7 171 9.2 
(4.8-65.3) (77.2-377) (3.2-26.7) 
Anefrische 37 1.0 61.0 1.6 
patienten (0.2-6.1) (13.4-277) (0.4-5.9) 
Conn syndroom 14 0.58 37.3 1.5 
(0.11-3.0) (17.9-77.4) (0.4-6.5) 
Normale vrouwen bij 47 8.8 91.8 8.6 
gebruik van orale 
anticonceptiva (2.3-33.2) (32.7-258) (3.1-24.4) 
Essentiele 68 13.8 115 10.0 
hypertensie (3.0-63.3) (40.4-330) (2.8-36.7) 
Renovasculaire 68 52.7 165 23.1 
hypertensie (10.0-277) (50.2-542) (8.1-66.1) 
Essentiele hypertensie 
bij gebruik van 45 65.5 241 19.7 
captopril 3dd 50 mg (3.4-1260) (42.9-1350) (3.0-68.1) 
Renovasculaire hypertensie 
bij gebruik van 46 463 593 41.1 
captopril 3 dd 50 mg (63.6-3360) (200-1750) (20.6-81.9) 
Bartter syndroom 9 923 690 54.7 
(352-2430) (635-4480) (32.7-91.5) 
Prekallikreine- 8 11.4 339 3.3 
deficientie (4.5-29.0) (171-669) (1.1-9.4) 
Zwangeren in het 9 17.5 1120 1.6 
eerste trimester (10.4-28.9) (898-1410) (0.8-2.0) 
Zwangeren in het 50 31.7 634 4.7 
derde trimester (10.0-100) (263-1530) (1.2-18.6) 
Prorenine producerende 1010 120000 0.8 
ovariumtumor 
De resultaten (gemidde1de en 95%-betrouwbaarheidsinterval) tonen dat, naarmate de spiegel van 
actief renine hoger is, prorenine ook hoger is. De procentuele stijging van actief renine is echter 
groter dan die van prorenine. Patienten met prekallikreinedeficientie (Fletcher trait) en zwangere 
vrouwen vormen uitzonderingen hierop. 
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geheel afkomstig van de nieren. Hoewel het gehalte aan prorenine bij de meeste 
patienten zonder nieren verlaagd was, was het bij sommigen binnen het normale 
bereik. Gemiddeld is het proreninegehalte bij deze patienten ongeveer eenderde 
van de gemiddelde waarde bij normale personen. Dus ongeveer eenderde van 
het prorenine in plasma van normale personen is van extrarenale oorsprong. 
Hoewel het onderzoek bij genefrectomeerde patienten er duidelijk opwijst dat 
prorenine, althans voor een deel, door de nieren aan het plasma wordt afgegeven, 
is het onder normale omstandigheden moeilijk het directe bewijs hiervoor te 
leveren d.m.v. bepalingen van prorenine in het plasma van nierarterie en niervene, 
vanwege de grote bloeddoorstroming van de nieren en de relatief lange plasma-
halfwaardetijd van prorenine (2-3 uur) 11 • Anders ligt het, wanneer slechts een 
van beide nieren prorenine produceert, de doorbloeding van deze nier verminderd 
is en de bijdrage van deze nier tot de totale productie van circulerend prorenine 
groot is. Dit is het geval bij eenzijdige nierarteriestenose. Bij patiertten met deze 
aandoening kon dan ook worden aangetoond dat de prorenineconcentratie in 
de niervene significant hoger was dan in de nierarterie. 
Terwijl de concentratie van prorenine is verlaagd bij genefrectomeerde pa-
tienten, is deze bij patienten met een toegenomen renale afgifte van actief renine 
verhoogd. Over het algemeen geldt bovendien hoe hoger de totale concentratie 
van renine (prorenine plus actief renine) in plasma, hoe groter het percentage 
aan actief renine (Fig.2). Waarschijnlijk is de procentuele bijdrage van het door 
denier geproduceerde prorenine aan de to tale produktie van circulerend prorenine 
onder deze omstandigheden ook groter. 
Er zijn echter twee belangrijke uitzonderingen op deze regel nl. patienten met 
erfelijke prekallikreinedeficientie (Fletcher trait) en zwangere vrouwen. Bij 
patienten met Fletcher trait is prorenine duidelijk verhoogcf, terwijl actief renine 
normaal of verlaagd is. De oorzaak hiervan kan gelegen zijn in het feit dat 
de omzetting van prorenine in renine geblokkeerd is. Dit zou dan beteken dat 
onze bevindingen in vitro, waaruit bleek dat plasmakallikreine in staat is prorenine 
om te zetten in het enzymatisch actieve renine, wel degelijk van fysiologisch 
belang zijn. 
Bij zwangeren zijn in het plasma zowel prorenine als actief renine verhoogd, 
maar prorenine is verhoudingsgewijs veel sterker gestegen dan actief renine. Dit 
is reeds het geval in het eerste trimester. Het ligt voor de hand om aan te nemen 
dat in dit geval het lage percentage aan actief renine_ verband houdt met een 
grotere extrarenale productie van prorenine. Een van de mogelijke bronnen is 
de placenta. In menselijk vruchtwater ( derde trimester) is de prorenineconcentratie 
ongeveer 6-10 maal hoger dan in plasma. Na de geboorte van de placenta daalt 
de concentratie van prorenine in plasma in de eerst 48 uur echter nauwelijks, 
dit in tegenstelling tot actief renine. 
Een andere bron van prorenine zou het ovarium kunnen zijn. Het is bekend 
dat de prorenineconcentratie van plasma in de luteale fa:se van de normale 
menstruele cyclus ongeveer tweemaal zo hoog is als in de folliculaire fase 12. 
Bij vrouwen, die worden gestimuleerd met injecties van gonadotroop hormoon 
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Fig.6.2. De relatie tussen het percentage enzymatisch actief renine en de totale renine concentratie 
(prorenine plus actief renine) in plasma. Zie ook Tabel 6.1. Capt= captopril behandeling 3 dd 
50 mg. EH = patienten met essentiele hypertensie. Nx = genefrectomeerde patienten, OC = vrouwen 
die orale anticonceptiva gebruiken. PK = patienten met prekallikreine deficientie. Preg 1 
trim = vrouwen in eerste trimester van de zwangerschap, Preg 3 trim = vrouwen in derde trimester 
van de zwangerschap, RAS = patienten met eenzijdige nierarteriestenose. 
ter voorbereiding van in vitro fertilisatie, treedt tijdens of vlak na de ovulatie 
een stijging van het plasmaprorenine op tot waarden die ook gedurende 
zwangerschap worden gezien13 . Wij hebben kunnen vaststellen dat de ovariele 
follikelvloeistof van deze vrouwen, ten tijde van het oogsten van het ovum, 
vlak voor de te verwachten ovulatie een zeer hoog gehalte aan prorenine heeft, 
ongeveer 30-40 maal hoger dan het gehalte in plasma. Bovendien is er een positieve 
correlatie tussen de prorenineconcentratie in de follikelvloeistof en het plasma 
( ongepubliceerde eigen waarneming). Een dergelijke correlatie is er niet voor 
wat betreft actief renine. Bij een vrouw zonder functionerende ovaria, die zwanger 
werd na het inbrengen van een 48 uur oud embryo, steeg het prorenine in plasma 
vrijwel niet tijdens het gehele beloop van de zwangerschap, terwijl bij normale 
zwangeren het prorenine reeds gedurende het eerste trimester stijgt met een factor 
5-6. Het gehalte aan actief renine in plasma liet bij deze patiente het normale 
beloop zien, mi.melijk een langzame stijging tot een niveau in het derde trimester 
tweemaal de uitgangswaarde voor de zwangerschap. Deze bevindingen maken 
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het aannemelijk dat in het ovarium prorenine wordt geprodu~eerd. De stijging 
van de concentratie van prorenine in plasma omstreeks de ovulatie bij de normale 
menstruele cyclus en de hogere concentratie van plasmaprorenine bij vrouwen 
die behandeld worden met gonadotroop hormoon maken het aannemelijk dat 
de productie en afgifte van prorenine door het ovarium door gonadotroop 
hormoon worden gestimuleerd. 
6.4. CONCLUSIES 
Wat is de fysiologische betekenis van prorenine? Is er een regelmechanisme voor 
de activatie van prorenine binnen de juxtaglomerulaire cellen? Is er activatie 
van prorenine nadat het door de juxtaglomerulaire cellen is afgescheiden en 
in het circulerende bloed is terechtgekomen? Wat is de functie van prorenine 
dat niet in de juxtaglomerulaire cellen maar elders, zoals in het ovarium, is 
gevormd? 
Ons onderzoek geeft geen rechtstreeks antwoord op deze vragen, maar onze 
resultaten laten wei enkele conclusies toe die het antwoord dichterbij kunnen 
brengen. 
1. Onze resultaten wijzen erop dat er inderdaad een mechanisme bestaat dat 
de verhouding regelt tussen de hoeveelheden actief renine en prorenine die door 
de juxtaglomerulaire cellen worden gesecerneerd in het circulerende bloed; bij 
stimulatie van de reninesecretie stijgt deze verhouding. Bij acute stimulatie neemt 
selectief de afgifte van actief renine toe. Bij chronische stimulatie neemt de afgifte 
van zowel actief renine als prorenine toe, terwijl de afgifte van actief renine 
relatief sterker toeneemt dan die van prorenine. De aard van dit mechanisme, 
dat na de translatie van prorenine-mRNA ingrijpt in de processen van opslag 
en secretie in de juxtaglomerulaire cell en, is onbekend. 
2. Onze resultaten tonen verder dat zowel het factor XII - kallikreine -
contactactivatiesysteem als plasmine in staat zijn om prorenine te activeren. Deze 
activatie is in vitro aileen mogelijk onder omstandigheden die sterk afwijken 
van die in het circulerende bloed. Bij onze eerdere bepalingen bij patienten met 
hypertensie werden na acute stimulatie van de afgifte van renine door de nier 
soms reciproke veranderingen in de concentraties van actief renine en prorenine 
in plasma waargenomen; actief renine steeg terwijl prorenine daalde, wat een 
omzetting van plasmaprorenine in het enzymatisch actieve renine zou kunnen 
suggereren 14•15 • Ook andere onderzoekers hebben dit beschreven 16- 18• Deze 
waarneniing kon bij recent onderzoek, o.a. met behulp van de directe RIA, 
echter niet worden bevestigd en berust op onvolledige activatie van prorenine 
tijdens de bepaling van dit enzym m.b.v. de indirecte RIA, waardoor te lage 
waarden worden gemeten. Activatie van prorenine in het circulerende bloed is 
dus erg onwaarschijnlijk. 
Terwijl het natieve prorenine slechts langzaam door plasmakallikreine en 
plasmine wordt geactiveerd, is prorenine, dat behandeld is met zuur, zeer gevoelig 
voor activatie door deze en andere proteasen. Zoals hoven beschreven, is het 
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Fig. 6.3. Hypothetische interactie tussen de renale en extrarenale- renine-angiotensine systemen. 
ACE= 'angiotensin-converting enzyme'.ANG I= angiotensine I. ANG II= angiotensine II. 
JGcel = juxtaglomerulaire eel. Lys = lysosoom. mRNA = messenger RNA. PR = prorenine. 
R = enzymatisch actief renin. RS = reninesubstraat. 
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denkbaar dat prorenine door het capillaire endotheel wordt opgenomen via het 
proces van de (receptor-afbankelijke) endocytose, waarna het wordt blootgesteld 
aan de lage pH van de receptosomen en aldaar wordt omgezet in de door ons 
in vitro ge!dentificeerde intermediaire vorm van geactiveerd prorenine (Fig.3.). 
W anneer deze intermediaire vorm van geactiveerd prorenine via het transcellulaire 
transport van de endocytotische blaasjes de contraluminale zijde van het capillaire 
endotheel bereikt, kan het door exocytose terecht komen in een milieu met neutrale 
pH, waarbij het hetzij snel overgaat in inactief renine hetzij door bepaalde 
proteasen snel kan worden omgezet in de actieve vorm van renine. Het is ook 
mogelijk dat deze proteolytische activatie binnen de eel plaats vindt, bijvoorbeeld 
door fusie van de endocytotische blaasjes met (pre-)lysosomen die pepsine-achtige 
enzymen, zoals cathepsine D, bevatten. Cathepsine D is in staat prorenine in 
vitro bij lage pH te activeren. Het is bekend dat de secretiegranula van de 
juxtaglomerulaire cellen behalve prorenin.e en renine ook cathepsine B , Cathepsin 
Den andere lysosomale enzymen bevatten19• 
De zojuist beschreven hypothese houdt in dat er, naast de vorming van 
circulerend actief renine door de juxtaglomerulaire cellen, ook lokale vorming 
van actief renine elders in het lichaam, buiten de nieren plaats vindt en dat 
deze locale vorming van renine geschiedt door activatie van uit het plasma 
opgenomen prorenine dat, evenals plasma renine, afkomstig is van de juxta-
glomerulaire cellen. 
Anderzijds is inmiddels bekend geworden dat, behalve de juxtaglomerulaire 
cellen, ook andere cellen elders in het lichaam in staat zijn prorenine en renine 
te synthetiseren. Chorioncellen synthetiseren en secerneren prorenine in het 
kweekmedium. Neuroblastoma X glioma cellijnen bevatten renine, evenals her-
senen, hypophyse (LH en groeihormoon producerende cellen), bijnier, schildklier 
en testis (Leydigcellen). Bovendien is komen vast te staan dat een aantal van 
deze cellen behalve renine ook andere componenten van het renine-angiotensine 
systeem, zoals reninesubstraat, bevatten, waardoor zij in staat zijn tot de 
intracellulaire vorming van angiotensine I en II (8-10,20). 
Het is mogelijk dat het locale (paracriene,autocriene) en intracellulaire (in-
tracriene) renine-angiotensinesysteem en het circulerende ( endocriene) renine-
angiotensinesysteem onafbankelijk van elkaar opereren, maar het is ook denkbaar 
dat er een interactie tussen deze systemen bestaat en dat circulerend prorenine 
via opname en locale activatie door bepaalde cellen, bijvoorbeeld vaatendotheel-
cellen, bij deze interactie betrokken is8- 10• 
3. De hoge concentraties van prorenine in de ovariele follikelvloeistof en in 
amnionvocht wijzen erop dat renine, via de vorming van angiotensine, niet aileen 
betrokken is bij de regulatie van de bloeddruk maar ook andere tot heden 
onbekende functies heeft. In aansluiting aan de ovulatie vindt luteinisatie van 
de follikel plaats. Dit gaat gepaard met een zeer snelle en uitgebreide vaat-
nieuwvorming in het zich ontwikkelende corpus luteum. Implantatie van ovariele 
follikelvloeistof afkomstig van vrouwen en implantatie van angiotensine II in 
de cornea van konijnen leidt tot vaatnieuwvorming vanuit de limbus corneae21•22 • 
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Het is dus denkbaar dat locale activatie van prorenine en vorming van angiotensine 
II betrokken zijn bij de vaatnieuwvorming in het zich ontwikkelende corpus 
luteum. Een dergelijke functie zou ook het door chorioncellen geproduceerde 
en in het amnionvocht gesecerneerde prorenine kunnen hebben. 
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7. SUMMARY 
7.1. AIM OF THE THESIS 
Renin h:ydrolyses the Leu-10-Val-11 bond of human angiotensinogen. Because 
this reaction is the rate-limiting step in a series of reactions leading to the formation 
of angiotensin II, a highly potent vasoconstrictor and aldosterone-releasing 
hormone, renin is considered to have a key role in blood pressure regulation 
and sodium and water homeostasis (Fig.l). The importance of the renin-
angiotensin system is illustrated by the blood pressure lowering effect of 
antagonists of angiotensin II. Inhibitors of the enzyme that causes conversion 
of angiotensin I into angiotensin II (angiotensin-converting enzyme) are now 
widely used in the treatment of patients with hypertension. 
On theoretical grounds it seems logical to use the plasma level of angiotensin 
II as a measure of the activity of the renin- angiotensin system in vivo. However, 
the plasma level of angiotensin II is low, a few picograms per ml, and the antibodies 
that are used in the radioimmunoassay crossreact with degradation products 
of angiotensin II. Angiotensin II measurements are therefore not widely used. 
In clinical practice plasma renin activity (PRA) is generally accepted as a measure 
of the formation of angiotensin II in vivo. In the PRA assay, plasma of the 
patient is incubated at 37 C. During this incubation in vitro, renin is catalysing 
the generation of angiotensin I from renin substrate. Plasma has angiotensinase 
activity, by which angiotensin I is hydrolysed. This degradation of angiotensin 
I can be prevented by the addition of angiotensinase inhibitors. These substances, 
however, also inhibit 'angiotensin-converting enzyme'. The reaction stops the-
refore at the generation of angiotensin I. Angiotensin I is measured by radio-
immunoassay. Under normal circumstances the plasma concentration of renin 
substrate (angiotensinogen) equals the Km value, which means that the generation 
of angiotensin I not only depends on the concentration of renin but also on 
the concentration of renin substrate (angiotensinogen). The interpretation of 
PRA measurements is difficult in circumstances where the concentration of 
substrate is not normaL Techniques were therefore developed, in which the 
reaction velocity in vitro is independent of the substrate concentration. In these 
assays renin is separated from its substrate or the substrate is selectively destroyed. 
Subsequently, an excess of more or less purified renin substrate is added. The 
generation of angiotensin I then only depends on the concentration of renin. 
The quantities of angiotensin I generated in this type of assay of the plasma 
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Fig.7.1. Components of the renin-angiotensin system. FXII = coagulation factor XII. 
FXIIa = activated factor XII. HMWK = High molecular weight kininogen. 
renin concentration (PRC) are greater than with the PRA method. This difference 
is not only caused by the addition of an excess of exogenous substrate. In most 
of the PRC methods used so far, the plasma is acidified (pH 3-4) in order to 
destroy the endogenous substrate. After the pH has been restored to neutral, 
saturating amounts of exogenous substrate are added. Lumbers and Morris 1 
demonstrated that the renin activity of human amniotic fluid was much higher 
after acidification then before acidification. In other words during incubation 
at 37 C at neutral pH more angiotensin I was generated per unit of time after 
acidification than before acidification, despite the fact that the concentration 
of substrate in the incubation mixture was the same. Similar results were obtained 
with human plasma. The increase in renin activity with acidification (acid-
activation) appears to depend on the activation of an enzymatically inactive 
form of renin. It has been suggested that this so-called inactive renin is a proenzyme 
(prorenin) and that the activation is caused by an enzyme active at low pH 
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and causing limited proteolysis of pro renin. Another theory is that inactive renin 
consists of an enzyme-inhibitor complex that dissociated at low piP. However, 
activation of inactive renin also occurs at neutral pH, when plasma is stored 
at 0- 4 C (cryoactivation). 
These observations have important consequences for both the technical 
procedure and interpretation of plasma renin determinations. We were, howe-
ver,more intrigued by the observation that about 90 percent of the renin in 
plasma of healthy volunteers is in the inactive form. In this respect, the renin-
angiotensin system is comparable with other proteolytic systems in plasma, such 
as the coagulation and fibrinolytic systems. Until recently, the renin- angiotensin 
system was considered to be a circulating hormonal system. In fact, the 
interpretation of PRA measurements, in which the in vitro generation of 
angiotensin I is thought to be a measure for the in vivo generation of angiotensin 
I (and II), is based on this view. In this thesis we addressed the possibility 
that the renin-angiotensin system not only acts by the proteolytic activity of 
circulating plasma renin, through cleavage of angiotensin I from circulating renin 
substrate, but also that local activation of prorenin may occur and that this 
activation is caused by enzymes that are also involved in the coagulation and 
fibrinolytic systems. 
This thesis consists of two parts, firstly biochemical in vitro experiments and 
secondly physiological investigations in animals and measurements of prorenin 
in plasma of healthy volunteers and patients with different diseases and in human 
amniotic fluid and ovarian follicular fluid 
7.2. ACTIVATION OF PRO RENIN IN VITRO 
7.2.1. Acid-activation and cryoactivation 
In the method of Skinner for measuring PRC3, the plasma is dialyzed for 24 
h at 0-4 C against a pH 3.3-buffer and then for another 24 h a:t 0-4 C against 
a pH 7.4-buffer, before the plasma is incubated with an excess of exogenous 
renin substrate. Our kinetic studies revealed that the renin activity immediately 
after restoration of pH to 7.4, following the first dialysis step was higher than 
before acidification. The greatest increase in renin activity, however, occurred 
during the second dialysis step at pH 7.4. This activation at pH 7.4 was blocked 
by serine protease inhibitors, such as aprotinin, soybean trypsin inhibitor and 
benzamidine. Experiments with plasma from patients with clotting factor XII 
(Hageman factor) deficiency or with plasma from patients with prekallikrein 
(Fletcher factor) deficiency demonstrated that both factors are essential for the 
activation of prorenin in acidified plasma, after restoration of pH to neutral. 
Activated factor XII (factor XIIa) and kallikrein are serine proteases, which 
are generated from factor XII and prekallikrein in acidified plasma after 
restoration of pH to neutral. 
Further investigations with purified /3-factor XIIa (light chain with Mr 28,000 
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and containing the active centre) and plasma kallikrein (the whole molecule 
Mr 85,000 as well as the light chain Mr 28,000) showed that kallikrein itself 
or enzymes activated by kallikrein are responsible for the activation of prorenin 
in acid-pretreated plasma. Factor XII is necessary for the conversion of 
prekallikrein into kallikrein. High molecular weight kininogen (Fitzgerald fac-
tor,HMWK, Mr 110,000), which is required for the rapid activation of factor 
XII and prekallikrein in the presence of a negatively charged surface (contact 
activation), is not essential for the increase in renin activity in acid-pretreated 
plasma; renin activity increased normally in a patient with a hereditary deficiency 
ofHMWK. 
Plasma kallikrein is under certain circumstances capable of converting plas-
minogen into plasmin. Plasmin is also capable of activating prorenin in acid-
pretreated plasma. However, the activation ofprorenin in acid-pretreated plasma 
was normal, also after plasminogen had been selectively removed. 
Factor XII and plasma kallikrein are activated when plasma is stored at 0-
4 C. We expected that this activation was the cause of the aforementioned so-
called cryoactivation of prorenin at neutral pH. This was indeed the case, because 
cryoactivation of prorenin did not take place in plasma of patients with hereditary 
factor XII or pre kallikrein deficiency. Reconstitution of these plasmas with highly 
purified factor XII or prekallikrein restored normal prorenin activation. Again, 
HMWK does not appear to be essential for the cryoactivation of prorenin. Cold-
promoted activation of prorenin was within the normal range in plasma deficient 
in either clotting factor V, VII, VIII:C, IX, X or XI, and also in plasma from 
which prothrombin had been removed by immunoadsorption. Thus, these factors, 
in contrast to factor XII and prekallikrein, are not essential for the cryoactivation 
of prorenin. 
Cryoactivation of prorenin is a slow process. Cryoactivation was much faster 
after the most important inhibitors of factor XII and kallikrein , i.e. C1-esterase 
inhibitor, a2-macroglobulin and antithrombin III, had been removed from plasma 
by immunoadsorption. After addition of the polyanion dextran sulfate (Mr 
500,000) to such inhibitor-depleted plasma, prekallikrein is known to be rapidly 
and completely activated . This so-called contact activation of prekallikrein 
depends on the presence of factor XII and HMWK, with dextran sulfate acting 
as a negatively charged surface. When this plasma was subsequently heated to 
37 C, there was also a rapid increase in renin activity, which did not occur 
when the inhibitors had not been previously removed. 
We conclude therefore that the increase in renin activity in plasma at neutral 
pH, both with and without pretreatment with acid, depends on the activation 
of factor XII and prekallikrein. In both cases the activation of factor XII and 
prekallikrein is probably facilitated by denaturation or inactivation of serine 
protease inhibitors. Indeed, when plasma was acidified to pH 3.3 and kept at 
this pH for 24 h at 0 - 4 C, C1-esterase inhibitor and antithrombin III were 
completely inactivated. The activity of armacroglobulin was reduced but not 
to zero. In addition, the activity of these serine protease inhibitors at 0-4 C 
is known to be much less than at 37 C. 
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Our studies of the activation of pro renin in vitro were extended with experiments 
with purified prorenin isolated from human amniotic fluid and· plasma. For 
purification we used ion exchange column chromatography, affinity chroma-
tography on a Blue Sepharose column and a Sepharose column to which a 
monoclonal renin antibody, reacting with both active renin and prorenin, had 
been coupled. Traces of active renin were removed by affinity chromatography 
on a column of pepstatin coupled to Sepharose. Pepstatin is an inhibitor of 
aspartyl proteases including enzymatically active renin. Prorenin is not bound 
to pepstatin. 
Purified prorenin could be activated by highly purified plasma kallikrein (the 
intact molecule as well as the light chain), plasmin or trypsin. The activation 
occurred at 37 C and neutral pH, and pretreatment with acid was not necessary. 
Purified factor XIIa (a-factor XIIa, the intact molecule), fi-factor XIIa (active 
light chain, Mr 28,000), thrombin and urokinase at concentrations up to 0.1 
tLM did not activate prorenin. 
7.2.2. Activation with and without proteolysis 
During the course of our work some investigators showed that inactive renin 
could be activated by acidification at pH 3.3, also when the aforementioned 
serine proteases were absent2•4• We could confirm these observations and raised 
the question whether a link might exist between the so-called acid-activation 
in plasma and amniotic fluid on the one hand and the activation by serine 
protease on the other. One of the possibilities was that pro renin is not an inactive 
proenzyme but a complex of active renin and an inhibitor, that this complex 
dissociates in an acidic environment, and that, after restoration of pH, the 
inhibitor is inactivated by a serine protease. In agreement with this hypothesis 
is the finding that acid-activation of prorenin in purified preparations is a 
reversible process; in a neutral environment the renin activity returns to its original 
level before acidification. This inactivation is also a reversible process, because 
after reacidification there is again an increase in renin activity. Also in plasma 
the acid-activation is reversible, provided the activation of factor XII and 
prekallikrein can be prevented by the addition of serine protease inhibitors such 
as aprotinin, soybean trypsin inhibitor or benzamidine. 
Enzyme-kinetic experiments with purified renin isolated from human plasma, 
amniotic fluid or kidney and with purified prorenin isolated from human plasma 
or amniotic fluid demonstrated that trypsin-activated prorenin from amniotic 
fluid and plasma had the same enzyme-kinetic properties (Km and Vmax) as 
naturally occurring active renin from amniotic fluid, plasma and kidney. There 
was also no difference in the pH optimum. Other investigators found that 
monoclonal antibodies directed against the pro-segment of renal prorenin, the 
biosynthetic precursor of active renin, reacted with plasma prorenin but not 
with naturally occurring active plasma renin5•6• Therefore it is very likely that 
the proteolytic activation of prorenin depends on the cleavage of the pro-segment 
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from the parent molecule. It is therefore correct to designate inactive renin as 
pro renin. 
In order to gain more insight into the role of the proteases in the acid-activation 
of prorenin, we studied in more detail the kinetics of acid-activation of pro renin 
in human amniotic fluid and plasma and in preparations of purified prorenin 
isolated from amniotic fluid and plasma. Conversion of pro renin (pR) into active 
renin (R) appeared to be two-step process involving the generation of an 
intermediary form of activated prorenin (pRa). The pR __. pRa step is a 
unimolecular process and involves an acid-induced reversible change in the 
conformation of the molecule and is not caused by the dissociation of a renin-
inhibitor complex. The pRa - R step is irreversible and proteolytic. 
pRa - R conversion occurred in amniotic fluid at low pH by the action 
of an endogenous aspartyl protease. In plasma pRa __. R conversion occurs 
after restoration of pH to neutral and is caused by the serine protease, plasma 
kallikrein. PRa - R conversion did not occur in purified preparations of pro renin. 
Thus, in contrast to pepsinogen, the acid-induced reversible conformational 
change is not followed by autocatalysis. 
pRa of amniotic fluid and plasma could be separated from R by affinity 
chromatography on Blue Sepharose, and R but not pRa was detected by an 
immunoassay using monoclonal antibodies reacting with R and not with pR. 
The first-order rate constant for pR- pRa conversion depends on the protonation 
of a polar group (or groups) with a pK ~ 3.4, the rate constant being proportional 
to the fraction of pR molecules that have this group protonated. This is analogous 
to the reversible acid-induced conformational change of pepsinogen that occurs 
before its proteolytic conversion into pepsin. Interaction of positively charged 
amino acid residues in the N-terminal pro-segment (44 amino acids) of hog 
pepsinogen and negatively charged carboxyl groups of the enzyme-segment keep 
the pepsinogen molecule in its inactive form. With acidification the electrostatic 
bonds are broken resulting in a reversible change in the conformation of the 
molecule, by which the catalytic apparatus becomes exposed. This is then followed 
by the irreversible proteolytic activation of pepsinogen. 
Kcat/Km for pRa - R conversion by plasmin and plasma kallikrein at pH 
7.4 and 37 C was 7.8 and 5.2 X 106 M-1 min-1 respectively, which was about 
50 to 70 times greater than for pR - R conversion. The susceptibility of pRa 
to proteolytic attack is high enough for the intrinsic factor XU-kallikrein pathway 
to cause rapid pRa- R conversion at 37 C, even in whole blood with its abundance 
of serine protease inhibitors. 
On the basis of these findings we can now describe more clearly the process 
of activation of prorenin in vitro. Cryoactivation of pro renin in plasma depends 
on limited proteolysis of prorenin leading to the formation of active renin (pR 
- R). This activation occurs by plasma kallikrein, which in turn is generated 
from prekallikrein by activated factor XII. These processes do not take place 
at body temperature, because of the inhibitory action of inhibitors of factor 
XII and kallikrein in plasma. During acid-activation the prorenin molecule 
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undergoes a non-proteolytic, reversible, conformational change by which the 
catalytic apparatus of the molecule is exposed. At low pH however, prorenin, 
in contrast to pepsinogen, does not possess catalytic activity, because the aspartyl 
residues (Asp-38 and Asp-226) in the active centre have higher pK-values than 
the corresponding aspartyl residues (Asp-32 and Asp-215) in pepsin. For the 
catalytic activity of renin, Asp-38 has to be in the ionized form and Asp-226 
in the non-ionized form. Therefore, pRa, which is formed at low pH, has to 
be brought back to neutral pH before it can hydrolyse renin substrate. Factor 
XII and prekallikrein are also activated after restoration of pH to neutral, 
probably because the inhibitors of activated factor XII and prekallikrein are 
denaturated at low pH. Because pRa is very sensitive for proteolytic conversion 
into R by kallikrein, the reverse reaction pRa - pR does not take place in 
normal plasma. Whereas in plasma pRa - R conversion takes place after 
restoration of pH to neutral, in acidified amniotic fluid the conversion takes 
place at low pH before pH is restored and this is due to the action of an endogenous 
aspartyl protease. 
The activation of pepsinogen in vivo in the stomach occurs at pH 2-3. It 
is possible that the formation of the intermediary active form of prorenin (pRa) 
in vivo occurs at low pH in intracellular compartments with low pH such as 
secretory granules and en do- or exocytotic vesicles 7• The membrane of the 
endocytotic vesicles (receptosomes), which are involved in the process of receptor-
dependent endocytosis, contains an active proton pump, which causes a fall 
in pH to 5 or perhaps lower. The pH is likely to be even lower at sites near 
the proton pump. In such an environment pRa can be formed. This intermediary 
form of activated prorenin is very sensitive to limited proteolysis so that local 
formation of R may occur. It is possible that part of the locally generated renin 
has originated from circulating prorenin8- 10• 
7.3. REGULATION OF PRORENIN IN VIVO 
7.3.1. Direct and indirect radioimmunoassays of prorenin 
In most of the studies reported in this thesis the renin concentration of plasma 
and other body fluids was determined with an enzyme-kinetic method. In this 
assay the velocity of angiotensin I generation in vitro under standardized 
circumstances, is measured by radioimmunoassay of angiotensin I (indirect RIA). 
For the measurement of prorenin, the proenzyme has to be converted into 
enzymatically active renin. The difference in renin activity before and after 
conversion is taken as a measure of prorenin concentration. For this to be valid 
the conversion has to be complete. It is also necessary that the procedures that 
are used for the conversion do not cause denaturation of prorenin, activated 
prorenin and naturally occurring active renin. Finally, it is necessary that the 
in vitro activated prorenin has the same enzyme- kinetic properties (Km and 
Vmax) as naturally occurring active renin. 
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The conversion of prorenin into enzymatically active renin in vitro can occur 
in several ways; 1) by storage of plasma or other body fluids at low temperature 
(cryoactivation), 2) by acid-treatment (acid-activation), and 3) by the addition 
of proteolytic enzymes. 
As discussed in the first part of this chapter, cryoactivation and acid-activation 
in plasma depend on the presence of factor XII and prekallikrein. When these 
factors are absent or when their concentration is low, the activation is not 
complete. Cryoactivation proceeds slowly, also in normal plasma. Therefore, 
cryoactivation is not suitable for practical purposes. After one week only 15% 
of the pro renin present in normal plasma is activated at 0 · C. Acid-activation 
appears to be more complete but careful adjustment of pH is of crucial importance. 
Below pH 3.1 prorenin and active renin are denaturated also at 0 C, and above 
pH 4.0 there is almost no activation at 0 C. Trypsin is often used for the activation 
of prorenin. High concentrations of trypsin are required to overcome the activity 
of the plasma inhibitors but such high concentrations may destroy renin or 
pro renin. We therefore initially used less aggressive serine pro teases such as 
plasmin and urokinase. The problem with the use of these proteases is that 
activation of prorenin only occurred after az-antiplasmin had been removed. 
We, therefore, have developed an assay of prorenin, in which the conversion 
of prorenin into renin occurred under apparently optimal condition, without 
any loss of pro renin, activated prorenin or naturally occurring active renin. Some 
characteristics of the assay were 1) pro renin was activated with Sepharose-bound 
trypsin at 0-4 C, 2) the concentration of the activator was not critical provided 
the incubation was prolonged until renin activity had reached a plateau, 3) this 
plateau was stable and had the same height as after maximal activation with 
acid, plasmin or urokinase, and 4) the activator can easily be removed by 
centrifugation. 
In the last two years monoclonal renin antibodies have become available with 
high affinity for active renin as well as prorenin. There are now also antibodies 
available that only recognize the active species. With these antibodies it is possible 
to measure total immunoreactive renin as well as enzymatically active renin 
(direct RIA). By comparing the results of the direct and indirect assays, in plasma 
as well in preparations of purified prorenin and renin, we could confirm that 
the indirect RIA, in which prorenin is converted into active renin by immobilized 
trypsin at 0 C, is a good measure of the prorenin concentration in plasma. 
During storage and handling of the plasma samples inadvertent cryoactivation 
of prorenin can occur. This leads to falsely high levels of active renin and low 
levels of prorenin in the indirect RIA. This was especially the case with plasma 
of women who were on oral contraceptives or with plasma of pregnant women. 
This might be related to the elevated levels of factor XII and prekallikrein in 
these women, whereas C1-esterase inhibitor is decreased in pregnant women. 
Moreover, pregnant women have elevated plasma prorenin levels, so that more 
prorenin is available for cryoactivation. The activation of prorenin during 
handling and storage of the plasma samples could be prevented by taking special 
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precautions and by adding a serine protease inhibitor, for instance soybean trypsin 
inhibitor, to the plasma samples. 
7.3.2. Concentration ofprorenin in plasma and other body fluids under physiological 
and pathological circumstances 
The levels of prorenin and enzymatically active renin in plasma of normal 
volunteers and patients are summarized in Table 1 and Fig.2. Active renin in 
Table 7.1. Plasma levels of active renin and prorenin in controls and in patients with different 
diseases. 
Active renin Pro renin Active renin 
n ILU/ml ILU/ml %of total 
Controls 112 17.7 171 9.2 
(4.8-65.3) (77.2-377) (3.2-26.7) 
Anephric 37 1.0 61.0 1.6 
patients (0.2-6.1) (13.4-277) (0.4-5.9) 
Conn's syndrome 14 0.58 37.3 1.5 
(0.11-3.0) (17.9-77.4) (0.4-6.5) 
Normal women using 47 8.8 91.8 8.6 
oral contraceptives (2.3-33.2) (32.7-258) (3.1-24.4) 
Essential 68 13.8 115 10.0 
hypertension (3.0-63.3) (40.4-330) (2.8-36.7) 
Renovascular 68 52.7 165 23.1 
hypertension (10.0-277) (50.2-542) (8.1-66.1) 
Essential hypertension 
during captopril 45 65.5 241 19.7 
therapy 50 mg tid (3.4-1260) ( 42.9-1350) (3.0-68.1) 
Renovascular hypertension 
during captopril 46 463 593 41.1 
therapy 50 mg tid (63.6-3360) (200-1750) (20.6-81.9) 
Hartter's syndrome 9 923 690 54.7 
(352-2430) (635-4480) (32.7-91.5) 
Pre kallikrein 8 11.4 339 3.3 
deficiency (4.5-29.0) (171-669) (1.1-9.4) 
Pregnant women 9 17.5 1120 1.6 
first trimester (10.4-28.9) (898-1410) (0.8-2.0) 
Pregnant women 50 31.7 634 4.7 
third trimester (10.0-100) (263-1530) (1.2-18.6) 
Prorenin producing 1010 120000 0.8 
ovary tumor 
The results mean and 95% confidence intervals (in parentheses) demonstrate that an increase in 
the plasma level of active renin is associated with an increase in the plasma level of prorenin. 
The percentual increase of active renin however is much greater than that of prorenin. Patients 
with prekallikrein deficiency (Fletcher trait) and pregnant women are an exception. 
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plasma of nephrectomized subjects is very low. Therefore, circulating active renin 
mainly originates from the kidney. Prorenin in most patients without kidneys 
is lower than in controls but some anephrics have plasma levels of prorenin 
within the normal range. The mean prorenin concentration in anephrics is about 
one third of that in controls. Therefore, about one third of the plasma prorenin 
in the normal subjects appears to be of extrarenal origin. Although our 
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Fig 7.2. The relation between the percentage of enzymatically active renin and the total renin (prorenin 
plus active renin) concentration in plasma. See also Table 7.1. Capt= Captopril 50 mg tid. 
EH = patients with essential hypertension. Nx = Nephrectomized patients. OC = Women using oral 
contraceptives. PK = Patients with hereditary prekallikrein deficiency. Preg 1 trim = women first 
trimester of pregnancy. Preg 3 trim= women third trimester of pregnancy. URAS =Patients with 
unilateral renal artery stenosis. 
observations in anephrics clearly demonstrate that part of the plasma prorenin 
is of renal origin, renal production is difficult to prove directly by measurements 
of prorenin in renal vein and renal artery, because of the high renal plasma 
flow and the relatively long plasma half-live of prorenin (2-3h)11 • In patients 
with unilateral renal artery stenosis, in whom only the affected kidney produces 
prorenin and the blood flow through this kidney is reduced, we could indeed. 
show that the prorenin concentration in the renal vein was significantly higher 
than in the renal artery. 
Whereas the concentration of prorenin is reduced in anephric subjects, it is 
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increased in patients with increased renal secretion of enzymatically active renin. 
Moreover, the higher the concentration of total renin (i.e. prorenin plus active 
renin), the higher the the percentage of active renin (Fig.2.). The percentual 
contribution of the kidney to the total production of circulating prorenin is 
probably also higher under these circumstances. 
There are, however, at least two exceptions to this rule. i.e. patients with 
hereditary plasma prekallikrein deficiency (Fletcher trait) and pregnant women. 
In patients with Fletcher factor deficiency the plasma concentration of prorenin 
is increased, whereas active renin is normal or low. The reason for this finding 
could be a block in the prorenin-renin conversion. This would mean that our 
in vitro finding that plasma kallikrein is capable to convert prorenin into renin 
is also of physiological significance. 
In pregnant women the plasma concentrations of both prorenin and active 
renin are increased, but the increase in plasma prorenin is much greater. This 
is already the case in the first trimester of pregnancy. It is possible that in 
this case the low percentage of active renin is related to the increased extrarenal 
production of prorenin. One of the possible sources is the placenta. In human 
amniotic fluid (third trimester) the prorenin concentration is about 6 to 10 times 
higher than in plasma. In normal pregnant women prorenin did not fall until 
the second day after parturation. In contrast, the half-live of plasma prorenin 
after bilateral nephrectomy in patients with renal failure was about two hours. 
These results suggest that the placenta is not a major source of maternal plasma 
pro renin. 
Another source of prorenin could be the ovary. Plasma prorenin in the luteal 
phase of the menstrual cycle is about two times higher than in the follicular 
phase12• An increase in plasma prorenin, at the time of the ovulation or shortly 
thereafter, comparable to the increase in pregnancy, has been reported in women 
who were on an in in vivo fertilization program and received gonadotropin 
injections 13• We found that the ovarian follicular fluid of these women, at the 
time of the collection of the oocyte, contained prorenin in very high concen-
trations, about 30-40 times higher than the concentration in plasma. Moreover, 
there was a positive correlation between the prorenin concentration in follicular 
fluid and plasma (unpublished results). Active renin levels were not correlated. 
In a woman without functioning ovaries, who became pregnant after transfer 
of a donated oocyte fertilized with the sperm of her husband, pre-pregnancy 
plasma levels of active renin and prorenin were normaL Active renin rose two-
fold during pregnancy both in the patient and in normal pregnant women. 
However, in the first eight weeks prorenin rose 156 MD/ml in the patient, whereas 
it rose by 869±169 MD/ml (mean±SD) in normal pregnant women. In the patient 
pro renin also remained abnormally low throughout the pregnancy. Because of 
these findings and in the light of recent evidence that the ovary is capable of 
producing high levels of prorenin in plasma of women with hyperstimulated 
cycles, it seems likely that the ovary is the main source of the elevated prorenin 
in pregnancy and that the production and secretion of prorenin by the ovary 
is under gonadotropic controL 
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Fig. 7.3. Hypothetical interactions between the renal and extarenal renin-angiotensin system. 
ACE= Angiotensin-converting enzyme, ANG I= angiotensin I, ANG II= angiotensin II, 
JGcell =juxtaglomerular cell, mRNA =messenger RNA, Lys =Lysosome, PR = prorenin, R 
=enzymatically active renin, RS =renin substrate. 
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7.4. CONCLUSIONS 
What is the physiological significance of prorenin? How is the activation of 
prorenin regulated within the juxtaglomerular cells ? Does activation of pro renin 
occur after it has been released by the kidney into the circulating blood? What 
is the function of extrarenally produced prorenin? 
Our investigations don't give a straightforward answer to these questions, 
but some conclusions can be drawn. 
1. Our results indicate that there is mechanism regulating the ratio between 
the amounts of active renin and prorenin secreted by the juxtaglomerular cells 
into the circulating blood. This ratio increases when the secretion of renin is 
stimulated. With acute stimulation it is the secretion of active renin that is 
selectively increased. During chronic stimulation the secretion of active renin 
as well as the secretion of prorenin are increased, but the increase in active 
renin is much greater. The nature of this post-translational mechanism, which 
is regulating the processes of storage and secretion in the juxtaglomerular cells, 
is unknown. 
2. Our results further show that the factor XII-kallikrein-contact activation system 
as well as plasmin are capable of activating prorenin. This activation in vitro 
is only possible under circumstances that differ from those in circulating blood. 
In previous experiments in patients with essential hypertension we found that, 
immediately after acute stimulation of the renal release of renin, the rise of 
active renin in plasma was associated with a fall of prorenin, suggesting that 
prorenin-renin conversion also occurred in vivo. 14, 15 • Such observations were also 
made by other investigators16- 18 • In recent experiments ,however, using the direct 
renin RIA, these observations could not be confirmed. Incomplete activation 
in the indirect RIA leading to falsely low values of prorenin is probably the 
main cause of this discrepancy. Activation of prorenin in circulating blood seems 
very unlikely. 
The activation of prorenin by plasma kallikrein or plasmin is a slow process. 
Prorenin pretreated with acid is very susceptible to activation by these and other 
proteases. As described above, it is possible that vascular endothelial cells are 
capable of taking up prorenin via a process of receptor-mediated endocytosis, 
after which it is exposed to the low pH of the receptosomes and is converted 
into the intermediary form of activated prorenin (Fig.3). The activated prorenin 
may be transported by the vesicles to the luminal or contraluminal side of the 
endothelial cell. After exocytosis it may enter a milieu with neutral pH, where 
it refolds to the original inactive form or is rapidly converted into active renin 
by one or more proteases. It is also possible that the proteolytic conversion 
takes place within the cell, for example by fusion of endocytotic with 
(pre-)lysosomes, which contain pepsin-like enzymes, such as cathepsin D. 
Cathepsin D is capable of activating prorenin in vitro at low pH. It is known 
that the secretory granules of the juxtaglomerular cells contain not only pro renin 
and renin but also cathepsin B, cathepsin D and other lysosomal enzymes19• 
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This hypothesis implies that, besides the formation of active renin by the 
juxtaglomerular cells, local formation of active renin may occur in other parts 
of the body, outside the kidney, and that such local formation of renin may 
occur by the activation of prorenin that originates from the kidney and is taken 
up from the plasma. 
On the other hand, it has now become known that, besides the juxtaglomerular 
cells, other cells in the body are capable of synthesizing prorenin and renin. 
Chorionic cells secrete prorenin. Neuroblastoma X glioma cell lines, brain, 
pituitary gland, adrenals thyroid gland and testis (Leydig cells) contain renin. 
Moreover, recent studies suggest that some of these cells are capable of 
synthesizing prorenin, renin and renin substrate, and intracellular production 
of angiotensin II has been demonstrated8- 10•20 • 
It is possible that the local (paracrine or autocrine) and intracellular (intracrine) 
renin-angiotensin systems on the one hand and the circulating (endocrine) renin-
angiotensin system on the other are operating independently, but it is also possible 
that an interaction exists between these systems and that circulating prorenin 
is involved, via uptake and local activation, for instance by endothelial cells 
(Fig.3. )s-lo. 
3. The high concentrations of prorenin in ovarian follicular fluid and amniotic 
fluid indicate that renin, via the formation of angiotensin II, is not only involved 
in blood pressure regulation but also in functions that are unknown as yet. 
In the ovary luteinization of the follicle takes place following ovulation. This 
coincides with rapid and extensive neovascularization of the developing corpus 
luteum. Implantation of human ovarian follicular fluid and implantation of 
angiotensin II in the cornea of the rabbit leads to neovascularization originating 
from the limbus cornea21•22• It is possible that local generation of prorenin and 
formation of angiotensin II are involved in the neovascularization in the 
developing corpus luteum. Prorenin produced by the chorionic cells and secreted 
into the amniotic fluid could have a similar function. 
It is not too far fetched to hope that in the near future further studies on 
the physiological functions of the extrarenal renin-angiotensin systems will 
produce some surprising results. 
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VERANTWOORDING 
Dit proefschrift werd bewerkt in het laboratorium van de afdeling Inwendige 
Geneeskunde I van het Academisch Ziekenhuis Dijkzigt. De vorm waarin het 
hier beschreven onderzoek is gepresenteerd doet echter onrecht aan de teamgeest 
in de groep, die eraan heeft meegewerkt. De geestelijke vader en grote animator 
achter het hele onderzoek was Maarten Schalekamp. Veel dank ben ik verschul-
digd aan Gre Schalekamp die mij de grondbeginselen van vele biochemische 
technieken heeft bijgebracht. Bonno Bouma verleende essentiele hulp bij een 
belangrijke fase van het onderzoek, toen namelijk duidelijk werd dat er een 
verband bestond tussen het renine-angiotensine systeem en de contact-activatie 
van de bloedstoiling. Met Emile Brommer en Kees Kluft van het Gaubius instituut 
uit Leiden was er een vruchtbare samenwerking voor wat betreft het onderzoek 
naar het verband met het fibrionolytische systeem. Het onderzoek bij de normale 
vrouwen, gebruiksters van de pil en zwangeren was niet gelukt zonder de 
medewerking van Bert Alberda, Gerard Zeilmaker, Wil Visser, Yolanda Ma-
kovitz, Inge Huisveld en Henk Wailenburg. Andries van Seyen verrichtte de 
meeste niervenecatheterisatiestudies. Rest nog de vermelding van de coilegaas 
van het eerste uur Gert-Jan Wenting, Arie Man in 't Veld, Lies Tan en Frans 
Boomsma en van wat latere datum Bart de Bruyn en J eroen Vincent, die aile 
fustraties en hoogtepunten van het onderzoek hebben meegemaakt. 
In de vele jaren van het onderzoek heb ik opvailend weinig "analisten" versleten. 
Jeanette van Gool, Rene de Bruin en Manorma Biharie hebben aile bepalingen 
met liefde, vakmanschap en grote zorg uitgevoerd. De hulp van Gusta, Pauline 
en W outrina in en rond de onderzoekscentrale en natuurlijk Carla Swaab de 
onmisbare stille kracht achter de vele iilustraties was onmisbaar. 
Tenslotte gaat mijn dank uit naar de patienten, in het bijzonder de patiente 
die in het laatste hoofdstuk is beschreven, studenten en niet genoemde coilegae 
die aan dit onderzoek hebben meegewerkt. 
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List of abbreviations and definitions 
a zAP 
a 1AT 
ANGI 
ANGII 
ATIII 
BSA 
C1-INH 
CNBr 
DEAE 
EDTA 
FXII 
a-Factor XIIa 
{3-Factor XIIa 
HMWK 
HSA 
azM 
Mr 
NaN3 
80HQ 
PMSF 
pNA 
PPAN 
pR 
pRa 
R 
RS 
SBTI 
SDS 
Tris 
v/v; w/v 
az-Antiplasmin 
a1-Antitrypsin 
Angiotensin I 
Angiotensin II 
Anti trombin III 
Bovine serum albumine 
C1-Esterase inhibitor 
Cyanogen bromide 
Diethylaminoethyl 
Ethylenediaminetetraacetic acid disodium salt 
Factor XII (zymogen, Mr. 80,000) 
the 80,000 Mr. form of activated factor FXII 
the 28,000 Mr. form of activated factor FXII 
High molecular weight kininogen 
Human serum albumin 
az-Macroglobulin 
Molecular weight 
Sodium azide 
8-Hydroxyquinoline sulfate 
Phenylmethylsulfonylfluoride 
Paranitroaniline 
H-D-Propyl-L-phenylanalyl-L-argine-p-nitroanilide 
proremn 
Intermediary form of activated prorenin 
Naturally occurring active renin or protease-activated prore-
mn 
Renin substrate (angiotensinogen) 
Soybean trypsin inhibitor 
Sodium dodecyl sulfate 
Tris (hydroxymethyl)~aminomethane 
Volume per volume; weight per volume 

